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Summary 
The epithelial absorbing cells of the small intestinal villi, the enterocytes, are the main 
protagonists for the transport of nutrients from the intestinal lumen to the interstitial fluids. 
The oriented flow of nutrients is carried out by different and complementary transport systems 
present in the apical and the basolateral domains of the enterocyte’s plasma membrane. One 
of the distinctive characteristics of those intestinal cells is the presence of numerous 
structurally distinct protrusions (referred as microvilli) on the apical surface of the plasma 
membrane. They confer the brush-like appearance of the microvillus border (commonly 
referred to as the “brush border”) typically observed in the light microscope. 
Over the years, there has been considerable interest to study the molecular mechanisms 
driving the transport of molecules across the intestinal brush border membrane (BBM). 
Defects have been described to cause a variety of pathological conditions, such as disorders in 
the metabolism of saccharides (glucose and galactose malabsorption, lactose intolerance), 
amino acids (Hartnup disease, aminoacidurias), ions (sodium and potassium in the case of 
familiar diarrhea), metals (zinc in acrodermatitis enteropathica) and cholesterol lipids 
(cardiovascular diseases). In particular, the essential role of the BBM in regulating the 
delicate balance between cholesterol influx and efflux from the lumen to the enterocyte has 
been recently highlighted through the genetic analysis of individuals suffering of cholesterol 
disorders as well as in several clinical studies involving the use of dietary plant sterols 
(phytostrerols) or specific protein inhibitors blocking essential components of the cholesterol 
absorption/resorption pathway.  
Most studies aimed at studying the enterocyte BBM have been conducted through gene 
analysis, activity tests and immunology assays. Its characterization at the protein level, 
however, has been hampered by the difficulty to isolate a pure fraction from the small 
intestine and by the nature of the targets of interest, being most of them transmembrane 
integral proteins. Predictably, the few proteomics studies reporting the identification of 
proteins localized in the BBM membrane failed to identify transporters and receptors that are 
known to be located in this fraction. Also, the very aggressive environment to which the 
enterocyte is exposed combined with the class of proteolytic enzymes present in this 
membrane imply the use of targeted strategies to maintain the structural integrity of the BBM 
proteins in the isolation protocol. 
The primary goal of this study was the development and the evaluation of mass spectrometry-
based analytical strategies for the analysis and the identification of hydrophobic proteins, such   12
as found in the enterocyte BBM. Analysis of membrane proteins in a complex mixture has 
always represented an obstacle in the proteomics field. Their hydrophobic nature requests a 
detergent for their solubilization and makes the use of traditional proteomics techniques less 
compatible (e.g. two-dimensional gel electrophoresis) while their low abundance in complex 
biological mixtures (in comparison to soluble proteins) requires additional purifications steps 
for their enrichment. Even at equal abundance, the identification rate of membrane proteins is 
lower than that of soluble proteins. The development of an optimized sample preparation 
protocol combined with a robust analytical method was expected to enable the investigation 
of proteins located in the BBM and so to confirm the findings of several other studies, namely, 
that the BBM contains proteins that participate in cholesterol regulation in the enterocytes. 
Finally, a third goal of this study was to investigate conditions for which a quantitative mass 
spectrometric experiment using a label-free strategy could be used to investigate biological 
samples, as technical variability and sample stability of the BBM preparation were not known. 
The reproducibility of the technical steps had to be monitored for the whole workflow, from 
the BBM preparation until the mass spectrometric analysis of the samples, so to pinpoint 
difficulties and limitation of the workflow and preparing the way for a label free 
quantification strategy using only the information from the LC-MS data. 
In this study, an analytical strategy enabling for the first time (to my knowledge) the direct 
characterization of BBM proteins previously described to participate in cholesterol absorption 
is presented. Key points of this strategy consisted of an improved protocol to reproducibly 
isolate and purify BBM preparations from the intestinal tissue, the design of an inhibitor 
cocktail specifically aimed at minimizing the proteolytic activity of the BBM endogeneous 
proteases, a targeted strategy to enrich the BBM transmembrane proteins from common 
cytosolic contaminants, and the use of a very robust and sensitive instrumentation using 
capillary liquid chromatography and tandem mass spectrometry. In particular, the original 
protocol from Kessler et al for purifying and enriching the proteins contained in the BBM 
fraction was significantly improved and extended to selectively remove cytosolic and 
basolateral contaminants. Whole intestine, or scrapped mucosa thereof for higher purity, was 
first lysed and a crude membrane fraction was isolated by differential centrifugation. The 
resulting pellet was then resuspended and the basolateral membrane fraction was specifically 
removed from the preparation by CaCl2 precipitation. The enriched BBM vesicles were then 
pelleted by centrifugation and subjected to additional washes in high salt and high pH to 
remove the remaining cytosolic and membrane-associated proteins. The performance of the 
protocol and the purity of the obtained BBM vesicles were monitored by Western Blot   13
analysis following a known basolateral (Na
+/K
+ ATPase a1) and BBM markers (FATP-4). 
The new protocol provided a 30- to 50-fold enrichment factor (versus about a 10-fold 
enrichment factor following the Kessler protocol) compared to the crude lysate while a known 
basolateral marker, Na
+/K
+ ATPase a1, remained undetected in the purified BBM fraction. 
Simultaneously, a significant part of the protocol optimization was devoted to the inhibition 
of the endogenous BBM vesicles proteases, most of them of the His-Zn dependent 
metalloprotease superfamily that are not inhibited by common Serine, Cysteine proteinase 
inhibitors. Partial inhibition (approximately 90%) was achieved by adding amastatin, a known 
partial inhibitor, and several peptide substrates in all buffers used in the BBM purification 
protocol. In addition, excess calcium (a known activator of this family of proteases) was 
removed by adding EDTA in the first wash step immediately following the calcium 
precipitation step.  
A tripilicate analysis of a purified mouse BBM fraction resulted in the reliable identification 
of 1460 proteins, of which 260 proteins were predicted to be transmembrane integral proteins. 
A detailed GO analysis revealed that the proteins identified in this study were equally 
distributed between plasma membrane, the ER/Golgi/endosome compartments, cytoskleleton 
and mitochondria while only a quarter of the BBM proteins were annotated as cytoplasmic. 
Using this protocol, a number of proteins known to play a critical role in cholesterol 
absorption were identified directly for the first time at the protein level. For example, the 
Niemann-Pick C1-like 1 protein (NPC1L1), an abundant protein of the BBM preparation, is a 
13-transmembrane segments protein described to play a critical role in cholesterol absorption. 
Similarly, the two half-size, 6-transmembrane segments ABC transporters ABCG5 and 
ABCG8 are involved in the biliary secretion of cholesterol and plant sterols. The complex 
formed by Caveolin-1 and Annexin-2 has been suggested as key element for the cholesterol 
trafficking from the BBM to the endoplasmic reticulum while SR-BI, a 4-transmembrane 
segments receptor, has been found to be involved in cholesterol uptake. The role of many of 
the proteins mentioned above and of several other proteins, such as CD36, Galectin-4, and 
ABCB1, is the subject of hot debates. Several studies have supported their involvement in 
cholesterol absorption but their precise mechanisms of action have remained unclear so far. 
Finally, it is worth mentioning here the presence of three lipoproteins, ApoA-I, ApoA-IV and 
ApoE, within the identified proteins of the BBM preparation. Their confident identification in 
this membrane preparation was rather unexpected as lipoproteins are by nature small, soluble 
proteins secreted by the liver and, therefore, they are not considered as constituents of the   14
BBM. Rather, their presence might be due to their tight interaction with some BBM 
constituents, such as LRP-1 and Cubilin, which are known to interact with apoliproproteins. 
The complexity of the present proteomics workflow raised the question whether it was 
possible to reproducibly and quantitatively survey hundreds of membrane proteins 
simultaneously in the enterocyte BBM vesicles. Some key parts of the study were therefore 
analyzed in greater details using the protein identification information (comparing the 
successful MS/MS analysis between bands) and comparative analysis of the precursor ion 
signals to investigate in a more systematic manner the factors weighting in the reproducibility 
of the overall analysis. Using both strategies, most of the technical steps, such as the LC-
MS/MS identification strategy, the separation of complex protein mixtures by 1-D-SDS-
PAGE, or the in-gel digestion of proteins using trypsin, were not identified as major 
contributors to the overall variability of the experiment if appropriately controlled. Taken as a 
whole, the systematic evaluation of the overall analytical process unambiguously confirmed 
the high reproducibility achieved by the LC-MS/MS process. Rather, the BBM isolation 
protocol itself was identified as a potential source of variability due to its relative length and 
complexity and due to the inclusion of several steps that might have been difficult to carry on 
quantitatively, such as the CaCl2 precipitation step. Also, the remaining proteolytic activity of 
the abundant BBM proteases, if unchecked, could also contribute to sample degradation and 
add extensive variability to the protein identification process. Finally, the variability in the 
number of commonly identified proteins was significantly lower when samples were 
compared to each other using a proper design of experiment.  
In conclusion, this study demonstrates the feasibility to reproducibly and quantitatively 
analyze membrane proteins in complex mixture such as isolated from the enterocyte BBM. 
Key elements for a successful analysis were a robust sample preparation protocol yielding 
highly enriched BBM vesicles, a tightly controlled analytical strategy, and a statistically 
driven data analysis scheme. In particular, and most importantly, in this BBM vesicle 
preparation highly enriched for membrane proteins, the number of different peptides and the 
average sum of peptide counts were reflective for the relative abundance of a given membrane 
protein in the preparation, independently of its number of transmembrane segments. However, 
those identified tryptic peptides were exclusively located within the loops or in the 
cytoplasmic regions of membrane proteins. Assuming that trypsin cleaves off transmembrane 
helices, that is, the transmembrane tryptic peptide is generated during the digestion procedure, 
the rather hydrophobic nature and the length (30-40 amino acids in average) of most of those 
peptides may hinder their extraction from the gel band or they may stick tube walls during   15
peptide extraction. Finally, very long and/or hydrophobic peptides might not be amenable to 
the standard RP-LC-MS/MS conditions used in this study. In this respect, the use of a 
different stationary phase, such as HILIC, might provide additional and complementary 
peptide information. 
Finally, this study opens the way for additional proteomics experiments focused on the BBM 
biology that will contribute and complement existing studies about inhibition of cholesterol 
absorption that have been focused so far at the gene expression level. In a preliminary 
experiment, the BBM preparations from an ApoE knockout mice (one of the most widely 
used mouse models to study dislipidemia in which the targeted deletion of the apoE gene 
leads to severe hypercholesterolemia and spontaneous atherosclerosis) and a wild type mouse 
of the same genetic background were compared. In the absence of biological replicates, only 
“black and white” differences were considered. Most interestingly, the Ileal Bile Acid 
Transporter (IBAT) protein and the ApoAI protein, which were robustly identified in the wild 
type animals, couldn’t be detected in the ApoE knockout mice. This finding was not described 
in any of the earlier published studies and strongly suggests a disruption of the bile acids 
metabolism in the knockout animal. In conclusion, the analytical strategy described in this 
study was shown sufficiently mature to perform comprehensive comparative analysis of mice 
that have, for example, been treated with specific compound or subjected to different diets. In 
due course, this study could has been followed by a full fledge proteomics study in which a 
much more comprehensive biological experiment could have been investigated, such as a 
control mouse vs statins vs ezetimibe treatment, and where the impact of those drugs in the 
BBM (unknown at present) could have been investigated in more detail.   16  17
Zusammenfassung 
Die absorbierenden Epithelzellen der Dünndarmzotten, die Enterozyten, spielen beim 
Transport der Nährstoffe vom intestinalen Lumen zu den interstitiellen Flüssigkeiten eine 
zentrale Rolle. Der gerichtete Fluss von Nährstoffen wird durch verschiedene komplementäre 
Transportsysteme gewährleistet, welche in den apikalen und basolateralen Domänen der 
Plasmamembrane der Enterozyten angesiedelt sind. Eine der besonderen Eigenschaften dieser 
Zellen ist das Vorkommen von zahlreichen Ausbuchtungen mit charakteristischer Struktur, 
sogenannten Mikrovilli, auf der apikalen Oberfläche der Plasmamembran. Diese verleihen 
dem Mikrovillusrand (auch als „Bürstensaum“ bezeichnet) das bürstenartige Aussehen, das 
im Lichtmikroskop typischerweise sichtbar ist. 
Es besteht seit Jahren ein starkes Interesse an der Erforschung der molekularen Mechanismen, 
die für den Transport der Moleküle durch die intestinale Bürstensaum-Membran 
verantwortlich sind. Defekte in diesen Transportmechanismen können eine Vielzahl von 
pathologischen Problemen auslösen, wie zum Beispiel Störungen im Metabolismus von 
Sacchariden (Glukose- und Galaktose-Fehlabsorption, Lactoseunverträglichkeit), von 
Aminosäuren (Hartnup Krankheit, Aminoazidurie), von Ionen (Natrium und Kalium bei 
Durchfall), von Metallen (Zink bei acrodermatitis enteropathica) und von Cholesterinlipiden 
(Herzgefäßkrankheiten). Insbesondere wurde vor Kurzem die wesentliche Rolle der 
Bürstensaum-Membran bei der Regulierung des empfindlichen Gleichgewichts zwischen 
Cholesterinaufnahme und -abgabe zwischen Lumen und Enterozyten hervorgehoben, 
einerseits durch die genetische Analyse von Einzelpersonen, die an Cholesterinstoffwechsel-
Störungen leiden, andererseits durch einige klinische Studien, die die Effekte von diätetischen 
Pflanzensterolen (phytosterols) oder spezifischen Proteininhibitoren auf wesentliche 
Komponenten der Cholesterinaufnahme-Systeme untersucht haben. 
Die Untersuchung der Bürstensaummembran ist in den meisten Studien mittels genetischer 
Analysen, Aktivitätstests und immunologischer Methoden durchgeführt worden. Deren 
Charakterisierung auf der Proteinebene wurde bisher durch den Umstand erschwert, dass eine 
Membran-Präparation von Dünndarm im geeigneten Reinheitsgrad sehr anspruchsvoll war, 
und weil die meisten Zielproteine integrale Membranproteine sind. In den wenigen 
existierenden Proteomik-Studien der Bürstensaummembran wurden bezeichnenderweise die 
meisten Transportproteine und Rezeptoren nicht identifiziert, die in dieser Fraktion erwartet 
würden. Das aggressive Umfeld und die proteolytischen Enzyme, denen die Enterozyten in   18
dieser Membran ausgesetzt sind, erfordern eine eigene Herangehensweise, um die strukturelle 
Integrität der Bürstensaum-Membranproteine im Isolationsprotokoll zu erhalten. 
Das Hauptziel dieser Studie war die Entwicklung und die Evaluierung von 
massenspektrometrischen Vorgehensweisen für die Analyse und Charakterisierung von 
hydrophoben Proteinen, wie sie zum Beispiel in den Enterozyten der Bürstensaummembran 
vorkommen. Die Analyse von Membranproteinen in einem komplexen Gemisch ist seit jeher 
eine Herausforderung in der Proteomik. Die Hydrophobizität von Membranproteinen 
erfordert den Einsatz von Detergenzien für ihre Solubilisierung, was den Gebrauch von 
traditionellen Proteomik-Techniken (z.B. der zweidimensionalen Gelelektrophorese) 
erschwert. In komplexen biologischen Proteingemischen ist ihre Konzentration im Vergleich 
zu löslichen Proteinen niedrig, weshalb zusätzliche Reinigungsschritte für ihre Anreicherung 
nötig sind. Selbst bei ähnlichen Konzentrationen ist die Identifikationsrate für 
Membranproteine niedriger als diejenige für lösliche Proteine. Die Entwicklung eines 
optimierten Isolationsprotokolls in Kombination mit einer robusten analytischen Methode 
sollte demnach die Untersuchung von Bürstensaum-Membranproteinen ermöglichen. Dadurch 
könnten die Ergebnisse anderer Studien bestätigt werden, die zeigen, dass die Bürstensaum-
Membranproteine enthält, die an der Cholesterinregelung in den Enterozyten beteiligt sind. 
Ein drittes Ziel dieser Studie war herauszufinden, unter welchen Bedingungen biologische 
Proben ohne den Einsatz von Isotopen-markierten Standards massenspektrometrisch 
quantifiziert werden können. Da weder die technische Reproduzierbarkeit noch die Stabilität 
der Bürstensaummembran-Präparation bekannt waren, musste die Reproduzierbarkeit der 
technischen Schritte für den vollständigen Arbeitsablauf überwacht werden, von der 
Bürstensaummembran-Präparation bis zur massenspektrometrischen Analyse der Proben, um 
rechtzeitig Schwierigkeiten und Einschränkungen zu identifizieren, die eine reine LC-MS-
Quantifizierungsstrategie beeinträchtigen könnten. 
In dieser Untersuchung wird (meines Wissens nach) erstmals ein analytisches Vorgehen 
beschrieben, welches die direkte Charakterisierung von Bürstensaum-Membranproteinen 
ermöglicht, deren Beteiligung bei der Cholesterinsynthese bereits beschrieben worden ist. Die 
Hauptelemente dieses Vorgehens sind ein verbessertes Protokoll, um reproduzierbar 
Bürstensaummembran-Präparation aus Dünndarmgewebe zu isolieren und aufzureinigen, das 
Design eines Proteaseninhibitorencocktails, der spezifisch die proteolytische Aktivität der 
endogenen Proteasen der Bürstensaum-Membran minimiert, ein gezieltes Vorgehen, um 
Bürstensaum Transmembranproteine aus den üblichen zytosolischen Kontaminanten 
aufzureinigen, und schliesslich die Verwendung eines robusten und empfindlichen   19
Instrumentariums auf der Basis von Kapillar-Flüssigchromatographie und Tandem-
Massenspektrometrie. Insbesondere wurde das Protokoll von Kessler et al für die 
Aufreinigung und Anreicherung der Proteine in der Bürstensaum-Membran deutlich 
verbessert und ausgedehnt auf die gezielte Entfernung von zytosolischen und basolateralen 
Verunreinigungen. Ganze Dünndärme, oder zur Erhöhung der Reinheit davon abgeschabte 
Dünndarmschleimhaut, wurde zuerst lysiert und eine Rohmembranfraktion wurde durch 
differentielle Zentrifugierung isoliert. Das Pellet wurde resuspendiert und die basolaterale 
Membranfraktion gezielt durch CaCl2-Fällung entfernt. Die angereicherten 
Bürstensaummembran-Vesikel wurden durch Zentrifugation sedimentiert und bei hoher 
Salzkonzentration und hohem pH-Wert gewaschen, um verbleibende zytosolische und 
membranassoziierte Proteine zu entfernen. Die Effizienz des Protokolls und die Reinheit der 
erhaltenen Bürstensaummembran-Vesikeln wurden durch Western-Blot-Analyse des 
bekannten basolateralen Markerproteins Na
+/K
+ ATPase a1 und des Bürstensaummembran-
Markers FATP-4 überprüft. Das neue Protokoll ergab einen 30- bis 50-fachen 
Anreicherungsfaktor (im Vergleich zu einem 10-fachen Anreicherungsfaktor nach 
Anwendung des Kessler-Protokolls) bezogen auf das Rohlysat, wobei der basolaterale Marker, 
Na
+/K
+ ATPase a1, in der gereinigten Bürstensaummembran-Fraktion nicht mehr 
nachgewiesen werden konnte. Besondere Beachtung wurde bei der Protokoll-Optimierung der 
Inhibition der endogenen Bürstensaum-Membran Proteasen geschenkt, von denen die meisten 
der His-Zn-abhängigen Metalloproteasen-Superfamilie angehören, welche nicht auf 
gewöhnliche Serin- und Cystein-Protease-Inhibitoren reagieren. Durch die Zugabe von 
Amastatin, eines bekannten Teilinhibitors, und verschiedener Peptidsubstrate in alle Puffer 
des Bürstensaummembran-Aufreininigungsprotokolls wurde eine partielle Inhibition von 
etwa 90% erzielt. Ausserdem wurde das überschüssige Kalzium (ein bekannter Aktivator 
dieser Protease-Familie) durch Zugabe von EDTA im ersten Waschschritt direkt im 
Anschluss an die Kalzium-Fällung entfernt.  
Eine Analyse mit Triplikaten der aufgereinigten Maus Bürstensaummembran-Fraktion ergab 
1460 zuverlässig identifizierte Proteine, von welchen 260 Proteine als integrale 
Transmembranproteine vorhergesagt wurden. Eine detaillierte Aufschlüsselung gemäss 
Genontologie ergab, dass sich die Proteine gleichmässig über die Plasmamembran, 
ER/Golgi/Endosom Kompartimente, das Zellskelett und die Mitochondrien verteilen, 
während nur ein Viertel der Bürstensaummembran-Proteine als zytoplasmatisch annotiert 
werden. Mittels dieses Protokolls wurden mehrere Proteine, welche bei der 
Cholesterinaufnahme eine wichtige Rolle spielen, erstmals auf Proteinebene direkt   20
identifiziert. Ein Beispiel dafür ist das Niemann-Pick C1-like 1 (NPC1L1) Protein, ein Protein 
mit 13 Transmembran-Domänen, welches in der Bürstensaummembran-Präparation stark 
vertreten war und das in der Literatur als zentral bei der Cholesterinaufnahme beschrieben 
wird. Gleiches gilt für die beiden ABC Transporter ABCG5 und ABCG8,  die an der biliären 
Sekretion von Cholesterin und planzlichen Sterolen beteiligt sind. Dem aus Caveolin-1 and 
Annexin-2 bestehenden Komplex wurde ebenfalls eine zentrale Rolle für den 
Cholesterintransport von der Bürstensaummembran zum endoplasmatischen Retikulum 
zugewiesen, während SR-BI, ein 4-Transmembrandomänen-Rezeptor, an der 
Cholesterinaufnahme beteiligt sein soll. Die Rolle vieler der oben erwähnten und weiterer 
Proteine wie zum Beispiel CD36, Galectin-4, und ABCB1 ist Gegenstand intensiver 
Diskussionen. Verschiedene Studien belegen ihre Beteiligung an der Cholesterinaufnahme, 
aber ihr genaues Wirkprinzip ist noch unklar. Bemerkenswert ist ausserdem der eindeutige 
Nachweis von drei Lipoproteinen, ApoA-I, ApoA-IV and ApoE, unter den identifizierten 
Proteinen der Bürstensaummembran-Präparation. Ihr Nachweis war kaum zu erwarten, da 
Lipoproteine kleine, lösliche, von der Leber sekretierte Proteine sind und deshalb nicht als 
Bestandteile der Bürstensaummembran gelten. Ihr Vorkommen dürfte einer engen Interaktion 
mit bestimmten Bürstensaummembran-Komponenten wie z.B. LRP-1 und Cubilin 
zuzuschreiben sein, von welchen bekannt ist, dass sie mit Apolipoproteinen interagieren. 
Angesichts der Komplexität der genutzten Proteomik-Vorgehensweise stellte sich die Frage, 
ob es möglich ist, reproduzierbar und quantitativ Hunderte von Membranproteinen 
gleichzeitig zu untersuchen. Einige Schritte wurden deshalb besonders gründlich analysiert, 
einerseits anhand der Protein-Identifikationen (Vergleich der MS/MS-Resultate zwischen 
Banden) und andererseits anhand des Peptidsignals, um systematisch die massgeblichen 
Faktoren für die Reproduzierbarkeit der Gesamtanalyse festzustellen. In beiden Fällen konnte 
gezeigt werden, dass die meisten technischen Schritte, wie z.B. das Verfahren für LC-MS/MS 
Identifikationen, die Auftrennung komplexer Proteingemische anhand von 1D-SDS-PAGE 
oder der In-Gel-Verdau von Proteinen mittels Trypsin, nur wenig zur Gesamtvariabilität 
beitrugen, sofern sie angemessen kontrolliert wurden. Die hohe Reproduzierbarkeit des LC-
MS/MS-Prozesses konnte dabei bestätigt werden. Hingegen konnte das 
Bürstensaummembran-Protokoll als mögliche Quelle der Variabilität identifiziert werden, da 
es relativ lang und komplex ist und Schritte enthält, deren Reproduzierbarkeit schwer zu 
gewährleisten ist, z.B. die CaCl2-Fällung. Ausserdem könnten Überreste proteolytischer 
Aktivität aus den stark vertretenen Proteasen Probenabbau bewirken und dadurch die 
Reproduzierbarkeit des Protein-Identifikationsprozesses  beträchtlich verringern. Die   21
Variabilität der Anzahl der Proteine, die in allen Proben gemeinsam identifiziert wurden, war 
aber bei der Verwendung einer optimierten Versuchsplanung deutlich geringer. 
Die vorliegende Arbeit zeigt, dass Membranproteine in einem komplexen Gemisch wie z.B. 
einem Isolat aus der Enterozyten-Bürstensaummembran reproduzierbar und quantitativ 
analysiert werden können. Entscheidend für den Erfolg der Analyse sind ein robustes 
Probenaufbereitung-Protokoll, um stark angereicherte Bürstensaummembran- Vesikeln zu 
erhalten, eine engmaschige Kontrolle der Analyseschritte und ein statistisch abgesichertes 
Vorgehen bei der Auswertung. Besonders wichtig zu bemerken ist, dass in diesen stark mit 
Membranproteinen angereicherten Bürstensaummembran-Vesikeln die Anzahl 
unterschiedlicher Peptide und die durchschnittliche Summe der Anzahl Peptide die relative 
Abundanz jedes Proteins widerspiegelt, unabhängig von der Anzahl seiner Transmembran-
Segmente. Allerdings stammen die identifizierten tryptischen Peptide ausschliesslich von 
Schleifen oder zytoplasmatischen Bereichen des Membranproteins. Wenn man annimmt, dass 
Trypsin Transmembranhelices spaltet, d.h. dass Transmembranpeptide während des Verdaus 
entstehen, so ist es gut möglich, dass die hydrophoben Eigenschaften und die Länge der 
meisten dieser Peptide (durchschnittlich 30-40 Aminosäuren) die Extraktion aus der Gel-
Bande erschweren, oder sie könnten während der Peptid-Extraktion an der Gefässwand haften 
bleiben. Ausserdem ist nicht klar, ob sehr lange oder hydrophobe Peptide unter den üblichen 
RP-LC-MS/MS-Bedingungen analysierbar sind. Unter diesem Gesichtspunkt könnte der 
Einsatz einer anderen stationären Phase wie z.B. HILIC zusätzliche, komplementäre 
Peptidinformation liefern. 
Diese Arbeit schafft auch eine Grundlage für zukünftige Proteomik-Experimente mit 
Schwerpunkt auf der Bürstensaummembran-Biologie, welche bereits existierende, auf 
Genexpressions-Daten basierte Studien zur Inhibition von Cholesterinabsorption vertiefen 
und ergänzen. In einem Vorexperiment wurden Bürstensaummembran-Präparationen einer 
ApoE Knockout-Maus und einer Wildtyp-Maus mit demselben genetischen Hintergrund 
untersucht. Die ApoE Knockout-Maus ist eines der am meistverbreiteten  Mausmodelle um 
Dislipidämie zu untersuchen, wobei eine gezielte Deletion des apoE-Gens eine schwere 
Hypercholesterämie und spontane Atherosklerose auslöst. Da biologische Replikate fehlen 
wurden nur “schwarz-weisse” Unterschiede betrachtet. Interessanterweise konnten das Ileal-
Bile-Acid-Transporter(IBAT)-Protein und das ApoAI-Protein in der ApoE-Knockout-Maus 
nicht nachgewiesen werden, während es bei Wildtyp-Mäusen durchwegs nachweisbar war. 
Dieser Befund ist in keiner der früher publizierten Untersuchungen beschrieben und deutet 
stark auf eine schwere Störung des Gallensäuren-Metabolismus  im Knockout-Tier hin.   22
Zusammenfassend kann gesagt werden, dass das analytische Vorgehen in der vorliegenden 
Arbeit eine umfassende vergleichende Analyse von Mäusen erlaubt, die z.B. mit bestimmten 
Wirkstoffen oder Futterzusammensetzungen behandelt wurden. Dieser Untersuchung könnte 
eine breit angelegte Proteomik-Studie folgen, in welcher ein viel umfassenderes biologisches 
Experiment untersucht würde, z.B. ein Vergleich zwischen Mäusen mit Statin-Behandlung, 
Ezetimibe-Behandlung und einer Kontrollgruppe von unbehandelten Mäusen. Der bislang 
unbekannte Effekt dieser Wirkstoffe auf die Bürstensaum-Membran könnte damit detaillierter 
untersucht werden. 
 
 
   23
1. INTRODUCTION 
1.1 Brush Border Membrane BBM 
1.1.1 Physiology of the small intestine  
The small intestine is the longest section of the digestive tube and consists of three segments 
forming a passage from the pylorus to the large intestine. The duodenum is a short section 
starting immediately after the stomach and which receives secretions from the pancreas and 
liver via the pancreatic and common bile ducts. It is followed by the jejunum, considered to 
be roughly 40% of the small intestine in man, but closer to 90% in animals, and by the ileum, 
which connects to the large intestine. The ileum is considered to be about 60% of the intestine 
in man. However, veterinary anatomists usually refer to it as being only the short terminal 
section of the small intestine. 
The structure of the small intestine looks on the first sight quite similar to other regions of the 
digestive tube. However, three features account for its huge absorptive surface area. The inner 
surface of the small intestine is not flat but wrinkled into circular folds (mucosal folds), which 
increase its surface area several-folds. The mucosa itself is composed of multitudes of 
projections (villi) which protrude into the lumen and are covered with epithelial cells. Finally, 
the lumenal plasma membrane of those absorptive epithelial cells is also folded and densely-
packed in microdomains named “microvilli”, whose border is commonly referred to as the 
"brush border" due to its appearance in the microscope (see Fig. 1.1). 
 
 
 
 
 
 
 
Figure 1.1: The small intestine inner surface.  The panels above depict the bulk of the small 
intestine surface area expansion, showing villi, the  epithelial cells that cover the villi, and the 
microvilli of the epithelial cells (downloaded from  web site 
http://www.vivo.colostate.edu:80/hbooks/pathphys/digestion/smallgut/anatomy.html ).   24
The epithelial cells of the small intestine mature into absorptive epithelial cells that cover the 
villi. These are the cells that take up and deliver to the blood stream virtually all nutrients 
from the diet. Two other major cell types populate the small intestinal epithelium: the 
enteroendocrine cells which, as part of the enteric endocrine system, sense the lumenal 
environment and secrete hormones such as cholecystokinin and gastrin into blood; and the 
Goblet cells, which secrete lubricating mucus into the intestinal lumen.  
1.1.2 Brush Border Membrane: Location and Function 
Intestinal epithelial cells are polar in their cellular organization. The intestinal brush border 
(synonyms: microvillus, luminal, apical) membranes of the enterocytes differ in protein and 
lipid composition from the inner side of the plasma membrane, the basolateral membrane 
(BLM) (see Fig. 1.2). The apical surface of polarized intestinal epithelial cells (the surface 
facing the intestinal lumen) is characterized by structurally distinct cell protrusions referred as 
microvilli or brush border membranes (BBMs), responsible for digestion and absorption of 
nutrients.  
 
Figure 1.2: Schematic representation of a typical intestinal epithelial cell. The apical 
membrane (BBM) has a different protein and lipid composition from the basolateral 
membrane. The BBM can be isolated from the BLM using protocols that take advantage of the 
difference in polarity between the two membranes (figure downloaded from web site: 
http://www.vivo.colostate.edu:80/hbooks/pathphys/digestion/smallgut/anatomy.html ). 
 
The processing capacity of enterocytes is directly proportional to the surface of absorptive 
epithelia BBM. BBM are supported by cytoskeletal actin filaments which are organized into   25
both more or less permanent and rapidly rearranging bundles. Cytoskeleton bundles are in 
turn interconnected with transmembrane protein complexes forming a highly organized 
import–export membrane interface specialized for a variety of digestive and absorptive 
functions, such as protein and peptide degradation, absorption of minerals, amino acids, 
sugars, lipids and cholesterol (1). Shortcomings in these mechanisms may cause a variety of 
pathological conditions such as disorders in the metabolism of saccharides (glucose galactose 
malabsorption, lactose intolerance) amino acids (Hartnup disease, aminoacidurias), ions 
(sodium and potassium in the case of familiar diarrhea), metals (zinc in acrodermatitis 
enteropathica) and cholesterol lipids (cardiovascular diseases).  
Recently, several proteomics studies have reported the identification of proteins localized in 
the BBM membrane (2, 3). Until now, however, these approaches have failed to identify 
transporters and receptors that are known to be located in the BBM membrane based on 
kinetic studies, immunological assays and in gene data, probably because of the complexity of 
the analyzed samples.  
1.1.3 Brush Border Membrane and Lipid Rafts microdomains 
Recent studies have suggested that plasma membranes might be organized into heterogeneous 
functional microdomains. One type of these microdomains, called lipid rafts, is stated to be 
enriched in glycosphingolipids/cholesterol and in typical sets of proteins, among them also 
cholesterol transporters (4). Lipid rafts can be isolated by taking advantage of their resistance 
to nonionic detergent extraction at cold and by their differential buoyancy on a density 
gradient ultracentrifugation. The lipid rafts hypothesis was originally proposed to explain how 
proteins and lipids were sorted to the apical surface of polarized cells. However, in recent 
years, several functions including signaling, cholesterol homeostasis, cell trafficking or even 
docking sites on mammalian cells for certain pathogens and toxins have also been attributed 
to lipid rafts (5, 6). Despite accumulated experimental data from biophysical, biochemical, 
and fluorescent microscopy studies supporting the fact that lipid rafts may exist in vivo, the 
lipid rafts hypothesis remains controversial at least for their size, stability and the mechanism 
of their formation (7). 
Lipid rafts isolated from the BBM have also been the subject of several recent proteomics 
studies (3, 8, 9). While these studies have reported the identification of proteins that were 
localized in the lipid rafts, almost none of these proteins were described to be involved in 
cholesterol absorption, a major area of interest for the analysis of the lipid rafts.   26
1.2 Cholesterol homeostasis  
The view of cholesterol as a nasty substance clogging arteries and causing heart disease is 
probably the one aspect that is better known to the general public. However, besides its 
unflattering reputation, cholesterol fulfills many other roles and is a vital component of cell 
membranes without which the cell would not function. It is also the precursor to all steroid 
hormones, bile acids and oxysterols, which by themselves are important regulatory molecules 
in many metabolic pathways.  
 
 
 
 
 
 
 
 
 
 
Figure 1.3:  Cellular cholesterol distribution and key enzymes of cellular cholesterol 
metabolism. The approximate cholesterol content of the membrane is indicated by shades of 
gray. The main processes of cholesterol metabolism, key enzymes involved, and their 
subcellular locations are indicated. Key enzyme in the cholesterol synthesis is 
hydroxymethylglutaryl COA reductase (HMG-CoAR). The 3’-OH group of cholesterol is 
esterified by the enzyme acyl-CoA: cholesterol acyltransferase (ACAT). The enzyme 
responsible for cholesterol esters degradation in lipid droplets is neutral cholesterol sterol 
hydrolase (nCEH). Cholesterol can be converted to bile salts via two pathways: the classic 
pathway, involving the key regulatory enzyme CYP7A1 hydrolase, and the alternative 
pathway, probably related to the oxysterol synthesis, involving the key enzyme sterol 27-
hydroxylase (CYP27A), located in the mitochondria. Cholesterol is an obligatory precursor 
for steroid hormone production (figure adapted from Ikonen Elina, (10)) 
Endogenous cholesterol is synthesized mainly in the liver in a regulated pathway. The 27-
carbon tetracyclic cholesterol molecule is synthesized from acetate in a series of ~30 
enzymatic reactions. The ER is the primary production site of cholesterol and the key rate-
limiting enzyme of this pathway is the ER-located hydroxymethylglutaryl COA reductase 
(HMG-CoAR) (figure 1.3). The sub-compartmentalization of the cholesterol biosynthetic 
pathway remains poorly understood as of today.   27
In general body cholesterol is primarily of endogenous origin and its homeostasis involves the 
movement of cholesterol between peripheral tissues and the liver (11). The liver regulates the 
de novo synthesis of cholesterol and the excretion of cholesterol into bile (directly or after 
conversion to bile acids), the secretion of cholesterol into blood as very low-density 
lipoproteins (VLDL), the modulation of receptor-mediated cholesterol uptake, the formation 
of esterified cholesterol (CE) and the storage of cholesterol. The intestine regulates 
cholesterol absorption and excretion into feces (12). 
1.2.1 Cholesterol absorption in the Small Intestine 
Intestinal cholesterol absorption is a complex process that involves multiple interrelated 
sequential degradative and synthetic pathways, many of them not yet clearly defined. This 
biological process has attracted the interest of many pharmaceutical companies because it 
might provide multiple therapeutic targets in the management of patients with 
hypercholesterolemia.  
Dietary cholesterol is absorbed from bile salt micelles with fatty acids and lysophospholipids 
in the proximal part of the small intestine. Key proteins involved in dietary cholesterol uptake 
by the enterocytes have been identified during the past few years and, in particular, the 
important role that the NPC1L1 protein plays in this process (13). The NPC1L1 protein is 
localized in the brush-border membrane of enterocytes and has been shown to be required for 
intestinal uptake of both cholesterol and plant sterols (14). Recent evidence suggests that this 
protein is the target of the cholesterol-lowering drug ezetimibe (15). Whether NPC1L1 
functions as a genuine cholesterol transporter, promoting cholesterol transfer through the 
plasma membrane, or is indirectly involved in the process is not yet known. In addition, the 
ABC transporter family half-transporters ABCG5 and ABCG8 (sterolin-1 and sterolin-2) 
constitute a functional heterodimeric unit limiting sterol absorption (16). The role of ABCG5 
and ABCG8 in dietary cholesterol absorption may not be direct, that is, by inhibiting dietary 
cholesterol uptake by enterocytes; rather, this transporter appears to stimulates hepatic sterol 
excretion into the bile and thereby modulates the bile-acid/sterol ratio, possibly to promote the 
secretion of absorbed sterols from the intestinal epithelium back into the gut lumen (17). Fig 
1.4 summarizes in more detail the cholesterol and sterols absorption in the enterocytes and 
possible proteins and pathways that are associated to this process.   28
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Absorption of dietary cholesterol and noncholesterol sterols in enterocyte. 
NPC1L1, expressed at the apical surface of enterocytes, may be the transporter that 
selectively absorbs dietary cholesterol (C) from micelles in the lumen of the small intestine, a 
step that is blocked by the drug ezetimibe. In this model, the NPC1L1 transporter permits the 
uptake of cholesterol (and noncholesterol sterols) into vesicles that then move through a sub-
apical endosomal sorting compartment. Mutations in either of the transporters ABCG5 or 
ABCG8 cause the hyperabsorption of dietary plant sterols (PS) and other noncholesterol 
sterols from the small intestine, resulting in the human disease sitosterolemia. The endosomal 
sorting compartment allows cholesterol to progress to the endoplasmic reticulum (ER), where 
it is esterified (CE) by ACAT-2 and then transferred to chylomicrons (pink) ready for 
secretion into the bloodstream; plant sterols are shunted through a pathway resulting in their 
transport back to the gut lumen via ABCG5 and ABCG8. Cholesterol that is synthesized de 
novo is also esterified by ACAT-2 and enters chylomicrons (figure adapted from Klett E.L. et 
al,(18))   29
1.3 Membrane proteomics 
1.3.1 Proteomics – Definition and workflow 
The genomic sequencing of numerous organisms has radically transformed biological and 
medical research, providing the foundation for the large-scale interpretation of gene and 
cellular function. In this context, the term “proteome”, coined in 1994 by Marc Wilkins (19), 
describes the entire protein complement of the genome. Proteomics, the studies of the 
proteome, encompass the identification, characterization and quantification of the complete 
set of proteins expressed in the lifetime of a given cell, tissue or organism, including isoforms, 
polymorphisms and modifications, protein-protein interactions and the structural description 
of proteins and their complexes. Most biological functions are carried out by proteins, and to 
understand how cells work, one must study which proteins are present, what they do, and how 
they interact with one another. If the genome represents the words in a dictionary, then the 
proteome provides the definitions, while the interactions of the proteins with one another and 
with the other molecules in their environment provide the grammar to form a meaningful 
language. 
Proteomics would not be possible without the previous achievements of genomics, which 
provide the information about the large, but finite number of gene products that are the focal 
point of proteomics studies. The challenges of proteomics are larger and far more complex 
than the huge but basically straightforward task of mapping the genome. In contrast to the 
static nature of the genome, which is essentially identical in every cell of an organism, the 
proteome is dynamic, constantly changing and responding to internal and external stimuli. 
Proteomics must deal with unavoidable problems of limited and variable sample material, 
sample degradation, vast dynamic range (more than 10
12 orders of magnitude for protein 
abundance in plasma), a multitude of post-translational modifications, almost endless tissue, 
developmental and temporal specificity, and disease and drug perturbations.  
Proteomics represents nowadays a large family of partially overlapping areas of interest 
evolving along with technology breakthroughs, bioinformatics advances, and certainly also 
with the personal interests of investigators. Some of those areas of application are mass 
spectrometry-based proteomics, proteome-wide biochemical  assays, systematic structural 
biology and imaging techniques, proteome informatics, and clinical applications of 
proteomics. The divisions between these areas are somewhat arbitrary, not least because 
technological breakthroughs often find immediate application on several fronts. More 
important, biologically useful insights into protein function often emerge from the   30
combination of different proteomic approaches. This study is mostly focused in mass 
spectrometry-based proteomics and this area will be discussed in more details in the following 
paragraphs.  
All proteomics experiments aim, in an ideal setting, to monitor quantitatively a full proteome 
at any time point of an experiment. However, the sheer complexity and dynamic range of an 
unfractionated proteome makes it technically impossible to address all its constituents 
simultaneously by any direct analytical means. As a result, it is often one of the most critical 
steps of a proteomics experiments to knowingly restrict the scope of the experiment to a 
biochemical-relevant sub-proteome that can be effectively monitored by the chosen analytical 
approach. A criterion often used in this process is to take advantage of some prior knowledge 
to “bias” the experiment towards a protein population of interest, for example by limiting the 
proteomics analysis towards a specific cell compartment (organelle-based proteomics), by 
isolating proteins with specific physical-chemistry characteristics  (cytosolic proteins, 
membrane proteins, cytoskeleton, etc.), or even to only consider proteins captured through 
specific interaction (“affinity” proteomics, chemical proteomics, etc.). The achieved analytical 
level of precision increases generally in pair with the degree of fractionation obtained, albeit 
sometimes at the danger of excluding an important (and usually unknown) aspect of the 
experiment to follow. Conversely, a comprehensive survey of a broadly-chosen proteomics 
experiment might require the analysis of so many different fractions (to ensure the monitoring 
of a significant portion of the proteome of interest) that such an experiment might not be 
practicable anymore from a technical point-of-view.  
Almost all mass spectrometry-based proteomic approaches are performed at the peptide level 
as the MS analysis of whole proteins (the so-called top-down approach) is less sensitive and 
the deconvolution of the generated multiply charged species is very difficult to handle from a 
bioinformatics point-of-view. A protein mixture of interest, isolated from a cell lysate, tissues, 
or enriched by a biochemical fractionation or affinity selection, is very often analyzed as a 
final fractionation step by 1D or 2D gel electrophoresis. Proteins are then in-gel digested (in 
the rare case an electrophoretic step is omitted, the proteins are then directly digested) and the 
extracted peptides can then be fractionated again by liquid chromatography before being 
analyzed by mass spectrometry. The types of chromatography and mass spectrometer that are 
used for an experiment depend mostly on the complexity and the type of questions that need 
to be answered for given analytical strategy.   31
The ability of mass spectrometers to quantitatively analyze ever smaller amounts of proteins 
from increasing complex mixture at a very high level of precision has been a primary driving 
force in this proteomics approach. In the last 2 years, new bioinformatics tools and the 
extended use of statistics in data processing and data analysis have enabled the design and 
execution of proteomics experiments that would not have been thinkable even 5 years ago. In 
particular, the high mass accuracy (below 2 ppm via Lock Mass injection, (20)) and the 
extended dynamic range shown by the newest generation of mass spectrometers now allow 
the statistical evaluation of the quality and the significance of a protein identification (via its 
constitutive peptides), while simultaneously being able to measure ion current of peptide ions 
at an unprecedented level of precision.  
1.3.2 Membrane Proteins - Importance and Characteristics  
Membranes play a critical role in cellular structure by providing a physical barrier between 
the cell and its environment and the various subcellular compartments within eukaryotic cells. 
Although the basic structure and function of biological membranes is provided by the lipid 
bilayer, membrane-spanning proteins confer unique compartment-specific functions and 
communication between separated environments.  
The plasma membrane provides a physical boundary between the cell and its environment, 
playing important roles in many fundamental biological processes such as cell-cell 
interactions, signal transduction, and material transport. The plasma membrane components 
have been extensively targeted for drug design; in particular, plasma membrane proteins may 
account for up to 70% of all known drug targets (e.g., HER2- and G protein-coupled 
receptors). For example, identification of overexpressed plasma membrane proteins in 
diseased cells could provide protein targets for the design of either therapeutic monoclonal 
antibodies or small-molecule drugs.  
Membrane proteins are by definition proteins that are associated with the membrane. 
However, in this context, the concept “associated” relates to several different situations. In a 
first case, the polypeptide chain spans the lipid bilayer a certain number of times and proteins 
belonging to this category are defined as “integral” or “intrinsic” membrane proteins. In a 
second case, the membrane-associated protein might be physically coupled to the membrane, 
whereas the association is mediated by a post-translation modification of the polypeptide, for 
example the grafting of a fatty acid, a polyisoprenyl chain, or through glycolipid anchors, 
such as the glycosylphosphatidyl inositol modification common in eukaryotic species. Such 
proteins are defined as “membrane-anchored” proteins. Finally there are proteins that are   32
associated to a membrane due to their interaction with other membrane proteins or some 
specific lipids, but which contain neither transmembrane domains nor lipid modifications. 
Such proteins are typically referred to as “membrane-associated”. 
The transmembrane domains of integral proteins can typically fold to form either an α-helix 
or a β-sheet secondary structure. α-helices are formed by the consecutive joining of mostly 
non-polar amino acids, with typically 15-25 amino acids required to span the membrane 
bilayer. These amino acids exhibit positive hydropathy values and hence are the major 
contributors to the hydrophobic character of the membrane proteins. β-sheet transmembrane 
domains are formed by alternating polar and non-polar amino acids in the amino acid 
sequence. Polar amino acid side chains face the aqueous channel while the side chain of the 
non-polar amino acids interface with the lipid bilayer. This type of proteins is considerably 
less hydrophobic than α-helical integral proteins. Proteins with β-sheet transmembrane 
segments tend to form a β-barrel structure that allows the passage of defined molecules. 
Structural prediction software for membrane proteins predicts nowadays quite successfully 
proteins with transmembrane α-helix structure but typically don't consider the β-sheet type. 
1.3.3 Proteomic approaches for Membrane Proteins 
Although the analysis of soluble proteins by mass spectrometry-based proteomics 
technologies has made rapid progress in recent years, the analysis of membrane proteins has 
lagged behind and their identification is typically underrepresented in datasets. Thus, the 
portion of membrane proteins reported in existing analysis is much lower than the 20–30 % 
predicted by the human genome (21).  
Traditionally the analysis of complex protein mixtures has been carried out using gel-based 
methods (22). Unfortunately, the well-known, highly-resolving two-dimensional IEF/SDS gel 
electrophoresis method has never been successfully applied for the separation of membrane 
proteins (23). Many hydrophobic proteins do not solubilize well in the non-ionic detergent 
required for the isoelectric focusing step and the few that survived this process tend to 
precipitate at their isoelectric point. In many studies, this separating method has been replaced 
by the more robust SDS-based one-dimensional gel coupled with mass spectrometry (24). 
Alternatively, several authors have described alternate two-dimensional gel electrophoresis 
separation technique, such as the so-called two dimensional blue native/SDS electrophoresis 
method (25) or diagonal SDS-PAGE electrophoresis (26). 
Membrane proteins (and their derived hydrophobic peptides) tend to show the same trends if a 
reverse-phase liquid chromatography separation step is used instead. Several approaches have   33
attempted to overcome this problem by using either strong organic acid-cyanogen bromide 
(27), detergents (28), acid labile surfactants (29), organic solvents (30), salts, or high pH 
conditions (31) to solubilize membrane proteins. Although these methods proved to be 
efficient one way or the other, they were usually bound with other disadvantages that limited 
their usefulness. The presence of detergents affects the performance of chromatographic 
separation and also leads to mass spectral signal suppression. Commonly-used proteases, like 
trypsin, cannot be used for digestion of proteins when organic acids are used due to low pH 
conditions, or the enzyme activity is significantly reduced in presence of high percentage of 
organic solvents. High pH-based methods use proteinase K to cleave proteins non-specifically 
at random amino acid sequences, which makes the resulting peptide mixture extremely 
complex to analyze. In general, all methods described above require extensive sample 
handling to make the sample compatible for mass spectral analysis. 
In summary, it is clear that there is a strong need for a simple and efficient method to analyze 
membrane proteins. The first step in this direction is the development of a suitable protocol 
for the enrichment of membrane proteins. As membrane proteins are typically lower in 
abundance then compared to soluble proteins, a biochemical fractionation method taking 
advantage of their unique physical-chemical properties is required to overcome their 
otherwise rather limited dynamic range in the analysis.   34
1.4 Mass spectrometry  
Mass spectrometry has been the analytical workhorse tool for biologists over the last quarter 
century. As its name implies, the mass spectrometer is an instrument to measure the mass of a 
substance. Initially used for the analysis of small, volatile molecules, its use has quickly 
become ubiquitous in the “biological” world with the invention of ionization sources 
compatibles with the analysis of the “big” molecules in the 1980s. 
Mass spectrometers have been used over the last hundred years for a wide variety of 
applications, ranging from estimating the masses of elements and their isotopes to small 
molecule identification and characterization to modern day proteomics analysis. According to 
the time period and the need, mass spectrometry and mass spectrometers have evolved. 
Various types of mass spectrometers exist today to address a wide variety of applications 
ranging from analyzing the soil of alien worlds in space research to structural characterization 
of complexes of proteins. 
All mass spectrometers consist of three basic components (Fig. 1.5). An ion source ionizes 
first the molecules to analyze, then a mass analyzer separates the generated ions according to 
their mass-to-charge ratio (m/z) and a detector measures the ion beam current. Each of these 
elements exists in several different forms so that a wide variety of mass spectrometers may 
exist to fulfill different needs. 
 
 
 
 
Figure 1.5: Schematic representation of the components of a mass spectrometer (Adapted 
from Lottspeich and Zorbas (32)). 
Mass spectrometers are operated under vacuum (ranging from 10
-4 for ion traps to 10-
10 Torr 
for FT-based instruments) to prevent the loss of the ions by collision with a gas molecule. 
1.4.1 A brief history of MS in biology 
First attempts to analyze intact peptides by mass spectrometry were achieved using fast atom 
bombardment (FAB) ionization, which was first described in 1981 by Barber and co-workers 
(33). This ionization method was able to desorb (for the time) rather large molecules in the 
mass range of 2000–17000 Da depending on the sensitivity required. The first method that 
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was able to ionize high-molecular mass molecules such as proteins was achieved using 
plasma desorption (PD) ionization in 1982 (34), based on an earlier method described by 
Macfarlane and co-workers (35). 
It is however only with the inventions of the electrospray ionization (ESI) and the matrix-
assisted laser desorption/ionization (MALDI) technique that peptides and proteins became 
really amenable to mass spectrometry analysis. In the eighties Fenn and co-workers 
(Yamashita & Fenn, 1984) developed electrospray ionization as a technique to ionize intact 
large molecules in solution. One of the peculiarities of ESI is to generate ions of differing 
charge states for the same analyte leading to spectra with numerous peaks. The nature of ESI 
has the advantage of being directly compatible with liquid chromatography and capillary 
electrophoresis systems so that peptides or proteins mixtures analyzed by one of those two 
methods can be investigated online by ESI-MS. During the same period Karas and 
Hillenkamp (36) discovered matrix assisted laser desorption/ionization (MALDI). Tanaka was 
able to obtain protein molecular ions of masses up to typically 25000 Da with a matrix made 
of an ultra fine metal powder mixed with glycerol (37) when Karas and Hillenkamp were 
investigating the polypeptide mellitin, 2843 Da, and the oligosaccharide stachyose, 666 Da. It 
is however the type of matrix that Karas and Hillenkamp used, a UV-light absorbing organic 
compound, that is the basis for most of the now existing MALDI applications (38). 
1.4.2 Ionization technique 
Matrix-assisted laser desorption/ionization (MALDI) and Electrospray ionization (ESI) are 
nowadays the most commonly used ionization processes to analyze proteins and peptides by 
mass spectrometriy. Their principles and characteristics are described below. 
1.4.2.1 Matrix-assisted laser desorption/ionization (MALDI) 
The generation of a protonated molecule in the gas phase using the MALDI ionization process 
is achieved by mixing the analyte of interest with a large excess of a matrix material and to let 
them co-crystallize onto a planar surface, typically a metallic target. The resulting crystal is 
then irradiated by nanosecond laser pulses, typically using a nitrogen laser at a wavelength of 
337 nm or, more recently, solid-state Nd: YAG laser at a wavelength of 355 nm. The matrix 
plays a particular role in the MALDI process (Fig. 1.6). First, the matrix absorbs the incoming 
energy of the laser pulse (therefore protecting    36
 
Figure 1.6:  Schematic representation of MALDI process and instrument. A sample 
cocrystallized with the matrix is irradiated by a laser beam, leading to sublimation and 
ionization of peptides (Adapted from Mann et al.,(39)). 
the analyte from a direct “hit”), which is then followed by a thermal explosion leading to 
desorption of the analyte and subsequent ionization by charge transfer from the matrix to the 
analyte in the gas phase. Matrices are typically small organic molecules with an absorbance 
maximum matching the wavelength of the laser employed, but differing in the amount of 
energy they impart to the biomolecules during desorption and ionization and hence the degree 
of fragmentation (unimolecular decay) that they may cause. Thus, peptides are typically 
analyzed using so-called hot matrices such as α-cyano-4-hydroxycinnamic acid or 
dihydrobenzoic acid while protein work would use “colder” matrices such as sinapinic acid. 
The MALDI ionization process is characterized by the formation of mostly singly-charged 
ions, therefore generating simple ion spectra, but putting a special requirement on mass 
analyzers to analyze the wide variety of ions (in respect to their m/z ratio) that can be 
generated. 
The precise nature of the ionization process in MALDI still remains speculative in its nature 
and the obtainment of high signal intensities with good resolution is determined to some 
extent by trial and error, depending on incorporation of the analytes into crystals, their 
likelihood of capturing and/or retaining a proton during the desorption process and a number 
of other factors including suppression effects in peptide mixtures. Proteins generally undergo 
fragmentation to some extent during the MALDI process, resulting in broad peaks and loss in 
sensitivity; therefore MALDI is mostly applied to the analysis of peptides.   37
1.4.2.2 Electrospray ionization (ESI) 
The electrospray ionization technique is performed using a liquid interface. A suitable solvent 
containing the analyte of interest is passed through a hypodermic needle set at high voltage to 
electrostatically disperse, or electrospray, small, micrometer-sized charged droplets, which 
rapidly evaporate and which impart their charge onto the analyte molecules (Fig. 1.7). The 
ionization process takes place at atmospheric pressure and is therefore very gentle (without 
fragmentation of analyte ions in the gas phase). The generated ionized molecules are 
transferred into the mass spectrometer with high efficiency for analysis. Depending of the 
flow rate (mid μl to ml/min), the electrospray process need to be assisted using nebulizer gas. 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Overview of the mechanics of the electrospray ionization technique. The high 
voltage applied to the spray sample causes positive charge to build up at the spray tip. Due to 
the charge and the pressure a so-called Taylor cone is formed. From the Taylor the charged 
droplets well decrease in size and split, until eventually single proteins or peptides with 
multiple charged are desorbed and transferred to the mass spectrometer inlet (Adapted from 
Lottspeich and Zorbas(32)). 
A wide range of compounds can be analyzed by ESI-MS; the only requirement is that the 
molecule should be sufficiently polar to allow attachment (in the positive ionization mode) or 
removal (in the negative ionization mode) of a charge. This includes proteins, 
oligonucleotides, sugars (with less sensitivity, as sodium rather than hydrogen is the charging 
agent), and polar lipids. For a given compound, the signal strength (peak height in the 
spectrum) increases linearly with the analyte concentration over a wide range until saturation 
occurs. Similarly, very low flow rate (below the μl/min range) also favor high sensitivity as   38
the inner diameter of the electrospray needle can be reduced to produce smaller droplets with 
enhanced ionization potential for the analyte. 
There does not seem to be an upper mass limit for analysis by ESI-MS. Large ions are 
typically multiply charged (proteins and peptides by added protons in the positive mode and 
abstracted protons in the negative mode), which brings them into the mass-to-charge (m/z) 
measurement range of most mass analyzers. The distribution of charges for an analyte gives 
rise to the typical multiple charge envelop. The resulting spectrum can then be simplified by 
deconvolution, an algorithm that sums up the signal intensity into a single peak at the 
molecular weight of the analyte. Very complex mixtures can be analyzed by ESI-MS, but 
spectra become increasingly difficult to interpret as the molecular weight of the components 
and their number increases. 
Electrospray can be performed either in infusion mode, the so-called nanoelectrospray format, 
or in combination with a liquid separating technique, such as high-performance liquid 
chromatography. When these two techniques are coupled in the so-called LC-MS 
configuration, the eluting components of the sample can be analyzed online by the mass 
spectrometer. In this scenario, sample cleanup, separation, and concentration are all achieved 
in a single step. 
1.4.3 The Mass Analyzer 
The mass analyzer is the part of the mass spectrometer in which ions of given m/z ratio can be 
separated from each other, therefore conferring to the mass spectrometer its analytical power. 
In the field of proteomics, critical parameters are mass accuracy, sensitivity, resolution, and 
the ability to generate fragment spectra (tandem MS) informative enough to infer the identity 
of the parent ion.  
MALDI and ESI ionization technique have been typically coupled to five types of mass 
analyzers: the ion trap, the time-of-flight (TOF), the quadrupole, the Fourier transform ion 
cyclotron (FT-MS) and the electrostatic ion trap (Orbitrap) analyzers. All these analyzers 
present different characteristics and performance profiles; most of them can be used either 
stand-alone or in combination with additional analyzers, either to combine the analytical 
strengths of two complementary ion selection strategies or to perform structural analysis of 
molecules by using successive ion selection processes. A summary of the most common mass 
analyzer configurations used in the proteomic field is shown in Fig. 1.8. 
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Figure 1.8:  Instrumental configurations of the commonly used mass spectrometers in 
proteomics. The typical ionization technique that is used for each of those mass spectrometers 
is indicated (Adapted from Aebersold, R and Mann, M. (40)). 
 
All ion trap mass analyzers share the ability to store ions for a certain time before ejecting 
them sequentially to a detector or to another mass analyzer. Their trapping capability make 
them very sensitive; however, only a limited number of ions can be accumulated at their 
point-like centre before space-charging distorts their distribution, which results in relatively 
low mass accuracy. The ‘linear’ or ‘two-dimensional ion trap’ (41) is a recent development 
where ions are stored in a cylindrical volume that is considerably larger than that of the 
traditional, three-dimensional ion traps. Linear ion traps can be operated either as a 
quadrupole (continuous) or as an ion trap (pulsed) analyzer, allowing increased sensitivity (1-
2 times), higher trapping capacity (40 times) and trapping efficiency (11-14 times) than 
conventional 3D traps. The FT-MS and the Orbitrap mass analyzers are also ion trapping 
instruments but they capture ions under high vacuum in a high magnetic or electrostatic field 
respectively, which enables exquisite mass accuracy, high resolution, and dynamic range. In 
their commercial versions, however, these two mass analyzers have been used as ion detectors 
and have been coupled with other types of analyzers, such as a linear ion trap or a quadrupole, 
for ion isolation and selection. 
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Time-of-Flight (TOF) mass analyzers are one of the simplest separating devices in the mass 
spectrometric field. Incoming ions are accelerated to high kinetic energy and are separated 
along a flight tube as a result of their different velocities before being detected. In a more 
complex configuration, the so-called “reflector time of flight” (reTOF) mass analyzer, 
incoming ions are turned around in a reflector (an electrostatic mirror) which compensates for 
slight differences in kinetic energy which might otherwise severely limit the resolution 
obtained by such mass analyzers. 
Quadrupole are versatile mass analyzers that can be used either as focusing lens (all ions go 
through at any time), as a time-dependent ion scanning device (ions of a given m/z ration are 
transmitted one after the other), or as a static mass filter (only ions of a given m/z ratio can be 
transmitted at any time). Quadrupole’s selectivity relies on an electric field of various 
intensity rotating between four hyperbolic rods, allowing a stable trajectory only for ions of a 
particular desired m/z range. While quadrupole-based mass spectrometers used to be quite 
common a decade ago, the analyzer’s rather low resolution has limited them to special mass 
spectrometric applications, such as quantification by multiple-reaction monitoring, or in 
combination with other mass analyzers, such as in the hybrid quadrupole-Time-of-Flight (Q-
TOF) mass spectrometer.  
Structural information of peptides is typically gained by collision-induced dissociation using 
tandem mass spectrometers. In this technique, an ion of interest is selected in the first mass 
spectrometer and is then dissociated by collision with an inert gas, such as argon or nitrogen, 
in a collision cell. The resulting fragments are then transmitted to the second mass 
spectrometer, producing the tandem mass, or MS/MS, spectrum. In most instruments in use 
today, multiple collisions impart energy onto the molecule until it fragments. (This is low-
energy fragmentation, in which any single hit is not sufficient to break a peptide bond. In 
high-energy fragmentation, the molecules have higher velocity and a single hit can break 
bonds). The most common ion types produced in the low-energy fragmentation mode are b 
and y ions, after fragmentation of the amide bond with charge retention on the N or C 
terminus, respectively (Fig. 1.9). Several of the mass spectrometers depicted in Fig. 1.8 are 
suitable for tandem mass spectrometry. For example, a TOF-TOF instrument (Fig. 1.8, panel 
b) includes a collision cell between two TOF sections. Ions of a given mass-to-charge (m/z) 
ratio are selected in the first TOF section, fragmented in the collision cell, and the masses of 
the fragments are separated in the second TOF section. In triple-quadrupole instruments, (Fig. 
1.8, panel c), ions of a particular m/z are selected in a first section (Q1), fragmented in a 
collision cell (q2), and the fragments are separated in Q3. The quadrupole TOF hybrid   41
instrument combines the front part of a triple quadruple instrument with a reflector TOF 
section for measuring the mass of the product ions. This instrument combines the versatility 
 
Figure 1.9: Product ions generated in the fragmentation of peptide molecules by tandem 
mass spectrometry. Collision-activated dissociation (CID) causes single cleavage to occur 
more or less randomly at the various amide bonds in the collection of peptide molecules. This 
process generates a series of fragments that differ by a single amino acid residue. Ions of type 
y contain the C terminus plus one or more additional residues. Ions of type b contain the N 
terminus plus one or more additional residues. Additional ion types such as a, c and x and z 
types correspond to cleavages at different positions in the backbone (Adapted from Lottspeich 
and Zorbas (32)). 
of a triple quadrupole instruments with the mass accuracy and resolution expected from a 
TOF analyzer. Finally, ion traps (Fig. 1.8, panels e, g, h) represent a special type of tandem 
mass spectrometer as ion traps can be operated both as a trapping device and a collision cell. 
Ions of interest with specific m/z ratio are first accumulated in the trap and then excited by 
resonance. The resulting fragments ions are trapped again in the ion trap analyzer until they 
are sequentially ejected from the trap for detection. 
1.4.3.1 The Linear Ion Trap-Orbitrap Mass Spectrometer  
The ever increasing demands in mass accuracy and resolution from research areas such as 
proteomics and metabolomics have stimulated the development of novel types of mass 
spectrometers combining high performance with moderate size at an affordable price. The 
Orbitrap-based mass spectrometer, manufactured by Thermo Electron (now Thermo Fischer 
Scientific) based on the invention of Makarov (42, 43), is the first novel mass analyzer 
introduced in the market in decades.  
The Orbitrap can be considered as a modified Kingdom trap or, more simply, as a modified 
form of a quadrupole ion trap using static electrostatic fields while the quadrupole ion trap 
uses a dynamic electric field (44). A cross-view of the Orbitrap mass analyzer is shown in Fig. 
1.10.   42
 
Figure 1.10: Cross-view of the Orbitrap mass analyzer. Ions are injected into the Orbitrap at 
the point indicated by the red arrow. The ions are injected with a velocity perpendicular to 
the long axis of the Orbitrap (the z-axis). Injection at a point displaced from z=0 gives the 
ions potential energy in the z-direction. Ion injection at this point on the z-potential is 
analogous to pulling back a pendulum bob and then releasing it to oscillate. Figure adapted 
from Hu et al., (45). 
Ions injected into the Orbitrap mass analyzer assume a circular movement in the trap due to 
the electrostatical field. The specially shaped electrodes produce an electrostatic potential 
containing no cross-terms in r and z so that, when ions are injected at a point displaced from 
z=0, the resulting potential in the z-direction is exclusively quadratic. Ion motion along the z-
axis may be described as an harmonic oscillator and is completely independent of r, ϕ motion 
(ϕ is the angular coordinate). Therefore, an ion mass/charge ratio m/z is simply related to the 
frequency of ion oscillation ω along the z-axis (Eq. 1) 
k m z ⋅ = ) / ( ω      (1) 
The main components of the commercially-available LTQ-Orbitrap hybrid mass spectrometer 
(Thermo Electron) are illustrated in the figure 1.11 (see also Hu et al. 2005 for a detailed 
description of the first orbitrap prototype). An electrospray source creates ions, which are 
transferred using RF-only guide quadrupoles and octapoles into a a linear quadrupole ion trap. 
The ion guide brings the ions through several stages of differential pumping, from the 
atmospheric pressure of the ion source to approximately 10
-5 Torr in the LTQ ion trap. The 
LTQ ion trap is required to couple the continuous electrospray ion source with the Orbitrap, 
which operates in a pulsed fashion. After a sufficient number of ions has been accumulated 
(typically taking 10–400 ms), the back lens of the linear ion trap is pulsed open and ions are 
collected in a C-shaped ion trap, which is used to store and collisionally cool ions before 
injection into the orbitral trap as defined ion packets with very small temporal (100–200 ns)    43
 
Figure 1.11: The commercially-available LTQ-Orbitrap mass spectrometer. Ions are 
produced by the electrospray ion source and then proceed through the source, the focusing 
lenses and octapoles to pass into the linear ion trap (LTQ). The LTQ mass analyzer can be 
used either as a stand-alone instrument, submitting ions to MS and MSn analysis, or it can 
serve as an ion accumulator and buncher, allowing the pulsed Orbitrap mass analyzer to be 
coupled to the continuous electrospray ionization source. After accumulation of a sufficient 
number of ions, they are axially ejected from the LTQ and collected in a C-shaped ion trap 
(C-Trap) from which they are passed into the Orbitrap mass analyzer. The trapped ions 
assume circular trajectories around the center electrode and their axial oscillations, along 
the center electrode, are detected and transformed back to mass spectrum using fast Fourrier 
Transform (Figure downloaded from the Thermo Fisher web site (http://www.thermo.com/) 
on July 19, 2008. 
and spatial spread. Once injected into the Orbitrap at a position offset from its equator, ion 
bunches start coherent axial oscillations without the need for any additional excitation. All 
ions have exactly the same amplitude, although ion packets of different mass/charge ratios 
will execute their axial oscillations at their respective frequencies. The exquisite resolution 
attained in the orbitrap mass analyzer is only possible if the ion packet remains spatially 
coherent during the analysis time (up to several seconds); beside superior manufacturing, the 
performance of the instrument is made possible by keeping the orbitrap analyzer at very high 
vacuum, approximately 10
-10 Torr. The detection of an ion image current due to motion along 
the Orbitrap axis is made possible by splitting the outer electrode in half at z=0. The ion 
current is differentially amplified from each half of the outer electrode and then undergoes 
analog-to-digital conversion before processing by customized control and acquisition software. 
The so-called resulting transient is the converted back to a mass spectrum using fast Fourrier 
transform. 
The superior performance of the LTQ-Orbitrap mass spectrometer was critical to carry on the 
protein identification of the BBM membrane and to enable the initial steps aiming at 
developing a label free quantification approach based on LC-MS/MS data. This instrument’s 
high mass accuracy (1-3 ppm), excellent resolution (up to 100,000 depending on the   44
acquisition time) and extended dynamic range (more than 3 orders of magnitude) made the 
Orbitrap the ideal analytical tool for this study. 
1.5 Data analysis and Bioinformatics tools 
The analysis of the large amount of data generated in mass spectrometry-based experiments is 
a significant challenge and is currently a bottleneck in many proteomics approaches. 
Nevertheless, a significant progress has been made in the form of software package for 
proteome analysis and their application to biological and clinical research. 
The vast majority of proteomic data nowadays are being generated by mass spectrometry, 
more specifically, by tandem mass spectrometers of ever increasing performance. These 
instruments and the diverse workflows they support have in common that they generate 
hundreds to tens of thousands of fragment ion spectra per hour of data acquisition. The 
assignment of these fragment ion spectra to peptide sequences, the inference of the proteins 
represented by the identified peptides and the determination of their abundances in the 
analyzed sample present complex computational and statistical challenges. It is essential for 
proteomics to develop and generally apply tools and solutions to these problems to provide 
accurate and reproducible results.  
1.5.1 Protein Identification  
The protein identification process follows a well-defined analytical scheme requiring the 
consideration of several parameters to return a successful and unambiguous answer. Not 
surprisingly, the type of sample preparation, choice of instrument, data acquisition and peak 
peaking parameters define which computational identification process can be selected and the 
scope of results that can be obtained.  
All protein identification algorithms used in high-throughput mass spectrometry-based 
proteomics experiments share in common the characteristic to compare an experimentally 
recorded mass spectrum with the protein/peptide information derived from a sequence 
database. The quality and the significance of the match are then provided back to the user in 
the form of more-or-less elaborate statistics, a topic which has seen many progresses recently. 
A few years ago, the experience of the mass spectrometer’s operator was often determinant to 
define at which thresholds a protein or a peptide hit was relevant in an experiment. The 
development of probabilistic approaches to rank the likeliness of protein/peptide identification 
and the use of decoy databases to estimate the false positive identification rate has been 
determinant to define generally applicable rules to protein identification.   45
There are two strategies commonly used for high-throughput protein identification based on 
mass spectrometry, the Peptide Mass Fingerprint (PMF) and Fragmentation Mass 
Fingerprinting (FMF). 
1.5.1.1 Peptide Mass Fingerprint (PMF method) 
Peptide mass fingerprinting (PMF) was the first available method for large-scale protein 
identification using mass spectrometry, and is still widely used (46, 47). This strategy 
compares the signals observed in a MS analysis with theoretical spectra obtained from an in 
silico digestion of each protein sequence from a reference database (Fig. 1.12). One of the 
main limitations of the PMF method consists in the basic assumption of the algorithm that the 
signals in the experimental spectrum must originate from one or from very few proteins, 
making this approach incompatible with the identification of proteins in complex mixtures. 
As a result, protein identification using PMF has been mostly carried out in proteomic 
approaches based on 2D gel electrophoresis, for fractionation of a biological sample, 
combined with MALDI TOF MS analysis of the usually rather pure 2D gel spots. 
 
 
 
 
 
 
 
 
 
Figure 1.12: PMF protein identification scheme. The protein in the sample is digested into 
peptides, whose mass-to-charge ratios are shown in the PMF spectra. The PMF spectra are 
compared with the simulated spectra of the in silico-digested proteins. Figure adapted from 
Song, Z. et al., (48). 
 
Used with the proper data, PMF remains popular and works well in practice because of its 
speed to compute PMF scores against a database. PMF yields in many cases protein 
identifications with high confidence, especially with organisms with smaller genomes. 
Interestingly, a confident PMF identification score can usually be obtained even in the 
presence of point mutations or occasional post-translational or chemical modifications, as 
long as a minimal number of peptides characteristic for a protein remains detectable in the 
spectrum. A non-confident identification score may pinpoint to splice variants, individual 
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sequence variants and errors in the database, or more prosaically, to the presence of a protein 
mixture in the sample or to incomplete digestion. As more sophisticated methods for scoring 
PMF are being developed, more proteins may now be identified with confidence (49). 
Another limitation of the PMF strategy is its sensitivity to database size. There is a direct 
correlation between the statistical confidence a PMF algorithm can ascribe to protein 
identification and the size of a sequence database. A larger database has an elevated chance of 
experimental masses randomly matching theoretical peptide masses in these databases, 
thereby decreasing the confidence of protein identifications using PMF. The same observation 
is also valid if mass spectra are searched against a database using very relaxed search criteria 
(for example, by relaxing the enzymatic specificity a peptide has to display for being 
considered in the search, or by increasing the error by which theoretical masses are allowed to 
match experimentally-determined peptide masses) or if many dynamic modifications are 
considered simultaneously (oxidation, phosphorylation, etc., which increase the actual size of 
the search database). 
Popular search engines to mine PMF data include Mascot, MS-Fit and ProFound. All these 
tools allow the user to set up their searching parameters, such as for example database choice, 
constant and variable modifications, mass accuracy error, and miss cleavages. Each engine 
returns the result of the search with a measure of confidence gauging how significant is the 
obtained identification. For example, Mascot (50) uses a proprietary algorithm based on the 
MOWSE scoring system (47). By calculating the distribution of peptide lengths across the 
entire search database, a probability can be calculated for each observed peak for this match 
being purely random. While, most of the time, all PMF search engines returns similar answers, 
it is also not uncommon that multiple search of PMF data by using different tools leads to 
different identifications because of the different scoring systems that each of these tools use. 
1.5.1.2 Fragmentation Mass Fingerprinting (FMF) 
The currency of information for tandem mass spectrometry-based proteomics is the fragment 
ion spectrum (MS/MS spectrum) of a specific peptide ion that was fragmented, typically, in 
the collision cell of a tandem mass spectrometer. The correct assignment of such a spectrum 
to a peptide sequence is a first and central step in proteomic data processing. A large number 
of computational approaches and software tools have been developed to automatically assign 
peptide sequences to fragment ion spectra. These can be classified into three categories: (i) 
Fragmentation Mass Fingerprinting (FMF), by correlating un-interpreted fragment ion spectra 
with theoretical spectra predicted for each peptide contained in a protein sequences database,   47
or by correlating acquired fragment ion spectra with libraries of experimental MS/MS spectra 
identified in previous experiments (spectral library searching); (ii) De novo sequencing, 
where peptide sequences are explicitly read out directly from fragment ion spectra; and (iii) 
hybrid approaches, such as those based on the extraction of short sequence tags of 3–5 
residues in length, followed by ‘error-tolerant’ database searching. 
The FMF strategy is to date the most frequently used peptide identification method for large-
scale proteomics studies; it was also used in this study and, for that reason, it will be 
described in more details in the following paragraph. 
Several MS/MS database search engines have been developed to support the FMF approach 
and their basic functionality is illustrated in the Fig. 1.13. Mascot and Sequest are the most 
commonly used programs for peptide identification using the FMF strategy. Mascot is based 
on the probabilistic MOWSE algorithm which uses the parent mass and the relative 
abundance of the derived fragment masses for that parent as constraints on the search space. 
The Sequest peptide identification process starts with the selection of candidate sequences 
based on the length of a continuous y/b fragment ions correlating with the input spectrum. A 
second, more sensitive and more computational-intensive correlation function returns scores 
based on the presence of significant peaks in the experimental spectrum corresponding to the 
expected y/b ion peaks in each theoretical spectrum in the database. Sequest outputs a ranked 
list of candidate peptide identifications.   48
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13:  Peptide identification by MS/MS database searching. An acquired MS/MS 
spectrum is correlated against theoretical spectra constructed for each database peptide that 
satisfies a certain set of database search parameters specified by the user. A scoring scheme 
is used to measure the degree of similarity between the spectra. Candidate peptides are 
ranked according to the computed search score, and the highest scoring peptide sequence is 
selected for further analysis. The figure was adapted from Nesvizhskii et al., (51).  
 
Regardless of the search engine used, the fraction of spectra identified is usually quite low, 
with 10–20% being typical, although some high-quality experiments may yield as high as 
50% identification rates. This is largely dependent on the quality of the sample, the type of 
mass spectrometer used, and the manner the mass spectrometer has been set up. 
One of the main weaknesses of this identification strategy is that a top-scoring peptide, as 
determined by the search engines, may not necessarily be the correct candidate. The 
remaining challenge is to determine whether the putative identifications are in fact correct. 
Five years ago, a standard procedure might have been to apply an arbitrary cutoff score and to 
manually inspect spectra and judge correctness. This was extremely labor intensive and 
subjective, thus not reproducible. Recently several computational strategies have emerged for 
validating the search results and assigning a false discovery rate at the peptide level for a 
given threshold. One of those strategies is to repeat the identification search using a reverse or 
a shifted database by applying the same searching criteria, thus allowing the estimation of a 
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false discovery rate for a given experiment (52). An alternate strategy consists of storing 
MS/MS data in a library at an early stage of the identification process. Comparison of MS/MS 
data occurs by comparing experimental spectra with those previously measured and stored in 
a database using a spectra-matching algorithm. Such an approach was proven to be very 
effective in the small molecule area (53). 
1.5.2 Validation of peptide and protein identification 
The purpose of most proteomic experiments is not the identification of peptides, but the 
identification of the proteins present in the sample before digestion. Thus, the peptide 
sequences which were identified from the fragment ion spectra need to be grouped 
accordingly to their corresponding protein, and a confidence measure needs to be recomputed 
at the level of proteins. This process is by far not straightforward owing to several challenges, 
and it has not been satisfactorily resolved up to today. First, many correctly identified 
peptides tend to cluster into a relatively small number of proteins, especially when there were 
very abundant proteins in the analyzed sample. At the same time, incorrect spectral 
identifications match randomly to a much larger number of proteins in the searched sequence 
database. Thus, almost every high scoring, incorrect spectral assignment introduces one 
additional incorrect protein identification, resulting in a significant increase in the false 
discovery rate when going from the peptide to the protein level. Second, an important number 
of peptides are not unique to a single protein and hence will point to more than a single entry 
in the protein sequence database. Such cases most often are the result of the presence of 
homologous proteins, splicing variants, or redundant entries in the sequence database. This 
problem is particularly serious in the case of higher eukaryotes, or when protein sequence 
databases are derived from genomic databases. Therefore it becomes critical to have an 
appropriate tool that is able to assess the validity of the protein inference and associate a 
probability to it. A tool such as ProteinProphet combines probabilities assigned to peptides 
identified by MS/MS to compute accurate probabilities for the proteins present (54). 
In order to increase the confidence level for peptide or protein identification, technical 
replicates of an analyzed sample might be necessary. In an LC-MS/MS proteomic approach, 
unique peptide coordinates (such as retention time and accurate mass) could be useful for 
validating identification.  
Another method to confirm the presence of a protein via the characterization of one (or 
several) of its constitutive peptides is to use Multiple Reaction Monitoring (MRM). In the 
MRM-targeted strategy, which is typically performed the same way as for a quantification   50
experiment (see section 1.6.2), one sets the mass spectrometer to specifically detect signature 
ions of the peptide of interest, usually in presence of its isotopically labeled counterpart to 
pinpoint the exact retention time in the analysis and to validate the chosen transitions. 
Performed on a triple quadrupole instrument (or hybrid quadrupole/linear ion trap instrument), 
the data acquired by setting both mass analyzers to predefined m/z values achieve increased 
selectivity while the non-scanning nature of this experiment accounts for an increased 
sensitivity. It thus allows detection and structural confirmation of low abundance analytes in 
complex biological samples.  
1.6 Quantification in Proteomics 
The determination of the relative levels of protein abundance in organisms or tissues exposed 
to different physiological or environmental conditions is essential to the study of disease 
processes and cellular responses to stress. Until recently, a quantitative proteomics experiment 
would have typically been performed by differential display analysis using two-dimensional 
gel electrophoresis (2DE), whereas protein spot intensities on associated gels would have 
been compared and the differences quantified. While this method compares favorably to the 
precision achieved by modern mass spectrometers in terms of sensitivity and reproducibility 
(especially in the DIfferential Gel Electrophoresis [DIGE] strategy pioneered by Amersham 
BioSciences, today GE Healthcare), its dependence on the two-dimensional gel 
electrophoresis platform limits its applicability and throughput, especially when fractionation 
is required. In the last few years, especially with the popularization of high-performance mass 
spectrometers around laboratories, several alternative strategies have been proposed for 
relative quantification via mass spectrometry (55). 
In this section three conceptually different strategies to perform quantitative LC-MS 
experiments will be presented and are summarized in the Fig. 1.14. In the first approach, 
quantification is achieved by spectral counting of fragment ion spectra assigned to a particular 
peptide; in the second approach, quantification is achieved by the differential detection of 
peptides or proteins compared to an internal standard in the form of their isotopically-labeled 
counterpart; and in the third approach, peptides and proteins are quantified “label-free” (that 
is, without internal standard) based on the precursor ion signal intensities.    51
 
Figure 1.14: Representation of LC-MS based quantification strategies in proteomics. In the 
first approach, spectral counting estimates abundance values based on the number of times a 
peptide was successfully identified by tandem mass spectrometry (MS/MS) and compare these 
across experiments (green). In the second approach using isotopic labeling, quantification is 
based on the differential analysis of two samples, X and Y, in the same LC-MS run whereas 
the peptide A (in sample X) and its stable isotope labeled counterpart A
* (in sample Y) are 
detected by their characteristic mass difference Δm/z (red). In the third approach using label-
free quantification, peptide signals are extracted by tracking the isotopic patterns along their 
chromatographic elution profile. Relative quantification between the LC-MS run 1 and the 
LC-MS run 2 is achieved by comparing the coordinates m/z, Tr and z of the peptide (blue). 
This picture is adapted from Mueller et al., (56). 
1.6.1 Semi-quantitative analysis based on Spectral Counting  
This type of analysis was originally developed to evaluate semi-quantitatively shotgun 
proteomic approaches. In this strategy, wherein the main goal of the experiment is to identify 
a maximum number of peptides per LC-MS run, the mass spectrometer is set up to 
automatically select a number of peptide precursor ions from the full scan MS for collision 
induced dissociation (CID) analysis according to predefined criteria (typically the 1-5 most 
intense precursor ions of every full scan is selected for MS/MS analysis). The quantification 
strategy is based on the number of times a precursor ion peptide is selected for fragmentation 
and identified in a large data set. This value is related to the abundance of a peptide 
represented by its precursor ion in the sample mixture. Spectral counts of peptides associated 
with a protein are then averaged into protein abundance index (57-60). 
Spectral counting approaches have most frequently been used for the analysis of low to 
moderate mass resolution LC-MS data as a convenient, fast, and intuitive quantification   52
strategy. A draw back in this type of approach is its dependency on the quality of MS/MS 
peptide identification, because errors in the assignment of peptides propagate directly into 
protein abundance indexes. The assembly of spectral counts of peptides into a protein index is 
unproblematic for peptides whose sequences belong to only one protein; however, it is 
difficult to resolve protein for which peptides map to multiple protein sequences (as, for 
example, for peptides from conserved protein regions). It has been suggested, therefore, that 
spectral counting ought to be used only with proteotypic peptides (61). 
Another hurdle with spectral counting is the manner spectral counts are computed if only a 
small number of peptide identifications have been achieved for a given protein. This situation 
can occur, for example, for proteins of low abundance (only a few representative peptides 
might be detected), for proteins of low molecular mass or with specific physicochemical 
characteristics that limit peptide observability (these proteins might generate only a few 
representative peptides for LC-MS/MS measurements), if peptide identification becomes 
ambiguous or if the sample complexity overwhelms the mass spectrometer’s dynamic range. 
As a result, the spectral counting quantification method should be used for high abundant 
proteins, based on a large number of peptide identifications. It becomes unreliable for proteins 
with one- to two-peptides identifications since low-abundance peptide identification is not 
reproducible between different LC-MS runs (precursor masses selection for MS/MS is 
skewed towards peptides of high abundance.  
In a modified quantification approach, peptide abundance can also be estimated from the 
extracted ion chromatograms (XIC), which, in this way, partially alleviate the MS/MS 
problem (62). In this approach, it is sufficient that a peptide has been successfully analyzed by 
MS/MS in at least one of all the LC-MS runs. The mass to charge ratio m/z and the retention 
time TR of the MS/MS of the precursor ion are then used for the extraction of the XIC of this 
peptide in the other LC-MS measurements. In this case, however, any fluctuation on the LC 
system will cause a drift on the retention time of the peptide (see also section 1.6.3). 
In summary, quantification approaches based on spectral counting or on the extracted ion 
chromatograms of an assigned peptide represent valuable techniques for LC-MS/MS data of 
low- and medium-resolution. This strategy is not recommended for underrepresented peptides 
as the MS/MS analytical strategy is biased for high abundant peptides in a mixture. 
1.6.2 Relative Quantification based on Differential Stable Isotope labeling 
Differential stable isotope labeling in combination with mass spectrometry has become an 
extremely popular method for quantitative proteomics (40). Absolute quantification has been   53
demonstrated whereas the peptides of a sample are compared against their spiked-in isotopic 
labeled synthetic analogues (63). Differential isotopic labeling also allows the relative 
quantification of peptide intensity between multiple biological samples within a single LC-
MS measurement.  
A variety of MS-compatible labeling techniques are now available. They can be roughly 
divided into two categories, isobaric or isotopic labeling strategies. Fig. 1.15 illustrates the 
workflow of these two approaches. 
 
Figure 1.15:  Schematic representation of the quantitation principles of isobaric and 
isotopic labeling. Isobaric labeling generates in the MS/MS different reporter ions that are 
used to calculate peptide abundance between different samples. On Isotopic approaches 
differentially label peptides or proteins from two samples (green / blue) produce isotopic 
pairs of characteristic mass shifts. Common to both approaches are the next steps where 
peptide ratios are computed, assembled into protein ratios and then statistically assessed to 
evaluate the significance of the detected fold changes. Figure is adapted from Mueller et 
al.,(56). 
Isobaric labeling reagents, as exemplified by the iTRAQ reagents (64), are peptide tags that 
introduce an identical mass shift to all derivatized peptides (that is, these peptides are 
undistinguishable in the MS spectrum), but produce MS/MS-specific reporter ions that are 
used for quantification. Differentially labeled samples are combined and simultaneously 
analyzed by shotgun LC-MS/MS analysis, and peptide abundance values are compared via the 
reporter fragments in the MS/MS spectra. In contrast, isotopic labeling methods, for example 
the ICAT reagents (65) and the SILAC protein labeling strategy (66), generate pairs of 
peptides with characteristic mass differences introduced by the applied label. Typically, the 
isotopic forms of an MS/MS identified peptide are detected by their mass shifts and identical 
elution profiles and are used to compute a peptide abundance ratio between the “heavy”   54
labeled peptide from one condition and the “light” peptide version of the other condition 
(Figure 1.14, blue and green coloring). 
Isobaric Labeling of Peptides can be achieved, for example, with the new 8-plex iTRAQ 
labeling reagent that allows the simultaneous quantification of up to eight biological samples 
(Choe et al., 2007). The isobaric reagent reacts with primary amino groups and produces in 
the MS/MS fragmentation spectrum eight different unique reporter groups, one per reagent 
flavor, at 113, 114, 115, 116, 117, 118, 119, and 121 m/z. iTRAQ labeling does not increase 
the sample complexity at the MS level because the reagent is based and relies on a fully 
MS/MS-dependent workflow. Therefore, the strength of the approach, and its limitation, is 
that only peptides subjected to CID fragmentation which could be successfully assigned to a 
peptide sequence are quantified. 
The Isotopic Labeling Techniques commonly used in proteomics for relative quantification 
experiments can be divided into three general categories: chemical tagging of peptides and 
proteins, stable isotope labeling of peptides during enzymatic digestion, and metabolic 
labeling of living cells and animals. 
The first strategy using chemical tagging of specific amino acids is the Isotope Coded Affinity 
Tag (ICAT) method. In this technique, two biological samples are labeled at the peptide or 
protein level using chemically identical but isotopic different reagents specifically targeting 
cysteine groups. The labeled peptides differ in their molecular weight by 8 mass units (the 
newer ICAT reagents now introduces 9 mass units). After the labeling step, the samples are 
combined and subjected to mass spectrometric analysis. In the following years, a number of 
related strategies have been developed in which the sets of reagents differ in specificity, 
structure, mass difference, and number of isotopic forms (67). All these labeling techniques 
have in common that they generate a complex sample mixture consisting of pairs of 
chemically identical peptides of different mass. Those pairs are then detected in the precursor 
ion mass spectrum, and the signal intensity is used to compute the relative abundance of the 
respective analyte in either sample. 
The incorporation of isotopic analogues as replacement of atomic elements in the peptide 
sequence can be done through enzymatic reaction. 
18O labeling is based on the incorporation 
of heavy oxygen into the C-termini of peptides during tryptic digestion of proteins in presence 
of heavy water (68). The major advantage of 
18O labeling is that the method is not limited to a 
specific subpopulation of peptides. This method is generic and can be applied in any kind of 
peptide sequence. However the optimization of the tryptic digestion process can be quite   55
difficult and the 
18O incorporation may not be very specific for the C-termini as other amino 
acids might be labeled, making data analysis more complex. 
Metabolic labeling has become very popular since the development of the SILAC approach. 
In its original version, cell cultures are grown in media containing either light 
12C- or heavy 
13C-labeled arginine and lysine that are then metabolically incorporated into proteins through 
the cell cycle. After mixing the two samples and digestion, the generated isotopic peptide 
pairs are detected by mass shifts of multitudes of 6 mass units for each lysine or arginine 
incorporated. Since the label is added at a very early stage of the experiment, this technology 
allows normalizing for experimental variations introduced in the sample processing steps. The 
main limitation of the SILAC labeling strategy is that is largely restricted to biological 
material grown in culture, as is metabolic labeling of tissues by 
15N (a popular method to 
isotopic label bacteria (69, 70)), and thus is not generally applicable to tissues, body fluids, or 
clinical applications. A promising, but rather expensive approach for 
15N labeling of all the 
amino acids with high level of incorporation in mammalian (non human!) organisms has been 
suggested by (71). In this approach, a young (typically a newborn or a fetus) animal is fed for 
several weeks a special diet in which the nitrogen source is isotopic labeled, resulting in high 
rates of labeling in organs. 
Multiple Reaction Monitoring (MRM) represents a MS-based quantification approach that is 
taking fully advantage of the labeling strategies mentioned above. MRM experiments differ 
from conventional proteomics approaches in that they are hypothesis-driven (i.e. screening for 
known or putative entities). As a part of this targeted approach proteotypic peptides (i.e. 
sequences that are unique to one single protein), and their corresponding fragmentation 
patterns are used to define MRM transitions. In such approaches, one starts by generating a 
list of proteins of interest, the corresponding proteotypic peptides are derived, and the 
associated fragment ions are predicted (or extracted from a database) to define the MRM 
transitions. Relative estimation of the elution times might also be made and all that 
information will then be used to generate a list of targeted peptides. Relative and absolute 
peptide quantification can be achieved by adding at some stage of the experiment the isotopic 
(not the isobaric!) labeled peptides and to measure all samples in presence of the same 
internal standards. As MRM is per se a multiplex methods (it has been claimed that several 
hundreds of peptides can be quantified in the same LC-MS experiment), it is thus possible to 
detect and quantify a large number of peptides in consecutive single LC/MS runs with 
minimal effort (72).   56
In summary, isotopic labeling strategies allow for the highly accurate quantification of LC-
MS experiments since the differential analysis is performed on single LC-MS runs where the 
peptide pairs can be very accurately detected by the distinct mass shifts characteristic to the 
utilized labels. The described isotopic labeling strategies have in common that the 
combination of multiple, differentially labeled samples increases drastically the complexity of 
the peptide population. This is particularly problematic for the identification of peptide–ions 
by MS/MS where only a limited number of peptide signals can be subject to CID 
fragmentation during an LC-MS experiment. The selection of precursor ions is biased toward 
high-intensity peptide signals and leads to a prominent undersampling of low-abundance 
peptides. This limits the range of isotopic and, up to a certain point, isobaric labeling 
techniques since the computation of peptide/protein ratios is based exclusively on peptides 
that were successfully identified by MS/MS. Similarly, the chemical labeling strategies (for 
both the isotopic and the isobaric methods) increase intrinsically the variability of the 
experimental design because of the additional sample processing steps required by the 
procedure. 
1.6.3 Label free quantitation of LC-MS data 
Newer mass spectrometers with high scanning rates and high mass accuracy, such as the new 
generation of ESI-TOF, the LTQ-FT and the LTQ-Orbitrap instruments, have opened the way 
for the label-free quantification of LC-MS data. Typically, peptide signals are detected in the 
full MS scan and distinguished from chemical noise through their characteristic isotopic 
pattern. These patterns can then be tracked across the retention time dimension and used to 
reconstruct a chromatographic elution profile of the monoisotopic peptide mass. The total ion 
current of the peptide signal is then integrated and used as a quantitative measurement of the 
original peptide concentration (see Fig. 1.15). In principle, every peptide signal within the 
sensitivity range of the MS analyzer can be extracted and quantified independently of a 
MS/MS acquisition (73). This strategy increases the dynamic range for peptide detection and 
minimizes the bias against low-abundance peptides commonly observed for MS/MS-based 
approaches. Full MS measurements performed by the mass spectrometers of the latest 
generation provide very high resolution power and mass precision in the low parts per million 
range. Thus, the peptide signal extracted from the full MS level has become so precise and 
specific that the quantification process may now be uncoupled from the identification process. 
In contrast to a differential labeling experiment, biological samples assessed in a label-free 
experiment are measured separately. The extracted peptide signals are then mapped across   57
multiple LC-MS measurements using the coordinates “mass to charge” (m/z) and retention 
time (Tr). A successful peptide tracking depends on the available mass resolution of the 
utilized mass spectrometer and the stability of the LC system. In this paradigm, the Tr 
reproducibility of each peptide across the LC-MS runs becomes critical and requires the use 
of bioinformatics tools for the correction of chromatographic fluctuations. High mass 
accuracy MS instruments in combination with sophisticated computational methods for signal 
intensity normalization offer a platform for the automated label-free quantification of complex 
biological mixtures in a linear dynamic range of 3 to 4 orders of magnitude without the 
requirement of MS/MS information. 
Biological information is not directly inferred from a list of differentially-regulated masses 
and requires structural information, typically by tandem mass spectrometry. In a label-free 
experiment, even when performed on a modern mass spectrometer, typically only a fraction of 
the detected and quantified peptide features are identified by an MS/MS peptide assignment 
(74). Fig. 1.16 schematically represents some of the processes to follow the identification of 
peptides showing interesting quantitative patterns. 
Peptide signals are extracted from the full MS (gray dots) and then tracked across LC-MS 
multiple measurements to generate a list of aligned peptides (red dots), which serves as a 
framework for further annotation efforts (75, 76). Each peptide signal is defined by its 
accurate mass and time tag (AMT) (77) on the mass and retention time dimension (blue flag), 
and a subset of these peptide elements are selected according to a specific property of the 
peptide signal (for example, here the intensity). These AMT tags are then subjected to post 
annotation where the identity of an AMT (i.e., protein name and peptide sequence) is derived 
by comparing its accurate mass and retention time coordinates to a map of AMT tags from 
successfully identified peptide signals (green flags). AMT tags can also be obtained from 
peptide identifications either in a targeted LC-MS/MS runs (inclusion list run) or in a large 
repository of MS/MS peptide identifications compiled from multiple LC-MS experiments (78) 
(MS/MS repository).   58
 
Figure 1.16: Schematic representation of post processing approaches to follow peptide 
characterization based on their accurate mass and retention time coordinates (AMT). An 
aligned peak list (red map) is generated by peak detection and alignment of multiple LC-MS 
runs (gray maps) AMT tags of peptide signals (blue flags) with interesting intensity profiles 
are then integrated into a list of AMT tags for annotation. Identities of AMT tags are derived 
from a map of identified peptides (green flags) by comparing AMT coordinates (mass and 
retention time) across LC-MS runs. These maps might be fed through a large repository of 
collected MS/MS peptide identifications or through targeted MS/MS via inclusion list runs. 
Figure is adapted from Mueller et al., (56). 
 
In summary, label-free quantification represents a key technology for the analysis of complex 
biological samples due to its ability to exhaustively sample peptide signals detected directly at 
the full MS level. However, in order to be able to use this approach, there is a need for 
sophisticated computational methodology to process the acquired data. 
In all the quantification approaches in order to be able to trust differential expressions of the 
quantified proteins it is very important to know what is the variability due to technical steps or 
biological replicates so that can be estimated what is significant different. Monitoring the 
technical variability and stability of the BBM preparation and the LC-MS system is part of 
this study, in order to develop the right tools and set the criteria that reflect what is common 
and what is different between the compared biological samples. 
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2. OBJECTIVES 
The primary goal of this study was the development and the evaluation of analytical strategies 
for the analysis and the identification of hydrophobic proteins by mass spectrometry. Analysis 
of membrane proteins in a complex mixture was always an obstacle for the proteomics field. 
Their hydrophobic nature requests a detergent for their solubilization and makes the use of 
traditional proteomics techniques less compatible (e.g. two-dimensional gel electrophoresis). 
Their low abundance in complex biological mixtures (in comparison to soluble proteins) 
requires additional purifications steps for their enrichment. Even at equal abundance, the 
identification rate of membrane proteins is lower than that of soluble proteins. This study 
aimed at better understanding constrains linked with the analysis of membrane proteins and at 
investigating possible improvements in this process. 
The Brush Border Membrane (BBM) from mice small intestine was chosen as an ideal source 
of membrane proteins. The investigation of proteins that are located in the BBM membrane 
and may play a key role in cholesterol absorption has been of increasing interest in the recent 
years for many pharmaceutical companies because of the correlation of cholesterol absorption 
malfunction with cardiovascular diseases. This proteomic approach should confirm the 
findings of several studies that were based on gene analysis, activity tests and immunology 
assays, namely that the BBM contain proteins that participate in cholesterol regulation in the 
enterocytes. 
A third goal of this study was to investigate conditions for which a quantitative mass 
spectrometric experiment using a label-free strategy could be used to investigate biological 
samples, as technical variability and sample stability of the BBM preparation were not known. 
The reproducibility of the technical steps has to be monitored for the whole workflow, from 
the BBM preparation until the mass spectrometric analysis of the samples, so to pinpoint 
difficulties and limitation of the workflow and preparing the way for a label free 
quantification strategy using only the information from the LC-MS data. 
An additional aim of this study was to set the grounds for the analysis of gene expression 
along the small intestine of a mouse, in particular with the goal to compare gene expression of 
differentially treated mice or of mice with different genetic background.  
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3. MATERIALS AND METHODS 
3.1 Materials / Chemicals  
Materials / Chemicals Company 
ABC Fluka
Acetic acid  Merk
Acetonitrile Merk
a-CYANO Bruker
Agarose Sigma
Amastatin Bachem AG
Angiotensin 1-5 Bachem AG
BCA-kit Pierce
Bestatin Bachem AG
beta Mercaptoethanol Fluka
C57B/6J-Bom male mice Taconic
Calcium chloride Fluka
CHAPS Sigma
Complete, inhibitor cocktail tablets  Roche
DTT Merck
ECL-kit GE healthcare
EDTA Fluka
EtBr Sigma
FA Pierce
Hyperfilm-ECL Amersham
Met-Bradykinin Bachem AG
Methanol Merk
MOPS buffer Invitrogen
PMSF Sigma
Ponceau S 1%  Sigma
PVDF Perkin  Elmer
PVDF membrane Millipore
SDS Fluka
Sodium chloride Fluka
Superblock blocking buffer Pierce
TFA Pierce
Transfer buffer Invitrogen
Tris Sigma
Tween-20 Merk
Whatmann papper  VWR    62
3.2 Methods 
3.2.1 BBM Preparation  
Brush Border Membrane (BBM) vesicles were isolated by using a modified protocol from 
Kessler et al. using calcium chloride precipitation (79). The small intestine (rinsed with PBS) 
or the scrapped mucosa thereof from wild type C57B/6J-Bom male mice (6-8 weeks old) was 
suspended in Homogenization buffer (50 mM Mannitol, 2 mM Tris, pH 7.1) in presence of 
protease inhibitor cocktail tablets (Complete , Roche) and 1 mM PMSF (from a 100 mM 
stock solution in ethanol). Each gram of tissue was suspended in 15 ml homogenization buffer. 
The suspension was homogenized four times 20 seconds using a Polytron (Kinemetica GmbH) 
at maximum speed with intervals of 40 seconds in ice. The homogenized tissue was then 
centrifuged at 3,000 x g for 15 min at 4 
°C and the cell debris was discarded. The supernatant 
was re-centrifuged at 27,000 x g for 30 min at 4 
°C. The resulting pellet was weighted and re-
suspended in Homogenization buffer (at the ratio of 1 gram of pellet in 15 ml 
Homogenization buffer) and CaCl2 was added to a final concentration of 10 mM (from a stock 
solution of 1M CaCl2 freshly prepared). After incubation on ice for 20 min, the 3,000 x g 
centrifugation step was repeated. The supernatant was then re-centrifuged at 27,000 x g for 30 
min at 4 
°C. The resulting pellet, which contained the BBM vesicles, was first washed twice 
with 1 M KCl, then twice with 0.1 M Na2CO3, with 30 min centrifugation at 50,000 g at 4 
°C 
after each washing step. The purified BBM pellet was finally solubilised in storage buffer 
(100 mM Mannitol, 1 mM Heppes-Tris pH 7.5, 1% SDS and 1% CHAPS) in presence of 
protease inhibitor cocktail tablets Complete and 1 mM PMSF and stored at -80 
°C. 
The targeted inhibition of the His-Zn-dependent metalloproteases was achieved by adding 1 
mM Amastatin (80, 81), 1 mM Angiotensin 1-5, and 1 mM Met-Bradykinin in all buffers and 
washing solutions. The excess of Ca
+2 after the calcium precipitation step was removed with 
40 mM EDTA at the first wash of the BBM fraction with KCl. (§ 4.1.2.3 figure 4.9: flow 
diagram of BBM preparation). 
3.2.2 Protein concentration estimation by the BCA method 
The BCA Protein assay is a detergent-compatible assay for the colorimetric detection and 
quantitation of total protein using bicinchroninic acid (BCA) as a reporting agent. The method 
combines the well known reduction of Cu
+2 to Cu
+1 by protein in an alkaline medium with the 
highly sensitive and selective colorimetric detection of Cu
+1 using a reagent containing 
bicinchrominic acid. The purple-colored reaction product of this assay is formed by the 
chelation of two molecules of BCA by one cuprous ion. The complex exhibits a strong   63
absorbance at 562 nm that is nearly linear over a broad working range (20 - 2,000 μg/ml). The 
macromolecular structure of the protein, the number of peptide bonds and the amino acids 
cysteine, cystine, tryptophan and tyrosine are responsible for the color formation with BCA. 
Protein concentrations are determined and reported with reference to standards of a common 
protein such as BSA. 
In this work, a dilution series of known concentrations of BSA was prepared and assayed 
alongside the unknown samples before the concentration of each unknown was determined 
based on the standard curve. It was very important that the buffer used for the dilution series 
of the standards was identical with the buffer of the samples to be assayed. 25 μl of each 
standard or of unknown sample replicate was pipetted in a microplate well. 200 μl of working 
reagent (50 volumes of reagent A: 1% BCA-Na2, 2 % Na2CO3⋅H2O, 0.16% Na2-tartrat, 0.4% 
NaOH, 0.95% NaHCO3, pH 11.25, mixed with 1 volume of reagent B: 4% CuSO4⋅5H2O) was 
added in each well. The plate was mixed thoroughly on a plate shaker for 30 sec before being 
incubated for 30 min at 37 
°C. The plate was allowed to cool down to room temperature after 
which the absorbance at 562 nm was measured on a plate reader. 
3.2.3 Protein Deglycosylation 
There are two methods for protein deglycosylation: the chemical and the enzymatic procedure. 
Hydrazinolysis of glycoproteins (82), although capable of removing both N- and O-linked 
sugars, results in the complete hydrolysis of the protein and the modification of many amino 
acids. A milder chemical method, such as the trifluoromethanesulphonic acid method (TFMS) 
(83, 84), leads to incomplete sugar removal, partial protein hydrolysis and modifications of 
several amino acids. On the other hand, the enzymatic deglycosylation provides complete 
removal of the N-linked sugars from the protein with no measurable side-reaction. In this 
study, protein deglycosylation was performed enzymatically under denaturing conditions 
(heating with SDS and βME) to increase the yield of deglycosylation. The removal of the N-
linked oligosaccharides was performed using N-Glycanase (PNGase F, Prozyme). The only 
amino acid modification that occurs in this reaction is the deamidation of the arsparagine 
residue to aspartic acid after the removal of the sugar from this residue. There is no enzyme 
comparable to N-Glycanase to remove intact O-linker sugars. Monosaccharides must be 
removed by a serie of exoglycosidases until only the Galβ (1-3)GalNAc core remains attached 
to the serine or threonine residue. O-Glycanase can then remove the core structure intact with 
no modification of the serine or threonine residues. Sialic acids attached to O-linked sugars 
can be removed by Sialidase A.   64
Samples were deglycosylated under denaturing conditions according to the protocol provided 
by the kit’s manufacturer (Prozyme). 10 μl of 5x incubation buffer (0.25 M sodium phosphate, 
pH 7.0) and 2.5 μl of denaturation solution (2 % SDS, 1M βME) were added to a maximum 
of 100 μg of sample (dissolved in 30 μl). The sample was heated for 5 min at 100
 °C and, 
once cooled down to room temperature, 2.5 μl of detergent solution (15% NP-40) were added. 
Finally, 1 μl (approximately 5 mU) of each deglycosylation enzyme (N-Glycanase, Sialidase 
A, and O-Glycanase) was added to the solution and the sample was incubated for 3 h at 37 
°C. 
The protein deglycosylation process was monitored by 1D SDS PAGE. 
3.2.4 1D SDS-PAGE electrophoresis  
Sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) is a method to 
resolve proteins according to their molecular size. The negatively-charged SDS molecules in 
the sample buffer bind to the heat-denatured proteins in a constant ratio (approx. 1.4 g SDS 
per g protein). As a result, SDS-loaded proteins migrate towards the positive pole in an 
electrical gradient, impeded by the polymerized and cross-linked polyacrylamide, at a 
mobility that is roughly proportional to their size. 
The following protocols were used for Novex Bis-Tris precast SDS gels (Invitrogen). 
3.2.4.1 Sample preparation and electrophoresis 
Each sample was reduced and alkylated before being applied onto the SDS gel. Samples 
(approximately 15-20 μg total protein) were mixed with the appropriate amount of 4x 
NuPAGE LDS sample buffer (1x NuPAGE LDS buffer contains 141mM Tris, 2 % LDS, 10 
% Glycerol, 0.51 mM EDTA 0.22 mM Coomasie Blue G250 and 0.175 mM Phenol Red pH: 
8.5 from Invitrogen). 100 mM freshly prepared DTT (in water) was added and the samples 
were incubated for 15 min at 70 
°C. The samples were then allowed to cool down to room 
temperature and 300 mM Iodacetimide (aliquots of 1 M iodoacetamide in 300 mM Tris pH 
8.8, 2.5% SDS, 10% Glycerol) was added. Each sample was incubated for 25 min at 45 
°C 
before being loaded onto a 10 % acrylamide Novex Bis-Tris SDS gel (Invitrogen) that had 
already been placed in the Mini cell module (Invitrogen). 10 μl of the prestained SDS 
molecular mass marker (See blue plus 2 from Invitrogen) was loaded in one well of the gel to 
calibrate the molecular mass of the separated proteins in each sample. The gel was run using 
the MOPS SDS running buffer system (20x MOPS SDS running buffer contains 1 M MOPS, 
1 M Tris, 69.3 mM SDS and 20.5 mM EDTA, pH: 7.7 from Invitrogen) at 200 volts constant 
for approximately 1 hour typically until the front dye had reached the bottom of the gel.   65
3.2.4.2 Protein staining 
Protein staining using colloidal Coomassie is based on the work of Neuhoff et al., (85). The 
method is based on the colloidal properties of Coomassie Blue dyes in aqueous or methanolic 
solutions in presence of inorganic acids and high salt conditions. The free dye in solution is 
greatly reduced due to the hydrophobic effect, resulting in low background and high affinity 
binding of the dye to the proteins fixed in the gel. A typical limit of detection of < 10 ng of 
BSA protein loaded onto a 1 mm 4-12 % acrylamide Tris Glycine gel can be obtained using 
this protein staining method. 
After completion of the run, the gel was removed from the mini cell. The gel was first 
incubated in freshly prepared fixing solution (50% methanol, 10% acetic acid in deionized 
water) for 10 min to obtain a more efficient staining. The gel was then shaken for a maximum 
of 12 hours in the staining solution (20% Methanol, 20% Stainer A (containing ammonium 
sulfate and phosphoric acid) and 5% Stainer B (containing Coomassie G250) in deionized 
water), after which the gel was then destained in deionized water until a clear background was 
obtained. 
3.2.5 Western Blotting 
A Western blot (alternately, immunoblot) refers to a method to immunodetect a specific 
protein, usually in a complex mixture, on a membrane support after electrophoretic separation. 
This process is performed in three steps. First, gel electrophoresis is used to separate native or 
denatured proteins by the length of the polypeptide (denaturing conditions) or by the 3-D 
structure of the protein (native/ non-denaturing conditions). Proteins are then transferred from 
the gel to a membrane support (i.e., nitrocellulose or PVDF) via electrotransfer. Finally the 
blot is processed for the detection of specific proteins using antibodies, the product of which 
is the final Western immunoblot. 
In this protocol, protein transfer from SDS gel to PVDF membrane was achieved using the 
Wet blotting technique. A PVDF membrane (cut to the size of the gel) was activated 
(immersed) in methanol for 30 seconds, briefly rinsed with water, and then equilibrated in the 
Transfer buffer (NuPAGE  Transfer buffer 1x: 25 mM Bicine, 25 mM Bis-Tris and 1 mM 
EDTA, pH: 7.2 complemented with 20 % methanol and 0.005% SDS) along with the two 
filter papers. Samples of interest were loaded and separated onto a 10% SDS Bis-Tris gel 
(Invitrogen) as described in the previous chapter. The gel was soaked in deionised water 
immediately after electrophoresis (for approximately 10 min) before to rinse it shortly in 
Transfer buffer before use. The XCell II SureLock Mini-Cell module (Invitrogen) was used   66
for the transfer of the proteins from the gel to the PVDF membrane. The sandwich of the 
PVDF membrane and the gel was placed in the XCell module according to the manufacturer’s 
instructions. The transfer took place at 38 volts constant for 90 minutes with a starting current 
of 100 mA with the module kept cold in an ice bath. 
After transfer, the PVDF membrane was rinsed briefly with deionised water and was stained 
with 0.1% Ponceau S for evaluating the efficiency of the protein transfer. The membrane was 
then destained with deionised water and was washed several times with TTBS buffer (50 mM 
Tris pH 8.0, 80 mM NaCl, 2 mM CaCl2, 0.1% Tween 20) until the stain was completely 
removed. Blocking was achieved by incubating the membrane in Superblock TBS blocking 
buffer (Pierce) and then in Blocking buffer (TTBS buffer plus 5% non-fat dried milk) for 30 
min each. The membrane was then incubated overnight at 4 
°C in blocking buffer with the 
primary antibody at an appropriate dilution. On the following day, the PVDF membrane was 
washed three times with TTBS buffer for 10 min each and 1 h in the blocking buffer. The 
membrane was then incubated for 90 min with the secondary antibody (HRP-conjugated) in 
the blocking buffer at room temperature. The membrane was washed subsequently three times 
with TTBS buffer for 10 minutes each. Immunodetection by chemiluminescence was 
performed by incubating the PVDF membrane in the ECL detection reagent (GE healthcare) 
for 1 min. Excess reagent was drained out and the membrane was wrapped up in a saran wrap. 
The blots were placed protein side-up in an X-ray film cassette and a sheet of 
chemiluminescence film (Hyperfilm ECL from Amersham Biosciences) was placed on the top 
of the membrane. The cassette was closed and the film was exposed for a given amount of 
time (typically, from 30 sec to 10 min) before being developed. This last step was repeated 
several times until an exposure time was considered as optimal from the signal point-of-view. 
3.2.6 In-gel protein digestion 
This protocol describes a method for the direct digestion of proteins in Coomassie- or 
colloidal blue-stained polyacrylamide gels. The absence of detergents and a minimal use of 
salt allow the direct analysis of the resulting digest by nanoLC-tandem mass spectrometry 
without an additional desalting step. In this study the protein digestion was performed by 
Trypsin, an enzyme that cleaves specifically after Lysine and Arginine except if the following 
amino acid is Proline. 
The colloidal blue-stained gel was placed on a clean glass plate and the gel bands of interest 
were excised out of the gel using a clean scalpel. Each band was cut into the smallest pieces 
possible that were placed in an Eppendorf tube. The bands were destained first with 50%   67
ACN for 10 min and second with destaining solution (100 mM ABC, 30% ACN) for 10 min. 
The last step was repeated if necessary until the acrylamide pieces were completely colorless. 
The protein reduction/alkylation step was skipped as the sample was already reduced and 
alkylated prior to SDS PAGE. The bands were then dehydrated with 100% ACN for 15 min 
after which the bands were dried in a Speed Vac for 10 min without heating. The dried gel 
pieces were re-swelled in 50 μl tryptic digestion buffer (40 mM ABC containing 10 ng/μl 
Trypsin (Promega)) for 30 min. Additional buffer (5 mM ABC) was then added to the gel 
pieces if they were not completely covered with buffer. Digestion was carried out overnight at 
room temperature. On the following day, the supernatant was first collected and additional 5 
mM ABC (50 μl) was added to the gel pieces for 15 min at 37 
°C. After collection of the 
supernatant, the gel pieces were further extracted with 300 μl 100% ACN for 10 min at room 
temperature, after which the supernatant was again collected. The gel pieces were then 
extracted with 50 μl of 5% Acetic acid, 5% ACN at 37 
°C for 15 min and the supernatant was 
collected. Finally, the gel pieces were extracted again with 300 μl 100% ACN at room 
temperature for 15 min. The above procedure has been adapted from several papers (86-88). 
The pooled supernatant was then dried in a speed Vac without heating and the peptide extract 
was kept at -80 
°C until further use. 
3.2.7 Mass spectrometry  
3.2.7.1 Packing of NanoLC columns 
An analytical fused silica emitter (75/360 μm i.d./o.d., tip diameter 8±1 μm, New Objectives) 
was packed with 12-15 cm of 3 μm Reprosil C18 A.Q. reverse phase material (Dr. Maisch). 
The resin was mixed with methanol (approximately 50 mg/ml) and the fused silica was 
packed at 170-200 bar using pressurized Nitrogen. The column was then rinsed with pure 
methanol at the same pressure and kept dried until use. 
3.2.7.2 Method development for NanoLC ESI-MS/MS 
Peptide samples were analyzed by nano liquid chromatography electrospray tandem mass 
spectrometry using an Ultimate 3000 nanoflow chromatographic system (Dionex) coupled to 
a LTQ-Orbitrap tandem mass spectrometer (Thermo Electron) equipped with a 
nanoelectrospray ion source (Proxeon Biosystems) 
The peptide mixture of each sample was dissolved in 20 μl of buffer A (2% ACN, 0.5% acetic 
acid). 10 μl of the sample was transferred to a glass vial of 0.25 ml volume (sun – sri) of 
which 5 μl were injected into the system at a flow rate of 450 nl/min at 100 % buffer A for 12   68
min. After loading, the flow was decreased to 250 nl/min and peptides were eluted from the 
reverse phase column as follows: 12—14 min, 0—5% buffer B (80% ACN, 0.5% acetic acid); 
14—30 min, 5—30% buffer B using the curve 4 (slightly concave) of the Chromoleon 
software (Dionex); 30—90 min, 30—55% Buffer B using the curve 6 (slightly convex) of the 
Chromeleon software. The column was then washed for 15 min with 100 % buffer B at 350 
nl/min, after which it was re-equilibrated for 25 min in 100% buffer A at 350 nl/min. 
Peptides were analyzed by tandem mass spectrometry using standard operating parameters as 
follows: the electrospray voltage was set to 2.2 kV and the ion transfer capillary temperature 
was at 170 
°C. Survey scans (scanning range m/z 400-1500) were recorded in the Orbitrap 
mass analyzer at a resolution of 30,000 with the lock mass option (20) enabled. Data-
dependent MS/MS spectra of the five most abundant ions from the survey scan were recorded 
in the LTQ ion trap using a normalized collision energy of 32% for MS/MS (30 ms activation, 
q=0.25) and a selection threshold of 500. Target ions selected for MS/MS were dynamically 
excluded for 30 sec. 
3.2.7.3 Data Processing Method and Protein Identification  
The raw data files of each LC-MS/MS run were processed using the SEQUEST search 
algorithm 27 (SEQUEST version 27.0, revision 12, Thermo Electron). Searches were 
performed against the in house-generated MouseGP database (Version January 2007, genome 
version mm8/NCBI36, 60862 entries). The MOUSEGP database is generated by taking the 
most recent version of all the non-redundant sets of Swissprot and Trembl sequences from 
human, mouse, rat, other vertebrates, drosophila, C. elegans and Yeast and blast the 
sequences against the mouse chromosomes. The putative exons are then assembled into genes. 
The alignments between genomic chromosome sequence and proteins are refined with 
GeneWise (89, 90), a tool that finds splice sites and corrects frame shifts. Data were searched 
with a mass tolerance of +/-5 ppm for parent ions and +/-1.0 Da for fragment ions. 
Methionines (reduced/oxidized; +15.9949 Da) were considered as differential modifications 
while cysteines were considered as fully carbamidomethylated (+57.0199 Da). Only fully 
tryptic peptides with no more than one miscleavage were considered for data analysis. 
Peptides were considered as unambiguously identified if their XCorr scores (91) exceeded 1.5, 
2.0 or 2.5 for singly, doubly and triply charged ions, respectively, and if the corresponding 
ΔCn scores (the normalized Sequest XCorr score difference between the first and the second 
best peptide match,(91)) were larger than 0.2. In this study, only proteins for which at least 
two different peptides were identified were considered as successfully identified. The False   69
Positive Discovery Rate at the peptide level was estimated by searching the raw data files 
against a shifted database. This database, which is generated from MOUSEGP, has an 
identical number of proteins and tryptic peptides by keeping fixed the position of the 
arginines and lysines while the position of all remaining amino acids were left-shifted by two 
positions. The raw files were searched by using the above searching criteria and the raw 
spectra were submitted to the scrambled database for scoring. These spectra were binned 
based on their score and the number of spectra in each bin was counted and stored in the 
database. An objective estimate of the false positive discovery rate at the peptide level is 
obtained by comparing the distribution and the counts of spectra for a given score for spectra 
that were scored against MOUSEGP and the scrambled database (52, 92, 93). Using the 
criteria mentioned above, the false positive discovery rate for 1+, 2+ and 3+ charged peptides 
was estimated to be 7.4%, 3.2%, and 0.6%, respectively. 
Comparison of the LC-MS raw data files based on the total ion current of the peptides was 
performed by using the Genedata RefinerMS (version 4.5) software suite. Software-specific 
settings were as follows: baseline subtraction (20% quantile value, m/z Window 10 Da, RT 
window 0.1 min); chromatogram retention time (RT) alignment (prior internal peak 
identification on m/z window with 5 points, RT window 0.5 min, gap penalty 0.75, RT search 
interval 100 scans); peak identification as in RT alignment; peak shaping (multiplicity: 67%); 
isotopic clustering (minimal charge 2, maximal charge 4, correlation threshold 0.5, maximal 
missing peaks 1, mass tolerance 0.05, ionization: protonation; mass consistency: peptides). 
The resulting peak table associates the m/z and RT of a feature with its extracted ion count 
(XIC) and signal-to-noise ratio (S/N) measured in each sample. Features with a median 
S/N<5.0 were excluded from the data analysis as these outliers displayed broad ranges of 
nonlinear chromatographic shifts across samples. 
3.2.7.4 Sequence and topology analysis 
The proteins’ cellular location and topology were analyzed with a variety of tools as follows. 
Prediction for signal peptide was performed using the in-house “signal_anchor” software tool 
(http://bioinfo.bas.roche.com:8080/sawicgi/sawi.cgi?signal_anchor) using an algorithm 
inspired by the web-based SignalPep tool (94) but using a support vector machine prediction 
model using Roche internal data rather than a neural net prediction model. 
Membrane protein prediction was performed using either the “ALOM” software tool 
(http://bioinfo.bas.roche.com:8080/sawicgi/sawi.cgi?alom) as described by Klein P et al. (95),   70
or the web-based “TMHMM 2.0” (http://www.cbs.dtu.dk/services/TMHMM-2.0/), as 
described by Krogh A. et al. (96). 
The version of the GO annotations (as described in Gene Ontology Consortium (2000)) used 
in this work was from June 2008. In this work, the multiple GO annotations of a protein were 
reduced to what was believed to be the most relevant entry according to the following rules: 
a)  plasma membrane > ER, GOLGI, endosome > lysosme, microsome, peroxisome> 
mitochondria > cytoplasm, cytosol > nucleus > other 
b)  integral > anchored > peripheral, associated to > no mention of membrane interaction 
c)  any membrane interaction > proteasome, cytoskeleton, vesicle, etc. >extracellular 
In doubt, the protein annotation of the SwissProt database was used to direct the selection to 
one or the other direction. 
3.2.8 RNA extraction from the small Intestine 
A typical mouse intestinal tissue (100 mg) contains about 150 μg total RNA. However, only 
1.0–1.5% of it is accounted as mRNA. RNA molecules, compared to DNA, are relatively 
unstable. In order to ensure accurate gene expression analysis, it is important that the RNA 
analyzed truly represents the in vivo gene expression of the sample. This is complicated by the 
fact that changes can occur during handling of the sample and isolation of the RNA. Two 
major types of artifacts are known to occur. Gene down regulation and enzymatic degradation 
of RNA, due to ribonucleases (RNases), result in an artificial reduction of both nonspecific 
and specific mRNA species. At the same time, other genes can be induced during handling 
and processing of the sample. The combination of these two effects can result in a 
transcription profile that differs from the true in vivo gene expression pattern.  
Efficient disruption and homogenization of the tissues under conditions that preserve the 
RNA stability is essential for the total RNA isolation procedure. In the current protocol, the 
freshly removed small intestine was flushed with PBS buffer (GIBCO) and RNAlater 
(QIAGEN) to better preserve the RNA from degradation. Approximately 100 mg of tissue 
was then embedded in 1 ml TRI Reagent (Sigma). As reported by Chomczynski et al. (97) the 
phenol and guanidine thiocyanate contained in the TriReagent are effective inhibitors of 
RNases. The tissue was homogenized with Lysing Fast RNA Matrix D tubes (Bio 101 
systems) using a FastPrep Cell disrupter (Thermo Savant) at a speed of 6 m/sec for 20 sec. 
The cell disruption process is due to the collision of matrix and sample within the FastPrep® 
Instrument sample tube. The rate of collision and energy of impact (both of which determine 
the effectiveness of the disruption process) are a function of the FastPrep® Instrument speed   71
settings and specific gravity of the bead material used. The homogenate was then separated 
into an aqueous and organic phase by adding 0.1 volume of chlorophorm. Alternatively the 
step of the homogenization of the tissue was replaced by grounding the tissue under liquid 
Nitrogen. In this case the TRI reagent was added to the grounded tissue and immediately after 
was following the step of the phase separation by addition of chlorophorm. In both cases the 
preparation were incubated on ice for 5 min and centrifuged at 12,000 x g for 15 min at 4 
°C. 
The RNA was present in the aqueous phase, the DNA in the inter-phase, and the proteins in 
the organic phase. Next, the RNA was precipitated from the aqueous phase by adding 2 
volumes of cold isopropanol. The preparation was incubated on ice for 15 min and 
centrifuged at 12,000 x g for 10 min at 4 
°C. The precipitate was washed with 75% ethanol 
and centrifuged at 7,000 x g for 5 min at 4 
°C. The extracted RNA was finally dissolved in 
RNase-free water and heated for 10 min at 65 
°C. RNA aliquots were then stored at -80 
°C 
until use. 
3.2.9 RNA Electrophoresis 
The overall quality of an RNA preparation may be assessed by electrophoresis using a 
denaturing agarose gel; this type of analysis provides simultaneously some information about 
RNA yield. A denaturing gel system is suggested, because most RNAs form extensive 
secondary structure via intramolecular base pairing, preventing them from migrating strictly 
according to their size. The quality of the extracted RNA was assessed using 1% agarose 
denaturating gel. 1 g of agarose was added to 72 ml of triple distilled water and heated until it 
was dissolved. The mixture was cooled to 60 
°C and 10 ml of 10x MOPS running buffer (10x 
MOPS buffer: 0.4 M MOPS, 0.1 M sodium acetate, 0.01 M EDTA, pH 7.0 adjusted with 
NaOH), 18 ml 37% formaldehyde (12.3 M) and 1 μl EtBr were added to the agarose solution. 
The gel was poured using a comb to form the wells for the samples. The gel was then 
assembled in a tank and 1x MOPS running buffer was added to cover the gel by a few 
millimeters. 
Each RNA sample (1–3 μg) was mixed with 2 volumes of formaldehyde Load Dye (Ambion) 
and heated for 15 minutes at 70 
°C. The gel was loaded and electrophoresis was performed at 
5 V/cm until bromophenol blue (the faster migrating dye) had migrated as far as 2/3 of the 
length of the gel. 
The gel was visualized on a UV transilluminator (EtBr fluoresces under UV light when 
intercalated into DNA or RNA). Intact total RNA will show sharp 28S and 18S rRNA bands 
(eukaryotic samples) on a denaturing gel. In an ideal case, the 28S rRNA band should be   72
approximately twice as intense as the 18S rRNA band, a good indication that the RNA is 
intact. Partially degraded RNA will have a smeared appearance, will lack the sharp rRNA 
bands, or will not exhibit a 2:1 ratio. Completely degraded RNA will appear as a very low 
molecular weight smear. For this effect, a RNA size marker was loaded on the gel to allow the 
size determination of any bands or smears and to serve also as a positive control to ensure the 
gel was run properly. Alternatively, RNA quality was assessed using the Experion Systen 
(BIO-RAD) an automated Electrophoresis station. The analysis of the samples was performed 
according to the manufacturer’s instructions.   73
4. RESULTS AND DISCUSSION 
4.1 An improved protocol for the specific isolation of BBM from 
small intenstine 
The first attempts to isolate BBM from the small intestine were performed following the 
protocol of Kessler et al. (79) developed initially for the kinetic measurements of sugar and 
mineral transporters in BBM. A piece of small intestine, or scrapped mucosa if a cleaner 
preparation was needed, was homogenized using a polytron and the cell debris was removed 
by a low-spin centrifugation step. The following step, a calcium chloride precipitation, was 
used to segregate the Brush Border Membrane (the apical side of the enterocyte’s plasma 
membrane) from the Basolateral membrane (the lumen side of the enterocyte’s plasma 
membrane). Due to the different polarity between the two sides of the membrane, the addition 
of CaCl2 specifically precipitated the basolateral membrane, which could then be removed 
from the preparation by low-spin centrifugation, while the BBM membrane remained in 
solution (the exact mechanism by which the process is driven is not known). The enriched 
BBM fraction could then be collected by high-spin centrifugation and resuspended in an 
appropriate buffer for further analysis. 
The degree of BBM enrichment from the small intestine was monitored by Western blot using 
a specific BBM marker (FATP-4) and a contaminant basolateral marker (Na+/K+ ATPase a1). 
The BBM fraction showed only a modest enrichment factor (approximately 10-fold compared 
to the crude lysate) and still contained a detectable contamination from the basolateral 
membrane (Fig. 4.4 and 4.5, see also below). Simultaneously, BBM preparations from  three 
different mucosa intestinal sections were prepared to investigate the level of purification (at 
the protein level) obtained with the Kessler protocol. Survey of the literature indicated that the 
protein composition of the BBM changes along the intestine. Hence, a highly enriched 
preparation was expected to result in protein patterns that should differentiate each of the 
sections. Fig. 4.1 shows the 1D-SDS-PAGE analysis of the BBM preparations from proximal, 
central, and distal mucosa sections obtained from a pool of three mice. The obtained protein 
patterns were almost identical with each other, with no obvious difference allowing 
discrimination between the three sections, indicating that the BBM preparations contained a 
significant level of contaminants masking the BBM-specific proteins.   74
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: 10% 1D-NuPAGE Bis-Tris gel analysis of the Kessler BBM preparation from 
the three mucosa intestinal sections. 15 μg total protein was loaded per sample. P_BBM, 
C_BBM, D_BBM: proximal, central, and distal BBM preparation, respectively; MW: 
Molecular Weight marker. 
For that reason a significant amount of time was spent to improve the performance of the 
original protocol. At first, my efforts were concentrated on the precipitation step, using 
several CaCl2 concentrations to obtain more specific precipitation conditions, and on the 
centrifugation conditions in an attempt to increase the purity of the BBM preparation. Results 
of this optimization process were mitigated at best and did not yield any noticeable change in 
the quality of the preparation (data not shown). As a next step, I chose to focus my attention 
on improving the isolation protocol by adding purification steps which could remove a large 
part of the cytosolic and membrane-associated contaminant proteins so that a higher 
enrichment of the BBM’s hydrophobic proteins could be achieved. First, a low- and high-spin 
centrifugation cycle was performed immediately after tissue homogenization so that the bulk 
of the cytosolic proteins could be removed from the membrane fraction before the CaCl2 
precipitation. Further, two washing steps using high salt (1 M KCl) and high pH (100 mM 
Na2CO3) were added after collection of the BBM fraction to remove most of the membrane 
associated proteins. A summary of the original and the modified protocol is represented on the 
flow diagram shown in Fig. 4.2. 
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Figure 4.2: Flow diagram of a BBM preparation from mucosa or from intestinal tissue. 
The original steps from the Kessler protocol are marked in black. The steps 2, 3 and 7-10, 
which were added to the original protocol, are highlighted in green. 
The improved BBM preparation protocol has been tested with intestinal tissue and mucosa 
scrapping, total tissue or in sections, with excellent results. The performance of the protocol 
and the level of BBM purification obtained from a total small intestine preparation are 
illustrated in Fig 4.3. Samples were collected along the BBM preparation and were analyzed 
by 1D-SDS-PAGE. 
Homogenization 
Homogenization Buffer: 
2mM Tris pH 7.1, 50 mM Mannitol
Washed BBM fraction in Storage buffer plus 1% SDS and 1% CHAPS
Intestinal tissue, mucosa scrapping
Homogenized tissue
Centrifugation at 3000 x g for 15 min, 4oC 
Supernatant 
Centrifugation at 27.000 x g for 30 min, 4oC
Step 1 
Step 2 
Step 3
Pellet 1
Step 4
Step 6
Pellet resuspension in Homogenization Buffer           
CaCl2 Precipitation (10mM final concentration)
20 min, on ice
Centrifugation at 3000 x g for 15 min, 4oC 
Supernatant 
Centrifugation at 27.000 x g for 30 min, 4oC 
Pellet 2                         
BBM fraction 
2 x washing with 1M KCl
Centrifugation at 50.000 x g for 30 min, 4oC
between each wash step 
2 x washing with 0.1M Na2CO3 Steps 7-10
Step 5
Homogenization 
Homogenization Buffer: 
2mM Tris pH 7.1, 50 mM Mannitol
Washed BBM fraction in Storage buffer plus 1% SDS and 1% CHAPS
Intestinal tissue, mucosa scrapping
Homogenized tissue
Centrifugation at 3000 x g for 15 min, 4oC 
Supernatant 
Centrifugation at 27.000 x g for 30 min, 4oC
Step 1 
Step 2 
Step 3
Pellet 1
Step 4
Step 6
Pellet resuspension in Homogenization Buffer           
CaCl2 Precipitation (10mM final concentration)
20 min, on ice
Centrifugation at 3000 x g for 15 min, 4oC 
Supernatant 
Centrifugation at 27.000 x g for 30 min, 4oC 
Pellet 2                         
BBM fraction 
2 x washing with 1M KCl
Centrifugation at 50.000 x g for 30 min, 4oC
between each wash step 
2 x washing with 0.1M Na2CO3 Steps 7-10
Step 5  76
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: 1D-SDS-PAGE analysis of the fractions collected during the improved BBM 
isolation protocol. A sample amount of 15 μg (according to the BCA protein assay) of total 
protein (except for the supernatants S1_27000 and S_KCl, where the maximum volume of 
sample was loaded) was loaded onto a 10 % 1D NuPAGE BisTris gel. Proteins were stained 
using colloidal Coomassie. 
It was clearly demonstrated, as shown in the 1D-SDS-PAGE analysis of the collected fraction, 
that the initial low/high spin centrifugation step removed a considerable number of 
contaminant proteins prior to the CaCl2 precipitation (Fig. 4.3, lane 8). Similarly, the high 
salt/high pH wash steps (1 M KCl followed by 100 mM Na2CO3, steps 7-10 of the protocol) 
of the initial BBM fraction also removed a number of membrane-associated proteins (Fig. 4.3, 
lanes 11, 12). Interestingly, the two washes clearly targeted different sets of proteins, as 
shown in the 1D-SDS-PAGE analysis. 
The purity and the enrichment of the isolated BBM from total intestinal tissue was assessed 
by Western Blotting using FATP-4, a transmembrane, BBM-specific protein (Fig. 4.4), and 
Na
+/K
+ ATPase a1, a transmembrane basolateral marker protein. 
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Figure 4.4: FATP-4 Western Blot analysis of the fractions collected during the improved 
BBM isolation protocol. 10 μg total protein were loaded for each sample. 1
st antibody 1:2000 
goat polyclonal specific for FATP-4 (Cat. No: sc-5835 Santa Cruz Biotechnology), 2nd 
antibody 1:7500 Horseradis peroxidase goat anti rabbit IgG. Lane 9 corresponds to the BBM 
purified with the new improved BBM isolation protocol while lane 10 corresponds to the 
BBM purified according to the Kessler’s protocol. 
The FATP-4 Western Blot analysis demonstrated convincingly that this BBM-specific protein 
was markedly more enriched in the BBM fraction collected with the improved protocol 
(approximately 30- to 50-fold compared to the crude lysate) than following the original 
Kessler’s protocol. Comparison of the BBM fraction before the washes (lane 3) and the 
Kessler’s BBM fraction (lane 10) illustrated that the first low/high spin centrifugation cycle 
was the key for improving the enrichment of the BBM fraction, most likely by removing the 
bulk of contaminant cytosolic proteins before the CaCl2 precipitation step. The high salt/high 
pH wash steps also contributed to the enrichment of the FATP-4 BBM marker, although to a 
lesser extent, by the removal of additional cytosolic and membrane-associated proteins. 
The quality of the improved BBM isolation protocol was also investigated with respect to the 
most likely BBM contaminant, the Basolateral membrane, using a Western Blot analysis 
against Na
+/K
+ ATPase a1, a specific marker of this compartment (Fig. 4.5).   78
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: Na
+/K
+ ATPase a1 Western Blot analysis of the fractions collected during the 
improved BBM isolation protocol. 10 μg total protein were loaded in each sample. 1
st 
antibody 1:10000 mouse monoclonal specific for Na
+/K
+ ATPase a1 (Cat. No: 05-369, 
Upstate), 2nd antibody 1:7500 Horseradis peroxidase rabbit anti mouse IgG. Lane 4 
corresponds to the BBM purified with the new improved BBM isolation protocol while lane 5 
corresponds to the BBM purified according to the Kessler’s protocol. Lane 6, positive control 
(rat liver extract) 
The Na
+/K
+ ATPase a1 western blot analysis of the BBM fractions confirmed the excellent 
quality of the improved BBM preparation protocol. The 100 kDa band was assigned to 
Na
+/K
+ ATPase a1 (according to the rat liver positive control) while the 60 kDa and 35 kDa 
signals most probably corresponded to antibody heavy and light chains (the secondary 
antibody was anti-mouse). There was no detectable basolateral membrane contamination (no 
signal for Na
+/K
+ ATPase a1 in lane 4) in the BBM fraction prepared according to the 
improved isolation protocol while the BBM fraction prepared according to Kessler’s protocol 
showed a low level basolateral membrane contamination (weak signal of Na
+/K
+ ATPase a in 
lane 5). 
In summary, an extended version of the original CaCl2 precipitation protocol from Kessler 
was demonstrated to yield a highly enriched and purified BBM fraction according to the 
Western Blot analyses against FATP-4, a specific BBM protein marker, and against Na
+/K
+ 
ATPase a1, a known basolateral protein marker. In particular, the improved isolation protocol 
removed many cytosolic and membrane-associated proteins, thus facilitating a better 
enrichment of the hydrophobic BBM proteins, and yielded a BBM fraction with undetectable 
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level of basolateral membrane, the major contaminant of BBM in all previous isolation 
protocols. 
4.1.1 1D-SDS-PAGE analysis of BBM fractions 
Throughout this study, BBM have been isolated from mice total intestinal tissue, from 
sections of intestinal tissue, from total intestinal mucosa, and from sections of intestinal 
mucosa. A BBM preparation from intestinal mucosa, for example, has the advantage that the 
starting material is highly enriched in enterocytes (the source cell type for BBM). Hence, as 
contaminations from erythrocytes and from the intestinal epithelium are avoided, the purity of 
the BBM preparations automatically increases. Conversely, scrapping mucosa from the inside 
wall of the intestine is a laborious process that has to be performed immediately after sacrifice 
(see also following sections on protein degradation). In certain types of experiments, because 
of logistic reasons, only intestinal tissue might become available. In this section, I summarize 
some of the findings on BBM preparations from diverse source materials. 
Fig. 4.6 shows a composite 1D-SDS-PAGE gel analysis of BBM preparations from total 
intestine, from total mucosa, and from mucosa sections that have been prepared following 
either the original Kessler protocol or the improved BBM isolation protocol (see previous 
section). The section A of the 1D-SDS-PAGE represents the BBM fractions isolated from the 
total small intestine. The protein pattern obtained from the BBM prepared using the improved 
protocol (section A, lane 2) shows clearly that a number of proteins have been removed 
compared to the BBM fraction prepared according to the Kessler’s protocol (section A, lane 
1). A significant increase in the number of proteins can be observed, especially in the lower 
mass range, when the BBM is prepared from mucosa tissue instead from the whole small 
intestine (see lanes 4 of sections B and C). However, the protein patterns of BBM prepared 
using mucosa sections following the improved isolation protocol (section C, lanes 2-4) show 
significant differences between the three different sections, in contrast to the almost identical 
protein patterns obtained from BBM isolated from mucosa sections that have been prepared 
according to Kessler’s protocol (section B lanes 2-4).   80
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: 1D SDS PAGE analysis of isolated BBM fractions. Section A: BBM fractions 
from total small intestine prepared either according to Kessler’s protocol (lane 1) or using 
the improved preparation protocol (lane 2). 15 μg total protein were loaded per lane in a 10 
% 1D NuPAGE Bis-Tris gel run in MOPS buffer system. Section B: BBM fractions from 
mucosa tissue in sections (lane 1-3) and total (lane 4), prepared according to Kessler’s 
protocol. 15 μg total protein were loaded per lane in a 10 % 1D NuPAGE Bis-Tris gel run in 
MOPS buffer system. Section C: BBM fraction from mucosa tissue in sections (lane 1-3) and 
total (lane 4), prepared according to the improved protocol. 30 μg total proteins were loaded 
per lane in a 10 % 1D NuPAGE Bis-Tris gel run in MES buffer. 
In summary, the results of the 1D-SDS-PAGE analysis from BBM fractions prepared from 
different starting materials using two different protocols, in combination with the results 
obtained from the Western blots analysis (see section 4.1), were clearly indicative that the 
initial BBM characterization should be performed with mucosa as starting material following 
the improved isolation protocol to ensure maximum purity.   81
4.1.2 BBM preparation and protein degradation  
4.1.2.1 Protein deglycosylation 
A large number of proteins located in the BBM are highly glycosylated. Indeed, the 1D-SDS-
PAGE analysis of a BBM fraction showed a large number of proteins tightly concentrated in 
the higher mass range of the gel. In order to better distribute those proteins in a wider mass 
range, and to achieve a better protein enzymatic digestion and peptide ionization in the mass 
spectrometer, an enzymatic deglycosylation process was performed under denaturing 
conditions (see section 3.2.3 for more experimental details). The BBM fraction was 
deglycosylated using N-Glycanase, Sialidase A, and O-Glycanase for 3 h at 37 
°C. The 
outcome of the deglycosylation process was monitored by 1D SDS PAGE electrophoresis 
(Fig. 4.7) 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: 1D-SDS-PAGE analysis of a BBM fraction before (lane 1) and after (lane 2) 
deglycosylation. 15 μg total protein were loaded per lane in a 10 % 1D NuPAGE Bis-Tris gel 
run in MOPS buffer. MW molecular weight marker 
According to the 1D-SDS-PAGE analysis, the deglycosylation process was successful as the 
protein patterns of the native and deglycosylated BBM fractions were quite different from 
each other. In the deglycosylated sample, many protein bands have been shifted to lower 
molecular range and the proteins were distributed in a wider range of molecular masses.    82
4.1.2.2 Western Blot analysis of Aminopeptidase N  
The quality and the extent of deglycosylation of the BBM protein fraction was examined in 
more detail through the Western blot analysis of Aminopeptidase N,  an abundant single 
transmembrane helix BBM protein marker predicted to bear 13 N-linked glycosylation sites. 
The Western blot analysis of Aminopeptidase N before and after the deglycosylation 
procedure should substantiate the completeness of the process and confirm that the molecular 
mass of Aminopeptidase N has been reduced to its predicted molecular mass (approx. 110 
kDa). For this procedure, a polyclonal antibody raised against the full amino acid sequence 
(69-966 amino acids) of mouse Aminopeptidase N was used. The results of the western blot 
analysis are represented in Fig. 4.8: 
 
 
 
 
 
 
 
 
 
Figure 4.8: Western blot analysis of Aminopeptidase N in a BBM fraction before and after 
deglycosylation. Lane 1: starting material (homogenized mucosa tissue); Lane 2: wBBM 
from total mucosa; Lane 3: deglycosylated BBM material from lane 2. Protein load is as 
indicated in the legend. 1
st antibody 1:1000 goat polyclonal anti-Aminopeptidase N (Cat. No: 
AF2335, RnDSystems), 2nd antibody 1:7500 Horseradish peroxidase donkey anti goat IgG. 
MW, Molecular Weight marker 
The results of the Western Blot analysis (Fig. 4.8) confirmed that Aminopeptidase N was an 
abundant BBM protein generating a very strong signal from a single band at around 170 kDa 
using 1 μg of total protein load (Fig. 4.8, lane 1). The generated signal was even stronger 
when the western blot was performed using 0.5 μg total protein load from the isolated BBM 
membrane (Fig. 4.8, lane 2). In contrast, the Western blot results obtained from the 
deglycosylated BBM fraction were quite different (Fig. 4.8, lane 3): the signal representative 
for Aminopeptidase N was shifted completely to a lower molecular mass, confirming that the 
protein deglycosylation procedure was successful. At the same time, however, a number of   83
additional signals at lower molecular masses than expected were also detected in the 
deglycosylated BBM fraction. As the primary antibody was polyclonal and was raised against 
the whole Aminopeptidase N protein sequence, we came to the conclusion that these 
additional bands could only represent Aminopeptidase N fragments, indicating that 
degradation was occurring during the deglycosylation process. 
Protein degradation is, by nature, one of the primary roles of the small intestine. It was 
believed, however, that the use of the commonly available Ser- and Cys-protease inhibitors 
cocktail during the BBM preparation combined with the storage of the BBM in high 
concentration of detergents (1% SDS and 1% CHAPS) should be sufficient to inhibit 
proteolytic degradation. Additionally, it was very surprising that these peptidases should 
remain active during the deglycosylation process as the procedure was performed under 
reducing, denaturing conditions and the sample was heated at 90 degrees before the addition 
of the deglycosidases.  
The presence of proteolytic enzymes in the BBM was confirmed by systematic protein 
identification of the glycosylated BBM fraction, as it will be discussed in the section 4.2, 
showing that the most abundant BBM proteins were indeed peptidases. These results, 
combined with the observation that abundant proteins were always identified in numerous 
fractions, confirmed that protein degradation plays a central role in the BBM. 
4.1.2.3 Inhibition of protein degradation 
The role of the many peptidases that were identified in the BBM membrane is to degrade 
proteins and long peptides to smaller molecules that can be easily transported through the 
small intestine. Based on the identification data, a high percentage of the most abundant BBM 
proteins was accounted by peptidases belonging to the family of His-Zn-dependent 
metalloproteases, such as Aminopeptidase N, Aminopeptidase A, Ileal dipeptidyl peptidase 
(NAALADase), Neprilysin, or Meprin, (see section 4.2 table 4.3), which are not inhibited by 
common Serin, Cystein proteinase inhibitors. Chemically, these peptidases can be inhibited 
efficiently using trifluoromethanesulphonic acid (83, 98). However, this procedure must take 
place in anhydrous conditions and this was clearly not compatible with the isolation protocol.  
The importance to inhibit these peptidases should not be underestimated: among others, 
proteolytic activity can lead to false results in a western blot data interpretation (epitope 
degradation) or to major difficulties when a label free protein quantitation is used for the 
comparison of the samples (signal dilution in several fractions, irreproducible isolation 
procedure). In order to reduce proteolytic activity, two peptidase partial inhibitors that were   84
described in the literature to be active against His-Zn metalloproteases, Amastatin and 
Bestatin (80), were evaluated. Using the same Western Blotting analysis as described in the 
previous section, Bestatin did not appear to have any effect while Amastatin was found to 
lessen but not suppress the proteolytic activity in the BBM fraction (results not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Optimized flow diagram of a BBM preparation from mucosa or from intestinal 
tissue. The original steps of the Kessler protocol are marked in black while the steps 2-3 and 
7-10, labeled in green, were added to the protocol during this study (see Fig. 4.3). The steps 
where Amastatin, the peptide substrates, and EDTA were added to the protocol are labeled in 
red. 
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Superior results were obtained when Amastatin was used in combination with the addition of 
high concentration of peptide substrates, such as Angiotensin 1-5 and Met-Lys-Bradykinin, 
which could significantly compete out BBM proteins from degradation. Finally, according to 
the literature (99) divalent cations, such as Ca
+2 and Mg
+2, activate His-Zn-dependent 
metalloproteases. It was then essential to remove the excess of Ca
+2 after the CaCl2 
precipitation and 40 mM EDTA was added to the first wash of the BBM membrane for this 
purpose. The flow diagram of the optimized BBM preparation, including the above 
modifications, is represented in the figure 4.9.  
In order to check the level of inhibition, a Western blot analysis of two BBM fractions (no 
inhibitor; in presence of the inhibitor, peptide substrates and EDTA) was performed to 
compare the levels of degradation of Aminopeptidase N (fig. 4.10):  
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.10:  Western Blot analysis of Aminopeptidase N of a control BBM (lanes 1, 2 
following protocol as in Fig. 4.3), of a BBM fraction isolated with inhibitor, peptide 
substrates and EDTA lanes 3-7, following protocol as in Fig. 4.9), and of a deglycosylated 
BBM fraction (lane 8, 9, following protocol as in Fig. 4.8). Total protein load of BBM were 
loaded as indicated in the legend. Probing and detection conditions were as indicated in Fig. 
4.8. MW, molecular weight marker. 
The Western Blot analysis against Aminopeptidase N of a dilution serie of the two BBM 
fractions demonstrated that the combination of a partial inhibitor, Amastatin, of two peptide 
substrates in large amounts, and of EDTA to remove excess Ca
2+ after CaCl2 precipitation, 
resulted in an approximately 10-fold reduction of degradation (Fig. 4.10, compare lanes 3-5   86
versus lanes 6, 7). Interestingly, the deglycosylation procedure appeared to completely void 
the relative protection conferred by the addition of the inhibitor, peptides substrates and 
EDTA. Once deglycosylated, the two BBM samples were observed with the same (extensive) 
level of Aminopetidase N degradation (Fig. 4.10, lanes 8, 9). Since protein degradation 
couldn’t be controlled in any way during the deglycosylation process, the glycosylated form 
of the BBM fraction was chosen for further investigation in the current study. 
The BBM fractions, isolated according to the modified protocol in presence and absence of 
inhibitors were compared in 1D SDS PAGE representation (Figure 4.11).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11: 1D SDS PAGE analysis of BBM fractions. Lane 1: wBBM_control, BBM   
isolated according to the modified protocol without addition of extra inhibitors (Fig. 4.3) 
Lane 2: wBBM_inhibitor, BBM  isolated according to the modified protocol in presence of 
Amastatin, the peptide substrates and EDTA. 15 μg total protein were loaded per lane in a 10 
% 1D NuPAGE Bis Tris gel run in a MOPS running buffer system. MW, molecular weight. 
The BBM fractions in presence and absence of the Zn-His metallopeptidase inhibitor, peptide 
substrates and EDTA, showed some differences in protein distribution on the 1D SDS PAGE 
analysis (figure 4.11). The BBM_control lane (lane 1) showed, in comparison to the 
BBM_inhibitors lane (lane 2), a higher diffusion of the proteins in the higher molecular 
masses and several prominent protein bands in the lower mass range, which is consistent with 
a higher degradation activity in the BBM fraction isolated without inhibitor. Characterization 
of the BBM fraction prepared in presence of Amastatin and the peptide substrates also   87
showed that protein identification was less redundant between SDS-PAGE bands (see also 
section 4.2) than with the BBM fraction isolated without inhibitor. Indirectly, this observation 
confirmed that protein degradation, the extent of which could be easily followed through the 
fragment distribution of abundant proteins in a SDS-PAGE analysis, was significantly 
reduced. As desirable as it would be, however, total inhibition of peptidase activity did not 
appear to be achievable without a major change of the BBM isolation protocol, which was 
outside of the scope of this study.  
4.2 Protein identification of BBM mice intestinal mucosa 
Proteins from the BBM mice intestinal mucosa were identified in triplicate using the 
following analytical strategy. A pool of intestinal mucosa (scrapped from 8 mice) was thawed, 
weighted, homogenized, and immediately divided in three equal parts. The BBM isolation 
procedure was performed in parallel for the three preparations. 30 μg of each purified BBM 
preparation were then analyzed on a single SDS-PAGE gel and each lane was then divided in 
19 unequal bands to keep the protein amount in each band as similar as possible. The 57 
resulting bands were then in-gel digested with trypsin and the extracted peptides were stored 
at -80 °C until further use. Each sample was then analyzed randomly (taking care not to 
analyze adjacent bands one after the other) by LC-ESI-MS/MS with one blank run between 
each sample to minimize carry over. The MS/MS analyses were then submitted to SEQUEST 
and the proteins identified in each of the 57 gel bands were stored in MSpresso to be then 
downloaded to Microsoft Excel.  
A unique, non-redundant protein list for each BBM preparation was created as follows: for 
each band, redundant protein entries were first removed by collapsing a common group of 
proteins to one single entry, preferably with a SWISS-PROT entry, so to remove splice 
variants and multiple naming of the same protein from the list. Further, a protein list for each 
BBM preparation was created by combining the protein lists of the 19 bands, removing the 
redundant identification of a protein among the analyses but keeping the maximum number of 
different peptides found in a given band and the sum of peptide counts in the whole 
preparation. Finally, in the absence of a validated protein scoring to determine a false 
discovery rate, a protein was arbitrary considered to be unambiguously identified if two 
different peptides belonging to the same protein could be characterized in a given band. 
Similarly, a protein was considered to be constitutively part of the BBM preparation if it was 
identified unambiguously with at least two different peptides in one band in one given 
preparation and with at least one peptide in another BBM preparation. Fig. 4.12 provides a   88
short overview of the protein identification from the triplicate measurement of BBM 
preparation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12: Overview of the protein identification obtained from a triplicate BBM 
membrane preparation.  
The 1307 proteins for which a valid SWISS-PROT/TrEMBL entry could be found are listed 
in appendix A1 (see also below). Proteins were ranked-ordered using their average peptide 
counts as a very rough estimate for their abundance in the sample. Spectral (peptide) counting 
is by far not an ideal measure for quantification purpose but this strategy is useful evaluating 
the dynamic range of the proteins included in the analysis. As the abundance of a protein  
rises in the sample, the amount of peptides derived from this protein also increases in the 
peptide mixture submitted to the mass spectrometer. Abundant peptides elute in wider 
chromatographic peaks than scarce peptides, and will therefore be picked up more often for 
MS/MS analysis. This strategy, however, tends to bias large, cytosolic proteins, which will 
generate numerous peptides, versus small proteins, for which only a small number of peptides 
can be found, or membrane proteins, of which only domains outside of the membrane regions 
are accessible for analysis by mass spectrometry (see also below). 
The first 50 rank-ordered proteins of the triplicate preparation are listed in Table 4.1. As 
expected, a large number of those abundant proteins are part of the cytoskeleton, an essential 
component of the membrane structure. The quality of the preparation can be measured by the 
presence of a number of multiply-transmembrane proteins, such as the Abcb1a or the high-
3286 different proteins identified with 1 or more different peptides
1639 different proteins identified with at least 2 different peptides
1463 commonly identified proteins in at least 2 different preparations
89.2% of the proteins were reproducibly 
identified among the preparations
wBBM_2 wBBM_1 wBBM_3  89
affinity sodium/glucose cotransporter 1 transporters, that have been identified for the first 
time in a proteomics study. Similarly, the Niemann-Pick C1-like protein 1, a predominant 
protein of the BBM and a major player in cholesterol absorption, was also found among the 
50 most abundant proteins of the preparation. Note also the presence of 9 proteases and 4 
glycosidases in this list, mirroring the major function of the small intestine in degrading 
complex molecules to facilitate their ingestion. 
Interestingly, the rank-order of the identified membrane proteins did not seem to be biased by 
the number of transmembrane domains that these proteins were predicted to contain. Thus, the 
Niemann Pick C1-like protein, a predominant protein of the BBM bearing 13 transmembrane 
helices, was identified with 32 different peptides and an average sum of 142 peptide counts. 
In contrast, the fatty acid transporter protein 4 (FATP-4), a protein bearing only two 
transmembrane helices, was identified with 3 different peptides and average sum of 3 peptide 
counts. In this preparation highly enriched for membrane proteins, the number of different 
peptides and the average sum of peptide counts reflected the relative abundance of a given 
membrane protein in the preparation. Thus, as an example, the FATP-4 protein could not be 
identified anymore in the preparation when the protein loading on the SDS-PAGE was 
reduced to 2/3 of the original amount (results not shown). 
   90
Rank 
order
Gene Symbol Gene Description
Max Diff 
peptide
Avg Pep 
count
# AA
Number 
of TM
1 Actb actin, beta, cytoplasmic 29 1737 375 0
2 Vil1 villin 1 58 1566 827 0
3 2010204N08Rik
hypothetical protein LOC69983 | 
sucrase-isomaltase (alpha-
glucosidase)
93 1464 1818 1
4 Mgam maltase-glucoamylase 81 1196 1857 1
5 Actg1 actin, gamma, cytoplasmic 1 29 983 375 0
6 Anpep Aminopeptidase N (EC 3.4.11.2)  54 961 966 1
7M yo1a myosin IA 75 780 1043 0
8M yo7b Myosin-VIIb. 108 733 2113 0
9S l c 5 a 1
High affinity sodium/glucose 
cotransporter 1 (Solute carrier 
family 5 member 1).
23 587 665 14
10 Enpep
Glutamyl aminopeptidase (EC 
3.4.11.7) (Aminopeptidase A)
53 431 945 1
11 Abcb1a
Multidrug resistance protein 3 (EC 
3.6.3.44) (ATP-binding cassette 
sub-family B member 1A)
51 311 1276 11
12 Cltc clathrin, heavy polypeptide (Hc) 73 303 1675 0
13 Acta1 actin, alpha 1, skeletal muscle 14 280 377 0
14 Actc1 actin, alpha, cardiac 14 280 377 0
15 Lct lactase 47 251 1220 0
16 Actg2
actin, gamma 2, smooth muscle, 
enteric
14 250 376 0
17 Acta2
actin, alpha 2, smooth muscle, 
aorta
14 250 377 0
18 Atp1a1
Sodium/potassium-transporting 
ATPase subunit alpha-1 precursor 
(EC 3.6.3.9) 
36 244 1023 10
19 Pcdh24 protocadherin 24 28 241 1308 1
20 Gna11
guanine nucleotide binding 
protein, alpha 11
28 236 359 0
21 Ubb ubiquitin B 8 226 76 0
22 Muc13
Mucin-13 precursor (MUC-13) 
(Cell surface antigen 114/A10)
13 219 573 1
23 Mep1b
Meprin A subunit beta precursor 
(EC 3.4.24.18) (Endopeptidase-2).
23 204 704 1
24 Pdzk1
PDZ domain containing 1 (Na/Pi 
cotransporter C-terminal-
associated protein)
38 179 519 0
25 2210407C18Rik
RIKEN cDNA 2210407C18 gene / 
EP1 protein (novel protein)
11 176 220 0
26 Mme
Neprilysin (EC 3.4.24.11) (Neutral 
endopeptidase 24.11)
39 175 750 1
27 Ace2
Angiotensin-converting enzyme 2 
precursor (EC 3.4.17.-) (ACE-
related carboxypeptidase) 
34 174 805 1
28 Myo1d myosin ID 54 172 1006 0
29 Npc1l1
Niemann-Pick C1-like protein 1 
precursor.
32 142 1333 13
30 Papss2
3'-phosphoadenosine 5'-
phosphosulfate synthase 2
33 140 366 0
31 Eps8l3 ESP8-like 3 28 140 600 0
32 Akp3
Intestinal alkaline phosphatase 
precursor (EC 3.1.3.1) (IAP).
28 137 559 0
33 Lima1 LIM domain and actin binding 1 18 136 753 0
34 Hsp90ab1
Heat shock protein HSP 90-beta 
(HSP 84)
33 136 724 0
35 Ezr ezrin 37 131 586 0
36 Ggt1
Gamma-glutamyltranspeptidase 1 
precursor (EC 2.3.2.2) (Gamma- 
glutamyltransferase 1)
14 127 568 1
37 AI427122 Plastin 1 (I isoform) homolog 34 122 630 0
38 Gnb1
guanine nucleotide binding protein 
(G protein), beta 1
15 116 130 0
39 Anxa2 annexin A2 29 115 339 0
40 Gnaq
guanine nucleotide binding 
protein, alpha q polypeptide
20 115 353 0
41 Tuba1b tubulin, alpha 1B 16 115 451 0
42 Ubc ubiquitin C 8 115 76 0
43 Dpep1d i peptidase 1 (renal) 19 113 410 0
44 Enpp3
Ectonucleotide 
pyrophosphatase/phosphodiestera
se family member 3 (E- NPP 3)
26 112 874 1
45 Dpp4
Dipeptidyl peptidase 4 (EC 
3.4.14.5) 
33 107 760 1
46 Gnb2
guanine nucleotide binding protein 
(G protein), beta 2
12 107 493 0
47 Tuba1c
Tubulin alpha-1C chain (Tubulin 
alpha-6 chain)
16 105 449 0
48 Hspa8 heat shock protein 8 33 104 646 0
49 Treh Trehalase precursor (EC 3.2.1.28) 26 103 576 0
50 Naaladl1
N-acetylated-alpha-linked acidic 
dipeptidase-like protein (EC 
3.4.17.21) (NAALADase L).
26 101 745 1
 
Table 4.1 The 50 most abundant proteins in the triplicate BBM preparation.  
Transmembrane proteins are noted in yellow, proteases are marked in pink.   91
Analysis of the nature and topology of the proteins identified in the triplicate BBM membrane 
preparation was performed as follows. Each of the 1463 protein sequences (which were 
originally derived from the mouseGP sequence database) was first matched to a SWISS-
PROT/TrEMBL entry, resulting in 1307 valid entries (see appendix A1). Further, histone 
proteins, ribosomal proteins, as well as entries pointing to pseudogenes, were also removed 
from the pool of proteins to be analyzed to simplify the ensuing data analysis. (Table 4.2).  
1463 mouseGP sequences  1206 SW/Tr sequence entries  further analyzed 
  38 histone protein entries  Not analyzed 
  54 ribosomal proteins  Not analyzed 
  9 pseudogenes  Not analyzed 
  156 unmatched gene products  Not found 
 
Table 4.2: Overview of the proteins identified in the triplicate BBM membrane preparation 
As there is no general method to comprehensively query the topology of a large number of 
protein species, the remaining 1206 entries were analyzed by partially overlapping strategies.  
First, proteins were categorized as “secreted”, “membrane proteins” or “cytoplasmic” based 
on the predicted presence of a signal peptide targeting the protein for secretion (signal_anchor 
tool) or on the presence of transmembrane sections anchoring a protein in a biological 
membrane (ALOM tool). The categorization “membrane protein” was further investigated 
with the TMHMM software package, which also allows predicting the number of 
transmembrane sections in a protein. Finally, the most relevant GO “cellular location” 
annotation of a protein was compiled to assess the nature and the topology of the 1206 
investigated proteins (see appendix A1). 
In a general manner, the three approaches provided similar results, albeit with considerable 
variation in respect to sensitivity and specificity. Fig. 4.13 shows the performance of the 
TMHMM and the ALOM algorithms (which both will flag a membrane protein) versus a 
manual search in the GO annotation filtered for the concept “integral membrane proteins”.   92
 
Figure 4.13: Predictive assignment of membrane proteins by the Alom software package 
and the TMHMM software package compared to the GO annotation of the 1206 proteins 
included in the analysis. The Go assignment included the terms “apical plasma membrane”, 
“basolateral plasma membrane” and “integral to membrane”. 
The GO annotation method and the TMHMM algorithm roughly flagged the same proteins 
with more than 85% of the potential candidates commonly identified as a membrane protein. 
On the other hand, the Alom algorithm assigned about 20% more candidates as membrane 
proteins as the other strategies. This algorithm might be slightly more sensitive than 
TMHMM to pick membrane proteins, at the cost of a large increase in false assignment. 
However, compared to the GO annotation method, both algorithms appear to significantly 
underestimate the number of integral mitochondrial membrane protein (e.g. ATP synthase, H
+ 
transporting mitochondrial F1 complex, beta subunit, ATPA_MOUSE, or solute carrier 
family 25 (mitochondrial carrier ornithine transporter), member 15, ORNT1_MOUSE) and 
ion channels (e.g. voltage-dependent anion channel 2, VDAC2_MOUSE). Most of those 
proteins most probably belong to the structural class of transmembrane β-barrel proteins, 
which can not be easily predicted even using the most recent software packages for structure 
predictions (100). 
The transmembrane segment distribution of the 260 membrane proteins predicted by the 
TMHMM algorithm is shown in Fig. 4.14. The distribution of membrane proteins with one or 
two predicted transmembrane segments represented more than 50% of all the membrane 
proteins, closely following a whole genome predictive analysis of the number of protein with 
(278)   93
transmembrane helices in human (101). The number of remaining membrane proteins was 
rather equally distributed among all the other membrane protein species with the interesting 
exception of the 7-transmembranes protein family (dominated by the GCPRs), which was 
underrepresented in this analysis while it is overrepresented and should account to 10% of all 
the proteins with transmembrane helices in human (Liu et al., 2001). This observation might 
reflect the main functional aspect of the enterocyte BBM, which is the transport of nutrients 
from the intestinal lumen to the lymphatic system rather than intracellular signaling. 
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Figure 4.14: Distribution of transmembrane segments in the 260 membrane proteins 
predicted by the TMHMM algorithm.  
At first sight, the prediction of “only” about 260 membrane proteins out of a total of 1206 
proteins (slightly more than 20%) might look disappointing. However, a detailed analysis of 
the GO annotation associated with the data showed a much more differentiated picture of the 
protein population that was characterized. As a note of caution, however, it should be noted 
that the vast majority of the protein analyzed was associated with more than one GO 
annotation, depending of the function and localization of the protein in a cell. Also, many of 
those annotations were rather vague or even sometimes contradictory. As a result, the GO 
annotations of all the considered proteins were manually filtered so to keep what was believed 
to be the most relevant entry in the context of the small intestine and the enterocyte function 
(see appendix B for a complete listing of the GO annotation kept in this analysis). Finally, the 
approximately 90 categories remaining after the first data compilation had to be further 
collapsed in organelle-based groups to enable a more general overview of the proteins (Table 
4.3)    94
 
“Collapsed” GO annotation  # proteins 
associated to plasma membrane  52 
anchored to plasma membrane  60 
integral to plasma membrane  144 
associated to vesicle/ER/Golgi/endosome/microsome  80 
anchored to vesicle/ER/Golgi/endosome/microsome  29 
integral to vesicle/ER/Golgi/endosome/microsome  104 
ER/Golgi/endosome/microsome matrix  23 
associated to mitochondrial membrane  19 
anchored to mitochondrial membrane  2 
integral to mitochondrial membrane  16 
mitochondrial matrix  26 
cytoskeleton 98 
proteasome 29 
cytoplasm 331 
nucleus 31 
integral to nuclear membrane  1 
extracellular 35 
No or ambiguous “GO“ annotation  126 
 
Table 4.3:  Overview of the collapsed GO annotation categories retained for 
analysis. ”associated”: described an interaction with a membrane (such as e.g. “peripheral 
proteins”); “anchored”: annotated as being anchored to the membrane through lipids or 
other types of membrane anchors; “integral”: annotated as having at least one 
transmembrane segment. 
As could have been expected from this type of membrane preparation, one of the most 
prominent groups of proteins in the BBM preparation comprised plasma membrane proteins, 
closely followed by a group of proteins interacting in large with the ER/Golgi/endosomal 
systems, which are known to be a major “contaminant” of a plasma membrane preparation. 
The vast majority of the proteins included in these two groups are channels, transporters, and 
membrane trafficking proteins most likely taking part in the import of nutrients in the 
enterocyte and the recycling of the membrane proteins back to the plasma membrane. A third 
important group in this preparation comprised cytoskletal proteins which have also been 
known to interact with the plasma membrane. In contrast, a comparatively small number of 
mitochondrial and nuclear proteins were characterized in this preparation, reflecting the high 
grade of purification achieved by this protocol. Only about a quarter of the proteins 
characterized in this preparation were annotated as “cytoplasmic”, representing many   95
metabolic pathways, but also proteins known to interact with membrane-bound proteins such 
as chaperonins or heat shock proteins. Finally, while the high number of ribosomal proteins 
might be reasoned by the tight interaction of the ER network with the plasma membrane, the 
presence of a large number of histone proteins in this preparation can not directly be 
explained, as they should locate exclusively in the nucleus. 
4.3 Examples of protein localization 
Some BBM proteins have been described in the literature to be localized in specific regions of 
the small intestine, so that the question was raised whether such specificity could be 
demonstrated using the BBM preparation described above. For this effect, BBMs from mice 
intestinal mucosa were prepared taking care to keep separate the proximal, central and distal 
segments of the small intestine. In this experiment, the three segments had equal length (the 
small intestine was cut in thee equal parts) although, according to the anatomical 
characteristics of the small intestine, the duodenum (the proximal part) is only a short section 
after the Pylorus, while the jejunum (the central part) accounts for 90% of the total length of 
the small intestine and the ileum (the distal part) is only a short terminus section. The BBM of 
each section were loaded in 1D SDS PAGE (see figure 4.6, panel C). Each gel lane was cut in 
21 unequal gel bands and the samples were in-gel digested with trypsin. The extracted 
peptides of each band were then analyzed by LC-MS/MS and the raw data were processed 
according to the criteria previously described. The proteins identified for each section and for 
the total mucosa are listed in Appendix A2 along with their distribution along the sections 
(based on the maximum of different peptides and the total peptide counts for each protein). 
This experiment clearly demonstrates that some proteins were identified with more peptides 
from BBM isolated in section rather than from whole mucosa. In particular, there were 
several proteins that clearly located exclusively in only one of the three sections, such as the 
SR-BI receptor. The identification of this receptor was rejected in the BBM prepared from 
whole intestinal mucosa because it was identified with only one peptide. The protein 
identification carried out in each section separately confirmed the existence of the SR-BI 
receptor and its specific localization in the proximal part (see table 4.4 below). This finding 
was in agreement with a Western blot analysis against SR-BI, where the scavenger receptor 
was present almost exclusively in the duodenum segment (Fig. 4.15).    96
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15: Western blot analysis of SR-BI in BBM prepared either from full intestinal 
mucosa or from sections. SR-BI immunoblot in BBM isolated from total mouse intestinal 
mucosa (lane 1) or from each section separately (lane 2-4). Mouse liver extract was used as a 
positive control (lane5). 30 μg of total protein was loaded in each case. 1
st antibody 1:2500 
rabbit polyclonal anti-SR-BI (Cat. No:NB 400-101, NOVUS Biologicals), 2nd antibody 
1:7500 Horseradish peroxidase goat anti rabbit IgG.  
 
In the sectional approach of protein identification in the BBM membrane, several proteins 
were found equally distributed along the small intestine (see examples on table 4.4). Some 
other proteins, such as FATP-4, were identified with more peptides in the BBM prepared 
from total mucosa than in sections. This might be due to more efficient washes (higher 
volume to mass ratio) of the BBM with high salt and high pH solutions. In this case, not only 
BBM contaminants were removed more effectively but also membrane-associated proteins 
and even integral proteins with one or two transmembrane helices were washed out. 
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GeneID Data Proximal Central Distal Total Protein Name
Max_Dif_pept 36 31 33 29
Sum_pept_count 200 179 215 148
Max_Dif_pept 3 1
Sum_pept_count 3 1
Max_Dif_pept 16 3 1 10
Sum_pept_count 32 3 1 11
Max_Dif_pept 2 6 5
Sum_pept_count 3 35 15
Max_Dif_pept 18 16 14 12
Sum_pept_count 99 62 69 50
M a x _ D i f _ p e p t 91 191 0
Sum_pept_count 42 41 32 32
Max_Dif_pept 29 38 28 42
Sum_pept_count 205 356 218 297
Max_Dif_pept 1 1 9
Sum_pept_count 12 1 0
Niemann-Pick C1-like protein 1 precursor
SR-BI
Long-chain-fatty-acid--CoA ligase
IBAT
Sterolin-2
Low affinity sodium-glucose cotransporter 3)
Na(+)/H(+) exchanger regulatory factor 3) 
FATP-4
237636
20778
26458
20494
67470
64452
59020
26569
 
Table 4.4: Examples of protein distribution along the BBM membranes of the small intestine.  
Comparison of BBM analysis in sections vs. total BBM. 
 
According to the data presented on the table 4.4, it is most probable to assign the SR-BI 
receptor and the long-chain-fatty acid-CoA ligase to be exclusively located in the proximal 
part of the small intestine and the IBAT transporter to the distal part.  
4.4 Cholesterol absorption 
4.4.1 Identified proteins related to Cholesterol absorption  
One of the stated goals of this study was to investigate whether a proteomics approach could 
confirm the presence of proteins known to be involved in cholesterol absorption in the BBM. 
Table 4.5 lists the proteins (among the 1300 proteins identified in the total BBM intestinal 
mucosa preparation) that have been described in the literature, mainly based on gene data or 
immunoassays, to play a role in cholesterol absorption in the enterocyte.   98
Rank Gene Symbol Gene Description / Protein Header
Avg Pep 
count
Max diff 
peptides
6 Anpep Alanyl (membrane) aminopeptidase 961 54
11 Abcb1a Multidrug resistance protein 3 (MDR1A) 311 51
29 Npc1l1 Niemann-Pick C1-like protein 1 precursor 142 32
39 Anxa2 Annexin A2 115 29
65 Lgals4 Galectin-4 (Lactose-binding lectin 4) 80 11
66 Abcc2 Canalicular multispecific organic anion transporter 1 78 27
78 Abcg2 ATP-binding cassette sub-family G member 2 (CD338 antigen) 63 20
102 Abcg8 ATP-binding cassette sub-family G member 8 (Sterolin-2) 50 14
108 Atp8b1 Potential phospholipid-transporting ATPase  48 24
190 Mttp Microsomal triglyceride transfer protein (MTP) 27 19
192 Abcg5 ATP-binding cassette sub-family G member 5 (Sterolin-1) 26 14
335 Cd36 Platelet glycoprotein 4 (CD36 antigen) 13 9
378 Apoa4 Apolipoprotein A-IV 11 8
389 Slc10a2 IBAT (Apical sodium- dependent bile acid transporter) 11 5
417 Anxa7 Annexin A7 10 7
479 Pdia3 Protein disulfide isomerase associated 3 8 5
501 Slc27a2  Fatty acid transport protein 2 (FATP-2) 8 8
545 Slc16a1 Monocarboxylate transporter 1 (MCT 1)  8 3
559 Apoa1 Apolipoprotein A-I 8 8
562 Npc1 Niemann-Pick type C1 protein 5 2
586 Lrp1 Low density lipoprotein receptor-related protein 1 8 8
614 Fabp6 Fatty acid binding protein 6, ileal (gastrotropin) 5 3
653 Abcb11 Bile salt export pump  (Sister of P-glycoprotein) 52
826 Cubn Cubilin (intrinsic factor-cobalamin receptor) 4 4
919 Cav1 Caveolin-1 3 3
947 Slc27a4 Long-chain fatty acid transport protein 4 (FATP-4)   3 3
1001 Scp2 Sterol carrier protein 2, liver 2 2
1055 Apoe Apolipoprotein E 3 3
1056 Sec14L2 Sec14-like 3 3
1452 Scarb1 Scavenger receptor class B member 1 (SR-BI) 2 1  
Table 4.5: Potential protein candidates for intestinal cholesterol transport. The Rank order 
is a very rough approximation for protein abundance, based on the average peptide counts 
combined with the maximum different peptides for a given protein, not taking into account its 
size (large proteins generate more peptides than small ones) or its hydrophobicity 
(hydrophilic proteins generate more peptides than hydrophobic ones). 
The Niemann-Pick C1-like 1 protein (NPC1L1) is a representative example of an abundant 
protein of the BBM preparation (table 4.5: rank order 29). This 13-transmembrane segments 
protein has been described to play a critical role in cholesterol absorption and it is believed to 
be the target of Ezetimibe, a cholesterol absorption inhibitor that blocks the transport of 
cholesterol and phytosterols across the BBM of enterocytes (13). Other studies have 
attempted to show that Aminopeptidase N (table 4.1: rank order 6) might represent the 
targeted protein of Ezetimibe (102). Further, malfunction or mutation affecting the two half-
size, 6-transmembrane segments ABC transporters ABCG5 and ABCG8 (table 4.5: rank order 
192 and 102, respectively) can lead to a rare autosomal recessive disorder called 
sitosterolemia or phytosterolemia and is caused by hyperabsorption and impaired biliary 
secretion of cholesterol and plant sterols. The complex formed by Caveolin-1 and Annexin-2 
(table 4.5: rank order 919 and 39) has been suggested as key element for the cholesterol 
trafficking from the BBM to the endoplasmic reticulum (103). Finally, a pioneering work of 
Hauser et al. (104) showed that cholesterol uptake is reduced if SR-BI, a 4-transmembrane 
segments receptor, is blocked by anti-SR-BI antibodies or by competitive ligands, such as   99
apolipoprotein A-I. Similarly, SR-BI overexpression was found to increase the intestinal 
cholesterol absorption (105). The role of many of the proteins mentioned above and of several 
other proteins, such as CD36, Galectin-4, and ABCB1, is the subject of hot debates. Several 
studies have supported their involvement in cholesterol absorption but their precise 
mechanisms of action have remained unclear so far (see for example a review from Levy E. et 
al. (106)). 
It is worth mentioning here the presence of three lipoproteins, ApoA-I, ApoA-IV and ApoE, 
within the identified proteins of the BBM preparation. Their confident identification in this 
membrane preparation was rather unexpected as lipoproteins are by nature small, soluble 
proteins secreted by the liver and, therefore, they are not considered as constituents of the 
BBM. Lipoproteins were expected to be washed out from the BBM preparation during the 
several high salt (1M KCl) and high pH (100 mM Na2CO3) washes and to be identified in 
rather large amounts in these two fractions. Surprisingly, they were found in the BBM 
preparation, and not in the wash fractions (table 4.6). 
 
 
 
Table 4.6: Maximum of different peptides obtained for the ApoA-I, ApoA-IV and ApoE 
proteins. Identification of the three apolipoproteins in the BBM fraction, the KCl and Na2CO3 
wash fractions.  
The finding that the three lipoproteins (ApoA-I, ApoA-IV and ApoE) were strongly enriched 
in the BBM fraction postulates a strong interaction between these lipoproteins and a BBM 
receptor or transporter. Indeed, two lipoproteins receptors, LRP-1 and Cubilin, were identified 
among the BBM-identified proteins; LRP-1 was shown to directly interact with ApoE (107) 
while Cubilin (by itself not a transmembrane receptor, but rather a co-transporter most 
probably located on the luminal side of the enterocyte plasma membrane) has been 
documented to interact with ApoA-I (108). Interestingly, in the kidney proximal tubule, 
cubilin interacts strongly with another receptor, megalin (also known as LRP-2) which is 
postulated to mediate internalization of cubilin and its ligands. Megalin, however, could not 
be identified in our study and was shown by mRNA study to be only present in the distal part 
of the intestine (109). Finally, as noted above, the SR-BI receptor has also been shown to 
interact with the apolipoprotein ApoA-I (110). 
Gene Name wBBM wNa2CO3  wKCl
ApoA-I 810
ApoA-IV 820
ApoE 300  100
In addition to the apical surface localization of the above described proteins (table 4.5), 
intestinal cholesterol transporters have also been detected in intracellular compartments. For 
example, SR-BI has been described to be mainly localized in the microvillar membrane of 
enterocytes in the fasting state, but was endocytosed during absorption of dietary fat (111). 
The role of NCP1L1 in cholesterol trafficking has also been documented: while it is mainly 
observed in endocytic recycling compartments as long as internal cholesterol pools are 
abundant, it is rapidly translocated to the plasma membrane in situation of cholesterol 
depletion, which in turn was associated with a large increase in cellular cholesterol uptake 
(112). 
These findings suggest that intestinal cholesterol transporters may also act intracellularly, 
mediating the movement of cholesterol from BBM to various organelles. In particular, they 
may assist in the shuttling of cholesterol from BBM to the endoplasmic reticulum where the 
incoming cholesterol represents the major source of substrate for ACAT and restrains HMG-
CoA reductase activity (113). The localization of several transporters and other cholesterol 
absorption related proteins to several organelles shows that the process of cholesterol 
absorption is probably much more complicated than is known at this point of time. More 
studies will clearly be required to help understand the molecular mechanism of intestinal 
transporter-mediated cholesterol trafficking and regulation. 
4.4.2 Comparison of protein expression in the BBM of wild type mice and 
ApoE knockout mice 
One of the most widely used mouse models to study dislipidemia is the apolipoprotein E–
deficient mice (ApoE-/- mice), in which targeted deletion of the apoE gene leads to severe 
hypercholesterolemia and spontaneous atherosclerosis. ApoE is synthesized in the liver and in 
macrophages and has a number of important anti-atherogenic functions. As a constituent of 
plasma lipoproteins, it serves as a ligand for the cell-surface lipoprotein receptors such as 
LDL-receptor (LDLr) and LDLr-related proteins (LRPs), thereby promoting the uptake of 
atherogenic particles from the circulation. Consequently, homozygous deletion of the apoE 
gene in mice results in a pronounced increase in the plasma levels of LDL and VLDL 
attributable to the failure of LDLr- and LRP mediated clearance of these lipoproteins (114). 
The finding that ApoE strongly interacts with the BBM membrane (for details see § 4.4.1), 
added to the fact that many proteins involved in cholesterol absorption could also be 
identified using our protocol, encouraged us to investigate in more details the protein 
expression differences that could be observed in the BBM membrane of wild type mice versus 
ApoE knockout mice using the same proteomics approach as described above. Possible   101
differences in protein abundance could contribute to shed a better understanding in the 
mechanisms of high cholesterol absorption observed for the ApoE knockout mice.  
The isolated BBM fractions of a pool of four male ApoE-deficient mice (B6.129P2-
Apoetm1Unc/Crl) and four non-transgenic male mice of the same genetic background and age, 
were loaded in triplicate onto a 1D NuPAGE gel (see figure 4.16).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16: 1D SDS-PAGE gel representation of the BBM fractions of wild type and 
ApoE-KO mouse. Each fraction (30 μg total proteins per lane) was loaded in a 10 % 1D 
NuPAGE Bis-Tris gel run in MES buffer. 
The gel bands of the fractions were cut and in-gel digested with trypsin. The extracted 
peptides of each band were then analyzed by LC-MS/MS and the proteins of each band were 
identified according to the criteria that have been described at the § 3.2.7.2-3. Identical bands 
of the compared BBM fractions were analyzed sequentially with washing intervals, to achieve 
the best possible technical reproducibility. 
It was reinsuring that, in large, the identified BBM proteins in this experiment were identical 
to the BBM proteins that were identified in the previous study (see § 4.4.1). Most 
interestingly, several differences in protein abundance (based in peptide counts and number of 
different peptides) were clearly observed between wild type mice and ApoE KO mice. Since 
the study did not follow any formal quantification workflow, and only technical replicates 
were performed, we concentrated our interest only in proteins with major difference in 
abundance between the two types of mice, summarized in Table 4.7. 
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Table 4.7: Examples of protein abundance differences between ApoE KO and wild type 
mice. Proteins labeled in yellow have been described to participate in cholesterol absorption 
while those showing a major change in abundance are highlighted in red. 
According to the data presented in Table 4.7, the Ileal Sodium/bile acid cotransporter (IBAT) 
and apolipoprotein A-I were confidently identified in the wild type mice but were completely 
absent in the ApoE knockout mice. This finding was confirmed in all the technical triplicates. 
These findings were further validated using Western Blot analysis, and the result for IBAT is 
shown in Fig. 4.17. Unfortunately, the Western Blot analysis for Apo-AI was inconclusive 
(complete absence of signal).  
   103
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17: Western blot analysis of IBAT. Lane 1, Homogenized intestinal mucosa tissue 
from WT mice with the same genetic background as the ApoE KO. Lane 2, BBM isolated from 
the total mouse intestinal mucosa of control mice C57B/6J. Lane 3, ApoE knockout mice and 
(lane 4) WT mice with the same genetic background as the ApoE-KO mice. 1
st antibody 1:500 
goat  polyclonal anti-IBAT (Cat. No: sc-27493), 2nd antibody 1:7500 Horseradis peroxidase 
donkey anti goat IgG. MW, molecular weight marker. 
Due to its function, IBAT’s down-regulation was expected to have an impact on the bile acid 
metabolism in the ApoE-knockout mice. For this purpose, a separate in-house study 
investigated the bile acid pool size and composition in apoE-deficient mice compared to that 
in wild type mice. Results of this study showed that the liver and intestinal bile acid pool sizes 
were significantly increased in the apoE-deficient mice compare to the wild type mice 
(Evelyne Chaput, unpublished data; see Fig. 4.18). Thus, the increased bile acid production in 
the liver is consistent with disrupted bile acid re-uptake from the intestinal lumen, as expected 
from reduced IBAT protein expression, and increase the secretion of bile acids in the 
pancreatic fluids. The increased amount of bile acids in the intestinal lumen might explain 
why cholesterol absorption is higher in apoE KO mice, since the cholesterol molecule is better 
solubilized and more easily absorbed. This scenario is well supported by our data, but 
additional studies need to confirm these findings. 
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Figure 4.18: Graphic representation of the total bile acids in liver (panel A) and small 
intestine (panel B) in ApoE knockout mice and wild type mice. The total bile acids are a 
sum of all the individual bile acids determined by GC-MS (Adapted from Evelyne Chaput, 
unpublished data).  
It is worth mentioning that conflicting data have been reported for the ApoE KO mice in the 
literature. For example, in disagreement with our observations, Hakansson et al. (115) 
reported that the bile acid pool size of apoE KO does not differ from that of wild-type mice. 
In addition, the authors report an increased IBAT activity based on the intestinal absorption of 
tauro-23-[75Se] selena-25-homocholic acid. In a contradictory report, and in agreement with 
our data, Woollett et al. (116) claim that plasma cholesterol and cholesterol absorption is 
higher in the ApoE KO mice than in the wild type. Interestingly, all these studies were based 
on gene data and on pharmacokinetic studies while our findings are based on protein-level 
datasets, which might be closer to the biological realm of the small intestine thann the above 
mentioned studies. Another interesting aspect is that most studies focus on the cholesterol 
absorption and the function of the intestine as a consequence of the cholesterol metabolism in 
the liver. Here, our data suggest that at least a part of the regulation of the cholesterol 
absorption happens in the small intestine independently of the liver metabolism. As a matter 
of fact, it could well be that the critical control elements of cholesterol metabolism are trigged 
at the small intestine level and that the liver is responding to this trigger rather than to lead it.  
4.5 Assessing the reproducibility of the improved BBM 
preparation 
In section 4.2, the measurement of a triplicate BBM preparation at the protein identification 
level (using rather stringent criteria) resulted in almost 9 proteins out of 10 being identified in 
at least two of the three replicates, a very encouraging result as to obtain BBM preparations in 
a reproducible and quantitative fashion. In the following paragraphs, we studied in a 
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systematic manner the technical steps that might affect most strongly the reproducibility and 
the stability of the BBM preparation, from the initial lysis step until the protein identification 
by LC-MS/MS. The inherently variable proteolytic activity of the numerous peptidases 
located in the BBM membrane was an additional reason to verify the reproducibility of the 
protein identification. Overall, the technical evaluation of a biological preparation represents 
an important first step to know how reproducibly identical samples can be prepared. It is also 
a necessary condition to evaluate with some probability to which extent the protein expression 
difference between sample and biological groups has to vary to become significant. 
4.5.1 BBM preparation procedure 
The BBM material required for the reproducibility experiment was generated by performing 
three technical replicates of the BBM preparation starting from the same intestinal mucosa 
pool of eight mice used in the protein identification experiment described in section 4.2. As 
mentioned above, the optimized BBM preparation protocol included the addition of 
Amastatin and the peptide substrates to all steps to reduce the proteolytic degradation to a 
minimum (see Fig. 4.9). The three BBM preparation technical replicates were analyzed by 1D 
SDS PAGE to ensure that the protein distribution between the three replicates were identical 
(Fig. 4.20).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20: 1D SDS PAGE analysis of the three BBM replicates wBBM_A, wBBM_B and 
wBBM_C (lane 1-3). 30 μg of protein were loaded per lane in a 10 % 1D NuPAGE Bis Tris 
gel run in a MES running buffer system.   106
4.5.2 Comparing the variability of the technical steps: design of experiment 
A systematic approach to study the variation that each technical step added to the total 
variability is shown schematically in Fig. 4.21. The variability of the preparation was 
examined using these following parameters: 
a)  Preparation variation (is the preparation reproducible?) 
b)  SDS-PAGE variation and band excision (what happens if banding patterns are not 
absolutely reproducible?) 
c)  LC-MS/MS variation (how reproducible is a LC-MS/MS analysis?) 
All these experiments were evaluated on the basis of three representative SDS-PAGE bands, 
Band 2, Band 9, and Band 11. Band 2 represented a very abundant, very well defined high 
molecular mass band (expectation: excellent reproducibility) while Band 9 represented a 
diffuse, very faint band (expectation: not so good reproducibility). Band 11 also displayed a 
well defined band but differed from Band 2 by the fact that the proteins present in the mass 
range of the gel might also encompass proteolytic products (expectation: average 
reproducibility). 
The analysis of the three technical replicates as displayed in Fig. 4.21, Panel A, with the gel 
bands excised serially and analyzed in a random order, using several batches of LC buffers 
and LC columns (as it was done for the identification experiment described in section 4.2), 
was representative of the effects observed if most of the sources of technical variations were 
taken into account in the study and provided therefore an estimate for the maximum technical 
variability that could be expected if biological or technical replicates could not be analyzed 
concomitantly. The analysis of the second set of three technical replicates of the BBM 
preparation loaded in the same gel (Fig. 4.21, Panel B), with the gel bands excised 
simultaneously (horizontally) and analyzed using the same batch of LC buffers or LC column 
provided the level of variability related mainly to the BBM preparation since all the following 
steps remained constant (negligible gel excision, column or buffer variability). The influence 
of the gel excision on the analysis reproducibility was investigated in more details using a 
pooled BBM preparation (generated by mixing an equal amount of total protein from each 
BBM preparation) loaded three times on one SDS-PAGE gel compared to the loading of the 
same pooled BBM preparation on three different gels (Fig. 4.21, panel C). Finally, replicate 
injections of the protein digests of band 2 and 9 were representative for the variability coming 
from the LC/MS system since LC column buffers remained the same for the whole analysis. 
The variability that was caused by the column or buffer change was estimated by the LC-MS 
analysis of a 50 fmol standard peptide mixture that was regularly analyzed between samples.    107
 
 
Figure 4.21: Schematic representation of the experimental design to estimate the variability 
of each technical step. Three representative bands were chosen for all analyses: 2, 9 and 11. 
All the samples of this experiment (except the ones from panel A) were measured using the 
same batch of LC column and LC buffers. Panel A: Total variation (TV). 1D SDS PAGE 
representation of the three technical replicates of the BBM membrane preparation. The 
samples were loaded in adjacent lanes but the bands were cut serially. This panel is identical 
to the samples that were analyzed for the BBM protein identification in section 4.2.  Panel B: 
Preparation variation (PV). 1D SDS PAGE representation of the three technical replicates of 
the BBM membrane preparation. The samples were loaded in adjacent lanes and the bands 
were cut horizontally. Panel C: A pool of the three technical replicates of BBM was 
generated (equal amount of protein from each fraction). 30 μg total proteins from the pooled 
BBM were loaded three times in the same gel in adjacent lanes (lanes 1-3) and once in three 
different gels (lanes A-C). Panel D: The bands 2 and 9 of the pooled BBM (see also Panel C, 
lane 1) were injected three times into the LC-MS system. See text for more details.   108
4.5.3 Estimation of experimental reproducibility 
The reproducibility of the technical steps and of the BBM preparation was estimated based on 
two different analyses. In the first approach, samples comparison was based on the 
identification rate in the samples considered. The number of commonly identified proteins in 
each representative band (2, 9 and 11) within the three replicates of each technical step was 
illustrated in the form of Venn diagrams. In the second approach, sample comparison was 
based on the total ion current of each sample’s ion chromatogram. Datasets were processed 
with the Gene data software using the processing filters that have been described in the § 
3.2.7.3. 
4.5.3.1 Estimation of experimental reproducibility based on Protein identification 
The study of the variability of each technical step based on protein identifications was 
performed using a set of rules that was different from the identification study. In particular, 
for the purpose of this investigation, proteins with one identified peptide were also considered 
as successfully identified. Sample comparison was performed in the form of Venn diagrams 
as there was no simple method to measure similarity between three samples. 
4.5.3.1.1 Venn diagrams representation 
Venn diagrams are a schematic representation to represent all the possible mathematical or 
logical relationship between groups. Each group is usually represented in the form of a circle, 
and overlapping area (intersections) stands for the similarity between groups. In this study, 
triplicate measurements of the three bands 2, 9 or 11, were compared to each other along the 
different technical steps. The Venn diagrams of all identified proteins in band 2 categorized 
by technical step are shown in Fig. 4.22. Each Venn circle represents an LC-MS analysis and 
the number of identified proteins for the band 2 in every of those analysis. The number 
outside the circle indicates the total number of proteins that have been identified with at least 
one peptide in this sample. The intersection between two circles shows the commonly 
identified proteins between the two compared samples, while the intersection of the three 
triplicates shows the number of commonly identified proteins in all the three compared 
samples. The triplicate injections of the band 2 from a BBM pool preparation (fig. 4.22, Panel 
A) was expected to exhibit the least variability of all the technical steps considered because it 
reflects the variability of the measurements in the mass spectrometer alone, keeping all other 
technical steps (nano LC column and buffers) constant. Comparison of the results shown in 
Panels B and C provides a measure about the variability that is due to the manner SDS-gel  
   109
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.22: Venn diagram representation of a triplicate analysis of the band 2 considering 
the variability of different technical steps. Panel A: Comparison of a triplicate injection of 
Band 2 obtained from a BBM pool preparation. Panel B: Triplicate comparison of Band 2 
obtained from a BBM pool preparation loaded in adjacent lanes of the same gel. Panel C: 
Triplicate comparison of Band 2 obtained from a BBM pool preparation loaded in three 
different gels. Panel D: Triplicate comparison of Band 2 obtained from the three BBM 
preparation. All LC-MS technical steps were kept constant. Panel E: Triplicate comparison 
of Band 2 obtained from the three BBM preparations taking into account all technical 
variability (e.g. including LC-MS) into account. 
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bands were excised, while panel D’s Venn diagram is showing the variability between the 
three BBM preparations since the samples were injected sequentially into the LC-MS system 
and all LC-MS technical steps were kept constant. The Venn diagram in Panel E reflects the 
variability observed for the proteins identified in Band 2 for the three BBM preparations when 
the samples were analyzed in a random fashion that is, taking into account all the technical 
variability of all the steps. Figure 4.23 and 4.24 show the Venn diagrams for the 
corresponding analysis of band 9 and 11.   111
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23: Venn diagram representation of a triplicate analysis of the band 9 considering 
the variability of different technical steps. Panel A: Comparison of a triplicate injection of 
Band 9 obtained from a BBM pool preparation. Panel B: Triplicate comparison of Band 9 
obtained from a BBM pool preparation loaded in adjacent lanes of the same gel. Panel C: 
Triplicate comparison of Band 9 obtained from a BBM pool preparation loaded in three 
different gels. Panel D: Triplicate comparison of Band 9 obtained from the three BBM 
preparation. All LC-MS technical steps were kept constant. Panel E: Triplicate comparison 
of Band 9 obtained from the three BBM preparations taking into account all technical 
variability (e.g. including LC-MS) into account. 
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Figure 4.24:  Venn diagram representation of a triplicate analysis of the band 11 
considering the variability of different technical steps. Panel A: Triplicate comparison of 
Band 11 obtained from a BBM pool preparation loaded in adjacent lanes of the same gel. 
Panel B: Triplicate comparison of Band 11 obtained from a BBM pool preparation loaded in 
three different gels. Panel C: Triplicate comparison of Band 11 obtained from the three BBM 
preparation. All LC-MS technical steps were kept constant. Panel D: Triplicate comparison 
of Band 11 obtained from the three BBM preparations taking into account all technical 
variability (e.g. including LC-MS) into account. 
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The number of commonly identified proteins in bands 2, 9 or 11 across the different technical 
steps provides a first overview about the variability of each technical step. A graphic 
representation of the commonly identified proteins in two or three replicates, for each band 
and for each technical step is shown in Fig. 4.25. 
Based on these results, it is apparent (and reinsuring) that the injection replicates show the 
highest reproducibility in respect to the number of commonly identified proteins, that is, the 
set-up and the operation of the LC-MS system was appropriate and reproducible for the 
number of proteins and the dynamic range expected for a 1D-SDS-PAGE band. Interestingly, 
the manner by which gel bands were cut (horizontally or one lane after the other) added some 
variability but the overall effect at the identification level was surprisingly moderate, 
indicating that, if proper care is taken, analysis run on several 1D-SDS gels are comparable. 
Further, the overall BBM preparation protocol (including a precipitation stage, several 
low/high spin centrifugation steps and many washes) appeared to be very stable and 
reproducible since the variability on the number of commonly identified proteins was in the 
same range as what was obtained with the BBM pool preparation loaded on the different gel 
variation and quite close to injection replicates. Finally, the comparison of panel E with 
panels C and D allow to draw some conclusions about the importance of a proper design of 
experiment to restrict unwanted variability. The major difference between those two 
conditions was that the LC-MS analysis performed for the panels C and D were purposely 
done using the same column and same buffer batch within the same sample measurement, 
whereas the LC-MS analysis performed for the panel E was done in a random order with 
sometimes column and buffer changes between the samples to be compared. Thus, the relative 
total variability increase observed for band 2 (see figure 4.22, panel E) was less than observed 
within band 9 (see figure 4.23, panel E) or 11 (see figure 4.24, panel D) because the three 
samples of band 2 were randomly analyzed however using the same column (additional 
variability might have been possibly due to the column history). The total variability for the 
band 9 was still moderate since there was only column change between the analyzed samples 
while the variability for band 11 was much higher, probably due to change of column and 
buffer between injections of the samples. This particular topic will be investigated more 
extensively in the next section. Interestingly, while band 2 was much more intense than bands 
11 and 9 (the band 9 was very faint), the number of proteins identified in band 9 was double 
compared to band 2. This might be due in part to ion suppression due to very high abundant 
proteins in the band 2 (The instrument’s duty cycle was limitating) and/or it might point to the 
presence of proteolytic fragments in this lower molecular mass band.   114
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.25: Graphic representation of Average intersections of 2 and 3 samples in each 
technical step for band 2 (Panel A), band 9 (Panel B) and band 11 (Panel C). 
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4.5.3.2 Estimation of experimental reproducibility based on LC-MS signals 
Comparison of samples based on protein identification is a very well known and accepted 
practice in a proteomics experiment. Its main drawback lies in the fact that protein 
identification is based on properly annotated and identified MS/MS data corresponding to at 
most 10-20% of the overall mass spectrometric information due to the duty cycle and the 
sensitivity of the instrument. In other words, 80% of the generated information cannot be 
directly used, because either the MS/MS spectrum could not be successfully assigned to a 
peptide sequence or because the parent mass observed in the full MS spectrum was not 
selected for tandem MS analysis. 
Recently, several groups (including ours) have started to consider the precursor ion intensity 
in the full spectrum as a more comprehensive descriptor for sample comparison. In this spirit, 
the data analysis performed at the peptide identification level was extended to include the MS 
precursor level. The variability of the BBM sample preparation and the influence of various 
technical parameters on the comparability of the samples were assessed to study how these 
can be directly derived at the MS level. Furthermore, the question on how much the 
information at the MS and the MS/MS levels corresponded was also explored. 
4.5.3.2.1 Comparative analysis of a standard peptide mixture 
In a first approach, a simple standard peptide mixture of 6 digested proteins Cytochrome C, 
Lysozyme, Alcohol dehydrogenase, Bovine serum albumin, Serotransferrin and ß-
Galactosidase, (the so-called LCP Dionex peptide mixture) was used to tune the data 
processing scheme and to become acquainted with the data behavior in ideal settings to 
understand how to judge (dis)similarity in this context. The simplistic nature of this sample 
makes it significantly easier to monitor the dilution effect and column or buffer variability. In 
a second step, the key learning from this idealized study was applied to a more complicated 
dataset, such as the bands 2, 9 and 11 that have been discussed in the preceding section. 
The raw data of each LC-MS run was processed according to the parameters described in       
§ 3.2.7.3. Filtered signals that were present in 2/3 of the runs analyzed were accepted as 
common signals. Each of those MS signals was associated with a run-specific RT and 
accurate mass to allow the pairwise comparison of the processed MS signals between two 
samples in the form of scatter plots. The linearity and data distribution at the diagonal (that is, 
the intensity deviation of the common signals from an ideal linear relationship) was expressed 
using the Spearman correlation. Spearman's rank correlation coefficient is a non-parametric 
measure of correlation – that is, it assesses how well an arbitrary monotonic function could   116
describe the relationship between two variables, without making any assumptions about the 
frequency distribution of the variables. In the case of perfect reproducibility, we expect all the 
data points to be located in a diagonal, which gives a correlation of 1.0. 
Fig. 4.26 shows the scatter plots representative for the comparison of three injection triplicates 
of a 50 fmol standard peptide mixture. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.26: Scatter plot representations of three injection replicates of a 50 fmol Standard 
Peptide Mixture.  Panel A: Scatter plots of all common MS signals found in the three 
replicates.  Panel B: Scatter plots of common MS signals which have been successfully 
assigned to a MS/MS identification. N states for the number of common signals. The 
Spearman value reflects the similarity of the signal intensities between the compared samples 
(ideal case Spearman correlation=1). Each red dot line parallel to the diagonal represents a 
two fold difference, i.e. across three lines, the fold change is 2*2*2=8. Accordingly, the axes 
represent an arbitrary mass spectrometric intensity (in counts) in log2 units. 
The scatter plots for each compared LC-MS(/MS) pair, based on the total MS signals (Panel 
A) or the successful MS/MS measurements (Panel B), highly correlated with each other. The 
clustering of the common features along the diagonal indicates that the precursor MS ions 
have the same intensity in the two considered samples, a feature to be expected in this 
experiment where replicates injections of the same sample were analyzed. Further, the 
Spearman correlation values for both types of analyses were almost identical, strengthening 
our conviction that a comparison of samples based on the precursor mass intensity should 
provide comparable results as using the protein identification descriptor. 
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Scatter plots as shown in Fig. 4.26 could also be used to visualize dilution effects. For 
example, as shown in Fig. 4.27, the precursor mass signal intensity of a 50 fmol standard 
peptide mixture is compared to the precursor mass signal intensity of a 125 fmol injection of 
the same peptide mixture. 
 
 
 
 
 
 
 
 
Figure 4.27: Scatter plot representations of a comparison between a 125 fmol and a 50 fmol 
injection of a Standard Peptide Mixture.  Panel A: Scatter plots of all the common MS 
signals between the samples. Panel B: Scatter plots of the MS Signals that correspond to 
successful MS/MS measurements. N is the number of common signals. The Spearman value 
reflects the similarity of the signal intensities between the compared samples (ideal case 
Spearman correlation=1). Each red dot line parallel to the diagonal represensts a two fold 
difference, i.e. across three lines, the fold change is 2*2*2=8. Accordingly, the axes represent 
an arbitrary mass spectrometric intensity (in counts) in log2 units. 
The 109 common precursor mass intensities based on MS/MS identification (Fig. 4.27, panel 
B) all clearly lied on a diagonal with an offset of approximately 2.5 fold difference from unity, 
as was expected from the experiment design. A similar pattern could also be observed for the 
5662 common precursor masses found in both samples (Fig. 4.27, panel A) with the exception 
that two ions populations were clearly detected. The first population, comprising the most 
abundant ions of the analysis, were lying on a diagonal with an offset of approximately 2.5 
fold difference similarly to the ions that were identified through a MS/MS identification. This 
first population was assumed to represent actual peptides that were differentially detected in 
the analysis. The second ion population, which included mostly low abundant signal, 
clustered along the diagonal, and could represent the consistent chemical noise that was co-
analyzed with the samples. 
More subtle effects, such as column ageing, could also be monitored using the same strategy. 
The effect of column history on MS signal intensity was put in evidence by following the 
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pattern of a 50 fmol standard peptide mixture analyzed in a new column and then again using 
the same column and LC buffers after several samples injections (Fig. 4.28). 
 
 
 
 
 
 
 
 
 
 
Figure 4.28: Scatter plot representations of two 50 fmol injections of a Standard Peptide 
Mixture, injected onto the same column with the interval of several samples. Panel A: 
Scatter plots of all the common MS signals between the samples. Panel B: Scatter plots of the 
MS Signals that correspond to successful MS/MS measurements. N is the number of common 
signals. The Spearman value reflects the similarity of the signal intensities between the 
compared samples (ideal case Spearman correlation=1). Each red dot line parallel to the 
diagonal represents a two fold difference, i.e. across three lines, the fold change is 2*2*2=8. 
Accordingly, the axes represent an arbitrary mass spectrometric intensity (in counts) in log2 
units. 
Not surprisingly, the common signals of the two identical peptide standards did not show the 
same intensity. MS signals were stronger when the fresh standard peptide mixture 
(ET_pepmix_50fmol_220807) was analyzed with a new column (for more details see 
appendix B: table of process variation time record). A Spearman correlation value of 0.74 for 
the total MS signals, or 0.755 for the MS signals with successful MS/MS identification, were 
significantly lower that for an ideal case, and demonstrated that column history might 
contribute to the experimental variability of comparable samples. 
The impact of changing column and/or buffers during samples measurement was also 
investigated. The comparison of standard peptide mixtures measured using two identical 
columns (identical dimensions, lot number and sample history) showed that common MS 
signal intensities deviated somehow from the diagonal, also reflected in the lower Spearman 
correlation value (Fig. 4.29), but without dramatic changes in the data behavior. 
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Figure 4.29: Scatter plot representations of two 50 fmol injection of a Standard Peptide 
Mixture, injected in two identical columns with the same sample history. Panel A: Scatter 
plots of all the common MS signals between the samples. Panel B: Scatter plots of the MS 
signals that correspond to successful MS/MS measurements. N is the number of common 
signals. The Spearman value reflects the similarity of the signal intensities between the 
compared samples (ideal case Spearman correlation=1). Each red dot line parallel to the 
diagonal represents a two fold difference, i.e. across three lines, the fold change is 2*2*2=8. 
Accordingly, the axes represent an arbitrary mass spectrometric intensity (in counts) in log2 
units. 
A similar data distribution was observed when the standard peptide mixture was analyzed on 
the same column but using different LC solvent batches (results not shown). However, these 
two effects acted synergistically when the standard peptide mixture was analyzed using 
different columns and different LC buffer batches (Fig. 4.30), as reflected by the lower 
Spearman correlation values. Interestingly, the column/buffer effects were consistently more 
pronounced at the global precursor MS level than at the common signals that were linked to a 
successful MS/MS measurement. However, the limited number of measurements that were 
performed using the standard peptide mixture did not allow to differentiate whether this 
difference in distribution was mostly due to a massive change of background ions distribution 
compared to the peptide signals, or whether the difference was due to minor mismatching of 
the precursor masses during sample analysis, leading to increased noise in the corresponding 
scatter plots. 
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Figure 4.30: Scatter plot representations of two injections of a 50 fmol Standard Peptide 
Mixture onto two different columns and using different buffers batches. Panel A: Scatter 
plots of all the common MS signals between the samples. Panel B: Scatter plots of the MS 
signals that correspond to successful MS/MS measurements. N is the number of common 
signals. The Spearman value reflects the similarity of the signal intensities between the 
compared samples (ideal case Spearman correlation=1). Each red dot line parallel to the 
diagonal represents a two fold difference, i.e. across three lines, the fold change is 2*2*2=8. 
Accordingly, the axes represent an arbitrary mass spectrometric intensity (in counts) in log2 
units. 
In summary, the analysis of a simple standard peptide mixture using idealized differential 
conditions of the LC-MS system confirmed that the precursor ion intensity embodies an 
appropriate descriptor to evaluate the similarity of a sample to another and to pinpoint to 
common experimental deviations, such as column and LC buffer changes, or dilution effects. 
In particular, the behavior of all the ions considered in a pair of samples was very comparable 
to the ion population that was characterized by tandem mass spectrometry to represent the 
mass spectrometric signals of peptides commonly shared by the two samples considered.  
The quality of this similarity was expressed using the Spearman correlation value, a non-
parametric function to evaluate the degree of correlation between two parented ion intensity 
population to follow an arbitrary monotonic function, here a simple linear function of slope 
x=1. It is of interest that the Spearman correlation value was calculated here taking into 
account all the ions considered. However, the graphic representation of the ion distribution in 
the form of scatter plot clearly separated two populations of ions. The first group mostly 
clustered at the diagonal independently of the samples being compared and tended to 
encompass the lower intensity ions. The second group, which included mostly the higher 
intensity ions, also clustered along a diagonal but with a distinct offset from the first group 
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depending on the type of samples being compared. It was our belief that these two groups 
represented the solvent and LC contaminants ions and the sample peptide ions, respectively, 
which should be considered separately in an ulterior version of this similarity measure. 
4.5.3.2.2 Comparative analysis of the BBM SDS gel bands 2, 9 and 11. 
The quality and the reproducibility of the BBM preparation was assessed at the precursor ion 
level on the basis of the analysis of the selected gel bands 2, 9 and 11. The goal of this 
analysis was two-fold: firstly, to explore whether a differential analysis based on precursor 
mass intensities would align with the findings derived from the comparison of the same 
samples based on protein identification; and secondly, to evaluate to which extent the 
(ir)reproducibility of the LC-MS system could be observed in a more complex protein 
mixture such as used for the BBM identification study. 
As already mentioned in section 4.5.2, all comparisons were performed using three 
representative SDS-PAGE bands, Bands 2, 9, and 11. Band 2 represented a very abundant, 
very well defined high molecular mass band (expectation: excellent reproducibility) while 
Band 9 represented a diffuse, very faint band (expectation: not so good reproducibility). Band 
11 also displayed a well defined band but differed from Band 2 by the fact that the proteins 
present in the mass range of the gel might also encompass proteolytic products (expectation: 
average reproducibility). For simplicity reason, only representative scatter plots of chosen 
sample comparisons will be shown. The complete set of scatter plots and Spearman 
correlation values for all comparisons can be found in appendix B3. 
Fig. 4.31 shows the comparison scatter plots for the three injection replicates of the band 2. 
The three replicates were very reproducible according to the scatter plot representation of all 
common MS signals and of the MS signals that correspond to successful MS/MS 
measurement. The Spearman correlation values for all comparisons were above 0.98 
underlining the very good linearity of the signals at the diagonal. Similarly to what was 
observed with the simple Dionex protein mixture, the MS signals which were successfully 
assigned a peptide sequence through MS/MS analysis were in large of high signal intensity 
(panel B). However, this ion population represented less than 10% of the overall common MS 
signals (compare N between panel A and B). 
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Figure 4.31: Scatter plot representations of the injection replicates of the band 2. Panel A: 
Scatter plots of all the common MS signals between the replicates. Panel B: Scatter plots of 
the MS signals that correspond to successful MS/MS measurements. N is the number of 
common signals. The Spearman value reflects the similarity of the signal intensities between 
the compared samples (ideal case Spearman correlation=1). Each red dot line parallel to the 
diagonal represents a two fold difference, i.e. across three lines, the fold change is 2*2*2=8. 
Accordingly, the axes represent an arbitrary mass spectrometric intensity (in counts) in log2 
units. All sample denominations are as described in Fig. 4.21. 
Further, the comparison scatter plots for a triplicate analysis of the band 2 excised from three 
adjacent SDS-PAGE lanes is shown in Fig. 4.32. The added variability of this technical step 
compared to the triplicate injection replicate was rather moderate as judged by the uniform 
and only slightly lower Spearman correlation values compared to the injection replicates. The 
main feature differentiating those two analyses were a broadening of the ion distribution along 
the diagonal, especially noticeable at the lower ion intensity scale, and a ion correlation 
matrix that did not include the least intense ion, probably because of lack of reproducibility 
(compare Fig. 4.31 and Fig. 4.32 panels A and panels B side by side). Interestingly, within the 
triplicate analysis included in Fig. 4.32, the samples pool_wBBM_2_2 and pool_wBBM_3_2 
appeared to correlate slightly better to each other than with the sample pool_wBBM_2_1, a 
finding that was not observed from the Venn diagrams analysis of the same samples (compare 
with Fig. 4.22, panel B). 
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Figure 4.32: Scatter plot representations of the variability for the band 2, cut horizontally 
from adjacent identical lanes. Panel A: Scatter plots of all the common MS signals between 
the replicates. Panel B: Scatter plots of the MS signals that correspond to successful MS/MS 
measurements. N is the number of common signals. The Spearman value reflects the 
similarity of the signal intensities between the compared samples (ideal case Spearman 
correlation=1). Each red dot line parallel to the diagonal represents a two fold difference, i.e. 
across three lines, the fold change is 2*2*2=8. Accordingly, the axes represent an arbitrary 
mass spectrometric intensity (in counts) in log2 units. All sample denominations are as 
described in Fig. 4.21. 
Similarly, the comparison scatter plots for a triplicate analysis of the band 2 excised from a 
lane run in three separate SDS-PAGE gels is shown in Fig. 4.33. As expected from the 
previous analysis, the added variability of this technical step was very comparable to the 
variability obtained from the triplicate bands excised from a single SDS-PAGE gel. The 
measurement reproducibility depended mostly on how accurately the bands were defined and 
excised from the SDS-PAGE gel, the type (wide/narrow; defined/diffuse, etc.) of bands that 
was analyzed, and how identically the gels to be compared had run. Interestingly, in this 
triplicate analysis shown in Fig. 4.33, the samples pool_wBBM_A2 and pool_wBBM_B2 
appeared to correlate slightly better to each other than with the samples pool_wBBM_C2, a 
finding that was not observed from the Venn diagrams analysis of the same samples (compare 
with Fig. 4.22, panel C). Taken together, the results obtained in Fig. 4.32 and 4.33 suggest 
that the SDS-PAGE step appeared non-critical for the reproducibility of an experiment as long 
as the parameters for protein separation and band excision were kept tightly controlled. 
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Figure 4.33: Scatter plot representations of the band 2 from identical BBM samples, loaded 
in three different gels. Panel A: Scatter plots of all the common MS signals between the 
replicates. Panel B: Scatter plots of the MS signals that correspond to successful MS/MS 
measurements. N is the number of common signals. The Spearman value reflects the 
similarity of the signal intensities between the compared samples (ideal case Spearman 
correlation=1). Each red dot line parallel to the diagonal represents a two fold difference, i.e. 
across three lines, the fold change is 2*2*2=8. Accordingly, the axes represent an arbitrary 
mass spectrometric intensity (in counts) in log2 units. All sample denominations are as 
described in Fig. 4.21. 
The comparison scatter plots for the LC-MS signals of the band 2 originating from three 
different technical BBM preparations is shown in Fig. 4.34. Since all technical steps (samples 
run on the same SDS-PAGE gel, band excision, digestion, column and buffer batch, LC-MS 
conditions) were maintained constant, the observed variability for the common signals should 
mainly reflect the reproducibility of the BBM preparation. The common MS signals (Panel A) 
and the common MS signals that were assigned to a successful MS/MS identification (Panel 
B) were clustered at the diagonal indicating a high level of similarity between the three BBM 
preparations. This observation was supported by a high Spearman correlation value (above 
0.94) for all the comparisons. This high degree of reproducibility was also noted for the 
preparation variation analysis of bands 9 and 11 (results not shown, for more details see 
appendix B) and correlated with the findings obtained from the protein identification level 
(see Fig. 4.22, panel E, Fig. 4.23, panel E and Fig. 4.24, panel D). These results demonstrate 
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that the BBM preparation protocol could be performed in a very stable and reproducible 
manner that added only a minimal variability compared to other technical steps. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.34: Scatter plot representations of the preparation variability for the band 2 from 
three BBM technical replicate preparations. Panel A: Scatter plots of all the common MS 
signals between the replicates. Panel B: Scatter plots of the MS signals that correspond to 
successful MS/MS measurements. N is the number of common signals. The Spearman value 
reflects the similarity of the signal intensities between the compared samples (ideal case 
Spearman correlation=1). Each red dot line parallel to the diagonal represents a two fold 
difference, i.e. across three lines, the fold change is 2*2*2=8. Accordingly, the axes represent 
an arbitrary mass spectrometric intensity (in counts) in log2 units. All sample denominations 
are as described in Fig. 4.21. 
Finally, the comparison scatter plots for the LC-MS signals of the band 2, 9 and 11 
originating from three different technical BBM preparations is shown in Fig. 4.35, 4.36 and 
4.37, respectively. In this last set of analyses, however, the technical steps were not as tightly 
controlled and the samples were analyzed in random orders. 
According to the scatter plot representation and the Spearman correlation values (Fig. 4.35), 
the variability observed for the band 2 was considerably lower than for the bands 9 and 11. In 
this experiment, variability must originate from the technical steps since the three BBM 
preparation were found to be highly reproducible in the previous section. In our experience, 
most  
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of the technical variability was due to different column history, column and LC buffer 
changes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.35: Scatter plot representations of the total variability for the band 2 from three 
BBM technical replicate preparations, randomly analyzed. Panel A: Scatter plots of all the 
common MS signals between the replicates. Panel B: Scatter plots of the MS signals that 
correspond to successful MS/MS measurements. N is the number of common signals. The 
Spearman value reflects the similarity of the signal intensities between the compared samples 
(ideal case Spearman correlation=1). Each red dot line parallel to the diagonal represents a 
two fold difference, i.e. across three lines, the fold change is 2*2*2=8. Accordingly, the axes 
represent an arbitrary mass spectrometric intensity (in counts) in log2 units. All sample 
denominations are as described in Fig. 4.21. 
Indeed, the triplicates of the band 2 were randomly analyzed along the whole experiment but 
the column and LC buffer remained the same for the three analyses. The Spearman correlation 
value was slightly lower than was found for the preparation variation alone but remained in 
the same range. The slightly elevated variability could be due to the manner the gel bands 
were excised from the gel (one after the other versus horizontal parallel cutting) and to the LC 
column history. Thus, according to the Spearman correlation value, the samples 
TV_wBBM_3_2 and TV_wBBM_2_2 were significantly better correlated than with 
TV_wBBM_1_2 probably, because these two first samples were analyzed very closely to 
each other at the LC-MS level (only 2 samples separated the two band 2 replicates). 
The variability observed for band 9 was significantly higher than that found for band 2 and 
was reflected in the scatter plots and the Spearman correlation values (Fig. 4.36). In our 
experience, this large increase in variability was due to column and buffer changes during the   127
analysis of the band 9 triplicates. Thus, the correlation of the replicates TV_wBBB_1_9 and 
TV_wBBM_3_9 was much higher than with TV_wBBM_2_9. TV_wBBB_1_9 and 
TV_wBBM_3_9 were analyzed on two different columns but using the same LC buffer batch, 
while TV_wBBM_2_9 was analyzed using a different column and another LC buffer batch. 
More details about the analysis sequence of all the samples included in this experiment can be 
found in the process variation measurement times in the appendix B. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.36: Scatter plot representations of the total variability for the band 9 from three 
BBM technical replicate preparations, randomly analyzed.  Panel A: Scatter plots of all the 
common MS signals between the replicates. Panel B: Scatter plots of the MS signals that 
correspond to successful MS/MS measurements. N is the number of common signals. The 
Spearman value reflects the similarity of the signal intensities between the compared samples 
(ideal case Spearman correlation=1). Each red dot line parallel to the diagonal represents a 
two fold difference, i.e. across three lines, the fold change is 2*2*2=8. Accordingly, the axes 
represent an arbitrary mass spectrometric intensity (in counts) in log2 units. All sample 
denominations are as described in Fig. 4.21. 
Column and buffer changes affected the analysis of band 11 in a similar fashion as seen in 
band 9 (see Fig. 4.37). Thus, the two replicates TV_wBBM_2_11 and TV_wBBM_3_11 
clustered significantly better to each other than with the replicate TV_wBBM_1_11. Indeed, 
the replicates TV_wBBM_2_11 and TV_wBBM_3_11 were measured using different 
columns but the same LC solvent batch, while TV_wBBM_1_11 was analyzed using a 
different column and another LC buffer batch. 
Interestingly, for all bands considered (but mostly for bands 9 and 11), the significantly lower 
comparability of the total variability analysis compared to the preparation variability analysis 
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was only partially observed at the protein identification level (see Fig. 4. 22, panel D and E; 
Fig. 4.23, panels D and E; and Fig. 4.24, panels C and D). The ion correlation matrix which  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.37: Scatter plot representations of the total variability for the band 11 from three 
BBM technical replicate preparations, randomly analyzed. Panel A: Scatter plots of all the 
common MS signals between the replicates. Panel B: Scatter plots of the MS signals that 
correspond to successful MS/MS measurements. N is the number of common signals. The 
Spearman value reflects the similarity of the signal intensities between the compared samples 
(ideal case Spearman correlation=1). Each red dot line parallel to the diagonal represents a 
two fold difference, i.e. across three lines, the fold change is 2*2*2=8. Accordingly, the axes 
represent an arbitrary mass spectrometric intensity (in counts) in log2 units. All sample 
denominations are as described in Fig. 4.21. 
was used to create the scatter plots depends heavily on a reproducible RT and m/z parameters 
linked with the measured ion signal intensity, whose variability was minimized  by measuring 
the samples to compare immediately one after another. Moreover, the correlation matrix took 
into account all MS signals that were commonly assigned to the samples, with a majority of 
them being rather of low intensity and subject to higher variability. In contrast, sample 
comparison by protein identification was based on a MS signal that was successfully assigned 
to an amino acid sequence through a MS/MS identification. Since this ion population 
comprised mostly well behaved, reproducible high intensity MS signal, the correlation matrix 
illustrated through Venn diagrams was much more resistant to intensity variability than for 
the common MS signals. 
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4.5.3.2.3 LC-MS reproducibility 
The total variability analysis for the bands 9 and 11 showed that a major part of the observed 
technical variability was caused by the LC buffer followed by the column changes. Buffer 
changes, in particular, had a major impact on the peptides’ retention times as shown in the 
figure 4.38 and 4.39. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.38:  Genedata Refiner MS signals representation of the retention time (RT) 
alignments of all the technical replicates related to band 2. The RT alignments of the total 
variation (TV) samples are marked in red while all other technical replicate samples are 
marked in blue. The two sample groups cluster according to the LC buffer and column batch 
they had been analyzed with, see text for additional details. The name conversion for the data 
files in the inset can be found in appendix B . 
The retention time alignment for the band 2 and 11 showed the obvious impact of LC buffer 
and column change on the MS signal alignment. In the case of band 2 (see figure 4.38) the RT 
alignment of the three “total variation” sample replicates (red traces) aligned very well with 
each other because these samples were analyzed using the same column and buffer batch. A 
similar good alignment was observed for all remaining LC-MS measurements (blue traces) of 
the band 2 as they were also measured using the same column and buffer batch. In this 
particular example, the rather different behaviors of both sample sets was due to the use of   130
different column and LC buffer batches, resulting in a less satisfying alignment between the 
common MS signals. 
The picture was somehow different for the RT alignment of the band 11. The MS signals of 
the samples TV_wBBM_2_11 and TV_wBBM_3_11 showed very good RT alignments 
(Figure 4.39, red traces) to each other, although they were analyzed with two different 
columns. On the other hand, the RT coordinates from the third triplicate TV_wBBM_1_11 
appeared to significantly deviate from the two other MS signals (see figure 4.39, green traces) 
due to a buffer change between the analysis of this sample and the other two replicates. 
Finally, all remaining LC-MS measurements (blue traces) of the band 11 were measured 
using the same column and buffer batch, thus showing a consistent RT alignment with each 
other. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.39: Genedata Refiner MS signals representation of the retention times (RT) 
alignments of all the technical replicates related to band 11. The RT alignments of the total 
variation (TV) samples are marked in red and green while all other technical replicate 
samples are marked in blue. The three sample groups cluster according to the LC buffer and 
column batch they had been analyzed with, see text for additional details. The name 
conversion for the data files in the inset can be found in appendix B.  
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4.5.3.3 Findings and discussion  
Many researchers in the field have claimed that the LC-MS/MS approach lacks the technical 
reproducibility to reliably identify proteins in a proteomics experiment. In this study, we 
aimed to examine this common belief by setting up an experiment in which we evaluated the 
reproducibility of the LC-MS measurements by counting how many proteins could reliably be 
identified in the analysis of triplicate technical BBM preparations. 
The triplicate LC-MS/MS measurements of the 19 gel bands corresponded to each BBM 
preparation (see § 4.2) resulted in almost 90% commonly identified proteins in at least two of 
three preparations with at least two different peptides in one of the reprlicates. This degree of 
reproducibility was much higher than what was optimistically expected in our group and 
better than what has been openly claimed so far by other proteomics groups. 
This unexpected outcome led me to investigate in more details whether this very high level of 
identification reproducibility achieved in this study was not based on an over-optimistic 
interpretation of the data. For this reason I decided to study in a systematic manner the 
contribution in variability that selected technical steps might add in the overall analytical 
process. For this purpose, the gel bands 2, 9 and 11, and a standard peptide mixture were used 
as references to set up an experiment to monitor the variability of the LC-MS(/MS) system 
(mass spectrometer performance, column history and column or/and buffer change), the gel 
band excision process, and the variations due to the BBM isolation protocol. 
Data analysis and interpretation proved to be a very hard and time consuming process, 
because there was no unique value to comprehensively report on the simultaneous comparison 
of three (or more) samples. One of the main reasons to adopt the Venn diagram representation 
was that the commonly identified proteins within the triplicate analysis could be easily 
visualized. Simultaneously, we sought to take advantage of the high mass accuracy provided 
by the Orbitrap mass spectrometer and the reproducibility of the liquid chromatographic 
system to evaluate, whether such a data analysis could also be performed using the precursor 
mass intensity. 
Taken as a whole, the systematic evaluation of the technical variability added by selected 
technical steps to the overall analytical process unambiguously confirmed the high 
reproducibility achieved by the LC-MS/MS process at the protein identification level. As 
expected, sample comparison based on injection replicates showed the best reproducibility, 
stressing the stability and the robustness of the LC-MS/MS system. The strategy used to 
excise bands from SDS-PAGE gels (horizontally in adjacent lanes of the same gel, or one lane   132
cut after the other on different gels) was identified to potentially represent a major cause of 
variability if not appropriately controlled. An irreproducible gel excision pattern might cause 
a considerable variability in the protein content of a given gel band leading to inconsistent 
identifications when compared to the equivalent gel band of another sample. 
The BBM isolation protocol itself was a potential source of variability due to its relative 
length and complexity and due to the inclusion of several steps that might have been difficult 
to carry out quantitatively, such as the CaCl2 precipitation step. Also, the remaining 
proteolytic activity of the abundant BBM proteases, if unchecked, could also contribute to 
sample degradation and add extensive variability to the protein identification process. The 
preparation variation as mirrored in the comparison of the BBM technical triplicate analysis 
of bands 2, 9 and 11 showed a very high level of reproducibility in the number of commonly 
identified proteins (almost at the level of injection replicates) as long as all other technical 
steps (SDS-PAGE gel, band excision strategy, LC-MS/MS conditions) were kept constant. 
The variability in the number of commonly identified proteins was significantly higher when 
the samples were analyzed without a design of experiment. Thus, the number of proteins 
commonly identified in the three technical replicates of band 2 was rather similar in the 
preparation variation study (all technical steps were controlled) and in the total variation study 
(analysis without design of experiment) while the number of commonly identified proteins in 
the technical replicates of band 9 and 11 was significantly lower in the total variation study 
compared to the preparation variation study. One of the main reasons for this differences is 
believed to be due to column and buffer changes during the analysis of the bands 9 and 11 
samples, while the analysis of the band 2 samples were performed using the same column and 
buffer batch. 
The degree of variability added by each technical step and by the BBM preparation protocol 
was also investigated at the full MS signal level. The comparative analysis of the precursor 
ion signals might provide additional information on sample similarity, since data comparison 
at the protein identification level (using successful MS/MS signals) makes use of only 10% of 
the total available signals. On the other hand, the sample similarity information that was 
derived from the MS/MS-based comparison must also be detected at the precursor ion signal 
intensity level. Overall, the scatter plot representations of the total MS signals and of the 
subset of MS signals that were identified through a successful MS/MS analysis correlated 
well with each other across all compared samples. Moreover, the derived Spearman 
correlation value, which indicated the degree of similarity between two samples, showed the 
same trends as what was observed using the Venn diagram representations. Thus, the scatter   133
plots representations and the associated Spearman correlation values also confirmed the very 
high degree of reproducibility observed between sample injection replicates, as previously 
shown at the protein identification level. Likewise, the gel band excision scheme was also 
identified as a potential source of variability, if gel bands could not precisely be cut from the 
gel, as for example in the case of band 11. Finally, the preparation variation study, as reflected 
in the scatter plots and the Spearman correlation values for all the three bands, showed also a 
high degree of reproducibility, strong evidence that the BBM preparation protocol could be 
performed robustly and quantitatively, if all technical steps were controlled. An unexpected 
finding of this systematic study was the large impact of LC buffer change on the analytical 
variability. This effect was best illustrated in the total variation study of band 11, where in one 
of the three triplicates clearly deviated from the two other samples. The MS signal alignment 
of those three samples showed clearly the major shift of the peptides’ retention time caused by 
the LC buffer change. In contrast, column change did not appear to contribute significantly to 
the overall technical variability, as minor column backpressure heterogeneities were 
compensated by the HPLC system’s active flow splitter system (the LC system measures the 
actual flow going through the column, meaning that the LC column pressure is adjusted to 
keep the linear velocity constant through the column).  
In summary, it is apparent that sample comparison based on protein identification or on 
precursor ion signals were inherently similar. However, it is obvious that the optimized use of 
the mass spectrometric information will heavily depend on the generation of reproducible 
experimental data following a standard operating procedure. As a general rule, samples that 
should be compared to each other should be analyzed with identical column and buffer 
batches. In cases where this is not feasible, it is very important that buffers and columns are 
reproducibly and accurately prepared. The repeated analysis of a standard complex peptide 
mixture along the experiment and after any changes of buffer or/and column allow to monitor 
the variation of the peptides’ retention time and to judge the “good health” of the 
chromatographic system. However, even in an optimal experimental setting, comparison of 
serially acquired LC-MS(/MS) data will require the development of bioinformatics tools 
attuned to this specific data type. As highlighted in this study, one of the most immediate 
tasks to perform in a differential study is to measure the level of variability present in a given 
analysis, which in turn defines the criteria of acceptance for a reproducibly observed signal. 
The assessment on how to define such a signal, including the noise and variability introduced 
by the various technical steps of the analytical protocol, has been one of the most challenging   134
problem in data analysis of proteomics experiments, but also central to determine to which 
degree a signal difference can be confidently interpreted as a real change. 
This study constitutes the first attempt of our group to compare biological samples using the 
precursor ion intensity information. In due course, this first step was to be followed by a full 
fledge proteomics study in which a much more comprehensive biological experiment could 
have been investigated, such as a control mouse vs statins vs ezetimibe treatment, knowing in 
advance the level of technical reproducibility that could be expected. Beside the obvious 
biological interest for such a study (the impact of those drugs in the BBM has not been 
investigated in detail), a long term goal of this experiment could have been to evaluate the 
feasibility of a label-free quantification scheme based on the common precursor ion signals. 
In this approach, every peptide signal within the sensitivity range of the MS analyzer can be 
extracted and incorporated into the quantification process independently of a MS/MS 
acquisition. In a first step, data acquisition is performed using a high resolution/high mass 
accuracy mass spectrometer using a stable chromatographic system to generate the most 
stable <m/z;RT;ion intensity> possible applying the analytical principles that this initial study 
helped to uncover. In a second step, the identity of the differentially regulated proteins is 
achieved using a targeted tandem mass spectrometry analysis approach using for example 
inclusion lists in selected LC-MS runs (78, 117, 118). 
4.6 Peptide identification by LC-MS/MS 
The reliable identification of membrane proteins in complex biological mixtures has always 
been a grey area in the proteomics field. As exemplified in this study, the contamination of 
even small amounts of cytosolic proteins in membrane preparations might significantly 
impede the identification of membrane proteins, especially if they are present in low 
abundance. The difficulties to obtain a high coverage of membrane proteins in biological 
preparations are several-fold: first, the biochemical enrichment of membrane proteins 
typically requires an extensive knowledge of the cell compartment to isolate, so to improve 
the yield in membrane proteins. However, optimized isolation protocols are not easily 
adjustable for other biochemical applications, so that most preparations do not achieve a level 
of purity sufficient for optimal detection of membrane proteins. Second, membrane proteins 
are by nature averse to most protein chemical purification methods (with maybe the exception 
of SDS-PAGE) and special care has to be taken to prevent their loss during the isolation 
protocol. Finally, membrane proteins are chemically composed of very hydrophobic stretches 
that, upon proteolytic cleavage, might not generate peptides detectable by mass spectrometry.   135
In general, it is not possible to specifically attribute the reasons for the limited success of a 
proteomics study to identify membrane proteins. However, since the BBM isolation protocol 
described in this study generated a preparation of highly enriched membrane proteins in 
complex mixture, there was a golden opportunity to investigate the nature, and more 
specifically, the length and the hydrophobicity of membrane proteins’ peptides that were 
identified using a standard RPLC-ESI-MS/MS setup (with a LTQ mass spectrometer as mass 
analyzer). 
4.6.1 Characteristics of identified peptides  
For the purpose of this investigation, only the 663 identified tryptic peptides that were derived 
from 35 confirmed transmembrane BBM proteins were considered for subsequent analysis. 
First, the GRand AVerage of hydropathicitY (GRAVY) was manually calculated for each 
peptide using the ProtParam tool available at Expasy web site 
(http://www.expasy.org/tools/protparam.htmlsequences). The GRAVY value is calculated as 
the sum of hydrophathy values of all the constituting amino acids divided by the number of 
residues in the sequence(119) and reflects somehow the hydrophobicity of a protein or a 
peptide. Fig. 4.40 shows a two-dimensional graphic representation linking the GRAVY scores 
and the amino acid lengths of the 663 identified tryptic peptides, assuming that the GRAVY 
score calculation can also be applied to peptides. Tryptic peptides containing methionine 
oxidation were excluded while cysteines were assumed to be in reduced form. 
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Figure 4.40: Two-dimensional representation linking the GRAVY scores with the peptide 
amino acid length for the 663 identified tryptic peptides. Tryptic peptides containing 
methionine oxidation were excluded while cysteines were assumed to be in reduced form. 
For convenience, peptides with GRAVY values above 0.5 will be referred to as hydrophobic, 
those with GRAVY values below -0.5 as hydrophilic, while the remainder will be considered 
to be of medium character. Peptides distribution in the GRAVY scores was remarkably 
symmetrical with a slight tendency to negative values. Most of the identified peptides were of 
medium character and were less than twenty amino acids of length. There was a small number 
of hydrophobic peptides with GRAVY score values above 1, but those very hydrophobic 
peptides were typically short, i.e. between 10 and 15 amino acids long. 
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4.6.2 Comparison of identified peptides with predicted tryptic 
transmembrane peptides 
In a next step, the position of the 663 identified tryptic peptides were determined in the 35 
protein sequences in the dataset and compared to the location of transmembrane segments, as 
predicted by the TMHMM software. Fig. 4.41 shows two examples for representative integral 
BBM membrane proteins. The first example, the Nieman Pick C1-like protein 1, was one of 
the most abundant membrane proteins in the BBM preparation. This protein was predicted to 
possess 13 transmembrane helices and was identified with 16 different peptides. The second 
example, the FATP-4 protein, was a protein of rather low abundance in the preparation. It was 
predicted to possess 2 transmembrane helices and was identified with 2 different peptides. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.41: Amino acid sequence of two representative integral transmembrane BBM 
proteins. Panel A: Niemann-Pick C1-like protein 1, and Panel B: Fatty acid transporter 
protein 4. Lysines (K) and arginines (R) are highlighted in green and blue, respectively. 
Identified tryptic peptides are marked in bold red while the predicted location of 
transmembrane helices is underlined and marked in bold. 
Fig. 4.41 clearly shows that none of the identified tryptic peptides were located in the 
transmembrane helices, but rather within the loops (NPC1L1) or in the large cytoplasmic 
region of the protein (FATP-4). 
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Further, the hydropathicity of the predicted 228 transmembrane tryptic peptides belonging to 
the 35 integral membrane BBM proteins was calculated using the ProtParam tool. Fig. 4.42 
shows a histogram comparing the amino acid lengths (panel A) and GRAVY scores (panel B) 
for the 663 identified tryptic peptides versus the 228 predicted tryptic transmembrane peptides. 
Not surprisingly, the vast majority of the identified tryptic peptides were much shorter and 
less hydrophobic than the predicted tryptic transmembrane peptides. However, according to 
these data, the two groups of peptides somehow overlap indicating that a small number of 
predicted transmembrane peptides should have been identified using the generic LC-MS 
conditions that were used in this experiment. 
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Figure 4.42: Histogram of the amino acid length (Panel A) and hydropathicity (Panel B) 
for the 663 identified tryptic peptides versus the 288 predicted tryptic transmembrane 
peptides derived from the 35 identified transmembrane proteins. The identified tryptic 
peptides are marked in red while the predicted transmembrane tryptic peptides are marked in 
blue. The total number of peptide counts was normalized. 
 
Fig. 4.43 shows a two-dimensional view of the two histograms of Fig. 4.42 linking the 
GRAVY scores with the amino acid lengths for the identified tryptic peptides and the 
predicted tryptic transmembrane peptides. 
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Figure 4.43:  Two-dimensional representation linking amino acid length and GRAVY 
scores for the 663 identified peptides and the 228 predicted transmembrane tryptic peptides. 
The observed tryptic peptides are marked in pink, the predicted tryptic transmembrane 
peptides in blue. 
Fig. 4.43 clearly confirms that the identified tryptic peptides were, in average, much shorter 
and somewhat less hydrophobic than their predicted tryptic transmembrane counterparts. It is 
evident that the GRAVY score was not discriminative to explain the lack of identification of 
those predicted transmembrane tryptic peptides. Indeed, a number of observed tryptic peptides 
bear a GRAVY score of 1 or above similarly to the predicted transmembrane tryptic peptides. 
Rather, the average length of the typical predicted transmembrane peptide seems to separate 
best the two populations. However, an overlap between those two peptides populations 
remains, with GRAVY values between 0 and 1 and peptide lengths between 20 and 30 amino 
acids, which strongly suggest that identification of at least a few of those transmembrane 
tryptic peptides should have been possible. 
4.6.3 Discussion 
One of the stated goals of this study was to ascertain at the experimental level the 
physicochemical properties of peptides derived from the proteolytic cleavage of membrane 
proteins, to determine if some of them belong to transmembrane helices, and to compare their 
characteristics with the predicted tryptic transmembrane peptides of the same identified 
proteins. The parameters that were chosen to characterize these peptides comprised the 
GRAVY score and the peptide length. The majority of the identified peptides were of medium 
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character (GRAVY scores between -0.5 and 0.5) and their lengths ranged from 10 to 20 
amino acids. In contrast, the majority of the predicted tryptic transmembrane peptides 
(containing up to one misscleavage since the search criteria for protein identification 
permitted it) were of 20-30 amino acids length and the GRAVY values ranged from 0.5 to 1.5. 
Surprisingly, no transmembrane tryptic peptide was experimentally identified although, 
according to the GRAVY score and peptide length predictions, there was a high degree of 
likelihood that at least a few of those peptides should have been experimentally detected. 
Overall, only one tryptic peptide could be identified whose amino acid sequence encompassed 
half of a transmembrane helix due to the presence of a lysine in the middle of the alpha helix 
segment. 
In this initial study, which was performed using a LTQ mass spectrometer, only peptides with 
assumed charge state of +1, +2 or +3 were selected for MS/MS analysis and peptide 
identification. As a consequence, peptides of mass above 4500 Da were not considered, 
excluding most of the potential transmembrane tryptic peptides. In subsequent analyses, 
peptide identification was performed using the newest generation mass spectrometer (the LTQ 
Orbitrap mass spectrometer) at 30,000 mass resolution and 2 ppm mass accuracy so that 
peptides with higher charge state could potentially be considered. Indeed, when the same 
samples were analyzed using the Orbitrap mass spectrometer, signals with charge state +4 and 
+5 were detected in the m/z range between 1000–1500 Da corresponding roughly to the mass 
of potential transmembrane tryptic peptides. However, due to software limitations and poor 
MS/MS spectral quality for highly charged precursor ions in the LTQ mass analyzer, these 
types of peptides were routinely excluded from the analysis in this first round of protein 
identification. Nevertheless, the exact nature of these high molecular mass, multiply charged 
peptides should be investigated in future studies. 
There are many other reasons that may lead to the absence of transmembrane tryptic peptides. 
Assuming that trypsin cleaves off transmembrane helices, that is, the transmembrane tryptic 
peptide is generated during the digestion procedure, the rather hydrophobic nature of most of 
these peptides may hinder their extraction from the gel band or they may stick to tube walls 
during peptide extraction. Finally, very long and/or hydrophobic peptides typically cannot be 
chromatographically analyzed on a C18 column and might require a different stationary 
phase, such as Hydrophilic-Interaction Liquid Chromatography (HILIC) (see appendix C for 
a detailed discussion).    142
The name Hydrophilic-Interaction Chromatography (HILIC) was originally coined by Alpert 
(120) for the separation of hydrophilic substances such as proteins, peptides and nucleic acids 
using polar stationary phase, such as polyhydroxyethyl aspartamide or 
polyhydroxysulfotamide aspartamide. Polar peptides are retained by the polar stationary 
phase in a hydrophobic solvent. The solute molecule is then eluted from the chromatographic 
beads by increasing the polarity of the mobile phase, for example by increasing the 
proportion of water or by adding salt. So far, HILIC has been suggested as an alternative to 
cation-exchange chromatography for the separation of polar peptides, such as glycopeptides, 
phosphopeptides and modified histone peptides (121). It is then typically coupled off-line 
with a RPLC-MS for peptide characterization. 
In contrast to other studies, we suggest the use of HILIC for the chromatographic separation 
of very hydrophobic peptides, such as typically found in transmembrane helices of membrane 
proteins. Such peptides, which consist of long stretches of aliphatic and hydrophobic amino 
acids, might not survive the initial buffer conditions of a RPLC separation: those peptides 
cannot be kept soluble in aqueous solutions as they form secondary structure and precipitate 
before being injected into the RPLC system. In addition, their hydrophobicity might cause 
them to stick so strongly to the stationary phase that their elution might not be possible with 
conventional buffer systems. In contrast, the highly organic character of the initial buffer 
composition of a HILIC separation would favor the stability of those kinds of peptides while 
the polarity of the carbonyl backbone should ensure their retention onto the polar 
chromatographic medium. Similarly to RPLC, HILIC can be directly coupled to an 
electrospray ionization interface if the salt concentration is kept to a minimum to avoid 
interference with the ionization process. In this configuration, HILIC-MS might provide 
complementary information to the conventional RPLC-MS peptide analysis.    143
28S rRNA 
18S rRNA 
4.7 Preparation of intact RNA from the Small Intestine 
4.7.1 Monitoring RNA degradation 
RNA extraction from the small intestine was prepared in sections as follows. The dissected 
small intestine was divided in three equal segments, which were named according to their 
location to the stomach. The proximal segment contained the duodenum and the proximal part 
of jejunum while the central segment included the central part of the jejunum. The distal 
segment contained the distal part of the duodenum and the ileum. This division did not follow 
accurately the physiological partition of the small intestine. However, it represented a good 
compromise for dividing quickly and reproducibly the small intestine into three representative 
parts while preserving most of the section specificity. Each section was then further divided 
into three parts to accommodate the amount of tissue in the Lysing Fast RNA Matrix D tubes. 
Homogenization was performed using a FastPrep Cell disrupter. Total RNA was extracted 
according to the protocol listed in paragraph 3.2.8, after which the RNA common to the same 
section was pooled. RNA quality was then assessed using a 1% agarose denaturating gel (Fig. 
4.44).  
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4.44: Total RNA analysis by denaturating agarose gel electrophoresis. Approximately 1 
µg total RNA extracted from the proximal, central, or distal sections of intestinal tissue were 
analyzed using a 1% agarose denaturating gel. The two intense bands highlighted by the 
arrows represent the heavy and the light subunit of ribosomal RNA. Lane 1, molecular weight 
marker (MW); Lanes 2-4 and 5-7: total RNA of the three sections from two different mice. 
P_S, proximal section; C_S, central section; D_S, distal section.  
Figure 4.44 shows that the 28S rRNA and 18S RNA was degraded in the proximal section of 
both mice while RNA quality was satisfactory for the central and distal sections. The RNA   144
28S rRNA 
18S rRNA 
extraction procedure was repeated on 5 additional intestinal samples to confirm that the 
extracted RNA was consistently degraded in the proximal sections (data not shown). 
This observation led to the hypothesis that high RNAse activity might be the cause for RNA 
degradation in the jejunum. These RNAses might be of a different enzymatic family than in 
the other segments of the intestine or their specific activity could be higher in the duodenum. 
In order to confirm this hypothesis, the proximal part of the intestine was cut in three 
segments, with the most proximal part containing the duodenum while the other two segments 
only containing parts of the jejunum. RNA was extracted from these sub-sections and the 
quality of the extracted RNA was assessed again by denaturating agarose gel electrophoresis 
(Fig. 4.45). RNA quality was found to significantly worsen as the tissue was excised closer to 
the stomach. RNA extracted from the duodenum was completely degraded, while the RNA 
extracted from the jejunum proximal and central sections was partially degraded (jejunum 
proximal) or even mostly intact (jejunum central). These results confirm our hypothesis that 
RNAse activity is very high in the duodenum in comparison to the other sections and requires 
specific handling in order to isolate intact RNA for subsequent analysis. 
 
 
 
 
 
 
 
 
 
 
 
Fig.4.45: Total RNA analysis by denaturating agarose gel electrophoresis. Approximately 1 
µg total RNA extracted from the three parts of the proximal section (duodenum, jejunum a, 
and jejunum b) were analyzed using a 1% agarose denaturating gel. The two intense bands 
highlighted by the arrows represent the heavy and the light subunit of ribosomal RNA. Lane 1, 
molecular weight marker (RNA ladder); Lanes 2-4 and 5-7: total RNA from the three parts of 
the proximal section of two different mice S_1 and S_2. 
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4.7.2 Inhibition of RNA degradation 
The analysis of gene expression along the small intestine of a mouse, in particular with the 
goal to compare gene expression of differentially treated mice or of mice with different 
genetic background, requires a much more complete inhibition of RNA degradation in the 
duodenum section than previously achieved. 
Attempts to improve the quality of the extracted RNA by adding RNAse inhibitors in the PBS 
buffer used to flush the intestine or by flushing and storing the sections in RNAlater directly 
did not significantly prevent RNA degradation in the duodenum. Similarly, shorter 
homogenization steps or setting the FastPrep Cell disrupter to lower homogenization speed 
did not result in any significant improvement of the RNA quality. Much better results were 
obtained using an alternate homogenization protocol involving tissue grinding under liquid 
nitrogen, pointing out to a temperature increase in the tissue during the homogenization step 
as being one of the major causes for RNA degradation. The main advantage of the grinding 
procedure consists in keeping the tissue constantly frozen until it is completely embedded in 
the phenol- and guanidine thiocyanate-containing TriReagent, which is an effective RNAse 
inhibitor. The reproducibility and the improved RNA quality using this alternate protocol 
were tested by processing the grinded dudenum from five different mice. The resulting RNA 
was assessed electrophoretically using the Experion System (Bio-Rad) as shown in Fig. 4.46. 
The general quality of the extracted RNA from grounded duodenum sections of five different 
mice was significantly better. The light and the heavy subunit of the ribosomal RNA did not 
appear to be degraded in any of the extractions and the ratio between the 28S and 16S RNA 
subunits (a quality assessment for RNA degradation) was superior to 1.5 in all the samples. 
These results demonstrate that significant RNA degradation in the jejunum section can be 
avoided provided that the samples temperature is controlled during the homogenization step.    146
28S rRNA 
18S rRNA 
 
 
 
 
 
 
 
 
 
Fig.4.46: Total RNA analysis using the automated electrophoresis Experion System (Bio-
Rad). Approximately 1 µg total RNA was loaded onto the system. The two intense bands 
highlighted by the arrows represent the heavy and the light subunit of ribosomal RNA. Lane 1, 
Molecular mass marker (RNA ladder); Lanes 2-6 extracted RNA of the dudenum section from 
five different mice prepared with the grinding process. 
 
4.7.3 Discussion  
A reliable protocol to extract good quality RNA is the first and most important factor for a 
successful differential analysis of gene expression. The small intestine, and in particular the 
duodenum, contains many peptidases and nucleases whose natural role is to degrade 
macromolecules such as proteins, RNA and DNA, to their constituents to facilitate their 
absorption through the small intestine. Their abundance and their intrinsic activity make RNA 
extraction of the small intestine quite challenging. A standard RNA extraction protocol based 
on tissue homogenization with Lysing Fast RNA Matrix D tubes in a solution that contained 
phenol and guanidine thiocyanate could not be used for RNA extraction of the jejunum as the 
endogeneous, highly active RNAses could not be inhibited sufficiently rapidly to prevent 
significant RNA degradation. In this study I developed a protocol for the extraction of high 
quality RNA enabling in future studies a comparison of gene expression between 
differentially treated mice. First attempts to modify the original protocol, such as speeding 
intestinal tissue collection and snap freezing in liquid nitrogen, flushing the collected tissue 
with PBS containing RNAse inhibitors, or flushing and storing the tissue in RNA later, as 
well as varying the homogenization process (shorter disruption time, slower disruption rate, 
increased cooling periods) failed to deliver a better RNA quality. A major breakthrough was 
obtained by replacing the homogenization step with a protocol including tissue grinding in 
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liquid nitrogen. This alternate procedure gave optimal results for the RNA extraction from the 
duodenum section. The current protocol, combining a speedy tissue collection, a quick wash 
with PBS, snap-freezing and tissue grinding in liquid nitrogen leads to the extraction of very 
good quality RNA that can be stored at –80 
oC for further use by gene chip analysis or qRT-
PCR.   148  149
5. CONCLUSIONS 
The study of membrane proteins is a difficult topic on its own because of the particular 
characteristics of these proteins. The study of membrane proteins in a complex mixture where 
degradation is a natural process is even more challenging. 
In this study I successfully developed a robust protocol for the BBM preparation from mouse 
intestinal mucosa, a tissue whose main function is to degrade nutrients in order to facilitate 
their ingestion. The inherent protein and RNA degradation which I faced during my early 
work had to be considered and taken care of to obtain a reproducible BBM preparation. A 
significant amount of time and effort was spent on developing protocols for the inhibition of 
protein and RNA degradation, which at the end was partially achieved. It is worth pointing 
out that none of the published studies previously dealing with BBM analysis using mass 
spectrometry, immunoassays or microarrays had mentioned any issue regarding tissue 
degradation. 
A triplicate identification of the proteins part of the BBM resulted in the identification of 
more than 1460 proteins, of which “only” 260 were integral membrane protein, an apparently 
disappointing result considered that the preparation was thought to be highly enriched in 
membrane proteins. However, a detailed analysis of the proteins identified in the BBM 
preparation made apparent that a large extent of the remainder was accounted for membrane-
associated, membrane-anchored proteins and cytoskeleton proteins involved in protein 
trafficking between cytosol and plasma membrane, thus closely related functionally to the 
BBM function. Even some of the 330 cytosolic proteins, such as the apolipropteins which 
could have been discounted as contaminant at a first glance, were demonstrated to be 
specifically co-enriched in the BBM fraction probably due to their interaction with a BBM-
specific component. 
A rough estimation of protein abundance based on peptide counts confirmed that membrane 
proteins and membrane-associated proteins represented the dominant species in the BBM 
preparation. In this analysis we didn’t observe any particular bias against proteins with many 
transmembrane helices. Nevertheless, the identification of these proteins was based on tryptic 
peptides exclusively located in the loops, in extracellular areas or in the intracellular domains 
of the proteins. I believe that the reason for the lack of identification of tryptic transmembrane 
peptides (assuming that trypsin was equally active in this environment) was due in many 
cases to the length of the generated peptides, typically of 40-50 amino acids long. Indeed, the 
elution of highly charges peptides of 5-6 kDa mass were occasionally observed in the elution   150
chromatograms. Unfortunately, due to software limitation (peptide with charge state above +3 
could not be considered in an automatic data analysis), these peptides were not analyzed and 
further studies will be required to confirm this observation. 
This study is the first proteomic approach in which numerous receptors and transporters and 
many relevant proteins to cholesterol absorption were identified. This is in contrast to several 
recently published proteomic studies (2, 122) claiming the characterization of specific 
membrane proteins of BBM. However, their protein lists were mostly restricted to Ras-related 
proteins and cytosolic or membrane associated-proteins. Aminopeptidase N and 
Sodium/Glucose co-transporter, two of the most abundant proteins in the BBM, were 
characterized in a proteomic approach for the first time in this study. Similarly, some 
proteomic studies have been based on the isolation of the lipid rafts (possible BBM micro 
domains responsible for cholesterol absorption) to enrich and identify proteins that participate 
in cholesterol absorption (3). None of these studies reports the identification the Niemann-
Pick C1-like protein 1, the target of ezetimibe (a cholesterol absorption inhibitor) and for 
many researchers the likely transporter of cholesterol. In this study, the Niemann-Pick C1-like 
protein 1 was one of the most abundant proteins in the purified BBM fraction. 
These data re-emphasize the critical importance of a reproducible isolation and fractionation 
of a membrane preparation in a high-throughput proteomic approach, even if using a mass 
spectrometer with high resolving power and excellent mass accuracy. In this study, a robust 
BBM isolation protocol (in which the unspecific proteolytic activity of the preparation was 
controlled by adding a cocktail of protease inhibitors and peptide substrates) led us to the 
characterization at the protein level of a large number of cholesterol- or fat absorption-related 
proteins which, until now, had only been characterized at the gene level or by immunoassays. 
Thus, a membrane proteomic approach is feasible and may yield excellent results when the 
analyzed membrane fraction is optimally purified. Evidently, the requirement for a complex 
purification and fractionation scheme is accompanied by an increasing analysis complexity. 
Preparation of the BBM in sections enabled the identification of some additional BBM-
specific proteins and provided some examples of protein localization along the small intestine. 
For example, the SR-BI receptor was identified in the BBM fraction prepared from total 
mucosa with one single peptide (and hence was not included in the final list in appendix A1). 
In contrast, it was robustly characterized in the BBM fraction prepared from the duodenum  
segment of the small intestine with three different peptides. The benefit of the additional 
fractionation was obvious in respect to the confident identification of this receptor. However, 
it required three times more measurement time and a rather large increase of starting material.   151
The cost/benefit of the selected isolation scheme needs to be carefully considered in respect to 
how many biological replicates or differential experiments are planned.  
The specific identification of the ApoE protein in the BBM fraction captured our interest and 
led us to a prototype comparison study between BBM preparations from ApoE knockout mice 
and wild type mice of the same genetic background. Following the same preparation protocol 
and a well established analytical strategy, we were able to see clear differences in the 
expression level of several proteins between the two different species. Since no quantification 
technique was applied and there was no biological replicate, we focused our interest in the 
“black and white” differences. Among them, the Ileal Bile Acid Transporter (IBAT) protein 
and the ApoAI protein, which were robustly identified in the wild type animals, couldn’t be 
detected in the ApoE knockout mice. This finding was not described in any of the earlier 
published studies that have attempted to elucidate the reasons why the ApoE knockout mice 
appear hypercholesterolemic, have high plasma cholesterol and high cholesterol absorption. 
In particular, the striking downregulation of the IBAT transporter in the ApoE knockout 
animal strongly suggests a disruption of the bile acids metabolism. This hypothesis is 
supported by a separate study that showed that the bile acid pool size in the liver and the 
intestine of the ApoE knockout mice was significantly increased compare to the wild type 
mice. The increase of the bile acids pool available in the small intestine of the ApoE knockout 
mice might explain the higher cholesterol absorption of these animals since cholesterol is 
better solubilized and, consequently, transported more easily through the BBM. This part of 
my study provides a completely new perspective to the high cholesterol absorption of these 
animals and opens a new field of research in this topic. 
Similarly to this prototype study, I am convinced that the analytical strategy described in this 
study is sufficiently mature to perform comprehensive comparative analysis of mice that have 
for example been treated with specific compound or that have been subjected to different diets. 
The simplistic analysis method used in the ApoE knockout example was sufficient to pinpoint 
to obvious changes. However, in a more complex dataset, a proper quantification strategy 
should provide a better leverage to discover differences with statistical significance. The 
15N 
full metabolic labeling of mice might represent an ideal strategy for this type of samples. The 
mixing of an internal standard in the form of a “heavy” BBM preparation in all the samples of 
interest enables very accurate protein quantification (in principle, all BBM proteins could be 
normalized to their specific internal standard) over the whole experiment. In addition, the co-
purification of the 
15N internal standard with the regular BBM preparation provides a mean to 
compensate for variability in degradation across the experiment.   152
A significant amount of time and effort was spent in this study for evaluating the stability of 
the BBM preparation protocol, the reproducibility of the analytical steps leading to the protein 
identification and, further, the consistence of these analyses with an initial comparative 
investigation of how to extract the same information directly from the LC-MS precursor ion 
signals. Overall, the BBM isolation protocol that was developed in this study, combined with 
a reproducible analytical strategy, enabled us to identify almost 90% of all the 1639 proteins 
identified in the BBM fraction in at least two of three triplicates. This level of reproducibility 
was beyond our expectations and encouraged us to individually monitor the variability of each 
of the technical steps involved in the procedure. The data confirmed the critical stability and 
reproducibility of the Orbitrap mass spectrometer for the high throughput analysis of such 
samples. The study pinpointed to an unexpected source of variation in the form of the LC 
buffers, which need to be tightly controlled to obtain reproducible chromatographic separation 
conditions. Ideally, samples to be compared must be analyzed using identical buffer and 
column batches on the LC system. 
My study in this respect initiated a discussion for better understanding the analytical 
requirements and the type of software tools that might allow in the future label-free 
quantification approaches based on LC-MS data alone. Quantification at the precursor mass 
signal intensity might provide a more general method of comparison for LC-MS-based 
proteomics studies than the comparison of protein lists, which only consider approximately 10 
to 20% of the available data. Protein identification of signals of interest can then be obtained 
using MS/MS inclusion lists, where an ion signal of specific m/z and RT is targeted for 
tandem mass spectrometric analysis. Most importantly, the ability to differentially compare 
samples across an experiment first requires the knowledge of what is common to the technical 
and biological replicates of samples so that the significance of a given change can be 
statistically appreciated. Within this study, we determined what was achievable with regards 
to reproducibility using standard protein purification technique and advanced analytical 
strategies but we also described the current limitations that will need to be addressed in the 
future to fully enable this strategy. 
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7. ABBREVIATION 
ABC Ammonium Bicarbonate
ACN Acetonitrile 
a-CYANO a-Cyano-4-hydroxy-cynnamic-acid
AF Ammonium Formate
BBM Brush Border Membrane
Bicine N,N-Bis(2-hydroxyethyl) Glycine
Bis-Tris Bis(2-hydroxyethyl)amino-tris(hydroxymethyl)methane
BSA Bovin  Seum  Albumin
βME beta Mercaptoethanol
DTT 1.4 Dithioerythritol
EDTA Ethylenediaminetetraacetic acid
ESI Electrospray ionization 
EtBr Ethidium Bromide
FA Formic Acid
GC Gas Chromatography 
GRAVY Grand average of hydropathicity
HILIC Hydrophilic Interaction Chromatography
IAA Iodoacetamide
KO Knockout 
LC Liquid Chromatography 
LDS Lithium dodecyl sulfate
MALDI Matrix-assisted laser desorption/ionization 
MOPS 3-(N-morpholino) ethane sulfonic acid 
PMSF Phenylmethylsulfonylfluorid
PVDF Polyvinylidene  difluoride
RPLC Reverse Phase chromatography
RT Retention time
SDS Sodium dodecyl sulfate
TBS Tris Buffer Saline 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran
TOF Time of flight
TTBS Tween Tris Buffer Saline
WT Wild type  
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APPENDIX 
Appendix A. Protein identification 
A1. BBM protein identification from whole mucosa 
Total list of the 1306 identified BBM proteins from whole mucosa with a valid Swissprot 
database entries, listed by topology, then alphabetically according to their gene symbol. The 
color coding is as follows: yellow, “membrane” protein as predicted by the ALOM tool; blue, 
“secreted” protein as predicted by the “signal_anchor” software tool; green, “non-membrane, 
non-secreted” (=cytosolic) protein; red, proteins not analyzed by those software packages and 
manually added to the table. 
Gene ID: internal Roche gene ID number 
Gene Symbol, Swissprot protein ID, Swissprot protein AC: associated gene symbol, 
protein ID and protein accession number in the Swissprot database. 
Gene Description: description of gene product as provided by the internal Roche database 
entry 
Max Diff peptide: maximum number of different peptides observed in anyone of the 
triplicate LC-MS/MS analysis 
Avg Pep count: sum of peptide counts for all the LC-MS analysis of this protein divided by 
the number of LC-MS analysis it has been detected. 
Rank order: protein abundance ranking based on average peptide counts in the tripliocate 
LC-MS analysis. 
Ortho Gene Symbol, Ortho Swissprot protein ID, Ortho Swissprot protein AC: 
associated orthologous (human) gene symbol, protein ID and protein accession number 
in the Swissprot database, as provided by the Roche internal database. 
Topology: predicted protein topology: c=cytosolic, tm=transmembrane, s, secreted. Proteins 
labelled “ad” were manually added to the table after the topology analysis was performed. 
GO term: GO annotation for the protein cellular location 
Protein length: length of protein in amino acids 
Number of TM: predicted number of transmembrane domains according to the TMHMM 
software package.   170
Gene ID 
(mouse)
Gene Symbol (mouse)
Swissprot protein 
ID (mouse)
Swissprot 
protein AC 
(mouse)
Gene Description
Max Diff 
peptide
Avg Pep 
count
Rank order
Ortho 
Gene ID
Ortho Gene 
Symbol
Swissprot protein 
ID
Swissprot 
protein AC
Topology GO term
Protein 
length
Number 
of TM
74556 9130404H23Rik Q9CU24_MOUSE Q9CU24 RIKEN cDNA 9130404H23 gene 2 2 1087 - - - - ad intrinsic to peroxisomal membrane 569 0
76279 Cyp2d26 CP2DQ_MOUSE Q8CIM7
cytochrome P450, family 2, 
subfamily d, polypeptide 26
8 8 483 1564 CYP2D7P1 Pseudogene - ad associated to endoplasmic reticulum membran 500 2
14972 H2-K1 HA1B_MOUSE P01901 histocompatibility 2, K1, K region 12 24 203 3107 HLA-C 1C07_HUMAN P10321 ad external side of plasma membrane 369 1
232714 Mgam - - maltase-glucoamylase 81 1196 4 8972 MGAM MGA_HUMAN O43451 ad integral to apical plasma membrane 1857 1
381417 RP23-357I14.1 A2AWR5_MOUSE A2AWR5
novel protein similar to solute 
carrier family 28 (sodium-coupled 
nucleoside transporter) member 2 
(Slc28a2)
4 6 565 - - - - ad membrane 660 14
22599 Slc6a20b S620B_MOUSE O88575
solute carrier family 6 
(neurotransmitter transporter), 
member 20B
3 4 789 54716 SLC6A20 S6A20_HUMAN Q9NP91 ad integral to plasma membrane 635 12
22187 Ubb UBIQ_MOUSE P62991 ubiquitin B 8 226 21 - - - - ad cytoplasm 76 0
52398 Sep 11 SEP11_MOUSE Q8C1B7 septin 11 5 5 635 55752 Sep 11 SEP11_HUMAN Q9NVA2 c septin complex 431 0
18951  Sept5 SEPT5_MOUSE Q9Z2Q6 septin 5 3 3 895 5413 SEPT5 SEPT5_HUMAN Q99719 c plasma membrane 369 0
235072  Sept7 SEPT7_MOUSE O55131 septin 7 4 6 558 989 SEPT7 SEPT7_HUMAN Q16181 c nucleus 436 0
66060 0610010O12Rik CE032_MOUSE Q8K353 UPF0467 protein C5orf32 homolog 2 7 538 84418 C5orf32 CE032_HUMAN Q9H1C7 c - 363 0
74190 1200009I06Rik CN073_MOUSE Q6DIA2 SEC6-like protein C14orf73 
homolog
5 8 474 91828 C14orf73 CN073_HUMAN Q17RC7 c - 762 0
75471 1700009N14Rik Q14AA6_MOUSE Q14AA6 novel Ras protein 5 27 185 - - - - c cytoplasm 216 0
112419 2010002M12Rik Q3U687_MOUSE Q3U687
homolog to Interferon-induced 
protein with tetratricopeptide 
repeats 1 (IFIT1_MOUSE)
20 3 870 3434 IFIT1 IFIT1_HUMAN P09914 c cytoplasm 466 0
70153 2210016F16Rik Q9D7X2_MOUSE Q9D7X2 hypothetical protein 3 2 1032 84267 C9orf64 CI064_HUMAN Q5T6V5 c cellular_component 159 0
70420 2610034B18Rik CO038_MOUSE Q9D0A3
UPF0552 protein C15orf38 
homolog
4 2 961 348110 C15orf38 CO038_HUMAN Q7Z6K5 c associated to plasma membrane at apical part  226 0
66469 2810405K02Rik CA093_MOUSE Q9DB60
Uncharacterized protein C1orf93 
homolog
7 12 360 127281 C1orf93 CA093_HUMAN Q8TBF2 c - 216 0
67268 2900073G15Rik Q6ZWQ9_MOUSE Q6ZWQ9 myosin light chain, regulatory B-like 3 4 769 10398 MYL9 MLRN_HUMAN P24844 c muscle myosin complex 1720
73205 3110043O21Rik CI072_MOUSE Q6DFW0
Uncharacterized protein C9orf72 
homolog
3 2 1038 203228 C9orf72 CI072_HUMAN Q96LT7 c - 821 0
70984 4931406C07Rik CK054_MOUSE Q91V76 Ester hydrolase C11orf54 homolog 6 5 622 28970 C11orf54 CK054_HUMAN Q9H0W9 c nucleus 315 0
78906 9130017N09Rik CS021_MOUSE Q9D279
Uncharacterized protein C19orf21 
homolog
8 29 170 126353 C19orf21 CS021_HUMAN Q8IVT2 c - 153 0
231151 AA474455 - -
transcriptional adaptor 2 (ADA2 
homolog, yeast)-beta
2 2 1165 93624 TADA2B TAD2B_HUMAN Q86TJ2 c nucleus 420 0
78894 Aacs AACS_MOUSE Q9D2R0 acetoacetyl-CoA synthetase 6 4 737 65985 AACS AACS_HUMAN Q86V21 c cytoplasm 672 0
234734 Aars SYAC_MOUSE Q8BGQ7 alanyl-tRNA synthetase 2 2 1167 16 AARS SYAC_HUMAN P49588 c cytoplasm 968 0
69684 Aarsd1 AASD1_MOUSE Q3THG9
alanyl-tRNA synthetase domain 
containing 1
3 2 1031 80755 AARSD1 AASD1_HUMAN Q9BTE6 c cytoplasm 412 0
24015 Abce1 ABCE1_MOUSE P61222
ATP-binding cassette, sub-family E 
(OABP), member 1
11 8 488 6059 ABCE1 ABCE1_HUMAN P61221 c cytoplasm 599 0
76491 Abhd14b ABHEB_MOUSE Q8VCR7 abhydrolase domain containing 14b 4 6 598 84836 ABHD14B ABHEB_HUMAN Q96IU4 c cytoplasm 210 0
52538 Acaa2 THIM_MOUSE Q8BWT1
acetyl-Coenzyme A acyltransferase 
2 (mitochondrial 3-oxoacyl-
Coenzyme A thiolase)
7 6 574 10449 ACAA2 THIM_HUMAN P42765 c mitochondrion 397 0
104112 Acly ACLY_MOUSE Q91V92 ATP citrate lyase 3 3 820 47 ACLY ACLY_HUMAN P53396 c cytoplasm 1091 0
11428 Aco1 Q8VDC3_MOUSE Q8VDC3 aconitase 1 3 3 929 48 ACO1 Q5VZA6_HUMAN Q5VZA6 c cytoplasm 899 0
11429 Aco2 ACON_MOUSE Q99KI0 aconitase 2, mitochondrial 9 7 522 50 ACO2 ACON_HUMAN Q99798 c mitochondrion 780 0
329910 Acot11 ACO11_MOUSE Q8VHQ9 acyl-CoA thioesterase 11 3 2 1050 26027 ACOT11 ACO11_HUMAN Q8WXI4 c cytoplasm 594 0
11430 Acox1 ACOX1_MOUSE Q9R0H0
acyl-Coenzyme A oxidase 1, 
palmitoyl
5 7 517 51 ACOX1 ACOX1_HUMAN Q15067 c mitochondrion 661 0
11431 Acp1 PPAC_MOUSE Q9D358 acid phosphatase 1, soluble 2 2 949 52 ACP1 PPAC_HUMAN P24666 c cytoplasm 158 0
11459 Acta1 ACTS_MOUSE P68134 actin, alpha 1, skeletal muscle 14 280 13 58 ACTA1 ACTS_HUMAN P68133 c cytoskeleton 377 0
11475 Acta2 ACTA_MOUSE P62737
actin, alpha 2, smooth muscle, 
aorta
14 250 17 72 ACTG2 ACTH_HUMAN P63267 c cytoskeleton 377 0
11461 Actb ACTB_MOUSE P60710 actin, beta, cytoplasmic 29 1737 1 60 ACTB ACTB_HUMAN P60709 c cytoskeleton 375 0
238880 Actbl2 ACTBL_MOUSE Q8BFZ3 actin, beta-like 2 8 37 131 345651 ACTBL2 ACTBL_HUMAN Q562R1 c cytoskeleton 376 0
11464 Actc1 ACTC_MOUSE P68033 actin, alpha, cardiac 14 280 14 70 ACTC1 ACTC_HUMAN P68032 c cytoskeleton 377 0
11465 Actg1 ACTG_MOUSE P63260 actin, gamma, cytoplasmic 1 29 983 5 71 ACTG1 ACTG_HUMAN P63261 c cytoskeleton 375 0
11468 Actg2 ACTH_MOUSE P63268
actin, gamma 2, smooth muscle, 
enteric
14 250 16 - - - - c cytoskeleton 376 0
109711 Actn1 ACTN1_MOUSE Q7TPR4 actinin, alpha 1 8 7 541 87 ACTN1 ACTN1_HUMAN P12814 c cytoskeleton 892 0
11472 Actn2 ACTN2_MOUSE Q9JI91 actinin alpha 2 2 2 1128 88 ACTN2 ACTN2_HUMAN P35609 c cytoskeleton 894 0
11474 Actn3 ACTN3_MOUSE O88990 actinin alpha 3 2 2 1129 89 ACTN3 ACTN3_HUMAN Q08043 c actin filament 900 0
60595 Actn4 ACTN4_MOUSE P57780 actinin alpha 4 18 25 196 81 ACTN4 ACTN4_HUMAN O43707 c cytosol 912 0
66713 Actr2 ARP2_MOUSE P61161 ARP2 actin-related protein 2 
homolog (yeast)
8 8 489 10097 ACTR2 ARP2_HUMAN P61160 c actin cytoskeleton 394 0
74117 Actr3 ARP3_MOUSE Q99JY9
ARP3 actin-related protein 3 
homolog (yeast)
14 15 290 10096 ACTR3 ARP3_HUMAN P61158 c actin cytoskeleton 418 0
109652 Acy1 ACY1_MOUSE Q99JW2 aminoacylase 1 6 3 823 95 ACY1 ACY1_HUMAN Q03154 c cytoplasm 408 0
11564 Adsl PUR8_MOUSE P54822 adenylosuccinate lyase 2 2 981 158 ADSL PUR8_HUMAN P30566 c cytoplasm 484 0
76223 Agbl3 CBPC3_MOUSE Q8CDP0 ATP/GTP binding protein-like 3 2 3 862 340351 AGBL3 CBPC3_HUMAN Q8NEM8 c cytoplasm 1006 0
269378 Ahcy SAHH_MOUSE P50247 S-adenosylhomocysteine hydrolase 12 13 334 191 AHCY SAHH_HUMAN P23526 c cytoplasm 432 0
229709 Ahcyl1 SAHH2_MOUSE Q80SW1
S-adenosylhomocysteine hydrolase-
like 1
14 21 236 10768 AHCYL1 SAHH2_HUMAN O43865 c endoplasmic reticulum 530 0
74340 Ahcyl2 SAHH3_MOUSE Q68FL4
S-adenosylhomocysteine hydrolase-
like 2
13 32 157 23382 AHCYL2 SAHH3_HUMAN Q96HN2 c - 303 0
102502 AI427122 Q3V0K9_MOUSE Q3V0K9 Plastin 1 (I isoform) homolog 34 122 37 5357 PLS1 PLSI_HUMAN Q14651 c cytoplasm 630 0
432442 Akap7 AKAP7_MOUSE O55074 A kinase (PRKA) anchor protein 7 3 2 969 9465 AKAP7 AKA7A_HUMAN O43687 c anchored to apical plasma membrane 810
58810 Akr1a4 AK1A1_MOUSE Q9JII6
aldo-keto reductase family 1, 
member A4 (aldehyde reductase)
16 31 160 10327 AKR1A1 AK1A1_HUMAN P14550 c apical plasma membrane 325 0
11677 Akr1b3 ALDR_MOUSE P45376
aldo-keto reductase family 1, 
member B3 (aldose reductase)
4 6 609 231 AKR1B1 ALDR_HUMAN P15121 c cytoplasm 316 0
11997 Akr1b7 ALD1_MOUSE P21300
aldo-keto reductase family 1, 
member B7
8 9 450 57016 AKR1B10 AK1BA_HUMAN O60218 c cytoplasm 316 0
622402 Akr1c12 Q9JLI0_MOUSE Q9JLI0 aldo-keto reductase family 1, 
member C12
77 5 4 3 -- - - c -
323 0
27384 Akr1c13 AK1CD_MOUSE Q8VC28
aldo-keto reductase family 1, 
member C13
81 0 4 1 2 -- - - c - 323 0
432720 Akr1c19 Q5I0T6_MOUSE Q5I0T6
aldo-keto reductase family 1, 
member C19
78 4 9 3 -- - - c -
323 0
110198 Akr7a5 ARK72_MOUSE Q8CG76
aldo-keto reductase family 7, 
member A5 (aflatoxin aldehyde 
reductase)
5 4 775 246181 AFAR3 ARK74_HUMAN Q8NHP1 c mitochondrion 367 0
11668 Aldh1a1 AL1A1_MOUSE P24549
aldehyde dehydrogenase family 1, 
subfamily A1
15 15 287 216 ALDH1A1 AL1A1_HUMAN P00352 c cytoplasm 501 0
72535 Aldh1b1 AL1B1_MOUSE Q9CZS1
aldehyde dehydrogenase 1 family, 
member B1
14 27 184 219 ALDH1B1 AL1B1_HUMAN P30837 c mitochondrion 519 0
107747 Aldh1l1 FTHFD_MOUSE Q8R0Y6
aldehyde dehydrogenase 1 family, 
member L1
3 2 1043 10840 ALDH1L1 FTHFD_HUMAN O75891 c cytoplasm 902 0
11669 Aldh2 ALDH2_MOUSE P47738 aldehyde dehydrogenase 2, 
mitochondrial
6 7 518 217 ALDH2 ALDH2_HUMAN P05091 c mitochondrion 519 0
56752 Aldh9a1 AL9A1_MOUSE Q9JLJ2
aldehyde dehydrogenase 9, 
subfamily A1
10 12 359 223 ALDH9A1 AL9A1_HUMAN P49189 c cytoplasm 494 0
11674 Aldoa ALDOA_MOUSE P05064 aldolase 1, A isoform 9 12 357 226 ALDOA ALDOA_HUMAN P04075 c - 196 0
230163 Aldob ALDOB_MOUSE Q91Y97 aldolase 2, B isoform 13 48 110 229 ALDOB ALDOB_HUMAN P05062 c cytoplasm 364 0
72074 Anks4b ANS4B_MOUSE Q8K3X6
ankyrin repeat and sterile alpha 
motif domain containing 4B
20 98 54 257629 ANKS4B ANS4B_HUMAN Q8N8V4 c plasma membrane 423 0
11737 Anp32a AN32A_MOUSE O35381
acidic (leucine-rich) nuclear 
phosphoprotein 32 family, member 
A
4 3 836 8125 ANP32A AN32A_HUMAN P39687 c cytoplasm 247 0
67628 Anp32b AN32B_MOUSE Q9EST5
acidic nuclear phosphoprotein 32 
family, member B
3 4 734 10541 ANP32B AN32B_HUMAN Q92688 c nucleus 272 0
16952 Anxa1 ANXA1_MOUSE P10107 annexin A1 3 3 844 301 ANXA1 ANXA1_HUMAN P04083 c basolateral plasma membrane 346 0
11744 Anxa11 ANX11_MOUSE P97384 annexin A11 7 19 248 311 ANXA11 ANX11_HUMAN P50995 c cytoplasm 503 0
69787 Anxa13 ANX13_MOUSE Q99JG3 annexin A13 18 69 70 312 ANXA13 ANX13_HUMAN P27216 c anchored to plasma membrane 317 0
12306 Anxa2 ANXA2_MOUSE P07356 annexin A2 29 115 39 302 ANXA2 ANXA2_HUMAN P07355 c plasma membrane 339 0
11746 Anxa4 ANXA4_MOUSE P97429 annexin A4 22 99 53 307 ANXA4 ANXA4_HUMAN P09525 c cytoplasm 319 0
11747 Anxa5 ANXA5_MOUSE P48036 annexin A5 9 6 553 308 ANXA5 ANXA5_HUMAN P08758 c cytoplasm 319 0
11750 Anxa7 ANXA7_MOUSE Q07076 annexin A7 7 10 417 310 ANXA7 ANXA7_HUMAN P20073 c plasma membrane 463 0
11764 Ap1b1 AP1B1_MOUSE O35643
adaptor protein complex AP-1, beta 
1 subunit
9 22 221 162 AP1B1 AP1B1_HUMAN Q10567 c clathrin adaptor complex 943 0
11765 Ap1g1 AP1G1_MOUSE P22892 adaptor protein complex AP-1, 
gamma 1 subunit
7 8 484 164 AP1G1 AP1G1_HUMAN O43747 c clathrin adaptor complex 822 0
11766 Ap1g2 AP1G2_MOUSE O88512
adaptor protein complex AP-1, 
gamma 2 subunit
6 4 688 8906 AP1G2 AP1G2_HUMAN O75843 c clathrin adaptor complex 791 0
11768 Ap1m2 AP1M2_MOUSE Q9WVP1
adaptor protein complex AP-1, mu 
2 subunit
13 13 323 10053 AP1M2 AP1M2_HUMAN Q9Y6Q5 c clathrin adaptor complex 423 0
11769 Ap1s1 AP1S1_MOUSE P61967
adaptor protein complex AP-1, 
sigma 1
4 5 628 1174 AP1S1 AP1S1_HUMAN P61966 c clathrin adaptor complex 158 0
11772 Ap2a2 AP2A2_MOUSE P17427
adaptor protein complex AP-2, 
alpha 2 subunit
3 4 711 161 AP2A2 AP2A2_HUMAN O94973 c clathrin adaptor complex 938 0
11773 Ap2m1 AP2M1_MOUSE P84091 adaptor protein complex AP-2, mu1 11 10 409 1173 AP2M1 AP2M1_HUMAN Q96CW1 c clathrin adaptor complex 435 0
232910 Ap2s1 AP2S1_MOUSE P62743
adaptor-related protein complex 2, 
sigma 1 subunit
2 2 967 1175 AP2S1 AP2S1_HUMAN P53680 c clathrin adaptor complex 142 0
55946 Ap3m1 AP3M1_MOUSE Q9JKC8
adaptor-related protein complex 3, 
mu 1 subunit
3 2 1019 26985 AP3M1 AP3M1_HUMAN Q9Y2T2 c clathrin adaptor complex 418 0
245282 Apol10a Q8CCA5_MOUSE Q8CCA5 apolipoprotein L 10a 5 4 702 - - - - c extracellular region 318 0
71898 Apol9b Q8C7I4_MOUSE Q8C7I4 apolipoprotein L 9b 3 2 1107 - - - - c extracellular region 310 0
11836 Araf ARAF_MOUSE P04627
v-raf murine sarcoma 3611 viral 
oncogene homolog
5 4 755 369 ARAF ARAF_HUMAN P10398 c cellular_component 604 0
213827 Arcn1 COPD_MOUSE Q5XJY5 archain 1 4 5 644 372 ARCN1 COPD_HUMAN P48444 c COPI vesicle coat 511 0
11840 Arf1 ARF1_MOUSE P84078 ADP-ribosylation factor 1 8 30 163 375 ARF1 ARF1_HUMAN P84077 c Golgi membrane 181 0
11841 Arf2 ARF2_MOUSE Q8BSL7 ADP-ribosylation factor 2 6 8 516 - - - - c Golgi apparatus 181 0
11843 Arf4 ARF4_MOUSE P61750 ADP-ribosylation factor 4 7 23 216 378 ARF4 ARF4_HUMAN P18085 c Golgi apparatus 180 0
11844 Arf5 ARF5_MOUSE P84084 ADP-ribosylation factor 5 7 28 172 381 ARF5 ARF5_HUMAN P84085 c Golgi apparatus 180 0
11845 Arf6 ARF6_MOUSE P62331 ADP-ribosylation factor 6 5 17 272 382 ARF6 ARF6_HUMAN P62330 c Golgi apparatus 175 0
11847 Arg2 ARGI2_MOUSE O08691 arginase type II 5 4 712 384 ARG2 ARGI2_HUMAN P78540 c mitochondrion 354 0
228359 Arhgap1 RHG01_MOUSE Q5FWK3 Rho GTPase activating protein 1 5 5 624 392 ARHGAP1 RHG01_HUMAN Q07960 c cytoplasm 439 1
544817 Arhgap27 RHG27_MOUSE A2AB59 Rho GTPase activating protein 27 2 2 1054 201176 ARHGAP27 RHG27_HUMAN Q6ZUM4 c associated to membrane 869 0
192662 Arhgdia GDIR1_MOUSE Q99PT1
Rho GDP dissociation inhibitor 
(GDI) alpha
3 5 643 396 ARHGDIA GDIR1_HUMAN P52565 c cytoplasm 204 0
230972 Arhgef16 ARHGG_MOUSE Q3U5C8
Rho guanine nucleotide exchange 
factor (GEF) 16
2 4 777 27237 ARHGEF16 ARHGG_HUMAN Q5VV41 c cytoplasm 713 0
104303 Arl1 ARL1_MOUSE P61211 ADP-ribosylation factor-like 1 4 4 699 400 ARL1 ARL1_HUMAN P40616 c Golgi apparatus 181 0
71619 Arl14 ARL14_MOUSE Q3SXC5 ADP-ribosylation factor-like 14 2 2 1034 80117 ARL14 ARL14_HUMAN Q8N4G2 c cytoplasm 192 0
218639 Arl15 ARL15_MOUSE Q8BGR6 ADP-ribosylation factor-like 15 2 2 1115 54622 ARL15 ARL15_HUMAN Q9NXU5 c - 569 0
56327 Arl2 ARL2_MOUSE Q9D0J4 ADP-ribosylation factor-like 2 4 3 854 402 ARL2 ARL2_HUMAN P36404 c intracellular 184 0
75423 Arl5a ARL5A_MOUSE Q80ZU0 ADP-ribosylation factor-like 5A 2 2 1109 26225 ARL5A ARL5A_HUMAN Q9Y689 c intracellular 179 0
75869 Arl5b ARL5B_MOUSE Q9D4P0 ADP-ribosylation factor-like 5B 2 2 1110 221079 ARL5B ARL5B_HUMAN Q96KC2 c anchored to membrane 179 0
68724 Arl8a ARL8A_MOUSE Q8VEH3 ADP-ribosylation factor-like 8A 5 8 507 127829 ARL8A ARL8A_HUMAN Q96BM9 c late endosome membrane 186 0
67166 Arl8b ARL8B_MOUSE Q9CQW2 ADP-ribosylation factor-like 8B 4 8 490 55207 ARL8B ARL8B_HUMAN Q9NVJ2 c anchored to late endosome membrane 186 0  171
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11867 Arpc1b ARC1B_MOUSE Q9WV32
actin related protein 2/3 complex, 
subunit 1B
6 6 566 10095 ARPC1B ARC1B_HUMAN O15143 c cytoskeleton 372 0
76709 Arpc2 ARPC2_MOUSE Q9CVB6 actin related protein 2/3 complex, 
subunit 2
8 15 294 10109 ARPC2 ARPC2_HUMAN O15144 c cytoskeleton 300 0
56378 Arpc3 ARPC3_MOUSE Q9JM76
actin related protein 2/3 complex, 
subunit 3
4 7 537 10094 ARPC3 ARPC3_HUMAN O15145 c cytoskeleton 178 0
68089 Arpc4 ARPC4_MOUSE P59999
actin related protein 2/3 complex, 
subunit 4
5 12 361 10093 ARPC4 ARPC4_HUMAN P59998 c cytoskeleton 168 0
67771 Arpc5 ARPC5_MOUSE Q9CPW4
actin related protein 2/3 complex, 
subunit 5
5 5 673 10092 ARPC5 ARPC5_HUMAN O15511 c cytoskeleton 151 0
74192 Arpc5l ARP5L_MOUSE Q9D898 actin related protein 2/3 complex, 
subunit 5-like
2 2 1108 81873 ARPC5L ARP5L_HUMAN Q9BPX5 c cytoskeleton 153 0
27053 Asns ASNS_MOUSE Q61024 asparagine synthetase 3 3 848 440 ASNS ASNS_HUMAN P08243 c cytosol 561 0
11946 Atp5a1 ATPA_MOUSE Q03265
ATP synthase, H+ transporting, 
mitochondrial F1 complex, alpha 
subunit, isoform 1
6 11 371 498 ATP5A1 ATPA_HUMAN P25705 c associated to mitochondrial inner membrane 553 0
11947 Atp5b ATPB_MOUSE P56480
ATP synthase, H+ transporting 
mitochondrial F1 complex, beta 
subunit
7 4 689 506 ATP5B ATPB_HUMAN P06576 c integral to mitochondrial inner membrane 529 0
11949 Atp5c1 ATPG_MOUSE Q91VR2
ATP synthase, H+ transporting, 
mitochondrial F1 complex, gamma 
polypeptide 1
5 4 714 509 ATP5C1 ATPG_HUMAN P36542 c associated to mitochondrial inner membrane 298 0
71679 Atp5h ATP5H_MOUSE Q9DCX2
ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit 
d
2 2 1157 10476 ATP5H ATP5H_HUMAN O75947 c mitochondrial inner membrane 161 0
28080 Atp5o ATPO_MOUSE Q9DB20
ATP synthase, H+ transporting, 
mitochondrial F1 complex, O 
subunit
3 3 900 539 ATP5O ATPO_HUMAN P48047 c associated to mitochondrial inner membrane 213 0
11972 Atp6v0d1 VA0D1_MOUSE P51863
ATPase, H+ transporting, lysosomal 
V0 subunit D1
6 8 464 9114 ATP6V0D1 VA0D1_HUMAN P61421 c associated to endomembrane system 351 0
11964 Atp6v1a VATA_MOUSE P50516
ATPase, H+ transporting, lysosomal 
V1 subunit A
6 4 756 523 ATP6V1A VATA_HUMAN P38606 c associated to endomembrane system 617 0
11966 Atp6v1b2 VATB2_MOUSE P62814
ATPase, H+ transporting, lysosomal 
V1 subunit B2
3 4 757 526 ATP6V1B2 VATB2_HUMAN P21281 c associated to endomembrane system 511 0
73834 Atp6v1d VATD_MOUSE P57746 ATPase, H+ transporting, lysosomal 
V1 subunit D
4 4 796 51382 ATP6V1D VATD_HUMAN Q9Y5K8 c proton-transporting two-sector ATPase comple 247 0
11973 Atp6v1e1 VATE1_MOUSE P50518
VATPase, H+ transporting, 
lysosomal V1 subunit E1
7 6 567 529 ATP6V1E1 VATE1_HUMAN P36543 c associated to endomembrane system 226 0
381476 B930007M17Rik CD037_MOUSE Q8C8J0
Uncharacterized protein C4orf37 
homolog
5 9 456 285555 C4orf37 CD037_HUMAN Q8N412 c - 534 0
66898 Baiap2l1 BI2L1_MOUSE Q9DBJ3 BAI1-associated protein 2-like 1 25 55 90 55971 BAIAP2L1 BI2L1_HUMAN Q9UHR4 c cellular_component 514 0
207495 Baiap2l2 BI2L2_MOUSE Q80Y61 BAI1-associated protein 2-like 2 7 7 529 80115 BAIAP2L2 BI2L2_HUMAN Q6UXY1 c - 578 0
53817 Bat1a UAP56_MOUSE Q9Z1N5 HLA-B-associated transcript 1A 3 4 726 7919 BAT1 UAP56_HUMAN Q13838 c nucleus 428 0
66813 Bcl2l14 B2L14_MOUSE Q9CPT0 Bcl2-like 14 (apoptosis facilitator) 5 3 816 79370 BCL2L14 B2L14_HUMAN Q9BZR8 c cytoplasm 328 0
170752 Bco2 BCDO2_MOUSE Q99NF1 beta-carotene oxygenase 2 4 3 940 83875 BCO2 BCDO2_HUMAN Q9BYV7 c intracellular 532 0
109778 Blvra BIEA_MOUSE Q9CY64 biliverdin reductase A 4 3 868 644 BLVRA BIEA_HUMAN P53004 c cytoplasm 295 0
233016 Blvrb BLVRB_MOUSE Q923D2
biliverdin reductase B (flavin 
reductase (NADPH))
4 3 872 645 BLVRB BLVRB_HUMAN P30043 c cytoplasm 206 0
12183 Bpgm PMGE_MOUSE P15327 2,3-bisphosphoglycerate mutase 4 4 790 669 BPGM PMGE_HUMAN P07738 c actin cytoskeleton 259 0
23827 Bpnt1 BPNT1_MOUSE Q9Z0S1 bisphosphate 3'-nucleotidase 1 12 21 235 10380 BPNT1 BPNT1_HUMAN O95861 c cytosol 308 0
71678 Brox BROX_MOUSE Q8K2Q7 BRO1 domain-containing protein 
BROX
5 4 771 148362 BROX BROX_HUMAN Q5VW32 c membrane 411 0
238386 Btbd7 BTBD7_MOUSE Q8CFE5 BTB (POZ) domain containing 7 4 6 581 55727 BTBD7 BTBD7_HUMAN Q9P203 c - 164 0
12237 Bub3 BUB3_MOUSE Q9WVA3
budding uninhibited by 
benzimidazoles 3 homolog (S. 
cerevisiae)
5 4 715 9184 BUB3 BUB3_HUMAN O43684 c nucleus 326 0
66882 Bzw1 BZW1_MOUSE Q9CQC6
basic leucine zipper and W2 
domains 1
3 2 1025 9689 BZW1 BZW1_HUMAN Q7L1Q6 c cytoplasm 419 0
66912 Bzw2 BZW2_MOUSE Q91VK1 basic leucine zipper and W2 
domains 2
2 2 1102 28969 BZW2 BZW2_HUMAN Q9Y6E2 c - 201 0
12283 Cab39 CAB39_MOUSE Q06138 calcium binding protein 39 6 4 716 51719 CAB39 CAB39_HUMAN Q9Y376 c cytoplasm 341 0
12301 Cacybp CYBP_MOUSE Q9CXW3 calcyclin binding protein 2 2 982 27101 CACYBP CYBP_HUMAN Q9HB71 c cytoplasm 229 0
12313 Calm1 CALM_MOUSE P62204 calmodulin 1 8 34 147 801 CALM1 CALM_HUMAN P62158 c plasma membrane 149 0
12314 Calm2 CALM_MOUSE P62204 calmodulin 2 8 34 148 805 CALM2 CALM_HUMAN P62158 c plasma membrane 149 0
12315 Calm3 CALM_MOUSE P62204 calmodulin 3 8 34 149 808 CALM3 CALM_HUMAN P62158 c plasma membrane 149 0
75600 Calml4 CALL4_MOUSE Q91WQ9 calmodulin-like 4 15 25 197 91860 CALML4 CALL4_HUMAN Q96GE6 c - 567 0
12331 Cap1 CAP1_MOUSE P40124 CAP, adenylate cyclase-associated 
protein 1 (yeast)
4 5 661 10487 CAP1 CAP1_HUMAN Q01518 c plasma membrane 474 0
12333 Capn1 CAN1_MOUSE O35350 calpain 1 6 5 662 823 CAPN1 CAN1_HUMAN P07384 c plasma membrane 713 0
12337 Capn5 CAN5_MOUSE O08688 calpain 5 2 2 1089 726 CAPN5 CAN5_HUMAN O15484 c cytosol 640 0
12340 Capza1 CAZA1_MOUSE P47753
capping protein (actin filament) 
muscle Z-line, alpha 1
6 12 358 829 CAPZA1 CAZA1_HUMAN P52907 c actin cytoskeleton 286 0
12343 Capza2 CAZA2_MOUSE P47754
capping protein (actin filament) 
muscle Z-line, alpha 2
5 10 402 830 CAPZA2 CAZA2_HUMAN P47755 c actin cytoskeleton 286 0
12345 Capzb CAPZB_MOUSE P47757 capping protein (actin filament) 
muscle Z-line, beta
12 15 292 832 CAPZB CAPZB_HUMAN P47756 c actin cytoskeleton 277 0
12350 Car3 CAH3_MOUSE P16015 carbonic anhydrase 3 2 2 1130 761 CA3 CAH3_HUMAN P07451 c cytoplasm 260 0
12362 Casp1 CASP1_MOUSE P29452 caspase 1 14 18 258 834 CASP1 CASP1_HUMAN P29466 c cytoplasm 402 0
12367 Casp3 CASP3_MOUSE P70677 caspase 3 5 11 391 836 CASP3 CASP3_HUMAN P42574 c cytoplasm 277 0
12368 Casp6 CASP6_MOUSE O08738 caspase 6 8 13 319 839 CASP6 CASP6_HUMAN P55212 c cytoplasm 276 0
12369 Casp7 CASP7_MOUSE P97864 caspase 7 6 7 533 840 CASP7 CASP7_HUMAN P55210 c mitochondrial inner membrane 303 0
12370 Casp8 CASP8_MOUSE O89110 caspase 8 10 9 434 841 CASP8 CASP8_HUMAN Q14790 c cytoplasm 480 0
12408 Cbr1 CBR1_MOUSE P48758 carbonyl reductase 1 10 17 261 873 CBR1 CBR1_HUMAN P16152 c cytoplasm 277 0
12461 Cct2 TCPB_MOUSE P80314 chaperonin subunit 2 (beta) 2 3 930 10576 CCT2 TCPB_HUMAN P78371 c cytoplasm 535 0
12462 Cct3 TCPG_MOUSE P80318 chaperonin subunit 3 (gamma) 5 5 629 7203 CCT3 TCPG_HUMAN P49368 c cytoskeleton 545 0
12464 Cct4 TCPD_MOUSE P80315 chaperonin subunit 4 (delta) 10 10 418 10575 CCT4 TCPD_HUMAN P50991 c cytoplasm 539 0
12465 Cct5 TCPE_MOUSE P80316 chaperonin subunit 5 (epsilon) 2 1 1184 22948 CCT5 TCPE_HUMAN P48643 c cytoplasm 541 0
12466 Cct6a TCPZ_MOUSE P80317 chaperonin subunit 6a (zeta) 9 9 440 908 CCT6A TCPZ_HUMAN P40227 c cytoplasm 531 0
12468 Cct7 TCPH_MOUSE P80313 chaperonin subunit 7 (eta) 7 9 463 10574 CCT7 TCPH_HUMAN Q99832 c cytoplasm 544 0
72269 Cda CDD_MOUSE P56389 cytidine deaminase 2 3 819 978 CDA CDD_HUMAN P32320 c cytoplasm 146 0
12534 Cdc2a CDC2_MOUSE P11440 cell division cycle 2 homolog A (S. 
pombe)
4 5 663 983 CDC2 CDC2_HUMAN P06493 c cytosol 297 0
12540 Cdc42 CDC42_MOUSE P60766
cell division cycle 42 homolog (S. 
cerevisiae) 7 28 176 643751 CDC42 - - c anchored to plasma membrane 191 0
12566 Cdk2 CDK2_MOUSE P97377 cyclin-dependent kinase 2 2 2 1131 1017 CDK2 CDK2_HUMAN P24941 c cytoplasm 346 0
69681 Cdk3 CDK3_MOUSE Q80YP0 cyclin-dependent kinase 3 2 2 1155 1018 CDK3 CDK3_HUMAN Q00526 c - 274 0
12568 Cdk5 CDK5_MOUSE P49615 cyclin-dependent kinase 5 3 3 894 1020 CDK5 CDK5_HUMAN Q00535 c cytoplasm 292 0
12631 Cfl1 COF1_MOUSE P18760 cofilin 1, non-muscle 12 37 134 1072 CFL1 COF1_HUMAN P23528 c cytoskeleton 166 0
234852 Chmp1a CHM1A_MOUSE Q921W0 chromatin modifying protein 1A 4 7 530 5119 CHMP1A CHM1A_HUMAN Q9HD42 c associated to endosome membrane 196 0
67064 Chmp1b CH1B1_MOUSE Q99LU0 chromatin modifying protein 1B 2 5 619 57132 CHMP1B CHM1B_HUMAN Q7LBR1 c cytoplasm 199 0
68953 Chmp2a CHM2A_MOUSE Q9DB34 chromatin modifying protein 2A 7 12 343 27243 CHMP2A CHM2A_HUMAN O43633 c associated to late endosome membrane 222 0
75608 Chmp4b CHM4B_MOUSE Q9D8B3 chromatin modifying protein 4B 9 25 201 128866 CHMP4B CHM4B_HUMAN Q9H444 c cytoplasm 224 0
66371 Chmp4c CHM4C_MOUSE Q9D7F7 chromatin modifying protein 4C 6 13 332 92421 CHMP4C CHM4C_HUMAN Q96CF2 c cytoplasm 232 0
76959 Chmp5 CHMP5_MOUSE Q9D7S9 chromatin modifying protein 5 4 5 674 51510 CHMP5 CHMP5_HUMAN Q9NZZ3 c cytoplasm 219 0
208092 Chmp6 CHMP6_MOUSE P0C0A3 chromatin modifying protein 6 4 8 491 79643 CHMP6 CHMP6_HUMAN Q96FZ7 c endosome membrane 200 0
56398 Chp CHP1_MOUSE P61022 Calcium-binding protein p22 5 5 638 11261 CHP CHP1_HUMAN Q99653 c cytoplasm 195 0
70261 Chp2 CHP2_MOUSE Q9D869 Calcineurin B homologous protein 2 15 48 109 63928 CHP2 CHP2_HUMAN O43745 c - 613 0
23991 Cib1 CIB1_MOUSE Q9Z0F4 calcium and integrin binding 1 
(calmyrin)
11 18 254 10519 CIB1 CIB1_HUMAN Q99828 c anchored to endoplasmic reticulum membrane 191 0
12709 Ckb KCRB_MOUSE Q04447 creatine kinase, brain 12 37 135 1152 CKB KCRB_HUMAN P12277 c cytoplasm 381 0
114584 Clic1 CLIC1_MOUSE Q9Z1Q5 chloride intracellular channel 1 13 15 295 1192 CLIC1 CLIC1_HUMAN O00299 c integral to apical plasma membrane 241 0
224796 Clic5 CLIC5_MOUSE Q8BXK9 chloride intracellular channel 5 12 86 62 53405 CLIC5 CLIC5_HUMAN Q9NZA1 c actin cytoskeleton 251 0
12757 Clta CLCA_MOUSE O08585 clathrin, light polypeptide (Lca) 3 3 837 1211 CLTA CLCA_HUMAN P09496 c clathrin coat 235 0
74325 Cltb CLCB_MOUSE Q6IRU5 clathrin, light polypeptide (Lcb) 5 5 641 1212 CLTB CLCB_HUMAN P09497 c clathrin coat 229 0
67300 Cltc CLH_MOUSE Q68FD5 clathrin, heavy polypeptide (Hc) 73 303 12 1213 CLTC CLH1_HUMAN Q00610 c clathrin  coat 1675 0
69574 Cmbl CMBL_MOUSE Q8R1G2 carboxymethylenebutenolidase-like 
(Pseudomonas)
2 2 1030 134147 CMBL CMBL_HUMAN Q96DG6 c - 648 0
22169 Cmpk2 CMPK2_MOUSE Q3U5Q7
cytidine monophosphate (UMP-
CMP) kinase 2, mitochondrial
7 9 435 129607 CMPK2 CMPK2_HUMAN Q5EBM0 c mitochondrion 447 0
12785 Cnbp CNBP_MOUSE P53996 cellular nucleic acid binding protein 2 2 1132 7555 CNBP CNBP_HUMAN P62633 c cytoplasm 178 0
66054 Cndp2 CNDP2_MOUSE Q9D1A2 CNDP dipeptidase 2 
(metallopeptidase M20 family)
13 18 255 55748 CNDP2 CNDP2_HUMAN Q96KP4 c - 548 0
12799 Cnp CN37_MOUSE P16330 2',3'-cyclic nucleotide 3' 
phosphodiesterase
3 2 950 1267 CNP CN37_HUMAN P09543 c membrane 420 0
12808 Cobl COBL_MOUSE Q5NBX1 cordon-bleu 14 68 71 23242 COBL COBL_HUMAN O75128 c - 487 0
68018 Col4a3bp C43BP_MOUSE Q9EQG9
collagen, type IV, alpha 3 
(Goodpasture antigen) binding 
protein
2 3 859 10087 COL4A3BP C43BP_HUMAN Q9Y5P4 c Golgi apparatus 624 0
12238 Commd3 COMD3_MOUSE Q63829 COMM domain containing 3 2 2 1088 23412 COMMD3 COMD3_HUMAN Q9UBI1 c - 340 0
54161 Copg COPG_MOUSE Q9QZE5
coatomer protein complex, subunit 
gamma
2 3 850 22820 COPG COPG_HUMAN Q9Y678 c COPI vesicle coat 874 0
12848 Cops2 CSN2_MOUSE P61202
COP9 (constitutive 
photomorphogenic) homolog, 
subunit 2 (Arabidopsis thaliana)
3 2 985 9318 COPS2 CSN2_HUMAN P61201 c cytoplasm 443 0
26754 Cops5 CSN5_MOUSE O35864
COP9 (constitutive 
photomorphogenic) homolog, 
subunit 5 (Arabidopsis thaliana)
2 2 1146 10987 COPS5 CSN5_HUMAN Q92905 c cytoplasm 334 0
26893 Cops6 CSN6_MOUSE O88545
COP9 (constitutive 
photomorphogenic) homolog, 
subunit 6 (Arabidopsis thaliana)
2 2 1011 10980 COPS6 CSN6_HUMAN Q7L5N1 c cytoplasm 324 0
26894 Cops7a CSN7A_MOUSE Q9CZ04
COP9 (constitutive 
photomorphogenic) homolog, 
subunit 7a (Arabidopsis thaliana)
2 2 1012 50813 COPS7A CSN7A_HUMAN Q9UBW8 c cytoplasm 275 0
56447 Copz1 COPZ1_MOUSE P61924
coatomer protein complex, subunit 
zeta 1
2 2 1149 22818 COPZ1 COPZ1_HUMAN P61923 c COPI vesicle coat 177 0
12721 Coro1a COR1A_MOUSE O89053 coronin, actin binding protein 1A 2 2 984 11151 CORO1A COR1A_HUMAN P31146 c cytoskeleton 461 0
72042 Cotl1 COTL1_MOUSE Q9CQI6 coactosin-like 1 (Dictyostelium) 2 2 1036 23406 COTL1 COTL1_HUMAN Q14019 c cytoskeleton 142 0
234577 Cpne2 CPNE2_MOUSE P59108 copine II 4 5 647 221184 CPNE2 CPNE2_HUMAN Q96FN4 c - 621 0
227231 Cps1 CPSM_MOUSE Q8C196 carbamoyl-phosphate synthetase 1 5 5 675 1373 CPS1 CPSM_HUMAN P31327 c mitochondrion 1500 0
12904 Crabp2 RABP2_MOUSE P22935
cellular retinoic acid binding protein 
II
3 3 838 1382 CRABP2 RABP2_HUMAN P29373 c cytoplasm 138 0
214897 Csnk1g1 KC1G1_MOUSE Q8BTH8 casein kinase 1, gamma 1 2 2 1162 53944 CSNK1G1 KC1G1_HUMAN Q9HCP0 c cytoplasm 459 0
70425 Csnk1g3 KC1G3_MOUSE Q8C4X2 casein kinase 1, gamma 3 11 10 413 1456 CSNK1G3 KC1G3_HUMAN Q9Y6M4 c cytoplasm 424 0
13007 Csrp1 CSRP1_MOUSE P97315 cysteine and glycine-rich protein 1 4 3 839 1465 CSRP1 CSRP1_HUMAN P21291 c nucleus 193 0
227292 Ctdsp1 CTDS1_MOUSE P58466
CTD (carboxy-terminal domain, 
RNA polymerase II, polypeptide A) 
small phosphatase 1
4 5 646 58190 CTDSP1 CTDS1_HUMAN Q9GZU7 c nucleus 261 0
69274 Ctdspl CTDSL_MOUSE P58465
CTD (carboxy-terminal domain, 
RNA polymerase II, polypeptide A) 
small phosphatase-like
2 2 1029 10217 CTDSPL CTDSL_HUMAN O15194 c nucleus 276 0
107869 Cth CGL_MOUSE Q8VCN5 cystathionase (cystathionine 
gamma-lyase)
3 3 912 1491 CTH CGL_HUMAN P32929 c cytoplasm 398 0
12388 Ctnnd1 CTND1_MOUSE P30999
catenin (cadherin associated 
protein), delta 1
2 2 983 1500 CTNND1 CTND1_HUMAN O60716 c plasma membrane 938 0
26554 Cul3 CUL3_MOUSE Q9JLV5 cullin 3 2 2 1145 8452 CUL3 CUL3_HUMAN Q13618 c Golgi apparatus 768 0
109672 Cyb5 CYB5_MOUSE P56395 cytochrome b-5 4 3 867 1528 CYB5A CYB5_HUMAN P00167 c integral to endoplasmic reticulum membrane 134 1
109754 Cyb5r3 NB5R3_MOUSE Q9DCN2 cytochrome b5 reductase 3 11 14 305 1727 CYB5R3 NB5R3_HUMAN P00387 c anchored to endoplasmic reticulum membrane 301 0
13063 Cycs CYC_MOUSE P62897 cytochrome c, somatic 2 1 1185 54205 CYCS CYC_HUMAN      P99999 c mitochondrial intermembrane space 105 0
28088 D10Wsu52e CV028_MOUSE Q99LF4 DNA segment, Chr 10, Wayne 
State University 52, expressed
3 3 849 51493 C22orf28 CV028_HUMAN Q9Y3I0 c - 192 0    172
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110957 D1Pas1 DDX3L_MOUSE P16381
DNA segment, Chr 1, Pasteur 
Institute 1
8 14 316 8653 DDX3Y DDX3Y_HUMAN O15523 c cytoplasm 660 0
225913 Dak DHAK_MOUSE Q8VC30
dihydroxyacetone kinase 2 homolog 
(yeast)
17 58 84 26007 DAK DHAK_HUMAN Q3LXA3 c - 1308 0
226414 Dars SYDC_MOUSE Q922B2 aspartyl-tRNA synthetase 11 9 443 1615 DARS SYDC_HUMAN P14868 c cytoplasm 501 0
13195 Ddc DDC_MOUSE O88533 dopa decarboxylase 2 1 1186 1644 DDC DDC_HUMAN P20711 c - 624 0
13202 Ddt DOPD_MOUSE O35215 D-dopachrome tautomerase 2 2 1133 1652 DDT DOPD_HUMAN P30046 c cytoplasm 118 0
104721 Ddx1 DDX1_MOUSE Q91VR5
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 1
3 3 911 1653 DDX1 DDX1_HUMAN Q92499 c cellular_component 740 0
68278 Ddx39 DDX39_MOUSE Q8VDW0
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 39
4 6 577 10212 DDX39 DDX39_HUMAN O00148 c nucleus 427 0
13205 Ddx3x DDX3X_MOUSE Q62167 DEAD/H (Asp-Glu-Ala-Asp/His) box 
polypeptide 3, X-linked
13 36 140 1654 DDX3X DDX3X_HUMAN O00571 c cytoplasm 662 0
26900 Ddx3y DDX3Y_MOUSE Q62095
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3, Y-linked
11 6 573 8653 DDX3Y DDX3Y_HUMAN O15523 c cytoplasm 658 0
13207 Ddx5 DDX5_MOUSE Q61656 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 5
4 7 534 1655 DDX5 DDX5_HUMAN P17844 c nucleus 614 0
232449 Dera DEOC_MOUSE Q91YP3
2-deoxyribose-5-phosphate 
aldolase homolog (C. elegans)
11 8 508 51071 DERA DEOC_HUMAN Q9Y315 c cytoplasm 318 0
54722 Dfna5h DFNA5_MOUSE Q9Z2D3 deafness, autosomal dominant 5 
homolog (human)
3 3 851 1687 DFNA5 DFNA5_HUMAN O60443 c - 419 0
13361 Dhfr DYR_MOUSE P00375 dihydrofolate reductase 3 2 986 1719 DHFR DYR_HUMAN P00374 c cellular_component 187 0
52585 Dhrs1 DHRS1_MOUSE Q99L04 dehydrogenase/reductase (SDR 
family) member 1
10 10 425 115817 DHRS1 DHRS1_HUMAN Q96LJ7 c endoplasmic reticulum 313 0
235339 Dlat ODP2_MOUSE Q8BMF4
dihydrolipoamide S-
acetyltransferase (E2 component of 
pyruvate dehydrogenase complex)
2 2 968 1737 DLAT ODP2_HUMAN P10515 c mitochondrion 642 0
15502 Dnaja1 DNJA1_MOUSE P63037
DnaJ (Hsp40) homolog, subfamily 
A, member 1
11 11 373 3301 DNAJA1 DNJA1_HUMAN P31689 c membrane 397 0
56445 Dnaja2 DNJA2_MOUSE Q9QYJ0 DnaJ (Hsp40) homolog, subfamily 
A, member 2
9 8 472 10294 DNAJA2 DNJA2_HUMAN O60884 c membrane 412 0
58233 Dnaja4 DNJA4_MOUSE Q9JMC3
DnaJ (Hsp40) homolog, subfamily 
A, member 4
2 1 1191 55466 DNAJA4 DNJA4_HUMAN Q8WW22 c membrane 397 0
56354 Dnajc7 DNJC7_MOUSE Q9QYI3
DnaJ (Hsp40) homolog, subfamily 
C, member 7
5 3 904 7266 DNAJC7 DNJC7_HUMAN Q99615 c - 505 0
13430 Dnm2 DYN2_MOUSE P39054 dynamin 2 6 11 372 1785 DNM2 DYN2_HUMAN P50570 c cytoskeleton 870 0
13437 Dnpep DNPEP_MOUSE Q9Z2W0 aspartyl aminopeptidase 11 12 351 23549 DNPEP DNPEP_HUMAN Q9ULA0 c cytoplasm 473 0
93838 Dqx1 DQX1_MOUSE Q924H9 DEAQ RNA-dependent ATPase 2 2 1042 165545 DQX1 DQX1_HUMAN Q8TE96 c nucleus 718 0
109620 Dsp Q8BP77_MOUSE Q8BP77 desmoplakin homolog 38 19 244 1832 DSP DESP_HUMAN P15924 c cytoskeleton 482 0
56431 Dstn DEST_MOUSE Q9R0P5 destrin 12 36 138 11034 DSTN DEST_HUMAN P60981 c actin cytoskeleton 165 0
13424 Dync1h1 DYHC1_MOUSE Q9JHU4 dynein cytoplasmic 1 heavy chain 1 73 71 69 1778 DYNC1H1 DYHC1_HUMAN Q14204 c microtubule 4644 0
235661 Dync1li1 DC1L1_MOUSE Q8R1Q8
dynein cytoplasmic 1 light 
intermediate chain 1
2 3 825 51143 DYNC1LI1 DC1L1_HUMAN Q9Y6G9 c microtubule 523 0
13627 Eef1a1 EF1A1_MOUSE P10126
eukaryotic translation elongation 
factor 1 alpha 1
18 97 56 1915 EEF1A1 EF1A1_HUMAN     P68104 c cytoplasm 462 0
13628 Eef1a2 EF1A2_MOUSE P62631
eukaryotic translation elongation 
factor 1 alpha 2
3 13 320 1917 EEF1A2 EF1A2_HUMAN Q05639 c cytoplasm 463 0
66656 Eef1d EF1D_MOUSE P57776
eukaryotic translation elongation 
factor 1 delta (guanine nucleotide 
exchange protein)
3 2 958 1936 EEF1D EF1D_HUMAN P29692 c cytosol 281 0
67160 Eef1g EF1G_MOUSE Q9D8N0
eukaryotic translation elongation 
factor 1 gamma
5 4 768 1937 EEF1G EF1G_HUMAN P26641 c cytosol 437 0
13629 Eef2 EF2_MOUSE P58252
eukaryotic translation elongation 
factor 2
18 52 97 1938 EEF2 EF2_HUMAN P13639 c cytoplasm 858 0
27984 Efhd2 EFHD2_MOUSE Q9D8Y0 EF hand domain containing 2 9 26 194 79180 EFHD2 EFHD2_HUMAN Q96C19 c - 494 0
76740 Efr3a EFR3A_MOUSE Q8BG67 EFR3 homolog A (S. cerevisiae) 3 3 863 23167 EFR3A EFR3A_HUMAN Q14156 c plasma membrane 819 0
433923 EG433923 - -
solute carrier family 25 
(mitochondrial carrier; adenine 
nucleotide translocator), member 6
2 2 1053 293 SLC25A6 ADT3_HUMAN P12236 c integral to mitochondrion inner membrane 298 2
13660 Ehd1 EHD1_MOUSE Q9WVK4 EH-domain containing 1 20 27 182 10938 EHD1 EHD1_HUMAN Q9H4M9 c anchored to plasma membrane 534 0
98878 Ehd4 EHD4_MOUSE Q9EQP2 EH-domain containing 4 9 9 442 30844 EHD4 EHD4_HUMAN Q9H223 c endoplasmic reticulum 541 0
74147 Ehhadh ECHP_MOUSE Q9DBM2
enoyl-Coenzyme A, hydratase/3-
hydroxyacyl Coenzyme A 
dehydrogenase
5 3 861 1962 EHHADH ECHP_HUMAN Q08426 c mitochondrion 718 0
13681 Eif4a1 IF4A1_MOUSE P60843
eukaryotic translation initiation 
factor 4A1
17 28 173 1973 EIF4A1 IF4A1_HUMAN P60842 c cytoplasm 406 0
13682 Eif4a2 IF4A2_MOUSE P10630 eukaryotic translation initiation 
factor 4A2
2 3 840 1974 EIF4A2 IF4A2_HUMAN Q14240 c cytosol 407 0
217869 Eif5 IF5_MOUSE P59325
eukaryotic translation initiation 
factor 5
2 2 1163 1983 EIF5 IF5_HUMAN P55010 c cytoplasm 429 0
16418 Eif6 IF6_MOUSE O55135 eukaryotic translation initiation 
factor 6
5 5 664 3692 EIF6 IF6_HUMAN P56537 c cytoplasm 245 0
13806 Eno1 ENOA_MOUSE P17182 enolase 1, alpha non-neuron 17 47 111 2023 ENO1 ENOA_HUMAN P06733 c plasma membrane 434 0
54357 Epb4.1l4b E41LB_MOUSE Q9JMC8 erythrocyte protein band 4.1-like 4b 5 5 687 54566 EPB41L4B E41LB_HUMAN Q9H329 c cytoskeleton 527 0
226352 Epb4.1l5 E41L5_MOUSE Q8BGS1 erythrocyte protein band 4.1-like 5 2 2 1164 57669 EPB41L5 E41L5_HUMAN Q9HCM4 c cytoskeleton 731 0
13860 Eps8 EPS8_MOUSE Q08509 epidermal growth factor receptor 
pathway substrate 8
11 49 103 2059 EPS8 EPS8_HUMAN Q12929 c - 574 0
98845 Eps8l2 ES8L2_MOUSE Q99K30 EPS8-like 2 16 48 107 64787 EPS8L2 ES8L2_HUMAN Q9H6S3 c cytoplasm 729 0
99662 Eps8l3 ES8L3_MOUSE Q91WL0 ESP8-like 3 28 140 31 79574 EPS8L3 ES8L3_HUMAN Q8TE67 c cytoplasm 600 0
13885 Esd ESTD_MOUSE Q9R0P3 esterase D/formylglutathione 
hydrolase
4 4 690 2098 ESD ESTD_HUMAN P10768 c cytoplasmic membrane-bounded vesicle 282 0
56226 Espn ESPN_MOUSE Q9ET47 espin 2 3 853 83715 ESPN ESPN_HUMAN B1AK53 c cytoskeleton 871 0
225363 Etf1 ERF1_MOUSE Q8BWY3
eukaryotic translation termination 
factor 1
2 2 1046 2107 ETF1 ERF1_HUMAN P62495 c cytoplasm 437 0
110826 Etfb ETFB_MOUSE Q9DCW4
electron transferring flavoprotein, 
beta polypeptide
4 3 869 2109 ETFB ETFB_HUMAN P38117 c mitochondrion 255 0
22350 Ezr EZRI_MOUSE P26040 ezrin 37 131 35 7430 EZR EZRI_HUMAN P15311 c cytoskeleton 586 0
14080 Fabp1 FABPL_MOUSE P12710 fatty acid binding protein 1, liver 9 27 183 2168 FABP1 FABPL_HUMAN P07148 c cytoplasm 127 0
14079 Fabp2 FABPI_MOUSE P55050
fatty acid binding protein 2, 
intestinal
10 19 249 2169 FABP2 FABPI_HUMAN P12104 c cytoplasm 132 0
16592 Fabp5 FABP5_MOUSE Q05816 fatty acid binding protein 5, 
epidermal
2 1 1188 2171 FABP5 FABP5_HUMAN Q01469 c cytoplasm 135 0
16204 Fabp6 FABP6_MOUSE P51162
fatty acid binding protein 6, ileal 
(gastrotropin)
3 5 614 2172 FABP6 FABP6_HUMAN P51161 c cytoplasm 128 0
216169 Fam108a F108A_MOUSE Q99JW1 Abhydrolase domain-containing 
protein FAM108A 
5 5 645 81926 FAM108A3 F18A1_HUMAN Q96GS6 c extracellular region 310 0
226016 Fam108b1 F108B_MOUSE Q7M759
Abhydrolase domain-containing 
protein FAM108B1 [Precursor]
4 2 966 51104 FAM108B1 F108B_HUMAN Q5VST6 c extracellular region 288 0
66590 Farsa SYFA_MOUSE Q8C0C7
phenylalanyl-tRNA synthetase, 
alpha subunit
4 3 857 2193 FARSA SYFA_HUMAN Q9Y285 c cytoplasm 508 0
14120 Fbp2 F16P2_MOUSE P70695 fructose bisphosphatase 2 4 4 691 8789 FBP2 F16P2_HUMAN O00757 c cytosol 339 0
110196 Fdps FPPS_MOUSE Q920E5 farnesyl diphosphate synthetase 4 4 797 2224 FDPS FPPS_HUMAN P14324 c cytoplasm 353 0
14194 Fh1 FUMH_MOUSE P97807 fumarate  hydratase 1 4 4 758 2271 FH FUMH_HUMAN P07954 c cytoplasm 507 0
14199 Fhl1 FHL1_MOUSE P97447 four and a half LIM domains 1 2 1 1187 2273 FHL1 FHL1_HUMAN Q13642 c cytoplasm 280 0
14228 Fkbp4 FKBP4_MOUSE P30416 FK506 binding protein 4 7 10 419 2288 FKBP4 FKBP4_HUMAN Q02790 c cytoplasm 458 0
286940 Flnb FLNB_MOUSE Q80X90 filamin, beta 14 9 444 2317 FLNB FLNB_HUMAN O75369 c cytoskeleton 2602 0
67457 Frmd8 FRMD8_MOUSE Q3UFK8 FERM domain containing 8 2 2 1154 83786 FRMD8 FRMD8_HUMAN Q9BZ67 c cytoskeleton 466 0
14381 G6pdx G6PD1_MOUSE Q00612
glucose-6-phosphate 
dehydrogenase X-linked
3 2 987 2539 G6PD G6PD_HUMAN P11413 c cytoplasm 515 0
74246 Gale GALE_MOUSE Q8R059 galactose-4-epimerase, UDP 14 14 303 2582 GALE GALE_HUMAN Q14376 c cytoplasm 347 0
14635 Galk1 GALK1_MOUSE Q9R0N0 galactokinase 1 6 5 613 2584 GALK1 GALK1_HUMAN P51570 c cytoplasm 391 0
319625 Galm GALM_MOUSE Q8K157 galactose mutarotase 2 2 1049 130589 GALM GALM_HUMAN Q96C23 c cytoplasm 342 0
14630 Gclm GSH0_MOUSE O09172 glutamate-cysteine ligase , modifier 
subunit
5 5 630 2730 GCLM GSH0_HUMAN P48507 c cytosol 274 0
14569 Gdi2 GDIB_MOUSE Q61598
guanosine diphosphate (GDP) 
dissociation inhibitor 2
15 21 225 2665 GDI2 GDIB_HUMAN P50395 c associated to membrane 445 0
54120 Gipc2 GIPC2_MOUSE Q9Z2H7
GIPC PDZ domain containing 
family, member 2
11 9 436 54810 GIPC2 GIPC2_HUMAN Q8TF65 c cytoplasm 314 0
384009 Glipr2 GAPR1_MOUSE Q9CYL5 GLI pathogenesis-related 2 2 2 1052 152007 C9orf19 GAPR1_HUMAN Q9H4G4 c associated to Golgi membrane 154 0
109801 Glo1 LGUL_MOUSE Q9CPU0 glyoxalase 1 3 2 1113 2739 GLO1 LGUL_HUMAN Q04760 c cytoplasm 184 0
69824 Glod5 GLOD5_MOUSE Q9D8I3 glyoxalase domain containing 5 6 4 696 392465 GLOD5 GLOD5_HUMAN A6NK44 c - 475 0
30926 Glrx3 GLRX3_MOUSE Q9CQM9 glutaredoxin 3 3 3 901 10539 GLRX3 GLRX3_HUMAN O76003 c cytoplasm 337 0
330440 Gm766 Q3UN63_MOUSE Q3UN63 hypothetical Sulfotransferase 2 2 1118 - - - - c - 171 0
218138 Gmds GMDS_MOUSE Q8K0C9 GDP-mannose 4, 6-dehydratase 13 11 388 2762 GMDS GMDS_HUMAN O60547 c cytoplasm 372 0
14672 Gna11 GNA11_MOUSE P21278
guanine nucleotide binding protein, 
alpha 11
28 236 20 2767 GNA11 GNA11_HUMAN P29992 c associated to plasma membrane 359 0
14673 Gna12 GNA12_MOUSE P27600 guanine nucleotide binding protein, 
alpha 12
2 2 951 2768 GNA12 GNA12_HUMAN Q03113 c plasma membrane 379 0
14674 Gna13 GNA13_MOUSE P27601
guanine nucleotide binding protein, 
alpha 13
19 43 119 10672 GNA13 GNA13_HUMAN Q14344 c membrane 377 0
14675 Gna14 GNA14_MOUSE P30677 guanine nucleotide binding protein, 
alpha 14
7 58 85 9630 GNA14 GNA14_HUMAN O95837 c plasma membrane 355 0
14681 Gnao1 GNAO_MOUSE P18872
guanine nucleotide binding protein, 
alpha O
5 24 204 2775 GNAO1 GNAO_HUMAN P09471 c membrane fraction 354 0
14682 Gnaq GNAQ_MOUSE P21279
guanine nucleotide binding protein, 
alpha q polypeptide
20 115 40 2776 GNAQ GNAQ_HUMAN P50148 c associated to plasma membrane 353 0
14688 Gnb1 GBB1_MOUSE P62874
guanine nucleotide binding protein 
(G protein), beta 1
15 116 38 2782 GNB1 GBB1_HUMAN P62873 c associated to membrane 130 0
14693 Gnb2 GBB2_MOUSE P62880
guanine nucleotide binding protein 
(G protein), beta 2
12 107 46 2783 GNB2 GBB2_HUMAN P62879 c associated to membrane 493 0
50798 Gne GLCNE_MOUSE Q91WG8 glucosamine 4 3 814 10020 GNE GLCNE_HUMAN Q9Y223 c cytoplasm 722 0
26384 Gnpda1 GNPI_MOUSE O88958 glucosamine-6-phosphate 
deaminase 1
5 4 723 10007 GNPDA1 GNPI_HUMAN P46926 c cytoplasm 289 0
57437 Golga7 GOGA7_MOUSE Q91W53
golgi autoantigen, golgin subfamily 
a, 7
3 4 766 51125 GOLGA7 GOGA7_HUMAN Q7Z5G4 c Golgi apparatus 137 0
66629 Golph3 GOLP3_MOUSE Q9CRA5 golgi phosphoprotein 3 4 4 733 64083 GOLPH3 GOLP3_HUMAN Q9H4A6 c associated to Golgi membrane 298 0
229593 Golph3l GLP3L_MOUSE Q8R088 golgi phosphoprotein 3-like 4 4 700 55204 GOLPH3L GLP3L_HUMAN Q9H4A5 c associated to Golgi membrane 285 0
14718 Got1 AATC_MOUSE P05201
glutamate oxaloacetate 
transaminase 1, soluble
4 2 952 2805 GOT1 AATC_HUMAN P17174 c cytoplasm 413 0
14555 Gpd1 GPDA_MOUSE P13707
glycerol-3-phosphate 
dehydrogenase 1 (soluble)
15 22 219 2819 GPD1 GPDA_HUMAN P21695 c cytoplasm 349 0
333433 Gpd1l GPD1L_MOUSE Q3ULJ0 glycerol-3-phosphate 
dehydrogenase 1-like
9 7 542 23171 GPD1L GPD1L_HUMAN Q8N335 c cytoplasm 351 0
76282 Gpt ALAT1_MOUSE Q8QZR5
glutamic pyruvic transaminase, 
soluble
7 6 597 2875 GPT ALAT1_HUMAN P24298 c cytoplasm 496 0
14775 Gpx1 GPX1_MOUSE P11352 glutathione peroxidase 1 7 8 485 2876 GPX1 GPX1_HUMAN P07203 c cytoplasm 201 0
14776 Gpx2 GPX2_MOUSE Q9JHC0 glutathione peroxidase 2 15 19 243 2877 GPX2 GPX2_HUMAN P18283 c cytoplasm 190 0
14784 Grb2 GRB2_MOUSE Q60631
growth factor receptor bound 
protein 2
7 3 806 2885 GRB2 GRB2_HUMAN P62993 c Golgi apparatus 217 0
69146 Gsdmd GSDC1_MOUSE Q9D8T2 gasdermin D 10 18 256 79792 GSDMDC1 GSDC1_HUMAN P57764 c - 420 0
14854 Gss GSHB_MOUSE P51855 glutathione synthetase 2 2 988 2937 GSS GSHB_HUMAN P48637 c - 512 0
14857 Gsta1 GSTA1_MOUSE P13745
glutathione S-transferase, alpha 1 
(Ya)
6 8 465 21357 | 293 GSTA5 | GSTA2 GSTA5_HUMAN Q7RTV2 c cytoplasm 223 0
14858 Gsta2 GSTA2_MOUSE P10648
glutathione S-transferase, alpha 2 
(Yc2)
6 8 466 221357 GSTA5 GSTA5_HUMAN Q7RTV2 c cytoplasm 222 0
14860 Gsta4 GSTA4_MOUSE P24472 glutathione S-transferase, alpha 4 2 2 1134 - - - - c cytoplasm 222 0
14862 Gstm1 GSTM1_MOUSE P10649 glutathione S-transferase, mu 1 6 4 717 2944 GSTM1 GSTM1_HUMAN    P09488 c cytoplasm 218 0
14864 Gstm3 GSTM4_MOUSE P19639 glutathione S-transferase, mu 3 11 7 523 - - - - c cytoplasm 218 0  173
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14873 Gsto1 GSTO1_MOUSE O09131 glutathione S-transferase omega 1 7 6 594 9446 GSTO1 GSTO1_HUMAN P78417 c cytoplasm 240 0
14870 Gstp1 GSTP1_MOUSE P19157 glutathione S-transferase, pi 1 6 9 451 2950 GSTP1 GSTP1_HUMAN P09211 c cytoplasm 210 0
14871 Gstt1 GSTT1_MOUSE Q64471 glutathione S-transferase, theta 1 2 2 1090 2952 GSTT1 GSTT1_HUMAN P30711 c cytoplasm 240 0
103140 Gstt3 Q6P6I4_MOUSE Q6P6I4 glutathione S-transferase, theta 3 5 4 698 25774 GSTTP1 GSTT4_HUMAN A8MPT4 c cytoplasm 241 0
14874 Gstz1 MAAI_MOUSE Q9WVL0
glutathione transferase zeta 1 
(maleylacetoacetate isomerase)
2 2 989 2954 GSTZ1 MAAI_HUMAN O43708 c cytoplasm 216 0
15107 Hadh HCDH_MOUSE Q61425
hydroxyacyl-Coenzyme A 
dehydrogenase
4 3 842 3033 HADH HCDH_HUMAN Q16836 c mitochondrial inner membrane 314 0
231086 Hadhb ECHB_MOUSE Q99JY0
hydroxyacyl-Coenzyme A 
dehydrogenase/3-ketoacyl-
Coenzyme A thiolase/enoyl-
Coenzyme A hydratase 
(trifunctional protein), beta subunit
4 3 871 3032 HADHB ECHB_HUMAN P55084 c cytosol 475 0
14651 Hagh GLO2_MOUSE Q99KB8 hydroxyacyl glutathione hydrolase 5 6 610 3029 HAGH GLO2_HUMAN Q16775 c - 245 0
15109 Hal HUTH_MOUSE P35492 histidine ammonia lyase 4 4 718 3034 HAL HUTH_HUMAN P42357 c cytoplasm 657 0
15115 Hars SYHC_MOUSE Q61035 histidyl-tRNA synthetase 2 2 1091 3035 HARS SYHC_HUMAN P12081 c cytoplasm 509 0
107435 Hat1 HAT1_MOUSE Q8BY71 histone aminotransferase 1 2 2 1112 8520 HAT1 HAT1_HUMAN O14929 c cytoplasm 416 0
15122 Hba-a1 HBA_MOUSE P01942 hemoglobin alpha, adult chain 1 4 7 524 3039 HBA1 HBA_HUMAN P69905 c hemoglobin complex 142 0
15129 Hbb-b1 HBB1_MOUSE P02088 hemoglobin, beta adult major chain 11 21 226 3043 HBB HBB_HUMAN P68871 c hemoglobin complex 147 0
15130 Hbb-b2 HBB1_MOUSE P02088 hemoglobin, beta adult minor chain 11 21 227 3043 HBB HBB_HUMAN P68871 c hemoglobin complex 147 0
15254 Hint1 HINT1_MOUSE P70349
histidine triad nucleotide binding 
protein 1
3 5 631 3094 HINT1 HINT1_HUMAN P49773 c cytoplasm 126 0
29816 Hip1r HIP1R_MOUSE Q9JKY5 huntingtin interacting protein 1 
related
2 3 813 9026 HIP1R HIP1R_HUMAN O75146 c clathrin-coated vesicle 1068 0
216019 Hkdc1 HKDC1_MOUSE Q91W97 hexokinase domain containing 1 3 2 964 80201 HKDC1 HKDC1_HUMAN Q2TB90 c - 267 0
15289 Hmgb1 HMGB1_MOUSE P63158 high mobility group box 1 4 4 791 10357 HMG1L1 - - c cytoplasm 215 0
53379 Hnrnpa2b1 ROA2_MOUSE O88569
heterogeneous nuclear 
ribonucleoprotein A2/B1
4 10 426 3181 HNRNPA2B1 ROA2_HUMAN P22626 c nucleus 353 0
98758 Hnrnpf HNRPF_MOUSE Q9Z2X1 heterogeneous nuclear 
ribonucleoprotein F
5 4 773 3185 HNRNPF HNRPF_HUMAN P52597 c nucleus 415 0
59013 Hnrnph1 HNRH1_MOUSE O35737
heterogeneous nuclear 
ribonucleoprotein H1
2 3 905 3187 HNRNPH1 HNRH1_HUMAN P31943 c nucleus 449 0
56258 Hnrnph2 HNRH2_MOUSE P70333
heterogeneous nuclear 
ribonucleoprotein H2
2 3 903 3188 HNRNPH2 HNRH2_HUMAN P55795 c nucleus 449 0
15387 Hnrnpk HNRPK_MOUSE P61979 heterogeneous nuclear 
ribonucleoprotein K
2 3 843 3190 HNRNPK HNRPK_HUMAN P61978 c nucleus 463 0
15444 Hpca HPCA_MOUSE P84075 hippocalcin 2 2 991 3208 HPCA HPCA_HUMAN P84074 c anchored to membrane 480 0
53602 Hpcal1 HPCL1_MOUSE P62748 hippocalcin-like 1 2 2 1015 3241 HPCAL1 HPCL1_HUMAN P37235 c anchored to membrane 364 0
15446 Hpgd PGDH_MOUSE Q8VCC1
hydroxyprostaglandin 
dehydrogenase 15 (NAD)
7 4 719 3248 HPGD PGDH_HUMAN P15428 c cytoplasm 269 0
15452 Hprt1 HPRT_MOUSE P00493 hypoxanthine guanine 
phosphoribosyl transferase 1
4 4 720 3251 HPRT1 HPRT_HUMAN P00492 c cytoplasm 218 0
15461 Hras1 RASH_MOUSE Q61411
Harvey rat sarcoma virus oncogene 
1
2 2 1135 3265 HRAS RASH_HUMAN P01112 c anchored to plasma membrane 189 0
193740 Hspa1a HS71A_MOUSE Q61696 heat shock protein 1A 12 13 326 3303 HSPA1A HSP71_HUMAN P08107 c cytoplasm 641 0
15511 Hspa1b HS71B_MOUSE P17879 heat shock protein 1B 12 13 324 3303 HSPA1A HSP71_HUMAN P08107 c cytoplasm 642 0
15512 Hspa2 HSP72_MOUSE P17156 heat shock protein 2 2 3 931 3306 HSPA2 HSP72_HUMAN P54652 c cytoplasm 633 0
15481 Hspa8 HSP7C_MOUSE P63017 heat shock protein 8 33 104 48 3312 HSPA8 HSP7C_HUMAN P11142 c cytoplasm 646 0
15505 Hsph1 HS105_MOUSE Q61699
heat shock 105kDa/110kDa protein 
1
2 2 992 10808 HSPH1 HS105_HUMAN Q92598 c cytoplasm 858 0
15926 Idh1 IDHC_MOUSE O88844 isocitrate dehydrogenase 1 
(NADP+), soluble
18 29 169 3417 IDH1 IDHC_HUMAN O75874 c cytoplasm 414 0
269951 Idh2 IDHP_MOUSE P54071
isocitrate dehydrogenase 2 
(NADP+), mitochondrial
9 12 362 3418 IDH2 IDHP_HUMAN P48735 c mitochondrial inner membrane 452 0
67834 Idh3a IDH3A_MOUSE Q9D6R2
isocitrate dehydrogenase 3 (NAD+) 
alpha
3 3 938 3419 IDH3A IDH3A_HUMAN P50213 c mitochondrial matrix 366 0
170718 Idh3b - - isocitrate dehydrogenase 3 (NAD+) 
beta
3 2 1045 3420 IDH3B IDH3B_HUMAN O43837 c mitochondrion 385 0
15929 Idh3g IDH3G_MOUSE P70404
isocitrate dehydrogenase 3 (NAD+), 
gamma
3 2 993 3421 IDH3G IDH3G_HUMAN P51553 c mitochondrion 393 0
319554 Idi1 IDI1_MOUSE P58044
isopentenyl-diphosphate delta 
isomerase
2 2 1168 3422  IDI1 IDI1_HUMAN       Q13907 c cytoplasm 227 0
15953 Ifi47 Q61635_MOUSE Q61635 interferon gamma inducible protein 
47
8 6 595 - - - - c
endoplasmic reticulum 420 0
15957 Ifit1 IFIT1_MOUSE Q64282
interferon-induced protein with 
tetratricopeptide repeats 1
10 11 374 3434 IFIT1 IFIT1_HUMAN P09914 c cytoplasm 463 0
54396 Iigp2 Q58E63_MOUSE Q58E63 interferon inducible GTPase 2 11 12 342 - - - - c - 435 0
16201 Ilf3 ILF3_MOUSE Q9Z1X4
interleukin enhancer binding factor 
3
6 11 375 3609 ILF3 ILF3_HUMAN Q12906 c nucleus 898 0
55980 Impa1 IMPA1_MOUSE O55023
inositol (myo)-1(or 4)-
monophosphatase 1
5 4 728 3612 IMPA1 IMPA1_HUMAN P29218 c cytoplasm 277 0
12695 Inadl INADL_MOUSE Q63ZW7 InaD-like (Drosophila) 5 15 293 10207 INADL INADL_HUMAN Q8NI35 c apical plasma membrane 1834 0
29875 Iqgap1 IQGA1_MOUSE Q9JKF1
IQ motif containing GTPase 
activating protein 1
14 12 354 8826 IQGAP1 IQGA1_HUMAN P46940 c associated to plasma membrane 1657 0
544963 Iqgap2 fragment - IQ motif containing GTPase 
activating protein 2
23 39 127 10788 IQGAP2 IQGA2_HUMAN Q13576 c actin cytoskeleton 1575 0
631323 Irgb10 Q0GUM3_MOUSE Q0GUM3
interferon-gamma-inducible p47 
GTPase
14 13 327 - - - - c - 417 0
15944 Irgm IRGM_MOUSE Q60766 immunity-related GTPase family, M 9 18 252 345611 IRGM IRGM_HUMAN A1A4Y4 c associated to Golgi membrane 409 0
16480 Jup PLAK_MOUSE Q02257 junction plakoglobin 16 12 352 3728 JUP PLAK_HUMAN P14923 c actin cytoskeleton 745 0
107351 Kank1 Q6AXG6_MOUSE Q6AXG6
KN motif and ankyrin repeat 
domains 1
2 3 864 23189 KANK1 KANK1_HUMAN Q14678 c cytoplasm 1202 0
16572 Kif5a KIF5A_MOUSE P33175 kinesin family member 5A 3 3 807 3798 KIF5A KIF5A_HUMAN Q12840 c cytoplasm 1027 0
16573 Kif5b KINH_MOUSE Q61768 kinesin family member 5B 3 3 808 3799 KIF5B KINH_HUMAN P33176 c microtubule associated complex 963 0
16574 Kif5c KIF5C_MOUSE P28738 kinesin family member 5C 3 3 809 3800 KIF5C KIF5C_HUMAN O60282 c cytoskeleton 956 0
16211 Kpnb1 IMB1_MOUSE P70168 karyopherin (importin) beta 1 2 2 953 3837 KPNB1 IMB1_HUMAN Q14974 c cytoplasm 876 0
16653 Kras RASK_MOUSE P32883
v-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog
7 10 420 3845 KRAS RASK_HUMAN P01116  c anchored to plasma membrane 189 0
16678 Krt1 K2C1_MOUSE P04104 keratin 1 4 25 195 3848 KRT1 K2C1_HUMAN P04264 c cytoskeleton 637 0
16663 Krt13 K1C13_MOUSE P08730 keratin 13 5 16 279 3860 KRT13 K1C13_HUMAN P13646 c intermediate filament 437 0
16664 Krt14 K1C14_MOUSE Q61781 keratin 14 18 28 175 3861 KRT14 K1C14_HUMAN P02533 c cytoskeleton 484 0
16667 Krt17 K1C17_MOUSE Q9QWL7 keratin 17 5 13 321 3872 KRT17 K1C17_HUMAN Q04695 c cytoplasm 433 0
16669 Krt19 K1C19_MOUSE P19001 keratin 19 8 18 259 3880 KRT19 K1C19_HUMAN P08727 c intermediate filament 403 0
16681 Krt2 K22E_MOUSE Q3TTY5 keratin 2 5 12 369 3849 KRT2 K22E_HUMAN P35908 c intermediate filament 707 0
68239 Krt42 K1C42_MOUSE Q6IFX2 keratin 42 15 27 189 - - - - c intermediate filament 452 0
110308 Krt5 K2C5_MOUSE Q922U2 keratin 5 14 16 285 3852 KRT5 K2C5_HUMAN P13647 c intermediate filament 580 0
77055 Krt76 Q3UV17_MOUSE Q3UV17 keratin 76 6 17 266 51350 KRT76 K22O_HUMAN Q01546 c intermediate filament 594 0
16691 Krt8 K2C8_MOUSE P11679 keratin 8 8 33 152 3856 KRT8 K2C8_HUMAN P05787 c cytoplasm 490 0
16763 Lad1 LAD1_MOUSE P57016 ladinin 11 49 105 3898 LAD1 LAD1_HUMAN O00515 c basement membrane 528 0
71835 Lancl2 LANC2_MOUSE Q9JJK2
LanC (bacterial lantibiotic 
synthetase component C)-like 2
2 2 1158 55915 LANCL2 LANC2_HUMAN Q9NS86 c plasma membrane 450 0
66988 Lap3 AMPL_MOUSE Q9CPY7 leucine aminopeptidase 3 16 25 199 51056 LAP3 AMPL_HUMAN P28838 c cytoplasm 519 0
16796 Lasp1 LASP1_MOUSE Q61792 LIM and SH3 protein 1 12 45 115 3927 LASP1 LASP1_HUMAN Q14847 c cortical actin cytoskeleton 263 0
30949 Lcmt1 A2RTH5_MOUSE A2RTH5 leucine carboxyl methyltransferase 
1
4 4 793 51451 LCMT1 LCMT1_HUMAN Q9UIC8 c - 321 0
24131 Ldb3 LDB3_MOUSE Q9JKS4 LIM domain binding 3 2 2 1008 11155 LDB3 LDB3_HUMAN O75112 c cytoskeleton 723 0
107753 Lgals2 LEG2_MOUSE Q9CQW5 lectin, galactose-binding, soluble 2 10 36 139 3957 LGALS2 LEG2_HUMAN P05162 c - 254 0
16854 Lgals3 LEG3_MOUSE P16110 lectin, galactose binding, soluble 3 5 8 467 3958 LGALS3 LEG3_HUMAN P17931 c plasma membrane 264 0
16855 Lgals4 LEG4_MOUSE Q8K419 lectin, galactose binding, soluble 4 11 80 65 3960 LGALS4 LEG4_HUMAN P56470 c plasma membrane 326 0
16859 Lgals9 LEG9_MOUSE O08573 lectin, galactose binding, soluble 9 7 21 233 284194 LOC284194 LE9LA_HUMAN Q3B8N2 c extracellular region 353 0
65970 Lima1 LIMA1_MOUSE Q9ERG0 LIM domain and actin binding 1 18 136 33 51474 LIMA1 LIMA1_HUMAN Q9UHB6 c actin cytoskeleton 753 0
22343 Lin7c LIN7C_MOUSE O88952 lin-7 homolog C (C. elegans) 4 4 693 55327 LIN7C LIN7C_HUMAN Q9NUP9 c associated to basolateral plasma membrane 197 0
214854 Lincr LINCR_MOUSE Q8CJC5
lung-inducible neuralized-related 
C3HC4 RING domain protein
2 2 1114 93082 LINCR LINCR_HUMAN Q96EH8 c - 483 0
16890 Lipe LIPS_MOUSE P54310 lipase, hormone sensitive 2 2 994 3991 LIPE LIPS_HUMAN Q05469 c membrane 759 0
214345 Lrrc1 LRRC1_MOUSE Q80VQ1 leucine rich repeat containing 1 2 2 1161 55227 LRRC1 LRRC1_HUMAN Q9BTT6 c associated to membrane 524 0
66508 Lrrc51 LRC51_MOUSE Q9DAK8
Leucine-rich repeat-containing 
protein 51
3 3 815 220074 LRRC51 LRC51_HUMAN Q96E66 c - 104 0
66606 Lrrc57 LRC57_MOUSE Q9D1G5 leucine rich repeat containing 57 7 7 540 255252 LRRC57 LRC57_HUMAN Q8N9N7 c - 271 0
16993 Lta4h LKHA4_MOUSE P24527 leukotriene A4 hydrolase 25 32 154 4048 LTA4H LKHA4_HUMAN P09960 c cytoplasm 611 0
17096 Lyn LYN_MOUSE P25911 Tyrosine-protein kinase Lyn 13 25 198 4067 LYN LYN_HUMAN P07948 c anchored to plasma membrane 512 0
18777 Lypla1 LYPA1_MOUSE P97823 lysophospholipase 1 3 7 519 10434 LYPLA1 LYPA1_HUMAN O75608 c cytoplasm 230 0
26394 Lypla2 LYPA2_MOUSE Q9WTL7 lysophospholipase 2 2 2 1142 11313 LYPLA2 LYPA2_HUMAN O95372 c cytoplasm 231 0
66905 M6prbp1 M6PBP_MOUSE Q9DBG5
mannose-6-phosphate receptor 
binding protein 1
3 3 858 10226 M6PRBP1 M6PBP_HUMAN O60664 c associated to endosome membrane 437 0
109731 Maob AOFB_MOUSE Q8BW75 monoamine oxidase B 6 5 623 4129 MAOB AOFB_HUMAN P27338 c integral to mitochondrial membrane 526 0
26395 Map2k1 MP2K1_MOUSE P31938
mitogen-activated protein kinase 
kinase 1
6 7 528 5604 MAP2K1 MP2K1_HUMAN Q02750 c cytosol 393 0
26397 Map2k3 MP2K3_MOUSE O09110
mitogen-activated protein kinase 
kinase 3
2 2 1143 5606 MAP2K3 MP2K3_HUMAN P46734 c - 148 0
71751 Map3k13 M3K13_MOUSE Q1HKZ5 mitogen-activated protein kinase 
kinase kinase 13
2 2 1035 9175 MAP3K13 M3K13_HUMAN O43283 c associated to membrane 959 0
26921 Map4k4 M4K4_MOUSE P97820
mitogen-activated protein kinase 
kinase kinase kinase 4
2 2 1095 9448 MAP4K4 M4K4_HUMAN O95819 c cellular_component 1233 0
83409 Mapbpip MAPIP_MOUSE Q9JHS3
mitogen-activated protein binding 
protein interacting protein
2 2 1041 28956 RP11-336K24.9 MAPIP_HUMAN Q9Y2Q5 c associated to late endosome membrane 125 0
26413 Mapk1 MK01_MOUSE P63085 mitogen-activated protein kinase 1 8 16 278 5594 MAPK1 MK01_HUMAN P28482 c cytoplasm 358 0
26414 Mapk10 MK10_MOUSE Q61831 mitogen-activated protein kinase 10 2 3 898 5602 MAPK10 MK10_HUMAN P53779 c cytoplasm 464 0
26415 Mapk13 MK13_MOUSE Q9Z1B7 mitogen-activated protein kinase 13 12 11 394 5603 MAPK13 MK13_HUMAN O15264 c - 404 0
26416 Mapk14 MK14_MOUSE P47811 mitogen-activated protein kinase 14 4 4 694 1432 MAPK14 MK14_HUMAN Q16539 c cytoplasm 360 0
26417 Mapk3 MK03_MOUSE Q63844 mitogen-activated protein kinase 3 17 31 161 5595 MAPK3 MK03_HUMAN P27361 c cytosol 380 0
26419 Mapk8 MK08_MOUSE Q91Y86 mitogen-activated protein kinase 8 2 3 899 5599 MAPK8 MK08_HUMAN P45983 c cytosol 384 0
227743 Mapkap1 SIN1_MOUSE Q8BKH7 mitogen-activated protein kinase 
associated protein 1
2 2 1047 79109 MAPKAP1 SIN1_HUMAN Q9BPZ7 c associated to plasma membrane 522 0
108645 Mat2b MAT2B_MOUSE Q99LB6 
methionine adenosyltransferase II, 
beta
3 4 738 27430 MAT2B MAT2B_HUMAN Q9NZL9 c nucleus 334 0
17449 Mdh1 MDHC_MOUSE P14152
malate dehydrogenase 1, NAD 
(soluble)
8 17 265 4190 MDH1 MDHC_HUMAN P40925 c cytoplasm 334 0
17448 Mdh2 MDHM_MOUSE P08249 malate dehydrogenase 2, NAD 
(mitochondrial)
13 11 392 4191 MDH2 MDHM_HUMAN P40926 c mitochondrial inner membrane 338 0
67881 mdp1 MGDP1_MOUSE Q9D967
Magnesium-dependent 
phosphatase 1
2 2 1028 145553 MDP-1 MGDP1_HUMAN Q86V88 c - 212 0
108098 Med21 MED21_MOUSE Q9CQ39 mediator complex subunit 21 2 3 866 9412 MED21 MED21_HUMAN Q13503 c nucleus 144 0
29808 Mga A2AWL7_MOUSE A2AWL7 MAX gene associated 2 2 1096 23269 MGA fragment c nucleus 3003 0
171580 Mical1 MICA1_MOUSE Q8VDP3
microtubule associated 
monoxygenase, calponin and LIM 
domain containing 1
6 10 432 64780 MICAL1 MICA1_HUMAN Q8TDZ2 c cytoskeleton 1048 0
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50932 Mink1 MINK1_MOUSE Q9JM52 misshapen-like kinase 1 (zebrafish) 2 2 1097 50488 MINK1 MINK1_HUMAN Q8N4C8 c - 332 0
68473 Mobkl1a MOL1A_MOUSE Q8BPB0
MOB1, Mps One Binder kinase 
activator-like 1A (yeast)
2 3 909 92597 MOBKL1A MOL1A_HUMAN Q7L9L4 c cytoplasm 216 0
232157 Mobkl1b MOL1B_MOUSE Q921Y0
MOB1, Mps One Binder kinase 
activator-like 1B (yeast)
2 3 913 55233 MOBKL1B MOL1B_HUMAN Q9H8S9 c - 240 0
17524 Mpp1 EM55_MOUSE P70290 membrane protein, palmitoylated 12 21 228 4354 MPP1 EM55_HUMAN Q00013 c anchored to plasma membrane 466 0
56217 Mpp5 MPP5_MOUSE Q9JLB2
membrane protein, palmitoylated 5 
(MAGUK p55 subfamily member 5) 10 15 289 64398 MPP5 MPP5_HUMAN Q8N3R9 c associated to plasma membrane 675 0
17698 Msn MOES_MOUSE P26041 moesin 2 2 995 4478 MSN MOES_HUMAN P26038 c cytoskeleton 577 0
70415 Mst4 MST4_MOUSE Q99JT2
Serine/threonine-protein kinase 
MST4
7 6 556 51765 MST4 MST4_HUMAN Q9P289 c Golgi apparatus 416 0
108156 Mthfd1 C1TC_MOUSE Q922D8
methylenetetrahydrofolate 
dehydrogenase (NADP+ 
dependent), 
methenyltetrahydrofolate 
cyclohydrolase, 
formyltetrahydrofolate synthase
3 2 963 4522 MTHFD1 C1TC_HUMAN P11586 c cytoplasm 935 0
17772 Mtm1 MTM1_MOUSE Q9Z2C5
X-linked myotubular myopathy gene 
1
7 5 665 4534 MTM1 MTM1_HUMAN Q13496 c cellular_component 603 0
17831 Muc2 Q8CIA2_MOUSE Q8CIA2 mucin 2 7 7 525 4583 MUC2 MUC2_HUMAN Q02817 c extracellular region 1096 0
78388 Mvp MVP_MOUSE Q9EQK5 major vault protein 12 17 264 9961 MVP MVP_HUMAN Q14764 c cytoplasm 861 0
17886 Myh9 MYH9_MOUSE Q8VDD5
myosin, heavy polypeptide 9, non-
muscle
12 12 341 4627 MYH9 MYH9_HUMAN P35579 c actin cytoskeleton 1960 0
17904 Myl6 MYL6_MOUSE Q60605
myosin, light polypeptide 6, alkali, 
smooth muscle and non-muscle 10 50 100 4637 MYL6 MYL6_HUMAN P60660 c myosin complex 151 0
67938 Mylc2b MLRB_MOUSE Q3THE2 myosin light chain, regulatory B 3 4 735 103910 MRLC2 Q13182_HUMAN Q13182 c myosin complex 172 0
107589 Mylk MYLK_MOUSE Q6PDN3 myosin, light polypeptide kinase 6 10 430 4638 MYLK MYLK_HUMAN Q15746 c cytoplasm 1941 0
217328 Myo15b - - myosin XVB 10 42 122 80022 MYO15B MY15B_HUMAN Q96JP2 c cytoskeleton 1530 0
432516 Myo1a MYO1A_MOUSE O88329 myosin IA 75 780 7 4640 MYO1A MYO1A_HUMAN Q9UBC5 c apical plasma membrane 1043 0
17913 Myo1c MYO1C_MOUSE Q9WTI7 myosin IC 7 8 468 4641 MYO1C MYO1C_HUMAN O00159 c basal plasma membrane 1028 0
338367 Myo1d MYO1D_MOUSE Q5SYD0 myosin ID 54 172 28 4642 MYO1D MYO1D_HUMAN O94832 c myosin complex 1006 0
71602 Myo1e Q80X36_MOUSE Q80X36 myosin IE 2 2 1106 4643 MYO1E MYO1E_HUMAN Q12965 c actin cytoskeleton 1107 0
17919 Myo5b MYO5B_MOUSE P21271 myosin Vb 3 6 568 4645 MYO5B MYO5B_HUMAN Q9ULV0 c myosin complex 1818 0
17920 Myo6 MYO6_MOUSE Q64331 myosin VI 29 67 73 4646 MYO6 MYO6_HUMAN Q9UM54 c clathrin-coated  endocytic vesicle 1265 0
17921 Myo7a MYO7A_MOUSE P97479 myosin VIIa 36 59 82 4647 MYO7A MYO7A_HUMAN Q13402 c cytoskeleton 2215 0
234664 Nae1 ULA1_MOUSE Q8VBW6 NEDD8 activating enzyme E1 
subunit 1
2 2 1166 8883 NAE1 ULA1_HUMAN Q13564 c associated to plasma membrane 534 0
59027 Nampt NAMPT_MOUSE Q99KQ4
nicotinamide 
phosphoribosyltransferase
8 10 427 10135 NAMPT NAMPT_HUMAN P43490 c cytoplasm 491 0
108124 Napa SNAA_MOUSE Q9DB05
N-ethylmaleimide sensitive fusion 
protein attachment protein alpha
11 14 304 8775 NAPA SNAA_HUMAN P54920 c associated to membrane 295 0
108123 Napg SNAG_MOUSE Q9CWZ7
N-ethylmaleimide sensitive fusion 
protein attachment protein gamma
3 2 962 8774 NAPG SNAG_HUMAN Q99747 c associated to endoplasmic reticulum membran 312 0
223646 Naprt1 PNCB_MOUSE Q8CC86
nicotinate 
phosphoribosyltransferase domain 
containing 1
6 6 601 93100 NAPRT1 PNCB_HUMAN Q6XQN6 c cytoplasm 538 0
70223 Nars SYNC_MOUSE Q8BP47 asparaginyl-tRNA synthetase 10 8 473 4677 NARS SYNC_HUMAN O43776 c cytoplasm 547 0
17961 Nat2 ARY2_MOUSE P50295
N-acetyltransferase 2 (arylamine N-
acetyltransferase)
5 5 666 9 NAT1 ARY1_HUMAN P18440 c cytoplasm 290 0
68342 Ndufb10 NDUBA_MOUSE Q9DCS9
NADH dehydrogenase (ubiquinone) 
1 beta subcomplex, 10
5 2 960 4716 NDUFB10 NDUBA_HUMAN O96000 c associated to mitochondrial inner membrane 176 0
66495 Ndufb3 NDUB3_MOUSE Q9CQZ6
NADH dehydrogenase (ubiquinone) 
1 beta subcomplex 3
2 2 1101 4709 NDUFB3 NDUB3_HUMAN O43676 c mitochondrial inner membrane 104 0
66916 Ndufb7 NDUB7_MOUSE Q9CR61
NADH dehydrogenase (ubiquinone) 
1 beta subcomplex, 7
3 2 1026 4713 NDUFB7 NDUB7_HUMAN P17568 c associated to mitochondrial inner membrane 137 0
59126 Nek6 NEK6_MOUSE Q9ES70 NIMA (never in mitosis gene a)-
related expressed kinase 6
4 3 906 10783 NEK6 NEK6_HUMAN Q9HC98 c cytoplasm 313 0
27045 Nit1 NIT1_MOUSE Q8VDK1 nitrilase 1 2 2 1147 4817 NIT1 NIT1_HUMAN Q86X76 c - 239 0
268973 Nlrc4 Q3UP24_MOUSE Q3UP24
NLR family, CARD domain 
containing 4
3 3 874 58484 NLRC4 NLRC4_HUMAN Q9NPP4 c cytoplasm 1024 0
446099 Nlrp4e NAL4E_MOUSE Q66X19 NLR family, pyrin domain containing 
4E
7 6 602 147945 NLRP4 NALP4_HUMAN Q96MN2 c - 193 0
18102 Nme1 NDKA_MOUSE P15532
non-metastatic cells 1, protein 
(NM23A) expressed in
6 6 569 4830 NME1 NDKA_HUMAN P15531 c cytoplasm 152 0
18103 Nme2 NDKB_MOUSE Q01768
non-metastatic cells 2, protein 
(NM23B) expressed in
6 8 486 4831 NME2 NDK8_HUMAN O60361 c mitochondrion 152 0
18126 Nos2 NOS2_MOUSE P29477 nitric oxide synthase 2, inducible, 
macrophage
16 24 210 4843 NOS2A NOS2A_HUMAN P35228 c cytoplasm 1144 0
19155 Npepps PSA_MOUSE Q11011
aminopeptidase puromycin 
sensitive
5 5 668 9520 NPEPPS PSA_HUMAN P55786 c cytoplasm 920 0
18176 Nras RASN_MOUSE P08556 neuroblastoma ras oncogene 5 3 845 4893 NRAS RASN_HUMAN P01111 c anchored to plasma membrane 189 0
18195 Nsf NSF_MOUSE P46460
N-ethylmaleimide sensitive fusion 
protein
9 6 554 4905 NSF NSF_HUMAN P46459 c cytoplasm 744 0
50773 Nt5c NT5C_MOUSE Q9JM14 5',3'-nucleotidase, cytosolic 2 2 1148 30833 NT5C NT5C_HUMAN Q8TCD5 c cytoplasm 200 0
26426 Nubp2 NUBP2_MOUSE Q9R061 nucleotide binding protein 2 2 2 1144 10101 NUBP2 NUBP2_HUMAN Q9Y5Y2 c nucleus 275 0
209586 Nudcd3 NUDC3_MOUSE Q8R1N4 NudC domain containing 3 2 1 1193 23386 NUDCD3 NUDC3_HUMAN Q8IVD9 c - 471 0
53893 Nudt5 NUDT5_MOUSE Q9JKX6
nudix (nucleoside diphosphate 
linked moiety X)-type motif 5
4 3 902 11164 NUDT5 NUDT5_HUMAN Q9UKK9 c intracellular 218 0
18222 Numb NUMB_MOUSE Q9QZS3 numb gene homolog (Drosophila) 4 6 555 8650 NUMB NUMB_HUMAN P49757 c integral to plasma membrane 653 0
246730 Oas1a OAS1A_MOUSE P11928 2'-5' oligoadenylate synthetase 1A 8 9 437 4938 OAS1 OAS1_HUMAN P00973 c mitochondrion 367 0
23960 Oas1g Q8K469_MOUSE Q8K469 2'-5' oligoadenylate synthetase 1G 4 6 572 4938 OAS1 OAS1_HUMAN P00973 c mitochondrion 367 0
18293 Ogdh ODO1_MOUSE Q60597 oxoglutarate dehydrogenase 
(lipoamide)
2 2 1136 4967 OGDH ODO1_HUMAN Q02218 c mitochondrial membrane 1023 0
20409 Ostf1 OSTF1_MOUSE Q62422 osteoclast stimulating factor 1 9 9 453 26578 OSTF1 OSTF1_HUMAN Q92882 c cytoplasm 215 0
107260 Otub1 OTUB1_MOUSE Q7TQI3
OTU domain, ubiquitin aldehyde 
binding 1
5 6 580 55611 OTUB1 OTUB1_HUMAN Q96FW1 c - 721 0
108737 Oxsr1 OXSR1_MOUSE Q6P9R2 oxidative-stress responsive 1 4 4 739 9943 OXSR1 OXSR1_HUMAN O95747 c - 639 0
23970 Pacsin2 PACN2_MOUSE Q9WVE8 protein kinase C and casein kinase 
substrate in neurons 2
5 7 527 11252 PACSIN2 PACN2_HUMAN Q9UNF0 c cytoplasm 486 0
18472 Pafah1b1 LIS1_MOUSE P63005
platelet-activating factor 
acetylhydrolase, isoform 1b, beta1 
subunit
14 14 297 5048 PAFAH1B1 LIS1_HUMAN P43034 c cytoskeleton 410 0
18476 Pafah1b3 PA1B3_MOUSE Q61205
platelet-activating factor 
acetylhydrolase, isoform 1b, alpha1 
subunit
3 3 810 5050 PAFAH1B3 PA1B3_HUMAN Q15102 c cytoplasm 232 0
100163 Pafah2 PAFA2_MOUSE Q8VDG7
platelet-activating factor 
acetylhydrolase 2
12 10 429 5051 PAFAH2 PAFA2_HUMAN Q99487 c cytoplasm 390 0
23971 Papss1 PAPS1_MOUSE Q60967
3'-phosphoadenosine 5'-
phosphosulfate synthase 1
9 10 424 9061 PAPSS1 PAPS1_HUMAN O43252 c - 147 0
23972 Papss2 PAPS2_MOUSE O88428 3'-phosphoadenosine 5'-
phosphosulfate synthase 2
33 140 30 9060 PAPSS2 PAPS2_HUMAN O95340 c - 366 0
58220 Pard6b PAR6B_MOUSE Q9JK83
par-6 (partitioning defective 6) 
homolog beta (C. elegans)
2 2 1100 84612 PARD6B PAR6B_HUMAN Q9BYG5 c associated to plasma membrane 371 0
57320 Park7 PARK7_MOUSE Q99LX0
Parkinson disease (autosomal 
recessive, early onset) 7
3 2 1021 11315 PARK7 PARK7_HUMAN Q99497 c cytoplasm 189 0
67307 Pbld2 PBLD2_MOUSE Q9CXN7 Phenazine biosynthesis-like domain-
containing protein 2
4 4 770 64081 PBLD PBLD_HUMAN P30039 c cellular_component 288 0
23983 Pcbp1 PCBP1_MOUSE P60335 poly(rC) binding protein 1 6 13 331 5093 PCBP1 PCBP1_HUMAN Q15365 c cytoplasm 356 0
18538 Pcna PCNA_MOUSE P17918 proliferating cell nuclear antigen 2 2 1138 5111 PCNA PCNA_HUMAN P12004 c nucleus 261 0
18557 Pctk3 PCTK3_MOUSE Q04899 PCTAIRE-motif protein kinase 3 4 5 667 5129 PCTK3 PCTK3_HUMAN Q07002 c cellular_component 451 0
68671 Pcyt2 PCY2_MOUSE Q922E4 phosphate cytidylyltransferase 2, 
ethanolamine
7 5 621 5833 PCYT2 PCY2_HUMAN Q99447 c cellular_component 404 0
56426 Pdcd10 PDC10_MOUSE Q8VE70 programmed cell death 10 9 18 260 11235 PDCD10 PDC10_HUMAN Q9BUL8 c - 339 0
18570 Pdcd6 PDCD6_MOUSE P12815 programmed cell death 6 5 5 615 10016 PDCD6 c associated to endoplasmic reticulum membran 191 0
18571 Pdcd6ip PDC6I_MOUSE Q9WU78
programmed cell death 6 interacting 
protein
21 16 280 10015 PDCD6IP PDC6I_HUMAN Q8WUM4 c cytoplasm 869 0
18585 Pde9a PDE9A_MOUSE O70628 phosphodiesterase 9A 7 5 632 5152 PDE9A PDE9A_HUMAN O76083 c cytoplasm 534 0
68263 Pdhb ODPB_MOUSE Q9D051 pyruvate dehydrogenase 
(lipoamide) beta
2 2 1103 5162 PDHB ODPB_HUMAN P11177 c mitochondrion 359 0
54132 Pdlim1 PDLI1_MOUSE O70400 PDZ and LIM domain 1 (elfin) 5 6 575 9124 PDLIM1 PDLI1_HUMAN O00151 c cytoskeleton 327 0
56376 Pdlim5 PDLI5_MOUSE Q8CI51 PDZ and LIM domain 5 4 6 576 10611 PDLIM5 PDLI5_HUMAN Q96HC4 c actin cytoskeleton 591 0
216134 Pdxk PDXK_MOUSE Q8K183
pyridoxal (pyridoxine, vitamin B6) 
kinase
4 3 824 8566 PDXK CU124_HUMAN Q96HW9 c cytoplasm 312 0
170761 Pdzd3 PDZD3_MOUSE Q99MJ6 PDZ domain containing 3 11 17 267 79849 PDZD3 PDZD3_HUMAN Q86UT5 c associated to membrane apical part of cell 498 0
59020 Pdzk1 PDZD1_MOUSE Q9JIL4
PDZ domain containing 1 (Na/Pi 
cotransporter C-terminal-associated 
protein)
38 179 24 5174 PDZK1 PDZD1_HUMAN Q5T2W1 c associated to membrane 519 0
67898 Pef1 PEF1_MOUSE Q8BFY6 penta-EF hand domain containing 1 5 5 639 553115 PEF1 PEF1_HUMAN Q9UBV8 c associated to membrane 275 0
18624 Pepd PEPD_MOUSE Q11136 peptidase D 13 12 353 5184 PEPD PEPD_HUMAN P12955 c - 193 0
18641 Pfkl K6PL_MOUSE P12382 phosphofructokinase, liver, B-type 6 7 549 5211 PFKL K6PL_HUMAN P17858 c cytoplasm 780 0
56421 Pfkp K6PP_MOUSE Q9WUA3 phosphofructokinase, platelet 18 24 212 5214 PFKP K6PP_HUMAN Q01813 c cytoplasm 784 0
18643 Pfn1 PROF1_MOUSE P62962 profilin 1 8 23 217 5216 PFN1 PROF1_HUMAN P07737 c actin cytoskeleton 140 0
18648 Pgam1 PGAM1_MOUSE Q9DBJ1 phosphoglycerate mutase 1 11 15 286 5223 PGAM1 PGAM1_HUMAN P18669 c cytosol 254 0
110208 Pgd 6PGD_MOUSE Q9DCD0 phosphogluconate dehydrogenase 17 29 171 5226 PGD 6PGD_HUMAN P52209 c - 1130 0
18655 Pgk1 PGK1_MOUSE P09411 phosphoglycerate kinase 1 17 26 193 5230 PGK1 PGK1_HUMAN P00558 c cytoplasm 417 0
66681 Pgm1 PGM2_MOUSE Q7TSV4 phosphoglucomutase 1 2 4 767 55276 PGM2 PGM2_HUMAN Q96G03 c cytoplasm 620 0
67078 Pgp PGP_MOUSE Q8CHP8 Phosphoglycolate phosphatase 2 2 1153 283871 PGP PGP_HUMAN A6NDG6 c - 323 0
237928 Phospho1 PHOP1_MOUSE Q8R2H9 phosphatase, orphan 1 2 3 873 162466 PHOSPHO1 PHOP1_HUMAN Q8TCT1 c - 561 0
18738 Pitpna PIPNA_MOUSE P53810 phosphatidylinositol transfer protein, 
alpha
3 3 811 5306 PITPNA PIPNA_HUMAN Q00169 c cytoplasm 271 0
56305 Pitpnb PIPNB_MOUSE P53811
phosphatidylinositol transfer protein, 
beta
5 4 729 23760 PITPNB PIPNB_HUMAN P48739 c cytoplasm 271 0
18770 Pklr KPYR_MOUSE P53657
pyruvate kinase liver and red blood 
cell
11 18 250 5313 PKLR KPYR_HUMAN P30613 c - 1337 0
18746 Pkm2 KPYM_MOUSE P52480 pyruvate kinase, muscle 26 95 57 5315 PKM2 KPYM_HUMAN P14618 c cytoplasm 531 0
18797 Plcb3 PLCB3_MOUSE P51432 phospholipase C, beta 3 10 9 452 5331 PLCB3 PLCB3_HUMAN Q01970 c associated to membrane 1234 0
18799 Plcd1 PLCD1_MOUSE Q8R3B1 phospholipase C, delta 1 6 4 692 5333 PLCD1 PLCD1_HUMAN P51178 c cytoplasm 756 0
18805 Pld1 PLD1_MOUSE Q9Z280 phospholipase D1 15 45 114 5337 PLD1 PLD1_HUMAN Q13393 c anchored to endoplasmic reticulum membrane 1074 0
71801 Plekhf2 PKHF2_MOUSE Q91WB4
pleckstrin homology domain 
containing, family F (with FYVE 
domain) member 2
2 3 860 79666 PLEKHF2 PKHF2_HUMAN Q9H8W4 c transport vesicle 249 0
54128 Pmm2 PMM2_MOUSE Q9Z2M7 phosphomannomutase 2 5 5 636 5373 PMM2 PMM2_HUMAN O15305 c cytoplasm 242 0
18950 Pnp1 PNPH_MOUSE P23492 purine-nucleoside phosphorylase 1 8 12 370 4860 NP PNPH_HUMAN P00491 c cytosol 289 0
67895 Ppa1 IPYR_MOUSE Q9D819 pyrophosphatase (inorganic) 1 4 3 818 5464 PPA1 IPYR_HUMAN Q15181 c cytoplasm 289 0
268373 Ppia PPIA_MOUSE P17742 peptidylprolyl isomerase A 13 28 174 5478 PPIA PPIA_HUMAN P62937 c cytoplasm 164 0
19045 Ppp1ca PP1A_MOUSE P62137
protein phosphatase 1, catalytic 
subunit, alpha isoform
12 10 421 5499 PPP1CA PP1A_HUMAN P62136 c cytoplasm 330 0
19046 Ppp1cb PP1B_MOUSE P62141
protein phosphatase 1, catalytic 
subunit, beta isoform
9 8 506 5500 PPP1CB PP1B_HUMAN P62140 c cytoplasm 327 0
19052 Ppp2ca PP2AA_MOUSE P63330
protein phosphatase 2 (formerly 
2A), catalytic subunit, alpha isoform 5 5 686 5515 PPP2CA PP2AA_HUMAN P67775 c cytoplasm 309 0  175
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51792 Ppp2r1a 2AAA_MOUSE Q76MZ3
protein phosphatase 2 (formerly 
2A), regulatory subunit A (PR 65), 
alpha isoform
12 14 301 5518 PPP2R1A 2AAA_HUMAN P30153 c cytosol 589 0
21770 Ppp2r5d Q7TNL5_MOUSE      Q7TNL5 protein phosphatase 2, regulatory 
subunit B (B56), delta isoform
3 6 596 5528 PPP2R5D 2A5D_HUMAN Q14738 c cytoplasm 595 0
18477 Prdx1 PRDX1_MOUSE P35700 peroxiredoxin 1 11 24 205 5052 PRDX1 PRDX1_HUMAN Q06830 c cytoplasm 199 0
21672 Prdx2 PRDX2_MOUSE Q61171 peroxiredoxin 2 6 8 487 7001 PRDX2 PRDX2_HUMAN P32119 c cytoplasm 198 0
54683 Prdx5 PRDX5_MOUSE P99029 peroxiredoxin 5 9 10 404 25824 PRDX5 PRDX5_HUMAN P30044 c mitochondrion 210 0
11758 Prdx6 PRDX6_MOUSE O08709 peroxiredoxin 6 14 21 231 9588 PRDX6 PRDX6_HUMAN P30041 c cytoplasm 224 0
105787 Prkaa1 AAPK1_MOUSE Q5EG47 protein kinase, AMP-activated, 
alpha 1 catalytic subunit
5 6 599 5562 PRKAA1 AAPK1_HUMAN Q13131 c intracellular 548 0
108079 Prkaa2 AAPK2_MOUSE Q8BRK8 protein kinase, AMP-activated, 
alpha 2 catalytic subunit
5 3 865 5563 PRKAA2 AAPK2_HUMAN P54646 c cytosol 552 0
19079 Prkab1 AAKB1_MOUSE Q9R078 protein kinase, AMP-activated, beta 
1 non-catalytic subunit
2 2 1092 5564 PRKAB1 AAKB1_HUMAN Q9Y478 c nucleus 270 0
18747 Prkaca KAPCA_MOUSE P05132 protein kinase, cAMP dependent, 
catalytic, alpha
11 11 376 5566 PRKACA KAPCA_HUMAN P17612 c cytoplasm 351 0
19082 Prkag1 AAKG1_MOUSE O54950 protein kinase, AMP-activated, 
gamma 1 non-catalytic subunit
9 9 441 5571 PRKAG1 AAKG1_HUMAN P54619 c cytoplasm 330 0
19087 Prkar2a KAP2_MOUSE P12367 protein kinase, cAMP dependent 
regulatory, type II alpha
19 57 86 5576 PRKAR2A KAP2_HUMAN P13861 c plasma membrane 401 0
18750 Prkca KPCA_MOUSE P20444 protein kinase C, alpha 17 20 238 5578 PRKCA KPCA_HUMAN P17252 c plasma membrane 672 0
18753 Prkcd KPCD_MOUSE P28867 protein kinase C, delta 20 36 141 5580 PRKCD KPCD_HUMAN Q05655 c cytoplasm 674 0
18761 Prkcq KPCT_MOUSE Q02111 protein kinase C, theta 3 4 721 5588 PRKCQ KPCT_HUMAN Q04759 c intracellular 707 0
18762 Prkcz KPCZ_MOUSE Q02956 protein kinase C, zeta 2 2 1139 5590 PRKCZ KPCZ_HUMAN Q05513 c cytoplasm 592 0
19092 Prkg2 KGP2_MOUSE Q61410 protein kinase, cGMP-dependent, 
type II
33 65 75 5593 PRKG2 KGP2_HUMAN Q13237 c - 340 0
114863 Prosc PROSC_MOUSE Q9Z2Y8 proline synthetase co-transcribed 2 2 1044 11212 PROSC PROSC_HUMAN O94903 c cytoplasm 274 0
26440 Psma1 PSA1_MOUSE Q9R1P4
proteasome (prosome, macropain) 
subunit, alpha type 1
6 6 611 5682 PSMA1 PSA1_HUMAN P25786 c proteasome complex 263 0
19166 Psma2 PSA2_MOUSE P49722
proteasome (prosome, macropain) 
subunit, alpha type 2
3 3 932 5683 PSMA2 PSA2_HUMAN P25787 c proteasome complex 234 0
19167 Psma3 PSA3_MOUSE O70435
proteasome (prosome, macropain) 
subunit, alpha type 3
3 3 846 5684 PSMA3 PSA3_HUMAN P25788 c proteasome complex 255 0
26441 Psma4 PSA4_MOUSE Q9R1P0
proteasome (prosome, macropain) 
subunit, alpha type 4
2 2 1009 5685 PSMA4 PSA4_HUMAN P25789 c proteasome complex 261 0
26442 Psma5 PSA5_MOUSE Q9Z2U1
proteasome (prosome, macropain) 
subunit, alpha type 5
5 5 617 5686 PSMA5 PSA5_HUMAN P28066 c proteasome complex 241 0
26443 Psma6 PSA6_MOUSE Q9QUM9
proteasome (prosome, macropain) 
subunit, alpha type 6
4 4 724 5687 PSMA6 PSA6_HUMAN P60900 c proteasome core complex 246 0
26444 Psma7 PSA7_MOUSE Q9Z2U0
proteasome (prosome, macropain) 
subunit, alpha type 7
5 4 695 5688 PSMA7 PSA7_HUMAN O14818 c proteasome complex 248 0
73677 Psma8 PSA7L_MOUSE Q9CWH6
proteasome (prosome, macropain) 
subunit, alpha type, 8
2 2 1159 143471 PSMA8 PSA7L_HUMAN Q8TAA3 c proteasome core complex 250 0
19170 Psmb1 PSB1_MOUSE O09061
proteasome (prosome, macropain) 
subunit, beta type 1
4 4 759 5689 PSMB1 PSB1_HUMAN P20618 c proteasome complex 240 0
19171 Psmb10 PSB10_MOUSE O35955
proteasome (prosome, macropain) 
subunit, beta type 10
4 4 722 5699 PSMB10 PSB10_HUMAN P40306 c proteasome complex 273 0
26445 Psmb2 PSB2_MOUSE Q9R1P3
proteasome (prosome, macropain) 
subunit, beta type 2
2 1 1190 5690 PSMB2 PSB2_HUMAN P49721 c proteasome complex 201 0
26446 Psmb3 PSB3_MOUSE Q9R1P1
proteasome (prosome, macropain) 
subunit, beta type 3
2 2 1010 5691 PSMB3 PSB3_HUMAN P49720 c proteasome complex 205 0
19175 Psmb6 PSB6_MOUSE Q60692
proteasome (prosome, macropain) 
subunit, beta type 6
3 2 954 5694 PSMB6 PSB6_HUMAN P28072 c proteasome core complex 238 0
19179 Psmc1 PRS4_MOUSE P62192
protease (prosome, macropain) 
26S subunit, ATPase 1
13 16 274 5700 PSMC1 PRS4_HUMAN P62191 c proteasome complex 440 0
19181 Psmc2 PRS7_MOUSE P46471
proteasome (prosome, macropain) 
26S subunit, ATPase 2
16 24 206 5701 PSMC2 PRS7_HUMAN P35998 c proteasome complex 433 0
19182 Psmc3 PRS6A_MOUSE O88685
proteasome (prosome, macropain) 
26S subunit, ATPase 3 10 14 298 5702 PSMC3 PRS6A_HUMAN P17980 c proteasome complex 442 0
23996 Psmc4 PRS6B_MOUSE P54775
proteasome (prosome, macropain) 
26S subunit, ATPase, 4
8 9 454 5704 PSMC4 PRS6B_HUMAN P43686 c proteasome complex 418 0
19184 Psmc5 PRS8_MOUSE P62196
protease (prosome, macropain) 
26S subunit, ATPase 5
13 14 299 5705 PSMC5 PRS8_HUMAN P62195 c proteasome complex 406 0
67089 Psmc6 PRS10_MOUSE P62334
proteasome (prosome, macropain) 
26S subunit, ATPase, 6 12 10 428 5706 PSMC6 PRS10_HUMAN P62333 c proteasome complex 389 0
69077 Psmd11 PSD11_MOUSE Q8BG32
proteasome (prosome, macropain) 
26S subunit, non-ATPase, 11
12 12 344 5717 PSMD11 PSD11_HUMAN O00231 c proteasome complex 422 0
66997 Psmd12 PSD12_MOUSE Q9D8W5
proteasome (prosome, macropain) 
26S subunit, non-ATPase, 12 10 10 407 5718 PSMD12 PSD12_HUMAN O00232 c proteasome regulatory particle 456 0
23997 Psmd13 PSD13_MOUSE Q9WVJ2
proteasome (prosome, macropain) 
26S subunit, non-ATPase, 13
8 10 411 5719 PSMD13 PSD13_HUMAN Q9UNM6 c proteasome complex 376 0
59029 Psmd14 PSDE_MOUSE O35593
proteasome (prosome, macropain) 
26S subunit, non-ATPase, 14 3 2 956 10213 PSMD14 PSDE_HUMAN O00487 c proteasome complex 310 0
22123 Psmd3 PSMD3_MOUSE P14685
proteasome (prosome, macropain) 
26S subunit, non-ATPase, 3
8 7 535 5709 PSMD3 PSMD3_HUMAN O43242 c proteasome complex 530 0
19185 Psmd4 PSMD4_MOUSE O35226
proteasome (prosome, macropain) 
26S subunit, non-ATPase, 4 2 2 1140 5710 PSMD4 PSMD4_HUMAN P55036 c proteasome complex 376 0
66413 Psmd6 PSMD6_MOUSE Q99JI4
proteasome (prosome, macropain) 
26S subunit, non-ATPase, 6
5 3 907 9861 PSMD6 PSMD6_HUMAN Q15008 c proteasome complex 389 0
57296 Psmd8 PSMD8_MOUSE Q9CX56
proteasome (prosome, macropain) 
26S subunit, non-ATPase, 8 2 3 855 5714 PSMD8 PSMD8_HUMAN P48556 c proteasome complex 257 0
19186 Psme1 PSME1_MOUSE P97371 proteasome (prosome, macropain) 
28 subunit, alpha
8 7 526 5720 PSME1 PSME1_HUMAN Q06323 c proteasome complex 249 0
19188 Psme2 PSME2_MOUSE P97372 proteasome (prosome, macropain) 
28 subunit, beta
7 11 377 5721 PSME2 PSME2_HUMAN Q9UL46 c proteasome complex 239 0
19205 Ptbp1 PTBP1_MOUSE P17225 polypyrimidine tract binding protein 
1
2 2 996 5725 PTBP1 PTBP1_HUMAN P26599 c nucleus 527 0
20459 Ptk6 PTK6_MOUSE Q64434 PTK6 protein tyrosine kinase 6 3 3 933 5753 PTK6 PTK6_HUMAN Q13882 c cytoplasm 451 0
15170 Ptpn6 PTN6_MOUSE P29351
protein tyrosine phosphatase, non-
receptor type 6
3 2 990 5777 PTPN6 PTN6_HUMAN P29350 c cytoplasm 595 0
19303 Pxn PAXI_MOUSE Q8VI36 paxillin 3 2 1093 5829 PXN PAXI_HUMAN P49023 c cytoskeleton 591 0
66824 Pycard ASC_MOUSE Q9EPB4 PYD and CARD domain containing 3 5 672 29108 PYCARD ASC_HUMAN Q9ULZ3 c cytoplasm 193 0
66194 Pycrl P5CR3_MOUSE Q9DCC4 pyrroline-5-carboxylate reductase-
like
3 3 856 65263 PYCRL P5CR3_HUMAN Q53H96 c - 204 0
97541 Qars Q8R1V9_MOUSE Q8R1V9 glutaminyl-tRNA synthetase 2 2 1160 5859 QARS SYQ_HUMAN P47897 c cytoplasm 606 0
19324 Rab1 RAB1A_MOUSE P62821
RAB1, member RAS oncogene 
family
14 89 60 5861 RAB1A RAB1A_HUMAN P62820 c anchored to Golgi membrane 205 0
53869 Rab11a RB11A_MOUSE P62492
RAB11a, member RAS oncogene 
family
11 14 302 8766 RAB11A RB11A_HUMAN P62491 c anchored to plasma membrane 216 0
19326 Rab11b RB11B_MOUSE P46638
RAB11B, member RAS oncogene 
family
12 60 81 9230 RAB11B RB11B_HUMAN Q15907 c anchored to plasma membrane 218 0
68365 Rab14 RAB14_MOUSE Q91V41
RAB14, member RAS oncogene 
family
12 28 178 51552 RAB14 RAB14_HUMAN P61106 c anchored to plasma membrane 215 0
104886 Rab15 RAB15_MOUSE Q8K386
RAB15, member RAS oncogene 
family
2 3 821 376267 RAB15 RAB15_HUMAN P59190 c anchored to membrane 212 0
19331 Rab19 RAB19_MOUSE P35294
RAB19, member RAS oncogene 
family
5 5 669 401409 RAB19 RAB19_HUMAN A4D1S5 c anchored to plasma membrane 217 0
76308 Rab1b RAB1B_MOUSE Q9D1G1
RAB1B, member RAS oncogene 
family
12 40 126 81876 RAB1B RAB1B_HUMAN Q9H0U4 c anchored to plasma membrane 201 0
19334 Rab22a RB22A_MOUSE P35285
RAB22A, member RAS oncogene 
family
6 5 616 57403 RAB22A RB22A_HUMAN Q9UL26 c anchored to endosome membrane 194 0
53868 Rab25 RAB25_MOUSE Q9WTL2
RAB25, member RAS oncogene 
family
8 10 403 57111 RAB25 RAB25_HUMAN P57735 c anchored to membrane 213 0
11891 Rab27a RB27A_MOUSE Q9ERI2
RAB27A, member RAS oncogene 
family
3 4 713 5873 RAB27A RB27A_HUMAN P51159 c anchored to membrane 221 0
80718 Rab27b RB27B_MOUSE Q99P58 RAB27b, member RAS oncogene 
family
6 8 476 5874 RAB27B RB27B_HUMAN O00194 c anchored to membrane 218 0
59021 Rab2a RAB2A_MOUSE P53994 RAB2A, member RAS oncogene 
family
12 37 137 5862 RAB2A RAB2A_HUMAN P61019 c anchored to ER-Golgi intermediate compartme 212 0
75985 Rab30 RAB30_MOUSE Q923S9 RAB30, member RAS oncogene 
family
5 6 557 27314 RAB30 RAB30_HUMAN Q15771 c anchored to plasma membrane 203 0
67844 Rab32 RAB32_MOUSE Q9CZE3 RAB32, member RAS oncogene 
family
3 3 908 10981 RAB32 RAB32_HUMAN Q13637 c anchored to mitochondrial membrane 223 0
19338 Rab33b RB33B_MOUSE O35963 RAB33B, member of RAS 
oncogene family
6 15 288 83452 RAB33B RB33B_HUMAN Q9H082 c anchored to Golgi membrane 229 0
77407 Rab35 RAB35_MOUSE Q6PHN9 RAB35, member RAS oncogene 
family
10 29 167 11021 RAB35 RAB35_HUMAN Q15286 c anchored to plasma membrane 201 0
19339 Rab3a RAB3A_MOUSE P63011 RAB3A, member RAS oncogene 
family
3 3 896 5864 RAB3A RAB3A_HUMAN P20336 c anchored to plasma membrane 220 0
19340 Rab3d RAB3D_MOUSE P35276 RAB3D, member RAS oncogene 
family
6 20 240 9545 RAB3D RAB3D_HUMAN O95716 c anchored to plasma membrane 219 0
69834 Rab43 RAB43_MOUSE Q8CG50 RAB43, member RAS oncogene 
family
5 6 578 339122 RAB43 RAB43_HUMAN Q86YS6 c anchored to plasma membrane 210 0
19341 Rab4a RAB4A_MOUSE P56371 RAB4A, member RAS oncogene 
family
10 14 311 5867 RAB4A RAB4A_HUMAN P20338 c anchored to membrane 213 0
19342 Rab4b RAB4B_MOUSE Q91ZR1 RAB4B, member RAS oncogene 
family
2 3 847 53916 RAB4B RAB4B_HUMAN P61018 c anchored to plasma membrane 213 0
271457 Rab5a RAB5A_MOUSE Q9CQD1 RAB5A, member RAS oncogene 
family
8 26 191 5868 RAB5A RAB5A_HUMAN P20339 c anchored to plasma membrane 215 0
19346 Rab6 RAB6A_MOUSE P35279 RAB6, member RAS oncogene 
family
8 13 325 5870 RAB6A RAB6A_HUMAN P20340 c anchored to Golgi membrane 208 0
270192 Rab6b RAB6B_MOUSE P61294 RAB6B, member RAS oncogene 
family
3 3 875 51560 RAB6B RAB6B_HUMAN Q9NRW1 c anchored to Golgi membrane 208 0
19349 Rab7 RAB7A_MOUSE P51150 RAB7, member RAS oncogene 
family
12 28 177 7879 RAB7A RAB7A_HUMAN P51149 c anchored to late endosome membrane 207 0
17274 Rab8a RAB8A_MOUSE P55258 RAB8A, member RAS oncogene 
family
14 32 156 4218 RAB8A RAB8A_HUMAN P61006 c anchored to plasma membrane 207 0
56382 Rab9 RAB9A_MOUSE Q9R0M6 RAB9, member RAS oncogene 
family
6 5 637 9367 RAB9A RAB9A_HUMAN P51151 c anchored to plasma membrane 201 0
56187 Rabggta PGTA_MOUSE Q9JHK4 Rab geranylgeranyl transferase, a 
subunit
5 4 794 5875 RABGGTA PGTA_HUMAN Q92696 c - 195 0
19354 Rac2 RAC2_MOUSE Q05144 RAS-related C3 botulinum substrate 
2
2 4 760 5880 RAC2 RAC2_HUMAN P15153 c associated to plasma membrane 192 0
170758 Rac3 RAC3_MOUSE P60764 RAS-related C3 botulinum substrate 
3
2 4 776 5881 RAC3 RAC3_HUMAN P60763 c anchored to plasma membrane 192 0
56044 Rala RALA_MOUSE P63321 v-ral simian leukemia viral 
oncogene homolog A (ras related)
10 32 155 5898 RALA RALA_HUMAN P11233 c anchored to plasma membrane 206 0
64143 Ralb RALB_MOUSE Q9JIW9 v-ral simian leukemia viral 
oncogene homolog B (ras related)
8 17 263 5899 RALB RALB_HUMAN P11234 c anchored to plasma membrane 206 0    176
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19384 Ran RAN_MOUSE P62827
RAN, member RAS oncogene 
family
6 29 166 5901 RAN RAN_HUMAN P62826 c cytoplasm 216 0
19385 Ranbp1 RANG_MOUSE P34022 RAN binding protein 1 2 3 897 5902 RANBP1 RANG_HUMAN P43487 c cytoplasm 203 0
109905 Rap1a RAP1A_MOUSE P62835 RAS-related protein-1a 11 21 229 5906 RAP1A RAP1A_HUMAN P62834 c anchored to plasma membrane 184 0
215449 Rap1b RAP1B_MOUSE Q99JI6 RAS related protein 1b 11 16 282 5908 RAP1B RAP1B_HUMAN P61224 c anchored to plasma membrane 184 0
74012 Rap2b RAP2B_MOUSE P61226
RAP2B, member of RAS oncogene 
family
4 6 579 5912 RAP2B RAP2B_HUMAN P61225 c anchored to plasma membrane 183 0
72065 Rap2c RAP2C_MOUSE Q8BU31
RAP2C, member of RAS oncogene 
family
10 12 345 57826 RAP2C RAP2C_HUMAN Q9Y3L5 c anchored to plasma membrane 183 0
104458 Rars SYRC_MOUSE Q9D0I9 arginyl-tRNA synthetase 11 14 312 5917 RARS SYRC_HUMAN P54136 c cytoplasm 660 0
70727 Rasgef1a Q3TYC0_MOUSE Q3TYC0
RasGEF domain family, member 
1A
2 3 939 221002 RASGEF1A RGF1A_HUMAN Q8N9B8 c intracellular 344 0
19428 Rasl2-9 RANT_MOUSE Q61820 RAS-like, family 2, locus 9 2 2 998 - - - - c nucleus 216 0
19660 Rbp2 RET2_MOUSE Q08652 retinol binding protein 2, cellular 7 16 277 5948 RBP2 RET2_HUMAN P50120 c cytoplasm 134 0
54150 Rdh7 RDH7_MOUSE O88451 retinol dehydrogenase 7 13 11 386 8608 RDH16 RDH16_HUMAN O75452 c integral to microsome membrane 316 0
19684 Rdx RADI_MOUSE P26043 radixin 2 2 999 5962 RDX RADI_HUMAN P35241 c cytoskeleton 583 0
66532 Rep15 REP15_MOUSE Q9D7T1 Rab15 effector protein 4 2 957 387849 REP15 REP15_HUMAN Q6BDI9 c associated to early endosome membrane 230 0
54391 Rfk RIFK_MOUSE Q8CFV9 riboflavin kinase 2 2 1098 55312 RFK RIFK_HUMAN Q969G6 c cytoplasm 155 0
19744 Rheb RHEB_MOUSE Q921J2 RAS-homolog enriched in brain 2 2 955 6009 RHEB RHEB HUMAN Q15382 c anchored to plasma membrane 184 0
11848 Rhoa RHOA_MOUSE Q9QUI0
ras homolog gene family, member 
A
8 22 222 387 RHOA RHOA_HUMAN P61586 c anchored to plasma membrane 193 0
11852 Rhob RHOB_MOUSE P62746
ras homolog gene family, member 
B
5 9 449 388 RHOB RHOB_HUMAN P62745 c anchored to plasma membrane 196 0
11853 Rhoc RHOC_MOUSE Q62159
ras homolog gene family, member 
C
8 21 232 389 RHOC RHOC_HUMAN P08134 c anchored to plasma membrane 193 0
11854 Rhod RHOD_MOUSE P97348
ras homolog gene family, member 
D
6 5 612 29984 RHOD RHOD_HUMAN O00212 c plasma membrane 210 0
23912 Rhof RHOF_MOUSE Q8BYP3 ras homolog gene family, member f 4 4 764 54509 RHOF RHOF_HUMAN Q9HBH0 c cytoskeleton 211 0
56212 Rhog RHOG_MOUSE P84096 ras homolog gene family, member 
G
10 17 262 391 RHOG RHOG_HUMAN P84095 c anchored to plasma membrane 191 0
52428 Rhpn2 RHPN2_MOUSE Q8BWR8
rhophilin, Rho GTPase binding 
protein 2 7 7 536 85415 RHPN2 RHPN2_HUMAN Q8IUC4 c cytoplasm 686 0
56532 Ripk3 RIPK3_MOUSE Q9QZL0
receptor-interacting serine-
threonine kinase 3
2 2 1150 11035 RIPK3 RIPK3_HUMAN Q9Y572 c cytoplasm 486 0
107702 Rnh1 RINI_MOUSE Q91VI7 ribonuclease/angiogenin inhibitor 1 9 10 431 6050 RNH1 RINI_HUMAN P13489 c cytoplasm 456 0
215615 Rnpep AMPB_MOUSE Q8VCT3
arginyl aminopeptidase 
(aminopeptidase B)
13 11 395 6051 RNPEP AMPB_HUMAN Q9H4A4 c plasma membrane / secreted 650 0
19889 Rp2h XRP2_MOUSE Q9EPK2
retinitis pigmentosa 2 homolog 
(human)
13 22 223 6102 RP2 XRP2_HUMAN O75695 c anchored to plasma membrane 347 0
245670 Rragb RRAGB_MOUSE Q6NTA4 Ras-related GTP binding B 2 2 1048 10325 RRAGB RRAGB_HUMAN Q5VZM2 c cytoplasm 374 0
54170 Rragc RRAGC_MOUSE Q99K70 Ras-related GTP binding C 3 2 1017 64121 RRAGC RRAGC_HUMAN Q9HB90 c cytoplasm 398 0
52187 Rragd RRAGD_MOUSE Q7TT45 Ras-related GTP binding D 3 2 1013 58528 RRAGD RRAGD_HUMAN Q9NQL2 c cytoplasm 449 0
66922 Rras2 RRAS2_MOUSE P62071
related RAS viral (r-ras) oncogene 
homolog 2
8 14 315 22800 RRAS2 RRAS2_HUMAN P62070 c anchored to plasma membrane 204 0
56505 Ruvbl1 RUVB1_MOUSE P60122 RuvB-like protein 1 2 2 1099 8607 RUVBL1 RUVB1_HUMAN Q9Y265 c nucleus 456 0
56045 Samhd1 SAMH1_MOUSE Q60710 SAM domain and HD domain, 1 10 8 471 25939 SAMHD1 SAMH1_HUMAN Q9Y3Z3 c nucleus 627 0
66397 Sar1b SAR1B_MOUSE Q9CQC9 SAR1 gene homolog B (S. 
cerevisiae)
5 7 539 51128 SAR1B SAR1B_HUMAN Q9Y6B6 c associated to endoplasmic reticulum membran 198 0
20226 Sars SYSC_MOUSE P26638 seryl-aminoacyl-tRNA synthetase 3 2 1000 6301 SARS SYSC_HUMAN P49591 c cytoplasm 512 0
66711 Sbds SBDS_MOUSE P70122
Shwachman-Bodian-Diamond 
syndrome homolog (human)
3 2 1023 51119 SBDS SBDS_HUMAN Q9Y3A5 c cytoplasm 250 0
20259 Scin ADSV_MOUSE Q60604 scinderin 15 16 275 85477 SCIN ADSV_HUMAN Q9Y6U3 c cytoskeleton 715 0
20280 Scp2 NLTP_MOUSE P32020 sterol carrier protein 2, liver 2 2 1001 6342 SCP2 NLTP_HUMAN P22307 c mitochondrion 547 0
13722 Scye1 MCA1_MOUSE P31230
small inducible cytokine subfamily 
E, member 1
3 3 841 9255 SCYE1 MCA1_HUMAN Q12904 c extracellular space 310 0
228765 Sdcbp2 SDCB2_MOUSE Q99JZ0 syndecan binding protein (syntenin) 
2
2 1 1194 27111 SDCBP2 SDCB2_HUMAN Q9H190 c plasma membrane 292 0
66945 Sdha DHSA_MOUSE Q8K2B3
succinate dehydrogenase complex, 
subunit A, flavoprotein (Fp)
4 3 935 6389 SDHA DHSA_HUMAN P31040 c associated to mitochondrial inner membrane 664 0
67680 Sdhb DHSB_MOUSE Q9CQA3
succinate dehydrogenase complex, 
subunit B, iron sulfur (Ip)
4 4 795 6390 SDHB DHSB_HUMAN P21912 c mitochondrial inner membrane 282 0
56529 Sec11a SC11A_MOUSE Q9R0P6 SEC11 homolog A (S. cerevisiae) 2 2 1020 23478 SEC11A SC11A_HUMAN P67812 c integral to endoplasmic reticulum membrane 179 1
110379 Sec13 SEC13_MOUSE Q9D1M0 SEC13 homolog (S. cerevisiae) 6 8 477 6396 SEC13 SEC13_HUMAN P55735 c cytoplasm 322 0
67815 Sec14l2 S14L2_MOUSE Q99J08 SEC14-like 2 (S. cerevisiae) 3 2 1027 23541 SEC14L2 S14L2_HUMAN O76054 c cytoplasm 403 0
20334 Sec23a SC23A_MOUSE Q01405 SEC23A (S. cerevisiae) 22 38 129 10484 SEC23A SC23A_HUMAN Q15436 c COPII vesicle coat 765 0
218811 Sec24c Q8CGF4_MOUSE Q8CGF4
SEC24 related gene family, 
member C (S. cerevisiae)
8 6 600 9632 SEC24C SC24C_HUMAN P53992 c COPII vesicle coat 105 0
69608 Sec24d Q6NXL1_MOUSE Q6NXL1 SEC24 related gene family, 
member D (S. cerevisiae)
5 5 640 9871 SEC24D SC24D_HUMAN O94855 c COPII vesicle coat 1032 0
69162 Sec31a SC31A_MOUSE Q3UPL0 SEC31 homolog A (S. cerevisiae) 12 25 200 22872 SEC31A SC31A_HUMAN O94979 c COPII  vesicle  coat 1230 0
20341 Selenbp1 SBP1_MOUSE P17563 selenium binding protein 1 2 4 761 8991 SELENBP1 SBP1_HUMAN Q13228 c associated to membrane 472 0
320213 Senp5 SENP5_MOUSE Q6NXL6 SUMO/sentrin specific peptidase 5 4 4 798 205564 SENP5 SENP5_HUMAN Q96HI0 c nucleus 749 0
68607 Serhl SERHL_MOUSE Q9EPB5 serine hydrolase-like 2 2 1104 253190 SERHL SEHL2_HUMAN Q9H4I8 c cytoplasm 311 0
20719 Serpinb6a SPB6_MOUSE Q60854 serine (or cysteine) peptidase 
inhibitor, clade B, member 6a
6 10 423 5269 SERPINB6 SPB6_HUMAN P35237 c cytoplasm 378 0
55948 Sfn 1433S_MOUSE O70456 stratifin 14 41 125 2810 SFN 1433S_HUMAN P31947 c cytoplasm 248 0
56726 Sh3bgrl SH3L1_MOUSE Q9JJU8
SH3-binding domain glutamic acid-
rich protein like
9 10 405 6451 SH3BGRL SH3L1_HUMAN O75368 c cytoplasm 114 0
20425 Shmt1 GLYC_MOUSE P50431
serine hydroxymethyltransferase 1 
(soluble)
7 10 410 6470 SHMT1 GLYC_HUMAN P34896 c cytoplasm 478 0
108037 Shmt2 Q3TFD0_MOUSE Q3TFD0
serine hydroxymethyltransferase 2 
(mitochondrial)
5 4 774 6472 SHMT2 GLYM_HUMAN P34897 c mitochondrial inner membrane 501 0
72171 Shq1 SHQ1_MOUSE Q7TMX5 SHQ1 homolog (S. cerevisiae) 3 2 1037 55164 SHQ1 SHQ1_HUMAN Q6PI26 c - 260 0
21402 Skp1a SKP1_MOUSE Q9WTX5
S-phase kinase-associated protein 
1A
2 2 1094 6500 SKP1 SKP1_HUMAN P63208 c cytosol 163 0
18408 Slc25a15 ORNT1_MOUSE Q9WVD5
solute carrier family 25 
(mitochondrial carrier ornithine 
transporter), member 15
2 2 1137 10166 SLC25A15 ORNT1_HUMAN Q9Y619 c integral to mitochondrial inner membrane 301 0
11740 Slc25a5 ADT2_MOUSE P51881
solute carrier family 25 
(mitochondrial carrier, adenine 
nucleotide translocator), member 5
8 17 271 292 SLC25A5 ADT2_HUMAN P05141 c integral to plasma membrane 298 2
26941 Slc9a3r1 NHERF_MOUSE P70441
solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 1
23 98 55 9368 SLC9A3R1 NHERF_HUMAN O14745 c apical plasma membrane 355 0
17128 Smad4 SMAD4_MOUSE P97471 MAD homolog 4 (Drosophila) 2 1 1189 4089 SMAD4 SMAD4_HUMAN Q13485 c cytoplasm 551 0
20619 Snap23 SNP23_MOUSE O09044 synaptosomal-associated protein 23 9 38 128 8773 SNAP23 SNP23_HUMAN O00161 c plasma membrane 210 0
67474 Snap29 SNP29_MOUSE Q9ERB0 synaptosomal-associated protein 29 4 3 817 9342 SNAP29 SNP29_HUMAN O95721 c associated to plasma membrane 260 0
56440 Snx1 SNX1_MOUSE Q9WV80 sorting nexin 1 3 4 731 6642 SNX1 SNX1_HUMAN Q13596 c associated to endosome membrane 522 0
67804 Snx2 SNX2_MOUSE Q9CWK8 sorting nexin 2 4 5 620 6643 SNX2 SNX2_HUMAN O60749 c cytoplasm 519 0
54198 Snx3 SNX3_MOUSE O70492 sorting nexin 3 4 4 727 8724 SNX3 SNX3_HUMAN O60493 c cytoplasm 162 0
69150 Snx4 SNX4_MOUSE Q91YJ2 sorting nexin 4 2 2 1105 8723 SNX4 SNX4 HUMAN O95219 c cytoplasm 450 0
69178 Snx5 SNX5_MOUSE Q9D8U8 sorting nexin 5 6 4 736 27131 SNX5 SNX5_HUMAN Q9Y5X3 c - 978 0
72183 Snx6 SNX6_MOUSE Q6P8X1 sorting nexin 6 5 4 697 58533 SNX6 SNX6_HUMAN Q9UNH7 c cytoplasm 406 0
76561 Snx7 SNX7_MOUSE Q9CY18 sorting nexin 7 3 2 1039 51375 SNX7 SNX7_HUMAN Q9UNH6 c cytoplasmic vesicle 387 0
66616 Snx9 SNX9_MOUSE Q91VH2 sorting nexin 9 2 2 1152 51429 SNX9 SNX9_HUMAN Q9Y5X1 c plasma membrane 595 0
20779 Src SRC_MOUSE P05480 Rous sarcoma oncogene 14 24 207 6714 SRC SRC_HUMAN P12931 c plasma membrane 541 0
109552 Sri SORCN_MOUSE Q6P069 sorcin 4 5 642 6717 SRI SORCN_HUMAN P30626 c cytoplasm 198 0
70356 St13 F10A1_MOUSE Q99L47 suppression of tumorigenicity 13 3 3 910 6767 ST13 F10A1 HUMAN P50502 c cytoplasm 371 0
70527 Stambp STABP_MOUSE Q9CQ26 Stam binding protein 2 2 1156 10617 STAMBP STABP_HUMAN O95630 c anchored to membrane 424 0
223255 Stk24 STK24_MOUSE Q99KH8 serine/threonine kinase 24 (STE20 
homolog, yeast)
11 11 396 8428 STK24 STK24_HUMAN Q9Y6E0 c cytoplasm 431 0
59041 Stk25 STK25_MOUSE Q9Z2W1 serine/threonine kinase 25 (yeast) 11 14 314 10494 STK25 STK25_HUMAN O00506 c Golgi apparatus 426 0
106504 Stk38 STK38_MOUSE Q91VJ4 serine/threonine kinase 38 5 3 822 11329 STK38 STK38_HUMAN Q15208 c cytoplasm 465 0
20911 Stxbp2 STXB2_MOUSE Q64324 syntaxin binding protein 2 16 27 188 6813 STXBP2 STXB2_HUMAN Q15833 c cellular_component 593 0
20912 Stxbp3a STXB3_MOUSE Q60770 syntaxin binding protein 3A 2 2 1002 6814 STXBP3 STXB3_HUMAN O00186 c cytoplasm 592 0
56362 Sult1b1 ST1B1_MOUSE Q9QWG7 sulfotransferase family 1B, member 
1
14 30 164 27284 SULT1B1 ST1B1_HUMAN O43704 c cytoplasm 299 0
54200 Sult2b1 ST2B1_MOUSE O35400 sulfotransferase family, cytosolic, 
2B, member 1
3 5 671 6820 SULT2B1 ST2B1_HUMAN O00204 c cytoplasm 338 0
21346 Tagln2 TAGL2_MOUSE Q9WVA4 transgelin 2 9 18 253 8407 TAGLN2 TAGL2_HUMAN P37802 c plasma membrane 212 0
21351 Taldo1 TALDO_MOUSE Q93092 transaldolase 1 6 11 393 6888 TALDO1 TALDO_HUMAN P37837 c cytoplasm 337 0
330177 Taok3 TAOK3_MOUSE Q8BYC6 TAO kinase 3 2 2 1051 51347 TAOK3 TAOK3_HUMAN Q9H2K8 c associated to plasma membrane 898 0
110960 Tars SYTC_MOUSE Q9D0R2 threonyl-tRNA synthetase 16 14 313 6897 TARS SYTC_HUMAN P26639 c cytoplasm 722 0
67673 Tceb2 ELOB_MOUSE P62869
transcription elongation factor B 
(SIII), polypeptide 2
3 3 937 6923 TCEB2 ELOB_HUMAN Q15370 c cytoplasm 118 0
21454 Tcp1 TCPA1_MOUSE P11984 t-complex protein 1 7 5 633 6950 TCP1 TCPA_HUMAN P17987 c cytoplasm 556 0
21753 Tes TES_MOUSE P47226 testis derived transcript 5 5 670 26136 TES TES_HUMAN Q9UGI8 c apical plasma membrane 423 0
21787 Tfg Q8C2C6_MOUSE Q8C2C6 Trk-fused gene 2 3 934 10342 TFG TFG_HUMAN Q92734 c cytoplasm 348 0
66834 Them2 THEM2_MOUSE Q9CQR4 thioesterase superfamily member 2 2 2 1024 55856 THEM2 THEM2_HUMAN Q9NPJ3 c mitochondrion 140 0
232078 Thnsl2 THNS2_MOUSE Q80W22 threonine synthase-like 2 (bacterial) 3 2 1117 55258 THNSL2 THNS2_HUMAN Q86YJ6 c - 507 0
50492 Thop1 THOP1_MOUSE Q8C1A5 thimet oligopeptidase 1 5 5 634 7064 THOP1 THOP1_HUMAN P52888 c cytoplasm 687 0
21881 Tkt TKT_MOUSE P40142 transketolase 23 43 121 7086 TKT TKT_HUMAN P29401 c cytosol 623 0
238799 Tnpo1 TNPO1_MOUSE Q8BFY9 transportin 1 4 4 701 3842 TNPO1 TNPO1_HUMAN Q92973 c cytoplasm 890 0
54473 Tollip TOLIP_MOUSE Q9QZ06 toll interacting protein 2 2 1018 54472 TOLLIP TOLIP_HUMAN Q9H0E2 c cytoplasm 274 0
66314 Tpd52l2 TPD54_MOUSE Q9CYZ2 tumor protein D52-like 2 2 2 1151 7165 TPD52L2 TPD54 HUMAN O43399 c cytoplasm 220 0
21991 Tpi1 TPIS_MOUSE P17751 triosephosphate isomerase 1 12 27 181 7167 TPI1 TPIS_HUMAN P60174 c cytosol 249 0
22003 Tpm1 TPM1_MOUSE P58771 tropomyosin 1, alpha 2 2 1003 7168 TPM1 TPM1_HUMAN P09493 c cytoskeleton 284 0
71609 Tradd TRADD_MOUSE Q3U0V2
TNFRSF1A-associated via death 
domain
10 13 333 8717 TRADD TRADD_HUMAN Q15628 c cytoskeleton 310 0
74735 Trim14 TRI14_MOUSE Q8BVW3 tripartite motif-containing 14 9 8 475 9830 TRIM14 TRI14_HUMAN Q14142 c cytoplasm 440 0
224762 Trim31 - - tripartite motif-containing 31 9 10 433 11074 TRIM31 TRI31_HUMAN Q9BZY9 c cytoplasm 425 0
22088 Tsg101 TS101_MOUSE Q61187 tumor susceptibility gene 101 2 2 1004 7251 TSG101 TS101_HUMAN Q99816 c cytoplasm 391 0
223723 Ttll12 TTL12_MOUSE Q3UDE2
tubulin tyrosine ligase-like family, 
member 12
3 2 1116 23170 TTLL12 TTL12_HUMAN Q14166 c - 483 0
22142 Tuba1a TBA1A_MOUSE P68369 tubulin, alpha 1A 9 57 87 7846 TUBA1A TBA1A_HUMAN Q71U36 c microtubule 451 0
22143 Tuba1b TBA1B_MOUSE P05213 tubulin, alpha 1B 16 115 41 10376 TUBA1B TBA1B_HUMAN P68363 c microtubule 451 0
22144 Tuba3a TBA3_MOUSE P05214 tubulin, alpha 3A 2 4 762 113457 TUBA3D Q8WU19_HUMAN Q8WU19 c microtubule 450 0
22147 Tuba3b TBA3_MOUSE P05214 tubulin, alpha 3B 2 4 763 112714 TUBA3E TBA3E_HUMAN Q6PEY2 c microtubule 450 0
238463 Tubal3 TBAL3_MOUSE Q3UX10 tubulin, alpha-like 3 5 8 492 79861 TUBAL3 TBAL3_HUMAN A6NHL2 c microtubule 446 0    177
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22151 Tubb2a TBB2A_MOUSE Q7TMM9 tubulin, beta 2a 11 28 179 7280 TUBB2A TBB2A_HUMAN Q13885 c microtubule 445 0
73710 Tubb2b TBB2B_MOUSE Q9CWF2 tubulin, beta 2b 11 28 180 347733 TUBB2B TBB2B_HUMAN Q9BVA1 c microtubule 445 0
227613 Tubb2c TBB2C_MOUSE P68372 tubulin, beta 2c 19 87 61 10383 TUBB2C TBB2C_HUMAN P68371 c microtubule 445 0
22153 Tubb4 TBB4_MOUSE Q9D6F9 tubulin, beta 4 3 4 792 10382 TUBB4 TBB4_HUMAN P04350 c microtubule 444 0
22154 Tubb5 TBB5_MOUSE P99024 tubulin, beta 5 19 64 76 203068 TUBB TBB5_HUMAN P07437 c cytoskeleton 444 0
67951 Tubb6 TBB6_MOUSE Q922F4 tubulin, beta 6 9 11 387 84617 TUBB6 TBB6_HUMAN Q9BUF5 c microtubule 447 0
19230 Twf1 TWF1_MOUSE Q91YR1
twinfilin, actin-binding protein, 
homolog 1 (Drosophila)
2 2 997 5756 TWF1 TWF1_HUMAN Q12792 c actin cytoskeleton 350 0
22166 Txn1 THIO_MOUSE P10639 thioredoxin 1 5 14 300 7295 TXN THIO_HUMAN P10599 c cytoplasm 105 0
53382 Txnl1 TXNL1_MOUSE Q8CDN6 thioredoxin-like 1 2 2 1014 9352 TXNL1 TXNL1_HUMAN O43396 c cytoplasm 289 0
50493 Txnrd1 TRXR1_MOUSE Q9JMH6 thioredoxin reductase 1 5 5 618 7296 TXNRD1 TRXR1_HUMAN Q16881 c cytoplasm 613 0
227620 Uap1 UAP1L_MOUSE Q3TW96
UDP-N-acteylglucosamine 
pyrophosphorylase 1-like 1
6 4 740 91373 UAP1L1 UAP1L_HUMAN Q3KQV9 c - 401 0
22190 Ubc UBIQ_MOUSE P62991 ubiquitin C 8 115 42 7316 UB UBIQ_HUMAN P62988 c cytoplasm 76 0
66105 Ube2d3 UB2D3_MOUSE P61079
ubiquitin-conjugating enzyme E2D 3 
(UBC4/5 homolog, yeast)
2 1 1192 7323 UBE2D3 UB2D3_HUMAN P61077 c - 527 0
22192 Ube2m UBC12_MOUSE P61082
ubiquitin-conjugating enzyme E2M 
(UBC12 homolog, yeast)
4 3 812 9040 UBE2M UBC12_HUMAN P61081 c cellular_component 183 0
93765 Ube2n UBE2N_MOUSE P61089 ubiquitin-conjugating enzyme E2N 4 4 772 7334 UBE2N UBE2N_HUMAN P61088 c cytoplasm 152 0
66589 Ube2v1 UB2V1_MOUSE Q9CZY3
ubiquitin-conjugating enzyme E2 
variant 1
3 2 1022 7335 UBE2V1 UB2V1_HUMAN Q13404 c cytoplasm 147 0
70620 Ube2v2 UB2V2_MOUSE Q9D2M8
ubiquitin-conjugating enzyme E2 
variant 2
3 2 1033 7336 UBE2V2 UB2V2_HUMAN Q15819 c cytoplasm 145 0
24109 Ubl3 UBL3_MOUSE Q9Z2M6 ubiquitin-like 3 3 2 1007 5412 UBL3 UBL3_HUMAN O95164 c anchored to plasma membrane 117 0
56207 Uchl5 UCHL5_MOUSE Q9WUP7 ubiquitin carboxyl-terminal esterase 
L5
2 3 852 51377 UCHL5 UCHL5_HUMAN Q9Y5K5 c cytosol 329 0
54122 Uevld UEVLD_MOUSE Q3U1V6
UEV and lactate/malate 
dehyrogenase domains
3 2 1016 55293 UEVLD UEVLD_HUMAN Q8IX04 c - 474 0
216558 Ugp2 UGPA_MOUSE Q91ZJ5 UDP-glucose pyrophosphorylase 2 3 2 965 7360 UGP2 UGPA_HUMAN Q16851 c cytoplasm 508 0
67003 Uqcrc2 QCR2_MOUSE Q9DB77
ubiquinol cytochrome c reductase 
core protein 2
3 3 936 7385 UQCRC2 QCR2_HUMAN P22695 c mitochondrial inner membrane 453 0
72088 Ush1c USH1C_MOUSE Q9ES64
Usher syndrome 1C homolog 
(human)
22 77 67 10083 USH1C USH1C_HUMAN Q9Y6N9 c apical part of cell 910 0
22217 Usp12 UBP12_MOUSE Q9D9M2 ubiquitin specific peptidase 12 2 2 1141 219333 USP12 UBP12_HUMAN O75317 c cellular_component 370 0
22323 Vasp VASP_MOUSE P70460
vasodilator-stimulated 
phosphoprotein
2 2 1005 7408 VASP VASP_HUMAN P50552 c actin cytoskeleton 375 0
26949 Vat1 VAT1_MOUSE Q62465
vesicle amine transport protein 1 
homolog (T californica)
7 11 385 10493 VAT1 VAT1_HUMAN Q99536 c integral to membrane 406 0
269523 Vcp TERA_MOUSE Q01853 valosin containing protein 6 13 322 7415 VCP TERA_HUMAN P55072 c protein complex 806 0
22334 Vdac2 VDAC2_MOUSE Q60930 voltage-dependent anion channel 2 6 8 469 7417 VDAC2 VDAC2_HUMAN P45880 c integral to mitochondrial outer membrane 296 0
22335 Vdac3 VDAC3_MOUSE Q60931 voltage-dependent anion channel 3 5 6 570 7419 VDAC3 VDAC3_HUMAN Q9Y277 c integral to mitochondrial outer membrane 283 0
22337 Vdr VDR_MOUSE P48281 vitamin D receptor 2 2 1006 7421 VDR VDR_HUMAN P11473 c nucleus 422 0
22349 Vil1 VILI_MOUSE Q62468 villin 1 58 1566 2 7429 VIL1 VILI_HUMAN P09327 c cytoskeleton 827 0
30930 Vps26a VP26A_MOUSE P40336
vacuolar protein sorting 26 homolog 
A (yeast)
4 4 725 9559 VPS26A VP26A_HUMAN O75436 c associated to endosome membrane 327 0
66914 Vps28 VPS28_MOUSE Q9D1C8 vacuolar protein sorting 28 (yeast) 4 2 959 51160 VPS28 VPS28_HUMAN Q9UK41 c cytosol 221 0
56433 Vps29 VPS29_MOUSE Q9QZ88
vacuolar protein sorting 29 (S. 
pombe)
5 4 765 51699 VPS29 VPS29_HUMAN Q9UBQ0 c associated to membrane 182 0
65114 Vps35 VPS35_MOUSE Q9EQH3 vacuolar protein sorting 35 11 10 406 55737 VPS35 VPS35_HUMAN Q96QK1 c associated to membrane 796 0
116733 Vps4a VPS4A_MOUSE Q8VEJ9 vacuolar protein sorting 4a (yeast) 8 9 455 27183 VPS4A VPS4A_HUMAN Q9UN37 c associated to late endosome membrane 437 0
20479 Vps4b VPS4B_MOUSE P46467 vacuolar protein sorting 4b (yeast) 8 10 422 9525 VPS4B VPS4B_HUMAN O75351 c late endosome membrane 444 0
66201 Vta1 VTA1_MOUSE Q9CR26
Vps20-associated 1 homolog (S. 
cerevisiae)
5 4 732 51534 VTA1 VTA1_HUMAN Q9NP79 c cytoplasm 309 0
22375 Wars SYWC_MOUSE P32921 tryptophanyl-tRNA synthetase 7 8 470 7453 WARS SYWC_HUMAN P23381 c cytoplasm 481 0
22388 Wdr1 WDR1_MOUSE O88342 WD repeat domain 1 12 16 281 9948 WDR1 WDR1_HUMAN O75083 c cytoskeleton 606 0
22436 Xdh XDH_MOUSE Q00519 xanthine dehydrogenase 9 6 571 7498 XDH XDH_HUMAN P47989 c cytosol 1335 0
103573 Xpo1 XPO1_MOUSE Q6P5F9 exportin 1, CRM1 homolog (yeast) 2 2 1111 7514 XPO1 XPO1_HUMAN O14980 c cytoplasm 1071 0
22612 Yes1 YES_MOUSE Q04736
Yamaguchi sarcoma viral (v-yes) 
oncogene homolog 1
14 24 211 7525 YES1 YES_HUMAN P07947 c cytoplasm 541 0
56418 Ykt6 YKT6_MOUSE Q9CQW1 YKT6 homolog (S. Cerevisiae) 4 4 730 10652 YKT6 YKT6_HUMAN O15498 c anchored to cytoplasmic vesicle membrane 198 0
54401 Ywhab 1433B_MOUSE Q9CQV8 
tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein, 
beta polypeptide
16 57 88 7529 YWHAB 1433B_HUMAN P31946 c cytoplasm 246 0
22627 Ywhae 1433E_MOUSE P62259
tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein, 
epsilon polypeptide
18 54 92 7531 YWHAE 1433E_HUMAN P62258 c cytoplasm 255 0
22628 Ywhag 1433G_MOUSE P61982
tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein, 
gamma polypeptide
15 37 136 7532 YWHAG 1433G_HUMAN P61981 c cytoplasm 247 0
22629 Ywhah 1433F_MOUSE P68510
tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein, 
eta polypeptide
14 48 106 7533 YWHAH 1433F_HUMAN Q04917 c cytoplasm 246 0
22631 Ywhaz 1433Z_MOUSE P63101
tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein, 
zeta polypeptide
19 84 63 7534 YWHAZ 1433Z_HUMAN P63104 c cytoplasm 245 0
77219 Zadh1 ZADH1_MOUSE Q8VDQ1
zinc binding alcohol 
dehydrogenase, domain containing 
1
2 2 1040 145482 PTGR2 ZADH1_HUMAN Q8N8N7 c cytoplasm 351 0
69036 1810010M01Rik ZG16_MOUSE Q8K0C5
Zymogen granule membrane 
protein 16 [Precursor]
5 24 213 123887 ZG16 ZG16_HUMAN O60844 s extracellular region 167 0
70178 2210412D01Rik F108C_MOUSE Q8VCV1
Abhydrolase domain-containing 
protein FAM108C1
3 5 648 58489 FAM108C1 F108C_HUMAN Q6PCB6 s 320 0
70564 5730469M10Rik CJ058_MOUSE Q9CYH2 RIKEN cDNA 5730469M10 gene 5 4 703 84293 C10orf58 CJ058_HUMAN Q9BRX8 s extracellular region 218 1
70025 Acot7 BACH_MOUSE Q91V12 acyl-CoA thioesterase 7 3 2 1059 11332 ACOT7 BACH_HUMAN O00154 s cytoplasm 381 0
433256 Acsl5 ACSL5_MOUSE Q8JZR0
acyl-CoA synthetase long-chain 
family member 5
23 34 150 51703 ACSL5 ACSL5_HUMAN Q9ULC5 s integral to endoplasmic reticulum membrane 683 1
11604 Agrp AGRP_MOUSE P56473 agouti related protein 4 6 582 181 AGRP AGRP_HUMAN O00253 s extracellular region 114 0
11657 Alb ALBU_MOUSE P07724 albumin 28 35 142 213 ALB ALBU_HUMAN P02768 s extracellular region 608 0
109960 Amy2-1 Q61297_MOUSE Q61297 amylase 2-1, pancreatic 2 2 1120 276 AMY1A AMY1_HUMAN P04745 s extracellular region 232 0
11806 Apoa1 APOA1_MOUSE Q00623 apolipoprotein A-I 8 6 559 335 APOA1 APOA1_HUMAN P02647 s extracellular region 264 0
11808 Apoa4 APOA4_MOUSE P06728 apolipoprotein A-IV 8 11 378 337 APOA4 APOA4_HUMAN P06727 s extracellular region 395 0
11816 Apoe APOE_MOUSE P08226 apolipoprotein E 3 2 1055 348 APOE APOE_HUMAN P02649 s extracellular region 311 0
108147 Atic PUR9_MOUSE Q9CWJ9
5-aminoimidazole-4-carboxamide 
ribonucleotide 
formyltransferase/IMP 
cyclohydrolase
6 8 481 471 ATIC PUR9_HUMAN P31939 s 592 0
11950 Atp5f1 AT5F1_MOUSE Q9CQQ7
ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit 
b, isoform 1
4 5 676 515 ATP5F1 AT5F1_HUMAN P24539 s mitochondrial inner membrane 256 0
12010 B2m B2MG_MOUSE P01887 beta-2 microglobulin 2 4 741 567 B2M B2MG_HUMAN P61769 s extracellular region 119 1
14422 B4galnt2 B4GN2_MOUSE Q09199
beta-1,4-N-acetyl-galactosaminyl 
transferase 2
6 5 677 124872 B4GALNT2 B4GN2_HUMAN Q8NHY0 s integral to Golgi membrane 510 1
12317 Calr CALR_MOUSE P14211 calreticulin 2 2 1119 811 CALR CALR_HUMAN P27797 s extracellular region 416 0
12351 Car4 CAH4_MOUSE Q64444 carbonic anhydrase 4 5 8 494 762 CA4 CAH4_HUMAN P22748 s anchored to plasma membrane 305 0
23844 Clca3 CLCA1_MOUSE Q9D7Z6
chloride channel calcium activated 
3
29 49 104 1179 CLCA1 CLCA1_HUMAN A8K7I4 s integral to plasma membrane 913 0
12764 Cmas NEUA_MOUSE Q99KK2
cytidine monophospho-N-
acetylneuraminic acid synthetase
4 4 778 55907 CMAS NEUA_HUMAN Q8NFW8 s nucleus 432 0
66588 Cmpk1 KCY_MOUSE Q9DBP5 cytidine monophosphate (UMP-
CMP) kinase 1
5 8 480 51727 CMPK1 KCY_HUMAN P30085 s cytoplasm 196 0
76703 Cpb1 - - carboxypeptidase B1 (tissue) 3 3 878 1360 CPB1 CBPB1_HUMAN P15086 s extracellular region 500 2
68631 Cryl1 CRYL1_MOUSE Q99KP3 crystallin, lambda 1 5 3 877 51084 CRYL1 CRYL1_HUMAN Q9Y2S2 s 319 0
12974 Cs CISY_MOUSE Q9CZU6 citrate synthase 4 4 779 1431 CS CISY_HUMAN O75390 s mitochondrial matrix 464 0
66473 Ctrb1 CTRB1_MOUSE Q9CR35 chymotrypsinogen B1 3 2 1058 440387 CTRB2 CTRB1_HUMAN P17538 s extracellular region 263 1
13040 Ctss CATS_MOUSE O70370 cathepsin S 4 4 742 1520 CTSS CATS_HUMAN P25774 s extracellular region 340 0
65969 Cubn CUBN_MOUSE Q9JLB4 cubilin (intrinsic factor-cobalamin 
receptor)
4 3 826 8029 CUBN CUBN_HUMAN O60494 s extrinsic to external side of brush border 
membrane
3623 0
66445 Cyc1 CY1_MOUSE Q9D0M3 cytochrome c-1 5 4 780 1537 CYC1 CY1_HUMAN P08574 s integral to mitochondrial inner membrane 325 1
13113 Cyp3a13 CP3AD_MOUSE Q64464
cytochrome P450, family 3, 
subfamily a, polypeptide 13
9 12 346 1577 CYP3A5 CP3A5_HUMAN P20815 s
associated to endoplasmic reticulum 
membrane
503 0
13479 Dpep1 DPEP1_MOUSE P31428 dipeptidase 1 (renal) 19 113 43 1800 DPEP1 DPEP1_HUMAN P16444 s anchored to apical plasma membrane 410 0
276770 Eif5a IF5A1_MOUSE P63242
eukaryotic translation initiation 
factor 5A
2 3 916 1984 EIF5A IF5A1_HUMAN P63241 s cytoplasm 154 0
109901 Ela1 Q91X79_MOUSE Q91X79 elastase 1, pancreatic 3 2 1060 1990 ELA1 ELA1_HUMAN Q9UNI1 s extracellular region 266 0
238011 Enpp7 A2A5N7_MOUSE A2A5N7
ectonucleotide 
pyrophosphatase/phosphodiesteras
e 7
10 53 94 339221 ENPP7 ENPP7_HUMAN Q6UWV6 s anchored to apical plasma membrane 425 1
13850 Ephx2 HYES_MOUSE P34914 epoxide hydrolase 2, cytoplasmic 11 17 268 2053 EPHX2 HYES_HUMAN P34913 s cytoplasm 554 0
14302 Frk FRK_MOUSE Q922K9 fyn-related kinase 18 45 116 2444 FRK FRK_HUMAN P42685 s cytoplasm 512 0
14433 Gapdh G3P_MOUSE P16858
glyceraldehyde-3-phosphate 
dehydrogenase
15 84 64 2597 GAPDH G3P_HUMAN P04406 s membrane 333 0
353172 Gars SYG_MOUSE Q9CZD3 glycyl-tRNA synthetase 2 2 1061 2617 GARS SYG_HUMAN P41250 s secretory granule 729 0
14544 Gda GUAD_MOUSE Q9R111 guanine deaminase 9 16 283 9615 GDA GUAD_HUMAN Q9Y2T3 s cytosol 454 0
14683 Gnas GNAS1_MOUSE Q6R0H7
GNAS (guanine nucleotide binding 
protein, alpha stimulating) complex 
locus
9 21 237 2778 GNAS
GNAS1_HUMAN, 
GNAS2_HUMAN, 
GNAS3_HUMAN
Q5JWF2, 
P63092, 
O95467
s 1133 0
14694 Gnb2l1 GBLP_MOUSE P68040
guanine nucleotide binding protein 
(G protein), beta polypeptide 2 like 
1
8 9 438 10399 GNB2L1 GBLP_HUMAN P63244 s cytoplasm 317 0
14719 Got2 AATM_MOUSE P05202
glutamate oxaloacetate 
transaminase 2, mitochondrial
4 3 941 2806 GOT2 AATM_HUMAN P00505 s mitochondrial inner membrane 430 0
114664 Hsd17b11 DHB11_MOUSE Q9EQ06
hydroxysteroid (17-beta) 
dehydrogenase 11
7 6 583 51170 HSD17B11 DHB11_HUMAN Q8NBQ5 s extracellular region 298 0
56348 Hsd17b12 DHB12_MOUSE O70503
hydroxysteroid (17-beta) 
dehydrogenase 12
4 3 942 51144 HSD17B12 DHB12_HUMAN Q53GQ0 s integral to endoplasmic reticulum membrane 312 1
22027 Hsp90b1 ENPL_MOUSE P08113
heat shock protein 90, beta 
(Grp94), member 1
10 19 245 7184 HSP90B1 ENPL_HUMAN P14625 s endoplasmic reticulum membrane 802 0
14828 Hspa5 GRP78_MOUSE P20029 heat shock protein 5 13 17 269 3309 HSPA5 GRP78_HUMAN P11021 s integral to endoplasmic reticulum membrane 655 0
212111 Inpp5a Q3TZT4_MOUSE Q3TZT4
inositol polyphosphate-5-
phosphatase A
5 3 827 3632 INPP5A I5P1_HUMAN Q14642 s anchored to membrane 420 0
66307 Isoc1 ISOC1_MOUSE Q91V64
isochorismatase domain containing 
1
4 3 915 51015 ISOC1 ISOC1_HUMAN Q96CN7 s peroxisome 297 1
16429 Itln1 ITL1A_MOUSE O88310
intelectin 1 (galactofuranose 
binding)
3 3 876 55600 ITLN1 ITLN1_HUMAN Q8WWA0 s extracellular region 313 0
228550 Itpka IP3KA_MOUSE Q8R071
inositol 1,4,5-trisphosphate 3-kinase 
A
2 1 1196 3706 ITPKA IP3KA_HUMAN P23677 s 459 0
56735 Krt71 K2C71_MOUSE Q9R0H5 keratin 71 3 4 799 112802 KRT71 K2C71_HUMAN Q3SY84 s cytoskeleton 524 0
17110 Lyz1 LYSCP_MOUSE P17897 lysozyme 1 3 6 603 4069 LYZ LYSC_HUMAN P61626 s extracellular region 148 0
110119 Mpi MPI_MOUSE Q924M7 mannose phosphate isomerase 2 2 1121 4351 MPI MPI_HUMAN P34949 s cytoplasm 423 0
110265 Msra MSRA_MOUSE Q9D6Y7 methionine sulfoxide reductase A 7 11 398 4482 MSRA MSRA_HUMAN Q9UJ68 s 233 0
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56428 Mtch2 MTCH2_MOUSE Q791V5
mitochondrial carrier homolog 2 (C. 
elegans)
3 2 972 23788 MTCH2 MTCH2_HUMAN Q9Y6C9 s integral to mitochondrial inner membrane 303 0
17777 Mttp MTP_MOUSE O08601
microsomal triglyceride transfer 
protein
19 27 190 4547 MTTP MTP_HUMAN P55157 s endoplasmic reticulum 894 0
52793 ORF9 FAM3B_MOUSE Q9D309 open reading frame 9 4 2 970 54097 FAM3B FAM3B_HUMAN P58499 s extracellular region 235 1
18453 P4hb PDIA1_MOUSE P09103
prolyl 4-hydroxylase, beta 
polypeptide
13 12 347 5034 P4HB PDIA1_HUMAN P07237 s extracellular region 509 0
14827 Pdia3 PDIA3_MOUSE P27773
protein disulfide isomerase 
associated 3
10 8 478 2923 PDIA3 PDIA3_HUMAN P30101 s endoplasmic reticulum lumen 505 0
94184 Pdxdc1 PDXD1_MOUSE Q99K01
pyridoxal-dependent decarboxylase 
domain containing 1
4 5 678 23042 PDXDC1 PDXD1_HUMAN Q6P996 s 787 0
66171 Pgls 6PGL_MOUSE Q9CQ60 6-phospho-gluconolactonase 7 5 625 25796 PGLS 6PGL_HUMAN O95336 s 257 0
53328 Pgrmc1 PGRC1_MOUSE O55022
progesterone receptor membrane 
component 1
4 2 971 10857 PGRMC1 PGRC1_HUMAN O00264 s integral to plasma membrane 195 1
18673 Phb PHB_MOUSE P67778 prohibitin 6 9 457 5245 PHB PHB_HUMAN P35232 s integral to plasma membrane 272 0
12034 Phb2 PHB2_MOUSE O35129 prohibitin 2 8 7 520 11331 PHB2 PHB2_HUMAN Q99623 s mitochondrial inner membrane 299 0
18720 Pip5k1a PI51A_MOUSE P70182
phosphatidylinositol-4-phosphate 5-
kinase, type 1 alpha
2 2 1169 8394 PIP5K1A PI51A_HUMAN Q99755 s associated to plasma membrane 546 0
19325 Rab10 RAB10_MOUSE P61027
RAB10, member RAS oncogene 
family
13 35 143 10890 RAB10 RAB10_HUMAN P61026 s anchored to plasma membrane 200 0
19329 Rab17 RAB17_MOUSE P35292
RAB17, member RAS oncogene 
family
10 14 306 64284 RAB17 RAB17_HUMAN Q9H0T7 s anchored to plasma membrane 214 0
216344 Rab21 RAB21_MOUSE P35282
RAB21, member RAS oncogene 
family
7 11 399 23011 RAB21 RAB21_HUMAN Q9UL25 s anchored to Golgi membrane 222 0
19344 Rab5b RAB5B_MOUSE P61021
RAB5B, member RAS oncogene 
family
8 18 257 5869 RAB5B RAB5B_HUMAN P61020 s anchored to plasma membrane 215 0
19345 Rab5c RAB5C_MOUSE P35278
RAB5C, member RAS oncogene 
family
10 52 96 5878 RAB5C RAB5C_HUMAN P51148 s anchored to plasma membrane 216 0
17252 Rdh11 RDH11_MOUSE Q9QYF1 retinol dehydrogenase 11 4 3 914 51109 RDH11 RDH11_HUMAN Q8TC12 s integral to endoplasmic reticulum membrane 316 0
56632 Sphk2 SPHK2_MOUSE Q9JIA7 sphingosine kinase 2 5 8 479 56848 SPHK2 SPHK2_HUMAN Q9NRA0 s membrane fraction 617 0
20751 Spr SPRE_MOUSE Q64105 sepiapterin reductase 2 2 1056 6697 SPR SPRE_HUMAN P35270 s cytoplasm 261 0
20846 Stat1 STAT1_MOUSE P42225
signal transducer and activator of 
transcription 1
11 11 397 6772 STAT1 STAT1_HUMAN P42224 s cytoplasm 749 0
66682 Trappc5 TPPC5_MOUSE Q9CQA1 trafficking protein particle complex 5 2 1 1195 126003 TRAPPC5 TPPC5_HUMAN Q8IUR0 s endoplasmic reticulum 1880
22122 Tsta3 FCL_MOUSE P23591
tissue specific transplantation 
antigen P35B
6 6 560 7264 TSTA3 FCL_HUMAN Q13630 s cytoplasm 321 0
105245 Txndc5 TXND5_MOUSE Q91W90 thioredoxin domain containing 5 5 4 743 81567 TXNDC5 TXND5_HUMAN Q8NBS9 s endoplasmic reticulum lumen 417 0
22273 Uqcrc1 QCR1_MOUSE Q9CZ13
ubiquinol-cytochrome c reductase 
core protein 1
2 2 1057 7384 UQCRC1 QCR1_HUMAN P31930 s mitochondrial inner membrane 480 0
22333 Vdac1 VDAC1_MOUSE Q60932 voltage-dependent anion channel 1 11 12 355 7416 VDAC1 VDAC1_HUMAN P21796 s integral to plasma membrane 296 0
170745 Xpnpep2 Q91Y31_MOUSE Q91Y31
X-prolyl aminopeptidase 
(aminopeptidase P) 2, membrane-
bound
18 37 132 7512 XPNPEP2 XPP2_HUMAN O43895 s anchored to plasma membrane 674 0
68617 1110012J17Rik K0802_MOUSE Q3UHU5 Uncharacterized protein KIAA0802 3 2 977 23255 KIAA0802 K0802_HUMAN Q9Y4B5 tm cytoskeleton 1945 0
435889 1810049H19Rik Q3V2E0_MOUSE Q3V2E0
Adult male stomach cDNA, RIKEN 
full-length enriched library, 
clone:2210415M03 product:TESP4 
(0910001B19RIK protein) 
(Trypsinogen 9), full insert 
sequence
2 9 4 4 8- - - - t m - 2 5 50
69864 1810065E05Rik Q5NC41_MOUSE Q5NC41 RIKEN cDNA 1810065E05 gene 2 4 804 - - - - tm - 235 0
625286 2010003H20Rik A2ARJ3_MOUSE A2ARJ3
FAM23A-like | hypothetical protein 
LOC625286
7 53 95 653567 FAM23A FA23A_HUMAN Q5W0B7 tm integral to membrane 344 5
67715 2010106E10Rik A2ANY3_MOUSE A2ANY3 RIKEN cDNA 2010106E10 gene 11 56 89 - - - - tm - 279 1
69983 2010204N08Rik  -   - 
hypothetical protein LOC69983 | 
sucrase-isomaltase (alpha-
glucosidase)
93 1464 3 6476 SI SUIS_HUMAN P14410 tm apical plasma membrane 1818 1
72273 2210404O07Rik YS019_MOUSE Q0VG18
Transmembrane protein HSPC323 
homolog precursor.
7 100 52 284422 LOC284422 YS019_HUMAN O75264 tm integral to membrane 120 1
78354 2210407C18Rik Q6YI28_MOUSE Q6YI28
RIKEN cDNA 2210407C18 gene / 
EP1 protein (novel protein)
11 176 25 - - - - tm - 220 0
69698 2310046K01Rik CT054_MOUSE Q9D6X5
Uncharacterized protein C20orf54 
homolog precursor.
4 11 390 113278 C20orf54 CT054_HUMAN Q9NQ40 tm integral to membrane 460 11
71955 2400003C14Rik K0174_MOUSE Q9CX00 Uncharacterized protein KIAA0174. 5 13 328 9798 KIAA0174 K0174_HUMAN P53990 tm ER-Golgi intermediate compartment 362 0
66674 6330409N04Rik CLLD6_MOUSE Q3TFQ1
Chronic lymphocytic leukemia 
deletion region gene 6 protein 
homolog
3 2 1075 57213 C13orf1 CLLD6_HUMAN Q5W111 tm - 196 0
217830 9030617O03Rik CN159_MOUSE Q8BH86
UPF0317 protein C14orf159 
homolog, mitochondrial precursor.
2 1 1206 80017 C14orf159 CN159_HUMAN Q7Z3D6 tm mitochondrion 617 0
67758 Aadac AAAD_MOUSE Q99PG0
Arylacetamide deacetylase (EC 
3.1.1.-) (AADAC).
4 4 803 13 AADAC AAAD_HUMAN P22760 tm integral to endoplasmic reticulum membrane 398 0
27413 Abcb11 ABCBB_MOUSE Q9QY30
Bile salt export pump (ATP-binding 
cassette sub-family B member 11) 
(Sister of P-glycoprotein).
2 5 653 8647 ABCB11 ABCBB_HUMAN O95342 tm integral to plasma membrane 1321 9
18671 Abcb1a MDR3_MOUSE P21447
Multidrug resistance protein 3 (EC 
3.6.3.44) (ATP-binding cassette sub-
family B member 1A) (P-
glycoprotein 3) (MDR1A).
51 311 11 5243 ABCB1 MDR1_HUMAN P08183 tm integral to plasma membrane 1276 11
18669 Abcb1b MDR1_MOUSE P06795
ATP-binding cassette, sub-family B 
(MDR/TAP), member 1B
27 19 246 - - - - tm apical plasma membrane 1276 10
74104 Abcb6 ABCB6_MOUSE Q9DC29
Mitochondrial ATP-binding cassette 
sub-family B member 6.
2 3 948 10058 ABCB6 ABCB6_HUMAN Q9NP58 tm integral to mitochondrial outer membrane 842 9
11306 Abcb7 ABCB7_MOUSE Q61102
ATP-binding cassette sub-family B 
member 7, mitochondrial (ATP-
binding cassette transporter 7) 
(ABC transporter 7 protein).
6 7 550 22 ABCB7 ABCB7_HUMAN O75027 tm integral to mitochondrial inner membrane 752 5
12780 Abcc2 MRP2_MOUSE Q8VI47
Canalicular multispecific organic 
anion transporter 1 (ATP-binding 
cassette sub-family C member 2).
27 78 66 1244 ABCC2 MRP2_HUMAN Q92887 tm integral to plasma membrane 1543 16
26357 Abcg2 ABCG2_MOUSE Q7TMS5
ATP-binding cassette sub-family G 
member 2 (Breast cancer 
resistance protein 1 homolog) 
(CD338 antigen).
20 63 78 9429 ABCG2 ABCG2_HUMAN Q9UNQ0 tm integral to plasma membrane 657 6
27409 Abcg5 ABCG5_MOUSE Q99PE8
ATP-binding cassette sub-family G 
member 5 (Sterolin-1).
14 26 192 64240 ABCG5 ABCG5_HUMAN Q9H222 tm integral to membrane 652 6
67470 Abcg8 ABCG8_MOUSE Q9DBM0
ATP-binding cassette sub-family G 
member 8 (Sterolin-2).
14 50 102 64241 ABCG8 ABCG8_HUMAN Q9H221 tm integral to membrane 673 6
66082 Abhd6 ABHD6_MOUSE Q8R2Y0
Abhydrolase domain-containing 
protein 6 (EC 3.-.-.-).
2 2 1173 57406 ABHD6 ABHD6_HUMAN Q9BV23 tm integral to membrane 336 1
11363 Acadl ACADL_MOUSE P51174
Long-chain specific acyl-CoA 
dehydrogenase, mitochondrial 
precursor (EC 1.3.99.13) (LCAD).
4 3 917 33 ACADL ACADL_HUMAN P28330 tm mitochondrial matrix 430 0
11421 Ace ACET_MOUSE P22967
Angiotensin-converting enzyme, 
somatic isoform precursor (EC 
3.4.15.1) (Dipeptidyl 
carboxypeptidase I) (Kininase II)
51 89 59 1636 ACE ACET_HUMAN P22966 tm integral to plasma membrane 732 1
70008 Ace2 ACE2_MOUSE Q8R0I0
Angiotensin-converting enzyme 2 
precursor (EC 3.4.17.-) (ACE-
related carboxypeptidase) 
34 174 27 59272 ACE2 ACE2_HUMAN Q9BYF1 tm integral to plasma membrane 805 1
11432 Acp2 PPAL_MOUSE P24638
Lysosomal acid phosphatase 
precursor (EC 3.1.3.2) (LAP).
4 3 943 53 ACP2 PPAL_HUMAN P11117 tm integral to plasma membrane 423 2
11487 Adam10 ADA10_MOUSE O35598
ADAM 10 precursor (EC 3.4.24.81) 
(A disintegrin and metalloproteinase 
domain 10) (Mammalian disintegrin-
metalloprotease) (Kuzbanian 
protein homolog) (CD156c antigen).
3 2 1062 102 ADAM10 ADA10_HUMAN O14672 tm integral to plasma membrane 749 1
11522 Adh1 ADH1_MOUSE P00329
Alcohol dehydrogenase 1 (EC 
1.1.1.1) (Alcohol dehydrogenase A 
subunit) (ADH-A2).
10 24 208 126 ADH1C ADH1G_HUMAN P00326 tm cytoplasm 375 0
11532 Adh5 ADHX_MOUSE P28474
Alcohol dehydrogenase class-3 (EC 
1.1.1.1) 
6 4 704 128 ADH5 ADHX_HUMAN P11766 tm cytoplasm 374 0
69117 Adh6a A1L3C0_MOUSE A1L3C0 alcohol dehydrogenase 6A (class V) 11 12 364 - - - - tm - 375 0
11529 Adh7 ADH7_MOUSE Q64437
Alcohol dehydrogenase class 4 
mu/sigma chain (EC 1.1.1.1) 
3 2 973 131 ADH7 ADH7_HUMAN P40394 tm cytoplasm 374 0
23795 Agr2 AGR2_MOUSE O88312
Anterior gradient protein 2 homolog 
precursor (mAG-2) (AG-2) 
(Secreted cement gland protein 
XAG-2 homolog) (Protein Gob-4).
5 8 503 10551 AGR2 AGR2_HUMAN O95994 tm extracellular region 175 0
11648 Akp3 PPBI_MOUSE P24822
Intestinal alkaline phosphatase 
precursor (EC 3.1.3.1) (IAP).
28 137 32 248 ALPI PPBI_HUMAN P09923 tm anchored to plasma membrane 559 0
11650 Akp5 PPBE_MOUSE P24823
Embryonic alkaline phosphatase 
precursor (EC 3.1.3.1) (EAP).
58 4 9 5 2 5 0
ALPP | 
ALPPL2
PPB1_HUMAN P05187 tm anchored to plasma membrane 529 0
69748 Aldh16a1 A16A1_MOUSE Q571I9
aldehyde dehydrogenase 16 family, 
member A1
10 17 270 126133 ALDH16A1 A16A1_HUMAN Q8IZ83 tm - 802 0
11671 Aldh3a2 AL3A2_MOUSE P47740
Fatty aldehyde dehydrogenase (EC 
1.2.1.3) (Aldehyde dehydrogenase, 
microsomal) (Aldehyde 
dehydrogenase family 3 member 
A2) (Aldehyde dehydrogenase 10).
3 3 918 224 ALDH3A2 AL3A2_HUMAN P51648 tm integral to endoplasmic reticulum membrane 484 1
67689 Aldh3b1 AL3B1_MOUSE Q80VQ0
aldehyde dehydrogenase 3 family, 
member B1
17 23 218 221 ALDH3B1 AL3B1_HUMAN P43353 tm - 468 0
93835 Amn AMNLS_MOUSE Q99JB7 Amnionless protein precursor. 2 2 1127 81693 AMN AMNLS_HUMAN Q9BXJ7 tm integral to membrane 458 1
16790 Anpep AMPN_MOUSE P97449
Aminopeptidase N (EC 3.4.11.2) 
(mAPN) (Alanyl aminopeptidase) 
(Microsomal aminopeptidase) 
(Aminopeptidase M) (Membrane 
protein p161) (CD13 antigen).
54 961 6 290 ANPEP AMPN_HUMAN P15144 tm integral to plasma membrane 966 1
11767 Ap1m1 AP1M1_MOUSE P35585
AP-1 complex subunit mu-1 
(Adaptor-related protein complex 1 
mu-1 subunit) 
7 7 551 8907 AP1M1 AP1M1_HUMAN Q9BXS5 tm associated to membrane 423 0
71770 Ap2b1 AP2B1_MOUSE Q9DBG3
AP-2 complex subunit beta-1 
(Adapter-related protein complex 2 
beta-1 subunit) (Beta2-adaptin) 
(Beta-adaptin)
6 6 591 163 AP2B1 AP2B1_HUMAN P63010 tm associated to plasma membrane 937 0
11826 Aqp1 AQP1_MOUSE Q02013
Aquaporin-1 (AQP-1) (Aquaporin-
CHIP) 
3 20 239 358 AQP1 AQP1_HUMAN P29972 tm integral to plasma membrane 269 6  179
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11842 Arf3 ARF3_MOUSE P61205 ADP-ribosylation factor 3. 8 30 165 377 ARF3 ARF3_HUMAN P61204 tm anchored to Golgi membrane 181 0
70497 Arhgap17 RHG17_MOUSE Q3UIA2
Rho GTPase-activating protein 17 
(Rho-type GTPase-activating 
protein 17)
2 3 890 55114 ARHGAP17 RHG17_HUMAN Q68EM7 tm associated to plasma membrane 846 0
54208 Arl6ip1 AR6P1_MOUSE Q9JKW0
ADP-ribosylation factor-like protein 
6-interacting protein 1 (ARL-6- 
interacting protein 1) (Aip-1) 
(Protein TBX2).
2 3 923 23204 ARL6IP1 AR6P1_HUMAN Q15041 tm integral to membrane 203 4
54447 Asah2 ASAH2_MOUSE Q9JHE3
Neutral ceramidase (EC 3.5.1.23) 
(N-CDase) 
17 63 77 56624 ASAH2 ASAH2_HUMAN Q9NR71 tm integral to plasma membrane 756 1
11928 Atp1a1 AT1A1_MOUSE Q8VDN2
Sodium/potassium-transporting 
ATPase subunit alpha-1 precursor 
(EC 3.6.3.9) 
36 244 18 476 ATP1A1 AT1A1_HUMAN P05023 tm integral to membrane 1023 10
98660 Atp1a2 AT1A2_MOUSE Q6PIE5
Sodium/potassium-transporting 
ATPase subunit alpha-2 precursor 
(EC 3.6.3.9) 
3 5 656 477 ATP1A2 AT1A2_HUMAN P50993 tm integral to plasma membrane 1020 8
232975 Atp1a3 AT1A3_MOUSE Q6PIC6
Sodium/potassium-transporting 
ATPase subunit alpha-3 (EC 
3.6.3.9)
3 5 659 478 ATP1A3 AT1A3_HUMAN P13637 tm integral to plasma membrane 1013 8
11931 Atp1b1 AT1B1_MOUSE P14094 Sodium/potassium-transporting 
ATPase subunit beta-1 
8 35 144 481 ATP1B1 AT1B1_HUMAN P05026 tm basolateral plasma membrane 304 1
67972 Atp2b1 Q05CJ5_MOUSE Q05CJ5
ATPase, Ca++ transporting, plasma 
membrane 1
14 22 224 490 ATP2B1 AT2B1_HUMAN P20020 tm integral to plasma membrane 313 0
11941 Atp2b2 AT2B2_MOUSE Q9R0K7
Plasma membrane calcium-
transporting ATPase 2 (EC 3.6.3.8)  2 3 828 491 ATP2B2 AT2B2_HUMAN Q01814 tm integral to membrane 1198 8
381290 Atp2b4 Q32ME1_MOUSE Q32ME1
ATPase, Ca++ transporting, plasma 
membrane 4
2 3 893 493 ATP2B4 AT2B4_HUMAN P23634 tm integral to plasma membrane 1120 7
50769 Atp8a2 AT8A2_MOUSE P98200
Probable phospholipid-transporting 
ATPase IB (EC 3.6.3.1)
3 3 832 51761 ATP8A2 AT8A2_HUMAN Q9NTI2 tm integral to membrane 1148 8
54670 Atp8b1 Q6R964_MOUSE Q6R964 ATPase, class I, type 8B, member 1 24 48 108 5205 ATP8B1 AT8B1_HUMAN O43520 tm apical plasma membrane 1251 10
12018 Bak1 BAK_MOUSE O08734
Bcl-2 homologous antagonist/killer 
(Apoptosis regulator BAK).
2 2 1122 578 BAK1 BAK_HUMAN Q16611 tm mitochondrial outer membrane 208 3
192970 BC022224 DHR11_MOUSE Q3U0B3
Dehydrogenase/reductase SDR 
family member 11 precursor (EC 1.-
.-.-).
6 5 658 79154 MGC4172 DHR11_HUMAN Q6UWP2 tm extracellular region 260 1
230579 BC026682 F151A_MOUSE Q8QZW3 Protein FAM151A. 3 5 627 338094 FAM151A F151A_HUMAN Q8WW52 tm integral to membrane 608 1
27061 Bcap31 BAP31_MOUSE Q61335
B-cell receptor-associated protein 
31 (BCR-associated protein Bap31) 
(p28 Bap31).
4 3 922 10134 BCAP31 BAP31_HUMAN P51572 tm integral to plasma membrane 245 2
12215 Bsg BASI_MOUSE P18572
Basigin precursor (Basic 
immunoglobulin superfamily) 
(Membrane glycoprotein gp42)
8 19 242 682 BSG BASI_HUMAN P35613 tm integral to plasma membrane 389 1
12182 Bst1 BST1_MOUSE Q64277
ADP-ribosyl cyclase 2 precursor 
(EC 3.2.2.5) (Cyclic ADP-ribose 
hydrolase 2)
8 34 151 683 BST1 BST1_HUMAN Q10588 tm anchored to plasma membrane 311 1
108058 Camk2d KCC2D_MOUSE Q6PHZ2
Calcium/calmodulin-dependent 
protein kinase type II delta chain 
(EC 2.7.11.17) (CaM-kinase II delta 
chain) 
5 5 684 817 CAMK2D KCC2D_HUMAN Q13557 tm cytoplasm 499 0
12330 Canx CALX_MOUSE P35564 Calnexin precursor. 5 4 744 821 CANX CALX_HUMAN P27824 tm integral to endoplasmic reticulum membrane 591 1
12389 Cav1 CAV1_MOUSE P49817 Caveolin-1. 3 3 919 857 CAV1 CAV1_HUMAN Q03135 tm integral to plasma membrane 178 1
12469 Cct8 TCPQ_MOUSE P42932 T-complex protein 1 subunit theta 
(TCP-1-theta) (CCT-theta).
11 8 509 10694 CCT8 TCPQ_HUMAN P50990 tm cytoplasm 548 0
12476 Cd151 CD151_MOUSE O35566
CD151 antigen (Platelet-endothelial 
tetraspan antigen 3) 
2 2 1063 977 CD151 CD151_HUMAN P48509 tm integral to plasma membrane 253 4
12491 Cd36 CD36_MOUSE Q08857 Platelet glycoprotein 4 (Platelet 
glycoprotein IV) 
9 13 335 948 CD36 CD36_HUMAN P16671 tm integral to plasma membrane 472 2
12494 Cd38 CD38_MOUSE P56528
ADP-ribosyl cyclase 1 (EC 3.2.2.5) 
(Cyclic ADP-ribose hydrolase 1) 
4 6 584 952 CD38 CD38_HUMAN P28907 tm integral to plasma membrane 304 1
16423 Cd47 CD47_MOUSE Q61735
Leukocyte surface antigen CD47 
precursor (Integrin-associated 
protein) (IAP). 
2 2 975 961 CD47 CD47_HUMAN Q08722 tm integral to plasma membrane 303 5
12520 Cd81 CD81_MOUSE P35762
CD81 antigen (26 kDa cell surface 
protein TAPA-1) 
2 2 1123 975 CD81 CD81_HUMAN P60033 tm integral to plasma membrane 236 4
12521 Cd82 CD82_MOUSE P40237
CD82 antigen (Inducible membrane 
protein R2) (C33 antigen) (IA4).
3 11 400 3732 CD82 CD82_HUMAN P27701 tm integral to plasma membrane 266 4
12550 Cdh1 CADH1_MOUSE P09803 Epithelial cadherin precursor (E-
cadherin) 
3 5 649 999 CDH1 CADH1_HUMAN P12830 tm integral to plasma membrane 884 1
12557 Cdh17 CAD17_MOUSE Q9R100
Cadherin-17 precursor (Liver-
intestine cadherin)
11 45 117 1015 CDH17 CAD17_HUMAN Q12864 tm basolateral plasma membrane 827 1
26365 Ceacam1 CEAM1_MOUSE P31809
Carcinoembryonic antigen-related 
cell adhesion molecule 1 precursor 
(Biliary glycoprotein 1) (BGP-1) 
4 32 153 634 CEACAM1 CEAM1_HUMAN P13688 tm integral to plasma membrane 521 1
72431 Ceacam18 Q9D871_MOUSE Q9D871
CEA-related cell adhesion molecule 
1
7 5 626 - - - - tm - 376 1
71601 Ceacam20 Q80Y42_MOUSE Q80Y42 CEA-related cell adhesion molecule 
20
15 21 234 125931 CEACAM20 CEA20_HUMAN Q6UY09 tm integral to membrane 577 1
107934 Celsr3 CELR3_MOUSE Q91ZI0
Cadherin EGF LAG seven-pass G-
type receptor 3 precursor.
3 3 891 1951 CELSR3 CELR3_HUMAN Q9NYQ7 tm integral to plasma membrane 3301 7
67006 Cisd2 CISD2_MOUSE Q9CQB5
CDGSH iron sulfur domain-
containing protein 2 (MitoNEET-
related 1 protein)
2 2 1175 493856 CISD2 CISD2_HUMAN Q8N5K1 tm integral to endoplasmic reticulum membrane 135 1
12716 Ckmt1 KCRU_MOUSE P30275
Creatine kinase, ubiquitous 
mitochondrial precursor (EC 
2.7.3.2) (U- MtCK) (Acidic-type 
mitochondrial creatine kinase) (Mia-
CK).
5 8 496
548596, 
1159
CKMT1A, 
CKMT1B
KCRU_HUMAN P12532 tm anchored to mitochondrial inner membrane 418 0
99663 Clca6 Q6Q473_MOUSE Q6Q473
chloride channel calcium activated 
6
13 43 120 22802 CLCA4 Q14CN2_HUMAN Q14CN2 tm - 924 1
60363 Cldn15 CLD15_MOUSE Q9Z0S5 Claudin-15. 2 3 924 24146 CLDN15 CLD15_HUMAN P56746 tm integral to plasma membrane 227 4
12739 Cldn3 CLD3_MOUSE Q9Z0G9
Claudin-3 (Clostridium perfringens 
enterotoxin receptor 2) (CPE- 
receptor 2) (CPE-R 2).
3 9 458 1365 CLDN3 CLD3_HUMAN O15551 tm integral to plasma membrane 219 4
29876 Clic4 CLIC4_MOUSE Q9QYB1
Chloride intracellular channel 
protein 4 (mc3s5/mtCLIC).
6 4 750 25932 CLIC4 CLIC4_HUMAN Q9Y696 tm integral to membrane 253 0
216705 Clint1 EPN4_MOUSE Q99KN9
Clathrin interactor 1 (Epsin-4) 
(Epsin-related protein) (EpsinR) 
(Enthoprotin).
3 4 753 9685 CLINT1 EPN4_HUMAN Q14677 tm associated to Golgi membrane 631 0
212070 Clrn3 CLRN3_MOUSE Q8BHH8
Clarin-3 (Transmembrane protein 
12).
3 31 159 119467 CLRN3 CLRN3_HUMAN Q8NCR9 tm integral to membrane 226 4
94220 Cnnm4 CNNM4_MOUSE Q69ZF7
Metal transporter CNNM4 (Cyclin-
M4) (Ancient conserved domain- 
containing protein 4) (mACDP4).
2 1 1204 26504 CNNM4 CNNM4_HUMAN Q6P4Q7 tm integral to plasma membrane 771 4
23789 Coro1b COR1B_MOUSE Q9WUM3 Coronin-1B (Coronin-2). 8 9 439 57175 CORO1B COR1B_HUMAN Q9BR76 tm cytoskeleton 484 0
23790 Coro1c COR1C_MOUSE Q9WUM4 Coronin-1C (Coronin-3). 11 15 296 23603 CORO1C COR1C_HUMAN Q9ULV4 tm actin cytoskeleton 474 0
107684 Coro2a COR2A_MOUSE Q8C0P5 coronin, actin binding protein 2A 11 10 416 7464 CORO2A COR2A_HUMAN Q92828 tm - 524 0
12857 Cox4i1 COX41_MOUSE P19783
Cytochrome c oxidase subunit 4 
isoform 1, mitochondrial precursor 
4 8 482 1327 COX4I1 COX41_HUMAN P13073 tm integral to mitochondrial inner membrane 169 1
70568 Cpne3 CPNE3_MOUSE Q8BT60 Copine-3 (Copine III). 7 9 461 8895 CPNE3 CPNE3_HUMAN O75131 tm cytoplasm 533 0
12946 Cr1l CRRY_MOUSE Q64735 Complement regulatory protein Crry 
precursor (Protein p65).
3 3 879 1378 CR1 CR1_HUMAN P17927 tm integral to plasma membrane 483 1
13052 Cxadr CXAR_MOUSE P97792
Coxsackievirus and adenovirus 
receptor homolog precursor 
(mCAR) (CAR).
4 10 414 1525 CXADR CXAR_HUMAN P78310 tm basolateral plasma membrane 365 1
20430 Cyfip1 CYFP1_MOUSE Q7TMB8
Cytoplasmic FMR1-interacting 
protein 1 (Specifically Rac1-
associated protein 1) (Sra-1).
9 7 521 23191 CYFIP1 CYFP1_HUMAN Q7L576 tm cytoplasm 1253 0
13088 Cyp2b10 CP2BA_MOUSE P12791
Cytochrome P450 2B10 (EC 
1.14.14.1) (CYPIIB10)
10 9 445 1555 CYP2B6 CP2B6_HUMAN P20813 tm integral to endoplasmic reticulum membrane 500 1
72303 Cyp2c65 Q148B1_MOUSE Q148B1
cytochrome P450, family 2, 
subfamily c, polypeptide 65
8 8 513 1558 CYP2C8 CP2C8_HUMAN P10632 tm integral to endoplasmic reticulum membrane 490 1
27999 D6Wsu176e FAM3C_MOUSE Q91VU0 Protein FAM3C precursor. 5 4 802 10447 FAM3C FAM3C_HUMAN Q92520 tm extracellular region 227 1
13200 Ddost OST48_MOUSE O54734
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase 48 kDa 
subunit precursor (EC 2.4.1.119) 
6 3 880 1650 DDOST OST48_HUMAN P39656 tm integral to endoplasmic reticulum membrane 441 2
13002 Dnajc5 DNJC5_MOUSE P60904
DnaJ homolog subfamily C member 
5 (Cysteine string protein) (CSP).
3 9 459 80331 DNAJC5 DNJC5_HUMAN Q9H3Z4 tm anchored to melanosome membrane 198 0
13482 Dpp4 DPP4_MOUSE P28843
Dipeptidyl peptidase 4 (EC 3.4.14.5) 
(Dipeptidyl peptidase IV) (DPP IV)  33 107 45 1803 DPP4 DPP4_HUMAN P27487 tm integral to plasma membrane 760 1
214593 Duox2 A2AQ99_MOUSE A2AQ99 dual oxidase 2 18 24 209 50506 DUOX2 DUOX2_HUMAN Q9NRD8 tm apical plasma membrane 1517 6
66811 Duoxa2 DOXA2_MOUSE Q9D311 Dual oxidase maturation factor 2. 4 5 654 405753 DUOXA2 DOXA2_HUMAN Q1HG44 tm integral to endoplasmic reticulum membrane 320 5
13595 Ebp EBP_MOUSE P70245
3-beta-hydroxysteroid-
Delta(8),Delta(7)-isomerase (EC 
5.3.3.5) (Cholestenol Delta-
isomerase)
2 2 1171 10682 EBP EBP_HUMAN Q15125 tm integral to plasma membrane 230 5
13641 Efnb1 EFNB1_MOUSE P52795
Ephrin-B1 precursor (EPH-related 
receptor tyrosine kinase ligand 2) 
(LERK-2) 
2 2 1064 1947 EFNB1 EFNB1_HUMAN P98172 tm integral to plasma membrane 345 1
13809 Enpep AMPE_MOUSE P16406
Glutamyl aminopeptidase (EC 
3.4.11.7) (EAP) (Aminopeptidase A)
53 431 10 2028 ENPEP AMPE_HUMAN Q07075 tm apical plasma membrane 945 1
209558 Enpp3 ENPP3_MOUSE Q6DYE8
Ectonucleotide 
pyrophosphatase/phosphodiesteras
e family member 3 (E- NPP 3) 
(Phosphodiesterase I/nucleotide 
pyrophosphatase 3) 
26 112 44 5169 ENPP3 ENPP3_HUMAN O14638 tm integral to plasma membrane 874 1
72090 Entpd8 ENTP8_MOUSE Q8K0L2
Ectonucleoside triphosphate 
diphosphohydrolase 8 (EC 3.6.1.5) 
(E- NTPDase 8) (NTPDase 8) 
(NTPDase8).
5 14 310 377841 ENTPD8 ENTP8_HUMAN Q5MY95 tm integral to plasma membrane 497 2
244373 Erlin2 ERLN2_MOUSE Q8BFZ9
Erlin-2 (Endoplasmic reticulum lipid 
raft-associated protein 2) 
4 5 685 11160 ERLIN2 ERLN2_HUMAN O94905 tm integral to endoplasmic reticulum membrane 340 0
16456 F11r JAM1_MOUSE O88792
Junctional adhesion molecule A 
precursor (JAM-A) (Junctional 
adhesion molecule 1) (JAM-1) 
(CD321 antigen).
4 8 498 50848 F11R JAM1_HUMAN Q9Y624 tm integral to plasma membrane 300 1
14104 Fasn FAS_MOUSE P19096 Fatty acid synthase (EC 2.3.1.85)  30 31 158 2194 FASN FAS_HUMAN P49327 tm cytoplasm 2504 0
66437 Fis1 FIS1_MOUSE Q9CQ92 Mitochondrial fission 1 protein (Fis1 
homolog) 
2 1 1201 51024 FIS1 FIS1_HUMAN Q9Y3D6 tm membrane 152 1    180
Gene ID 
(mouse)
Gene Symbol (mouse)
Swissprot protein 
ID (mouse)
Swissprot 
protein AC 
(mouse)
Gene Description
Max Diff 
peptide
Avg Pep 
count
Rank order
Ortho 
Gene ID
Ortho Gene 
Symbol
Swissprot protein 
ID
Swissprot 
protein AC
Topology GO term
Protein 
length
Number 
of TM
14257 Flt4 VGFR3_MOUSE P35917
Vascular endothelial growth factor 
receptor 3 precursor (EC 2.7.10.1) 
(VEGFR-3) (Tyrosine-protein kinase 
receptor FLT4).
2 2 1065 2324 FLT4 VGFR3_HUMAN P35916 tm integral to plasma membrane 1363 1
14263 Fmo5 FMO5_MOUSE P97872
Dimethylaniline monooxygenase [N-
oxide-forming] 5 (EC 1.14.13.8)  6 5 650 2330 FMO5 FMO5_HUMAN P49326 tm integral to endoplasmic reticulum membrane 533 1
69976 Galk2 GALK2_MOUSE Q68FH4
N-acetylgalactosamine kinase (EC 
2.7.1.157) (GalNAc kinase) 
(Galactokinase 2).
2 2 1176 2585 GALK2 GALK2_HUMAN Q01415 tm cytoplasm 458 0
66569 Gdpd1 GDPD1_MOUSE Q9CRY7
Glycerophosphodiester 
phosphodiesterase domain-
containing protein 1 (EC 3.1.-.-) 
(Glycerophosphodiester 
phosphodiesterase 4).
4 3 925 284161 GDPD1 GDPD1_HUMAN Q8N9F7 tm integral to membrane 314 2
14583 Gfpt1 GFPT1_MOUSE P47856
Glucosamine--fructose-6-phosphate 
aminotransferase [isomerizing] 1 
(EC 2.6.1.16) (Glutamine:fructose 6 
phosphate amidotransferase 1) 
14 14 307 2673 GFPT1 GFPT1_HUMAN Q06210 tm cytoplasm 697 0
14598 Ggt1 GGT1_MOUSE Q60928
Gamma-glutamyltranspeptidase 1 
precursor (EC 2.3.2.2) (Gamma- 
glutamyltransferase 1)
14 127 36 2678 GGT1 GGT1_HUMAN P19440 tm integral to membrane 568 1
14678 Gnai2 GNAI2_MOUSE P08752
guanine nucleotide binding protein 
(G protein), alpha inhibiting 2
17 75 68 2771 GNAI2 GNAI2_HUMAN P04899 tm - 355 0
14679 Gnai3 GNAI3_MOUSE Q9DC51
Guanine nucleotide-binding protein 
G(k) subunit alpha (G(i) alpha-3).
16 68 72 2773 GNAI3 GNAI3_HUMAN P08754 tm anchored to plasma membrane 354 0
59290 Gpa33 GPA33_MOUSE Q9JKA5
Cell surface A33 antigen precursor 
(Glycoprotein A33) (mA33).
8 19 247 10223 GPA33 GPA33_HUMAN Q99795 tm integral to plasma membrane 319 1
14751 Gpi1 G6PI_MOUSE P06745
Glucose-6-phosphate isomerase 
(EC 5.3.1.9) (GPI) 
(Phosphoglucose isomerase) (PGI) 
(Phosphohexose isomerase) (PHI) 
(Neuroleukin) (NLK).
12 14 308 2821 GPI G6PI_HUMAN P06744 tm extracellular space 558 0
239853 Gpr128 GP128_MOUSE Q8BM96
Probable G-protein coupled 
receptor 128 precursor.
11 59 83 84873 GPR128 GP128_HUMAN Q96K78 tm integral to plasma membrane 785 8
625249 Gpx4 GPX41_MOUSE O70325
Phospholipid hydroperoxide 
glutathione peroxidase, 
mitochondrial precursor (EC 
1.11.1.12)
7 8 515 2879 GPX4 GPX4_HUMAN P36969 tm mitochondrial inner membrane 197 0
66790 Grtp1 GRTP1_MOUSE Q9D3N8
Growth hormone-regulated TBC 
protein 1 (TBC1 domain family 
member 6). 
4 3 887 79774 GRTP1 GRTP1_HUMAN Q5TC63 tm cytoplasm 359 0
14782 Gsr GSHR_MOUSE P47791
Glutathione reductase, 
mitochondrial precursor (EC 
1.8.1.7) (GRase) (GR).
4 3 829 2936 GSR GSHR_HUMAN P00390 tm mitochondrion 500 0
14917 Gucy2c GUC2C_MOUSE Q3UWA6
Heat-stable enterotoxin receptor 
precursor (EC 4.6.1.2) (STA 
receptor) (Intestinal guanylate 
cyclase) (GC-C). 
10 16 276 2984 GUCY2C GUC2C_HUMAN P25092 tm apical plasma membrane 1072 1
14933 Gyk GLPK_MOUSE Q64516
Glycerol kinase (EC 2.7.1.30) 
(ATP:glycerol 3-
phosphotransferase) 
(Glycerokinase) (GK).
3 3 920 2710 GK GLPK_HUMAN P32189 tm mitochondrial outer membrane 524 0
14960 H2-Aa HA2B_MOUSE P14434
H-2 class II histocompatibility 
antigen, A-B alpha chain precursor 
(IAalpha).
3 6 561 3117 HLA-DQA1 HA22_HUMAN P04226 tm integral to plasma membrane 256 1
14961 H2-Ab1 HB2A_MOUSE P14483
H-2 class II histocompatibility 
antigen, A beta chain precursor.
7 8 497 3120 HLA-DQB2 HB2X_HUMAN P05538 tm integral to plasma membrane 265 1
14964 H2-D1 HA11_MOUSE P01899
H-2 class I histocompatibility 
antigen, D-B alpha chain precursor 
(H- 2D(B)).
8 12 348 3107 HLA-C 1C01_HUMAN P30499 tm integral to plasma membrane 362 1
15000 H2-DMb2 2DMB_MOUSE P35737
histocompatibility 2, class II, locus 
Mb2
4 5 651 3109 HLA-DMB 2DMB_HUMAN P28068 tm integral to late endosome membrane 261 1
14980 H2-L Q31149_MOUSE Q31149 MHC class I-alpha 8 12 349 - - - - tm - 365 1
15006 H2-Q1 Q66JR0_MOUSE Q66JR0
histocompatibility 2, Q region locus 
1
2 3 881 - - - - tm - 341 1
110557 H2-Q6 P79568_MOUSE P79568
histocompatibility 2, Q region locus 
6
2 3 892 - - - - tm - 327 0
15018 H2-Q7 HA17_MOUSE P14429
histocompatibility 2, Q region locus 
7
2 3 882 - - - - tm integral to membrane 334 1
15043 H2-T3 HA1U_MOUSE P14433
histocompatibility 2, T region locus 
3
5 4 705 - - - - tm integral to membrane 361 1
27400 Hsd17b6 H17B6_MOUSE Q9R092
Hydroxysteroid 17-beta 
dehydrogenase 6 precursor (EC 
1.1.1.62) 
10 9 460 8630 HSD17B6 H17B6_HUMAN O14756 tm endoplasmic reticulum 317 0
15519 Hsp90aa1 HS90A_MOUSE P07901
Heat shock protein HSP 90-alpha 
(HSP 86) (Tumor-specific 
transplantation 86 kDa antigen) 
(TSTA).
24 46 113 3320 HSP90AA1 HS90A_HUMAN P07900 tm cytoplasm 733 0
15516 Hsp90ab1 HS90B_MOUSE P11499
Heat shock protein HSP 90-beta 
(HSP 84) (Tumor-specific 
transplantation 84 kDa antigen) 
(TSTA).
33 136 34 3326 HSP90AB1 HS90B_HUMAN P08238 tm cytoplasm 724 0
16004 Igf2r MPRI_MOUSE Q07113
Cation-independent mannose-6-
phosphate receptor precursor (CI 
Man-6-P receptor)
2 2 1066 3482 IGF2R MPRI_HUMAN P11717 tm integral to plasma membrane 2483 1
71927 Itfg1 TIP_MOUSE Q99KW9
T-cell immunomodulatory protein 
precursor (Protein TIP) (Integrin- 
alpha FG-GAP repeat-containing 
protein 1).
5 5 655 81533 ITFG1 TIP_HUMAN Q8TB96 tm integral to membrane 610 1
106581 Itfg3 ITFG3_MOUSE Q8C0Z1
integrin alpha FG-GAP repeat 
containing 3
2 3 928 83986 ITFG3 ITFG3_HUMAN Q9H0X4 tm integral to membrane 555 1
16400 Itga3 ITA3_MOUSE Q62470
Integrin alpha-3 precursor 
(Galactoprotein B3) (GAPB3) (VLA-
3 alpha chain) 
2 3 883 3675 ITGA3 ITA3_HUMAN P26006 tm integral to plasma membrane 1053 2
16403 Itga6 ITA6_MOUSE Q61739
Integrin alpha-6 precursor (VLA-6) 
(CD49 antigen-like family member 
F) (CD49f antigen) [Contains: 
Integrin alpha-6 heavy chain; 
Integrin alpha-6 light chain].
3 4 745 3655 ITGA6 ITA6_HUMAN P23229 tm integral to plasma membrane 1091 1
16412 Itgb1 ITB1_MOUSE P09055
Integrin beta-1 precursor 
(Fibronectin receptor subunit beta) 
(Integrin VLA-4 subunit beta) (CD29 
antigen).
5 4 706 3688 ITGB1 ITB1_HUMAN P05556 tm integral to plasma membrane 798 1
545156 Kalrn KALRN_MOUSE A2CG49
Kalirin (EC 2.7.11.1) (Protein Duo) 
(Serine/threonine kinase with Dbl- 
and pleckstrin homology domain).
9 23 215 8997 KALRN KALRN_HUMAN O60229 tm actin cytoskeleton 2964 0
16548 Khk KHK_MOUSE P97328
Ketohexokinase (EC 2.7.1.3) 
(Hepatic fructokinase).
6 8 510 3795 KHK KHK_HUMAN P50053 tm cytoplasm 298 0
385643 Kng2K N G 1 _MOUSE O08677 kininogen 2 4 3 835 3827 KNG1 KNG1_HUMAN P01042 tm extracellular region 661 0
16783 Lamp1 LAMP1_MOUSE P11438
Lysosome-associated membrane 
glycoprotein 1 precursor (LAMP-1) 
(Lysosomal membrane glycoprotein 
A) 
4 9 446 3916 LAMP1 LAMP1_HUMAN P11279 tm integral to lysosomal membrane 406 1
16784 Lamp2 LAMP2_MOUSE P17047
Lysosome-associated membrane 
glycoprotein 2 precursor (LAMP-2) 
4 6 585 3920 LAMP2 LAMP2_HUMAN P13473 tm integral to plasma membrane 415 1
16818 Lck LCK_MOUSE P06240
Proto-oncogene tyrosine-protein 
kinase LCK (EC 2.7.10.2) 
(Lymphocyte cell-specific protein-
tyrosine kinase) (p56-LCK) (LSK).
2 2 1067 3932 LCK LCK_HUMAN P06239 tm anchored to plasma membrane 509 0
226413 Lct Q3TZ78_MOUSE Q3TZ78 lactase 47 251 15 3938 LCT LPH_HUMAN P09848 tm apical plasma membrane 1220 0
16828 Ldha LDHA_MOUSE P06151
L-lactate dehydrogenase A chain 
(EC 1.1.1.27) (LDH-A) 
16 52 98 3939 LDHA LDHA_HUMAN P00338 tm cytoplasm 332 0
70361 Lman1 LMAN1_MOUSE Q9D0F3
Protein ERGIC-53 precursor (ER-
Golgi intermediate compartment 53 
kDa protein) (Lectin mannose-
binding 1) (p58).
4 3 889 3998 LMAN1 LMAN1_HUMAN P49257 tm integral to endoplasmic reticulum membrane 517 1
66890 Lman2 LMAN2_MOUSE Q9DBH5
Vesicular integral-membrane 
protein VIP36 precursor (Lectin 
mannose- binding 2).
4 3 888 10960 LMAN2 LMAN2_HUMAN Q12907 tm integral to ER-Golgi intermediate compartment  358 1
231876 Lmtk2 LMTK2_MOUSE Q3TYD6
Serine/threonine-protein kinase 
LMTK2 precursor (EC 2.7.11.1) 
(Lemur tyrosine kinase 2) (Brain-
enriched kinase).
2 2 1182 22853 LMTK2 LMTK2_HUMAN Q8IWU2 tm integral to membrane 1471 2
16971 Lrp1 LRP1_MOUSE Q91ZX7
Prolow-density lipoprotein receptor-
related protein 1 precursor (LRP) 
(Alpha-2-macroglobulin receptor) 
(A2MR) 
8 6 586 4035 LRP1 LRP1_HUMAN Q07954 tm integral to plasma membrane 4545 1
17113 M6pr MPRD_MOUSE P24668
Cation-dependent mannose-6-
phosphate receptor precursor (CD 
Man-6-P receptor) 
5 6 587 4074 M6PR MPRD_HUMAN P20645 tm integral to plasma membrane 278 1
17161 Maoa AOFA_MOUSE Q64133
Amine oxidase [flavin-containing] A 
(EC 1.4.3.4) (Monoamine oxidase 
type A) (MAO-A).
10 14 317 4128 MAOA AOFA_HUMAN P21397 tm integral to mitochondrial outer membrane 526 0
26396 Map2k2 MP2K2_MOUSE Q63932
Dual specificity mitogen-activated 
protein kinase kinase 2 (EC 
2.7.12.2)
6 8 504 5605 MAP2K2 MP2K2_HUMAN P36507 tm cytoplasm 401 0
26420 Mapk9 MK09_MOUSE Q9WTU6 mitogen-activated protein kinase 9 2 3 921 5601 MAPK9 MK09_HUMAN P45984 tm - 423 0
17287 Mep1a MEP1A_MOUSE P28825
Meprin A subunit alpha precursor 
(EC 3.4.24.18) (Endopeptidase-2) 
(MEP-1).
11 35 145 4224 MEP1A MEP1A_HUMAN Q16819 tm integral to plasma membrane 747 1
17288 Mep1b MEP1B_MOUSE Q61847
Meprin A subunit beta precursor 
(EC 3.4.24.18) (Endopeptidase-2).
23 204 23 4225 MEP1B MEP1B_HUMAN Q16820 tm integral to plasma membrane 704 1
17380 Mme NEP_MOUSE Q61391
Neprilysin (EC 3.4.24.11) (Neutral 
endopeptidase 24.11)
39 175 26 4311 MME NEP_HUMAN P08473 tm integral to plasma membrane 750 1
233549 Mogat2 MOGT2_MOUSE Q80W94
2-acylglycerol O-acyltransferase 2 
(EC 2.3.1.22) (Monoacylglycerol O- 
acyltransferase 2) 
5 5 660 80168 MOGAT2 MOGT2_HUMAN Q3SYC2 tm integral to endoplasmic reticulum membrane 334 1
67247 Mosc2 MOSC2_MOUSE Q922Q1
MOSC domain-containing protein 2, 
mitochondrial precursor (EC 1.-.-.-).
6 6 605 54996 MOSC2 MOSC2_HUMAN Q969Z3 tm associated to mitochondrial outer membrane 338 1  181
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69826 Ms4a10 M4A10_MOUSE Q99N03
Membrane-spanning 4-domains 
subfamily A member 10.
5 14 318 341116 MS4A10 M4A10_HUMAN Q96PG2 tm integral to membrane 267 4
17709 mt-Co2 COX2_MOUSE P00405
Cytochrome c oxidase subunit 2 
(Cytochrome c oxidase polypeptide 
II).
2 1 1197 4513 MT-CO2 COX2_HUMAN P00403 tm integral to mitochondrial inner membrane 227 2
17063 Muc13 MUC13_MOUSE P19467
Mucin-13 precursor (MUC-13) (Cell 
surface antigen 114/A10) 
(Lymphocyte antigen 64).
13 219 22 56667 MUC13 MUC13_HUMAN Q9H3R2 tm integral to plasma membrane 573 1
666339 Muc3 Q6PDD8_MOUSE Q6PDD8 mucin 3, intestinal 8 16 284 140453
MUC17 | 
MUC3A
MUC17_HUMAN Q685J3 tm anchored to plasma membrane 275 1
72040 Mupcdh MUCDL_MOUSE Q8VHF2
Mucin and cadherin-like protein 
precursor (Mu-protocadherin). 
13 100 51 53841 MUPCDH MUCDL_HUMAN Q9HBB8 tm integral to plasma membrane 831 1
17922 Myo7b MYO7B_MOUSE Q99MZ6 Myosin-VIIb. 108 733 8 4648 MYO7B MYO7B_HUMAN Q6PIF6 tm cytoskeleton 2113 0
381204 Naaladl1 NALDL_MOUSE Q7M758
N-acetylated-alpha-linked acidic 
dipeptidase-like protein (EC 
3.4.17.21) (NAALADase L).
26 101 50 10004 NAALADL1 NALDL_HUMAN Q9UQQ1 tm apical plasma membrane 745 1
94181 Nans Q99J77_MOUSE Q99J77
N-acetylneuraminic acid synthase 
(sialic acid synthase)
2 2 1083 54187 NANS SIAS_HUMAN Q9NR45 tm cytoplasm 359 0
59287 Ncstn NICA_MOUSE P57716 Nicastrin precursor. 6 7 531 23385 NCSTN NICA_HUMAN Q92542 tm integral to plasma membrane 708 1
101613 Nlrp6 NALP6_MOUSE Q91WS2
NACHT, LRR and PYD domains-
containing protein 6 (PYRIN-
containing APAF1-like protein 5-
like).
12 11 383 171389 NLRP6 NALP6_HUMAN P59044 tm cytoplasm 869 0
18145 Npc1 NPC1_MOUSE O35604 Niemann-Pick C1 protein precursor. 2 6 562 4864 NPC1 NPC1_HUMAN O15118 tm integral to plasma membrane 1278 12
237636 Npc1l1 NPCL1_MOUSE Q6T3U4
Niemann-Pick C1-like protein 1 
precursor.
32 142 29 29881 NPC1L1 NPCL1_HUMAN Q9UHC9 tm apical plasma membrane 1333 13
20320 Nptn NPTN_MOUSE P97300
Neuroplastin precursor (Stromal cell-
derived receptor 1) (SDR-1).
3 4 708 27020 NPTN NPTN_HUMAN Q9Y639 tm integral to plasma membrane 281 1
18300 Oit1 FAM3D_MOUSE P97805
Protein FAM3D precursor 
(Oncoprotein-induced protein 1) 
(Protein EF- 7).
2 4 800 131177 FAM3D FAM3D_HUMAN Q96BQ1 tm extracellular region 223 1
330962 Ostb OSTB_MOUSE Q80WK2
Organic solute transporter subunit 
beta (OST-beta).
2 2 1183 123264 OSTbeta OSTB_HUMAN Q86UW2 tm basolateral plasma membrane 128 1
69602 Otop3O T O P 3 _MOUSE Q80UF9 Otopetrin-3. 2 2 1079 347741 OTOP3 OTOP3_HUMAN Q7RTS5 tm integral to membrane 577 12
18438 P2rx4 P2RX4_MOUSE Q9JJX6
P2X purinoceptor 4 (P2X4) (ATP 
receptor) (Purinergic receptor).
8 8 499 5025 P2RX4 P2RX4_HUMAN Q99571 tm integral to plasma membrane 388 2
70584 Pak4 PAK4_MOUSE Q8BTW9
Serine/threonine-protein kinase 
PAK 4 (EC 2.7.11.1) (p21-activated 
kinase 4) (PAK-4).
2 2 1081 10298 PAK4 PAK4_HUMAN O96013 tm Golgi apparatus 593 0
268663 Pcdh24 Q3UN77_MOUSE Q3UN77 protocadherin 24 28 241 19 54825 PCDH24 PCD24_HUMAN Q9BYE9 tm apical plasma membrane 1308 1
71853 Pdia6 PDIA6_MOUSE Q922R8
Protein disulfide-isomerase A6 
precursor (EC 5.3.4.1) (Thioredoxin 
domain-containing protein 7).
2 2 1126 10130 PDIA6 PDIA6_HUMAN Q15084 tm endoplasmic reticulum lumen 440 0
224020 Pi4ka Q6DIC7_MOUSE Q6DIC7
phosphatidylinositol 4-kinase, 
catalytic, alpha polypeptide
6 6 607 5297 PI4KA PI4KA_HUMAN P42356 tm Golgi-associated vesicle 2044 0
18719 Pip5k1b PI51B_MOUSE P70181 
Phosphatidylinositol-4-phosphate 5-
kinase type-1 beta (EC 2.7.1.68)
2 2 1172 8395 PIP5K1B PI51B_HUMAN O14986 tm associated to membrane 539 0
56460 Pkp3 PKP3_MOUSE Q9QY23 Plakophilin-3. 3 4 785 11187 PKP3 PKP3_HUMAN Q9Y446 tm cytoplasm 797 0
665270 Plb1 PLB1_MOUSE Q3TTY0
Phospholipase B1, membrane-
associated precursor 
(Phospholipase B) (Phospholipase 
B/lipase) (PLB/LIP)
5 15 291 151056 PLB1 PLB1_HUMAN Q6P1J6 tm apical plasma membrane 1478 1
72287 Plekhf1 PKHF1_MOUSE Q3TB82
Pleckstrin homology domain-
containing family F member 1 (PH 
domain- containing family F 
member 1)
2 2 1082 79156 PLEKHF1 PKHF1_HUMAN Q96S99 tm cytoplasm 279 0
22038 Plscr1 PLS1_MOUSE Q9JJ00
Phospholipid scramblase 1 (PL 
scramblase 1)
3 12 356 5359 PLSCR1 PLS1_HUMAN O15162 tm integral to plasma membrane 328 0
19012 Ppap2a LPP1_MOUSE Q61469
Lipid phosphate phosphohydrolase 
1 (EC 3.1.3.4) (Phosphatidic acid 
phosphatase 2a)
5 8 500 8611 PPAP2A LPP1_HUMAN O14494 tm integral to plasma membrane 283 6
50784 Ppap2c LPP2_MOUSE Q9DAX2
Lipid phosphate phosphohydrolase 
2 (EC 3.1.3.4) (Phosphatidic acid 
phosphatase 2c) (PAP-2c)
4 6 590 8612 PPAP2C LPP2_HUMAN O43688 tm integral to membrane 276 6
106564 Ppcs PPCS_MOUSE Q8VDG5
phosphopantothenoylcysteine 
synthetase
7 5 683 79717 PPCS PPCS_HUMAN Q9HAB8 tm - 311 0
19035 Ppib PPIB_MOUSE P24369
Peptidyl-prolyl cis-trans isomerase 
B precursor (EC 5.2.1.8) (PPIase) 
(Rotamase) 
2 1 1198 5479 PPIB PPIB_HUMAN P23284 tm integral to endoplasmic reticulum membrane 208 1
110854 Ppp2r4 PTPA_MOUSE P58389
Serine/threonine-protein 
phosphatase 2A regulatory subunit 
B' 
5 8 514 5524 PPP2R4 PTPA_HUMAN Q15257 tm cytoplasm 323 0
108099 Prkag2 AAKG2_MOUSE Q91WG5
5'-AMP-activated protein kinase 
subunit gamma-2 (AMPK gamma-2 
chain) (AMPK gamma2).
5 6 592 51422 PRKAG2 AAKG2_HUMAN Q9UGJ0 tm cytoplasm 566 0
19146 Prss7 ENTK_MOUSE P97435
Enteropeptidase (EC 3.4.21.9) 
(Enterokinase) (Serine protease 7)
4 11 379 5651 PRSS7 ENTK_HUMAN P98073 tm apical plasma membrane 1069 1
19164 Psen1 PSN1_MOUSE P49769
Presenilin-1 (EC 3.4.23.-) (PS-1) 
(Protein S182)
2 5 652 5663 PSEN1 PSN1_HUMAN P49768 tm integral to plasma membrane 467 9
17463 Psmd7 PSD7_MOUSE P26516
26S proteasome non-ATPase 
regulatory subunit 7 (26S 
proteasome regulatory subunit 
rpn8) 
6 7 544 5713 PSMD7 PSD7_HUMAN P51665 tm cytosol 321 0
19243 Ptp4a1 TP4A1_MOUSE Q63739
Protein tyrosine phosphatase type 
IVA 1 (EC 3.1.3.48) 
5 4 707 7803 PTP4A1 TP4A1_HUMAN Q93096 tm anchored to plasma membrane 173 0
19264 Ptprc CD45_MOUSE P06800
Leukocyte common antigen 
precursor (EC 3.1.3.48) (L-CA) 
(Lymphocyte antigen 5) (Ly-5) 
(T200) (CD45 antigen)
2 3 945 5788 PTPRC CD45_HUMAN P08575 tm integral to plasma membrane 1291 2
108705 Pttg1ip PTTG_MOUSE Q8R143
Pituitary tumor-transforming gene 1 
protein-interacting protein precursor 
2 4 752 754 PTTG1IP PTTG_HUMAN P53801 tm integral to nuclear membrane 174 2
19330 Rab18 RAB18_MOUSE P35293 Ras-related protein Rab-18. 7 11 401 22931 RAB18 RAB18_HUMAN Q9NP72 tm anchored to plasma membrane 206 0
235442 Rab8b RAB8B_MOUSE P61028 Ras-related protein Rab-8B. 10 18 251 51762 RAB8B RAB8B_HUMAN Q92930 tm anchored to plasma membrane 207 0
19353 Rac1 RAC1_MOUSE P63001
Ras-related C3 botulinum toxin 
substrate 1 precursor (p21-Rac1).
9 27 187 5879 RAC1 RAC1_HUMAN P63000 tm anchored to plasma membrane 192 0
13476 Reep5 REEP5_MOUSE Q60870
Receptor expression-enhancing 
protein 5 (Polyposis locus protein 1 
homolog) (TB2 protein homolog) 
(GP106).
2 2 1170 7905 REEP5 REEP5_HUMAN Q00765 tm integral to membrane 185 2
70335 Reep6 REEP6_MOUSE Q9JM62 
Receptor expression-enhancing 
protein 6 (Polyposis locus protein 1- 
like 1) (TB2 protein-like 1)
2 6 606 92840 REEP6 REEP6_HUMAN Q96HR9 tm integral to membrane 201 3
69581 Rhou RHOU_MOUSE Q9EQT3
Rho-related GTP-binding protein 
RhoU (Wnt-1 responsive Cdc42 
homolog 1) (WRCH-1) (Rho 
GTPase-like protein ARHU).
3 2 1078 58480 RHOU RHOU_HUMAN Q7L0Q8 tm anchored to plasma membrane 261 0
103963 Rpn1 RPN1_MOUSE Q91YQ5
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 
1 precursor (EC 2.4.1.119) 
4 3 834 6184 RPN1 RPN1_HUMAN P04843 tm integral to endoplasmic reticulum membrane 608 1
20014 Rpn2 RPN2_MOUSE Q9DBG6
Dolichyl-diphosphooligosaccharide--
protein glycosyltransferase subunit 
2 precursor (EC 2.4.1.119) 
3 2 1068 6185 RPN2 RPN2_HUMAN P04844 tm integral to endoplasmic reticulum membrane 631 3
20130 Rras RRAS_MOUSE P10833
Ras-related protein R-Ras 
precursor (p23).
6 13 336 6237 RRAS RRAS_HUMAN P10301 tm anchored to plasma membrane 218 0
20168 Rtn3 RTN3_MOUSE Q9ES97 Reticulon-3. 2 4 782 10313 RTN3 RTN3_HUMAN O95197 tm integral to endoplasmic reticulum membrane 964 3
83493 Sacm1l SAC1_MOUSE Q9EP69
Phosphatidylinositide phosphatase 
SAC1 (EC 3.1.3.-) (Suppressor of 
actin mutations 1-like protein).
2 2 1180 22908 SACM1L SAC1_HUMAN Q9NTJ5 tm integral to endoplasmic reticulum membrane 587 2
107767 Scamp1 SCAM1_MOUSE Q8K021
Secretory carrier-associated 
membrane protein 1 (Secretory 
carrier membrane protein 1).
2 2 1181 9522 SCAMP1 SCAM1_HUMAN O15126 tm integral to membrane 338 4
12492 Scarb2 SCRB2_MOUSE O35114
Lysosome membrane protein 2 
(Lysosome membrane protein II) 
(LIMP II) (Scavenger receptor class 
B member 2)
3 2 974 950 SCARB2 SCRB2_HUMAN Q14108 tm integral to lysosomal membrane 478 2
20333 Sec22b SC22B_MOUSE O08547
Vesicle-trafficking protein SEC22b 
(SEC22 vesicle-trafficking protein 
homolog B) 
4 3 830 9554 SEC22B SC22B_HUMAN O75396 tm integral to endoplasmic reticulum membrane 215 1
27054 Sec23b SC23B_MOUSE Q9D662
Protein transport protein Sec23B 
(SEC23-related protein B).
11 12 363 10483 SEC23B SC23B_HUMAN Q15437 tm COPII vesicle coat 767 0
77371 Sec24a SC24A_MOUSE Q3U2P1
Protein transport protein Sec24A 
(SEC24-related protein A).
10 11 382 10802 SEC24A SC24A_HUMAN O95486 tm COPII vesicle coat 1090 0
20703 Serpina1d A1AT1_MOUSE Q00897
Alpha-1-antitrypsin 1-4 precursor 
(Serine protease inhibitor 1-4) 
(Alpha-1 protease inhibitor 4).
2 2 1071 5265 SERPINA1 A1AT_HUMAN P01009 tm extracellular region 413 0
66222 Serpinb1a ILEUA_MOUSE Q9D154
Leukocyte elastase inhibitor A 
(Serine protease inhibitor EIA) 
(Serpin B1a).
15 25 202 1992 SERPINB1 ILEU_HUMAN P30740 tm cytoplasm 379 0
14057 Sfxn1 SFXN1_MOUSE Q99JR1 Sideroflexin-1. 3 3 944 94081 SFXN1 SFXN1_HUMAN Q9H9B4 tm integral to mitochondrial inner membrane 322 4
20397 Sgpl1 SGPL1_MOUSE Q8R0X7
Sphingosine-1-phosphate lyase 1 
(EC 4.1.2.27) (SP-lyase) (mSPL) 
(Sphingosine-1-phosphate 
aldolase).
2 3 946 8879 SGPL1 SGPL1_HUMAN O95470 tm integral to endoplasmic reticulum membrane 568 1
20494 Slc10a2 NTCP2_MOUSE P70172
Ileal sodium/bile acid cotransporter 
(Ileal Na(+)/bile acid cotransporter) 
(Na(+)-dependent ileal bile acid 
transporter)
5 11 389 6555 SLC10A2 NTCP2_HUMAN Q12908 tm apical plasma membrane 348 8
20496 Slc12a2 S12A2_MOUSE P55012
Solute carrier family 12 member 2 
(Bumetanide-sensitive sodium- 
(potassium)-chloride cotransporter 
1) (Basolateral Na-K-Cl symporter).
4 4 746 6558 SLC12A2 S12A2_HUMAN P55011 tm integral to plasma membrane 1205 12
20500 Slc13a2 S13A2_MOUSE Q9ES88
Solute carrier family 13 member 2 
(Renal sodium/dicarboxylate 
cotransporter) (Na(+)/dicarboxylate 
cotransporter 1) (NaDC-1).
10 29 168 9058 SLC13A2 S13A2_HUMAN Q13183 tm integral to plasma membrane 586 13  182
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56643 Slc15a1 S15A1_MOUSE Q9JIP7
Solute carrier family 15 member 1 
(Peptide transporter 1) 
(Oligopeptide transporter, small 
intestine isoform) (Intestinal 
H(+)/peptide cotransporter) (Proton-
coupled dipeptide cotransporter).
20 92 58 6564 SLC15A1 S15A1_HUMAN P46059 tm integral to plasma membrane 709 9
20501 Slc16a1 MOT1_MOUSE P53986
Monocarboxylate transporter 1 
(MCT 1) (Solute carrier family 16 
member 1).
3 8 501 6566 SLC16A1 MOT1_HUMAN P53985 tm integral to plasma membrane 493 11
20510 Slc1a1 EAA3_MOUSE P51906
Excitatory amino acid transporter 3 
(Sodium-dependent 
glutamate/aspartate transporter 3) 
(Excitatory amino-acid carrier 1) 
(Solute carrier family 1 member 1).
2 2 1069 6505 SLC1A1 EAA3_HUMAN P43005 tm integral to plasma membrane 523 9
20514 Slc1a5 AAAT_MOUSE P51912
Neutral amino acid transporter B(0) 
(ATB(0)) (Sodium-dependent 
neutral amino acid transporter type 
2)
2 1 1199 6510 SLC1A5 AAAT_HUMAN Q15758 tm integral to plasma membrane 553 9
20520 Slc22a5 S22A5_MOUSE Q9Z0E8
Solute carrier family 22 member 5 
(Organic cation/carnitine transporter 
2) (High-affinity sodium-dependent 
carnitine cotransporter).
5 5 681 6584 SLC22A5 S22A5_HUMAN O76082 tm integral to plasma membrane 557 11
20522 Slc23a1 S23A1_MOUSE Q9Z2J0
Solute carrier family 23 member 1 
(Sodium-dependent vitamin C 
transporter 1) (Na(+)/L-ascorbic 
acid transporter 1) (Yolk sac 
permease-like molecule 3).
5 4 747 9963 SLC23A1 S23A1_HUMAN Q9UHI7 tm integral to plasma membrane 605 11
13358 Slc25a1 Q3TDH6_MOUSE Q3TDH6
solute carrier family 25 
(mitochondrial carrier, citrate 
transporter), member 1
3 4 781 6576 SLC25A1 TXTP_HUMAN P53007 tm integral to mitochondrial inner membrane 311 0
27376 Slc25a10 DIC_MOUSE Q9QZD8
Mitochondrial dicarboxylate carrier 
(Solute carrier family 25 member 
10).
2 2 1073 1468 SLC25A10 DIC_HUMAN Q9UBX3 tm integral to mitochondrial outer membrane 287 0
18674 Slc25a3 MPCP_MOUSE Q8VEM8
Phosphate carrier protein, 
mitochondrial precursor (Phosphate 
transport protein) (PTP) (Solute 
carrier family 25 member 3).
6 6 604 5250 SLC25A3 MPCP_HUMAN Q00325 tm integral to plasma membrane 357 2
13521 Slc26a2 S26A2_MOUSE Q62273
Sulfate transporter (Diastrophic 
dysplasia protein homolog) (Solute 
carrier family 26 member 2) (ST-
OB).
2 5 680 1836 SLC26A2 S26A2_HUMAN P50443 tm integral to plasma membrane 739 9
13487 Slc26a3 S26A3_MOUSE Q9WVC8
Chloride anion exchanger (Down-
regulated in adenoma) (Protein 
DRA) (Solute carrier family 26 
member 3).
2 5 679 1811 SLC26A3 S26A3_HUMAN P40879 tm integral to plasma membrane 757 11
171429 Slc26a6 Q812E2_MOUSE Q812E2 solute carrier family 26, member 6 14 54 93 65010 SLC26A6 S26A6_HUMAN Q9BXS9 tm integral to membrane 735 9
26458 Slc27a2 S27A2_MOUSE O35488
Very long-chain acyl-CoA 
synthetase (EC 6.2.1.-) (VLACS) 
(VLCS) (EC 6.2.1.3) (Fatty acid 
transport protein 2)
8 7 545 11001 SLC27A2 S27A2_HUMAN O14975 tm integral to endoplasmic reticulum membrane 620 2
26569 Slc27a4 S27A4_MOUSE Q91VE0
Long-chain fatty acid transport 
protein 4 (EC 6.2.1.-) (Fatty acid 
transport protein 4) (FATP-4)
3 3 947 10999 SLC27A4 S27A4_HUMAN Q6P1M0 tm integral to plasma membrane 643 2
434203 Slc28a1 Q6P8I9_MOUSE Q6P8I9
solute carrier family 28 (sodium-
coupled nucleoside transporter), 
member 1
5 6 608 9154 SLC28A1 S28A1_HUMAN O00337 tm integral to plasma membrane 648 10
269346 Slc28a2 S28A2_MOUSE O88627
Sodium/nucleoside cotransporter 2 
(Na(+)/nucleoside cotransporter 2) 
(Sodium-coupled nucleoside 
transporter 2) 
6 9 447 9153 SLC28A2 S28A2_HUMAN O43868 tm integral to plasma membrane 660 11
56485 Slc2a5 GTR5_MOUSE Q9WV38
Solute carrier family 2, facilitated 
glucose transporter member 5 
(Glucose transporter type 5, small 
intestine) (GLUT-5) (Fructose 
transporter).
5 13 337 6518 SLC2A5 GTR5_HUMAN P22732 tm integral to plasma membrane 501 12
435818 Slc2a7 GTR7_MOUSE P0C6A1
Solute carrier family 2, facilitated 
glucose transporter member 7 
(Glucose transporter type 7) (GLUT-
7).
3 6 564 155184 SLC2A7 GTR7_HUMAN Q6PXP3 tm integral to membrane 513 10
117591 Slc2a9 Q99JJ2_MOUSE Q99JJ2
solute carrier family 2 (facilitated 
glucose transporter), member 9
4 12 367 56606 SLC2A9 GTR9_HUMAN Q9NRM0 tm integral to plasma membrane 416 10
226781 Slc30a10 ZNT10_MOUSE Q3UVU3
Zinc transporter 10 (ZnT-10) 
(Solute carrier family 30 member 
10).
7 11 384 55532 SLC30A10 ZNT10_HUMAN Q6XR72 tm integral to membrane 470 6
20529 Slc31a1 COPT1_MOUSE Q8K211
High affinity copper uptake protein 1 
(Copper transporter 1) (CTR1) 
(Solute carrier family 31 member 1).
2 2 1070 1317 SLC31A1 COPT1_HUMAN O15431 tm integral to plasma membrane 196 3
20531 Slc34a2 NPT2B_MOUSE Q9DBP0
Sodium-dependent phosphate 
transport protein 2B (Sodium-
phosphate transport protein 2B) 
11 35 146 10568 SLC34A2 NPT2B_HUMAN O95436 tm apical plasma membrane 697 9
72022 Slc35f2 S35F2_MOUSE Q7TML3 Solute carrier family 35 member F2. 3 11 381 54733 SLC35F2 S35F2_HUMAN Q8IXU6 tm integral to membrane 375 9
215335 Slc36a1 S36A1_MOUSE Q8K4D3
Proton-coupled amino acid 
transporter 1 (Proton/amino acid 
transporter 1) (Solute carrier family 
36 member 1).
2 6 593 206358 SLC36A1 S36A1_HUMAN Q7Z2H8 tm integral to plasma membrane 475 11
56857 Slc37a2 SPX2_MOUSE Q9WU81
Sugar phosphate exchanger 2 
(cAMP-inducible protein 2) (Solute 
carrier family 37 member 2).
3 2 1074 219855 SLC37A2 SPX2_HUMAN Q8TED4 tm integral to membrane 501 12
72027 Slc39a4 S39A4_MOUSE Q78IQ7
Zinc transporter ZIP4 precursor (Zrt-
and Irt-like protein 4) (ZIP-4) (Solute 
carrier family 39 member 4) 
(Activated in W/Wv mouse stomach 
2) (mAWMS2).
4 13 329 55630 SLC39A4 S39A4_HUMAN Q6P5W5 tm integral to plasma membrane 660 6
20532 Slc3a1 O55093_MOUSE O55093 solute carrier family 3, member 1 23 62 79 6519 SLC3A1 SLC31_HUMAN Q07837 tm integral to plasma membrane 685 1
17254 Slc3a2 4F2_MOUSE P10852
4F2 cell-surface antigen heavy 
chain (4F2hc).
17 27 186 6520 SLC3A2 4F2_HUMAN P08195 tm integral to plasma membrane 526 1
215113 Slc43a2 LAT4_MOUSE Q8CGA3 Large neutral amino acids transporte 2 4 787 124935 SLC43A2 LAT4_HUMAN Q8N370 tm integral to membrane 568 12
100434 Slc44a1 CTL1_MOUSE Q6X893
Choline transporter-like protein 1 
(Solute carrier family 44 member 1) 
(CD92 antigen).
2 1 1205 23446 SLC44A1 CTL1_HUMAN Q8WWI5 tm integral to membrane 653 9
70129 Slc44a4 CTL4_MOUSE Q91VA1
Choline transporter-like protein 4 
(Solute carrier family 44 member 4).
6 11 380 80736 SLC44A4 CTL4_HUMAN Q53GD3 tm integral to membrane 707 10
52466 Slc46a1 PCFT_MOUSE Q6PEM8
Proton-coupled folate transporter 
(Heme carrier protein 1) 
(PCFT/HCP1) (Solute carrier family 
46 member 1).
3 14 309 113235 SLC46A1 PCFT_HUMAN Q96NT5 tm apical plasma membrane 459 10
20533 Slc4a1 B3AT_MOUSE P04919
Band 3 anion transport protein 
(Anion exchange protein 1) (AE 1) 
(Solute carrier family 4 member 1) 
(MEB3) (CD233 antigen).
3 3 884 6521 SLC4A1 B3AT_HUMAN P02730 tm integral to plasma membrane 929 12
20537 Slc5a1 SC5A1_MOUSE Q8C3K6
Sodium/glucose cotransporter 1 
(Na(+)/glucose cotransporter 1) 
(High affinity sodium-glucose 
cotransporter) (Solute carrier family 
5 member 1).
23 587 9 6523 SLC5A1 SC5A1_HUMAN P13866 tm apical plasma membrane 665 14
233836 Slc5a11 SC5AB_MOUSE Q49B93
Sodium-coupled monocarboxylate 
transporter 2 (Electroneutral sodium 
monocarboxylate cotransporter) 
7 31 162 159963 SLC5A11 SC5AB_HUMAN Q8WWX8 tm integral to membrane 673 14
241612 Slc5a12 SC5AC_MOUSE Q9ET37
Low affinity sodium-glucose 
cotransporter (Sodium/glucose 
cotransporter 3) (Na(+)/glucose 
cotransporter 3) (Solute carrier 
family 5 member 4).
6 12 368 6527 SLC5A12 SC5AC_HUMAN Q1EHB4 tm apical plasma membrane 619 13
64452 Slc5a4a SC5A4_MOUSE Q5U4D8
Sodium-dependent multivitamin 
transporter (Na(+)-dependent 
multivitamin transporter) (Solute 
carrier family 5 member 6).
8 20 241 8884 SLC5A4 SC5A4_HUMAN Q9NY91 tm integral to membrane 656 14
64454 Slc5a4b A0PJT9_MOUSE A0PJT9
solute carrier family 5 (neutral 
amino acid transporters, system A), 
member 4b
12 61 80 - - - - tm - 659 14
330064 Slc5a6 SC5A6_MOUSE Q8BYF6
Sodium-coupled monocarboxylate 
transporter 1 (Electrogenic sodium 
monocarboxylate cotransporter) 
(Solute carrier family 5 member 8).
2 4 754 160728 SLC5A6 SC5A6_HUMAN Q9Y289 tm integral to plasma membrane 634 13
216225 Slc5a8 SC5A8_MOUSE Q8VDT1
Sodium/glucose cotransporter 4 
(Na(+)/glucose cotransporter 4) 
(mSGLT4) (Solute carrier family 5 
member 9).
5 13 340 200010 SLC5A8 SC5A8_HUMAN Q8N695 tm apical plasma membrane 613 13
230612 Slc5a9 SC5A9_MOUSE Q8K0E3
Sodium/myo-inositol cotransporter 2 
(Na+/myo-inositol cotransporter 2) 
(Sodium/glucose cotransporter 
KST1) 
7 12 350 115584 SLC5A9 SC5A9_HUMAN Q2M3M2 tm integral to membrane 685 14
56774 Slc6a14 S6A14_MOUSE Q9JMA9
Sodium- and chloride-dependent 
neutral and basic amino acid 
transporter B(0+)
3 2 976 11254 SLC6A14 S6A14_HUMAN Q9UN76 tm integral to plasma membrane 638 12
74338 Slc6a19 S6A19_MOUSE Q9D687
Sodium-dependent neutral amino 
acid transporter B(0) .
9 46 112 340024 SLC6A19 S6A19_HUMAN Q695T7 tm integral to plasma membrane 634 12
102680 Slc6a20a S620A_MOUSE Q8VDB9
solute carrier family 6 
(neurotransmitter transporter), 
member 20A
5 12 366 54716 SLC6A20 S6A20_HUMAN Q9NP91 tm integral to plasma membrane 635 12
102857 Slc6a8 SC6A8_MOUSE Q8VBW1
Sodium- and chloride-dependent 
creatine transporter 1 (Creatine 
transporter 1) (CT1) (Solute carrier 
family 6 member 8).
3 2 979 6535 SLC6A8 SC6A8_HUMAN P48029 tm integral to plasma membrane 640 12
328059 Slc7a15 Q50E62_MOUSE Q50E62
solute carrier family 7 (cationic 
amino acid transporter, y+ system), 
member 15
2 2 1085 - - - - tm - 488 12  183
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50934 Slc7a8 LAT2_MOUSE Q9QXW9
Large neutral amino acids 
transporter small subunit 2 (L-type 
amino acid transporter 2) (mLAT2)
5 7 546 23428 SLC7A8 LAT2_HUMAN Q9UHI5 tm integral to plasma membrane 531 12
30962 Slc7a9 BAT1_MOUSE Q9QXA6
B(0,+)-type amino acid transporter 1 
(B(0,+)AT) (Glycoprotein- 
associated amino acid transporter 
b0,+AT1) 
3 6 563 11136 SLC7A9 BAT1_HUMAN P82251 tm integral to plasma membrane 487 12
105243 Slc9a3 Q8BZU0_MOUSE Q8BZU0
solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3
16 51 99 6550 SLC9A3 SL9A3_HUMAN P48764 tm apical plasma membrane 196 0
58994 Smpd3 NSMA2_MOUSE Q9JJY3
Sphingomyelin phosphodiesterase 
3 (EC 3.1.4.12) (Neutral 
sphingomyelinase II)
4 10 408 55512 SMPD3 NSMA2_HUMAN Q9NY59 tm integral to plasma membrane 655 2
100340 Smpdl3b ASM3B_MOUSE P58242
Acid sphingomyelinase-like 
phosphodiesterase 3b precursor 
(EC 3.1.4.-) (ASM-like 
phosphodiesterase 3b).
10 21 230 27293 SMPDL3B ASM3B_HUMAN Q92485 tm extracellular region 456 0
20655 Sod1 SODC_MOUSE P08228
Superoxide dismutase [Cu-Zn] (EC 
1.15.1.1).
4 4 784 6647 SOD1 SODC_HUMAN P00441 tm cytoplasm 154 0
20322 Sord DHSO_MOUSE Q64442 sorbitol dehydrogenase 7 4 783 6652 SORD DHSO_HUMAN Q00796 tm - 357 0
66624 Spcs2 SPCS2_MOUSE Q9CYN2
Signal peptidase complex subunit 2 
(EC 3.4.-.-) (Microsomal signal 
peptidase 25 kDa subunit) (SPase 
25 kDa subunit).
2 2 1124 9789 SPCS2 SPCS2_HUMAN Q15005 tm integral to endoplasmic reticulum membrane 226 2
76650 Srxn1 SRXN1_MOUSE Q9D975
Sulfiredoxin-1 (EC 1.8.98.2) 
(Neoplastic progression protein 3).
2 1 1202 140809 SRXN1 SRXN1_HUMAN Q9BYN0 tm cytoplasm 136 0
20832 Ssr4 SSRD_MOUSE Q62186
Translocon-associated protein 
subunit delta precursor (TRAP-
delta) (Signal sequence receptor 
subunit delta) (SSR-delta).
2 2 1072 6748 SSR4 SSRD_HUMAN P51571 tm integral to endoplasmic reticulum membrane 172 1
68991 Ssu72 SSU72_MOUSE Q9CY97
RNA polymerase II subunit A C-
terminal domain phosphatase 
SSU72 (EC 3.1.3.16) (CTD 
phosphatase SSU72).
3 2 1077 29101 SSU72 SSU72_HUMAN Q9NP77 tm cytoplasm 194 0
20443 St3gal4 SIA4C_MOUSE Q91Y74
CMP-N-acetylneuraminate-beta-
galactosamide-alpha-2,3-
sialyltransferase (EC 2.4.99.-) 
4 3 831 6484 ST3GAL4 SIA4C_HUMAN Q11206 tm integral to Golgi membrane 333 1
76205 Stard3nl MENTO_MOUSE Q9DCI3
MLN64 N-terminal domain homolog 
(STARD3 N-terminal-like protein).
2 2 1179 83930 STARD3NL MENTO_HUMAN O95772 tm integral to late endosome membrane 235 4
13830 Stom STOM_MOUSE P54116
Erythrocyte band 7 integral 
membrane protein (Stomatin) 
(Protein 7.2b).
11 66 74 2040 STOM STOM_HUMAN P27105 tm integral to plasma membrane 284 1
100226 Stx12 STX12_MOUSE Q9ER00 Syntaxin-12. 6 7 548 23673 STX12 STX12_HUMAN Q86Y82 tm integral to Golgi membrane 274 1
20908 Stx3 STX3_MOUSE Q64704 Syntaxin-3. 12 37 133 6809 STX3 STX3_HUMAN Q13277 tm apical plasma membrane 289 1
20909 Stx4a STX4_MOUSE P70452 Syntaxin-4. 5 4 709 6810 STX4 STX4_HUMAN Q12846 tm basolateral plasma membrane 298 1
53331 Stx7 STX7_MOUSE O70439 Syntaxin-7. 4 4 751 8417 STX7 STX7_HUMAN O15400 tm integral to plasma membrane 261 1
243659 Styk1 STYK1_MOUSE Q6J9G1
Tyrosine protein-kinase STYK1 (EC 
2.7.10.2) (Serine/threonine/tyrosine 
kinase 1) (Novel oncogene with 
kinase domain) (mNOK). 
10 24 214 55359 STYK1 STYK1_HUMAN Q6J9G0 tm integral to plasma membrane 429 1
71733 Susd2 SUSD2_MOUSE Q9DBX3
Sushi domain-containing protein 2 
precursor.
16 42 123 56241 SUSD2 SUSD2_HUMAN Q9UGT4 tm integral to membrane 820 1
19027 Sypl SYPL1_MOUSE O09117
Synaptophysin-like protein 1 
(Pantophysin).
3 8 511 6856 SYPL1 SYPL1_HUMAN Q16563 tm integral to plasma membrane 261 3
17075 Tacstd1 Q61512_MOUSE Q61512
tumor-associated calcium signal 
transducer 1
9 55 91 4072 TACSTD1 TACD1_HUMAN P16422 tm integral to plasma membrane 314 1
21817 Tgm2 TGM2_MOUSE P21981
Protein-glutamine gamma-
glutamyltransferase 2 (EC 2.3.2.13)
5 4 748 7052 TGM2 TGM2_HUMAN P21980 tm plasma membrane 686 0
21838 Thy1 THY1_MOUSE P01831
Thy-1 membrane glycoprotein 
precursor (Thy-1 antigen) (CD90 
antigen).
3 6 588 7070 THY1 THY1_HUMAN P04216 tm anchored to plasma membrane 162 0
142980 Tlr3 TLR3_MOUSE Q99MB1
Toll-like receptor 3 precursor 
(CD283 antigen).
3 2 1084 7098 TLR3 TLR3_HUMAN O15455 tm integral to plasma membrane 905 1
68059 Tm9sf2 TM9S2_MOUSE P58021
Transmembrane 9 superfamily 
member 2 precursor.
4 7 532 9375 TM9SF2 TM9S2_HUMAN Q99805 tm integral to plasma membrane 662 9
107358 Tm9sf3 TM9S3_MOUSE Q9ET30
Transmembrane 9 superfamily 
member 3 precursor.
2 4 805 56889 TM9SF3 TM9S3_HUMAN Q9HD45 tm integral to membrane 587 9
353499 Tmc4 TMC4_MOUSE Q7TQ65
Transmembrane channel-like 
protein 4.
9 13 330 147798 TMC4 TMC4_HUMAN Q7Z404 tm integral to membrane 694 8
74424 Tmc5 TMC5_MOUSE Q32NZ6 Transmembrane channel-like 
protein 5.
6 12 365 79838 TMC5 TMC5_HUMAN Q6UXY8 tm integral to membrane 967 9
68581 Tmed10 TMEDA_MOUSE Q9D1D4
Transmembrane emp24 domain-
containing protein 10 precursor (21 
kDa transmembrane-trafficking 
protein) 
2 3 926 10972 TMED10 TMEDA_HUMAN P49755 tm integral to Golgi membrane 219 2
103694 Tmed4 TMED4_MOUSE Q8R1V4
Transmembrane emp24 domain-
containing protein 4 precursor 
(p26).
3 5 657 222068 TMED4 TMED4_HUMAN Q7Z7H5 tm integral to endoplasmic reticulum membrane 227 2
66676 Tmed7 - -
transmembrane emp24 protein 
transport domain containing 7
4 4 710 51014 TMED7 TMED7_HUMAN Q9Y3B3 tm integral to endoplasmic reticulum membrane 224 1
67511 Tmed9 TMED9_MOUSE Q99KF1
Transmembrane emp24 domain-
containing protein 9 precursor 
(Glycoprotein 25L2).
3 5 682 54732 TMED9 TMED9_HUMAN Q9BVK6 tm integral to endoplasmic reticulum membrane 214 0
105722 Tmem16f TM16F_MOUSE Q6P9J9 Transmembrane protein 16F.  18 43 118 196527 TMEM16F TM16F_HUMAN Q4KMQ2 tm integral to membrane 911 8
407243 Tmem189 TM189_MOUSE Q99LQ7 Transmembrane protein 189. 3 2 1086 387521 TMEM189 TM189_HUMAN A5PLL7 tm integral to endoplasmic reticulum membrane 271 2
73067 Tmem192 TM192_MOUSE Q9CXT7 Transmembrane protein 192. 2 2 1178 201931 TMEM192 TM192_HUMAN Q8IY95 tm integral to membrane 266 4
69981 Tmem30a CC50A_MOUSE Q8VEK0
Cell cycle control protein 50A 
(Transmembrane protein 30A).
3 3 833 55754 TMEM30A CC50A_HUMAN Q9NV96 tm integral to membrane 364 2
238257 Tmem30b CC50B_MOUSE Q8BHG3
Cell cycle control protein 50B 
(Transmembrane protein 30B).
5 17 273 161291 TMEM30B CC50B_HUMAN Q3MIR4 tm integral to membrane 353 2
67878 Tmem33 TMM33_MOUSE Q9CR67
Transmembrane protein 33 (DB83 
protein).
3 2 1076 55161 TMEM33 TMM33_HUMAN P57088 tm integral to membrane 247 3
77975 Tmem50b TM50B_MOUSE Q9D1X9 Transmembrane protein 50B. 2 1 1203 757 TMEM50B TM50B_HUMAN P56557 tm integral to plasma membrane 158 4
72519 Tmem55a TM55A_MOUSE Q9CZX7
Transmembrane protein 55A (EC 
3.1.3.-) (Type II phosphatidylinositol 
4,5-bisphosphate 4-phosphatase)
2 2 1177 55529 TMEM55A TM55A_HUMAN Q8N4L2 tm integral to late endosome membrane 257 2
219024 Tmem55b TM55B_MOUSE Q3TWL2
Transmembrane protein 55B (EC 
3.1.3.-) (Type I phosphatidylinositol 
4,5-bisphosphate 4-phosphatase) 
(PtdIns-4,5-P2 4-Ptase I).
3 2 980 90809 TMEM55B TM55B_HUMAN Q86T03 tm integral to late endosome membrane 284 2
66601 Tmigd1 TMIG1_MOUSE Q9D7L8
Transmembrane and 
immunoglobulin domain-containing 
protein 1 precursor.
4 8 512 388364 TMIGD1 TMIG1_HUMAN Q6UXZ0 tm integral to membrane 261 1
50528 Tmprss2 TMPS2_MOUSE Q9JIQ8
Transmembrane protease, serine 2 
(EC 3.4.21.-) (Epitheliasin) (Plasmic 
transmembrane protein X)
3 3 885 7113 TMPRSS2 TMPS2_HUMAN O15393 tm integral to plasma membrane 490 1
214523 Tmprss4 TMPS4_MOUSE Q8VCA5
Transmembrane protease, serine 4 
(EC 3.4.21.-) (Channel-activating 
protease 2) (mCAP2).
2 4 786 56649 TMPRSS4 TMPS4_HUMAN Q9NRS4 tm integral to membrane 435 1
59069 Tpm3 TPM3_MOUSE P21107
Tropomyosin alpha-3 chain 
(Tropomyosin-3) (Tropomyosin 
gamma). | Tropomyosin alpha-3 
chain (Tropomyosin-3) 
(Tropomyosin gamma).
5 7 547 7170 TPM3 TPM3_HUMAN P06753 tm cytoskeleton 284 0
58866 Treh TREA_MOUSE Q9JLT2
Trehalase precursor (EC 3.2.1.28) 
(Alpha,alpha-trehalase) 
(Alpha,alpha-trehalose 
glucohydrolase).
26 103 49 11181 TREH TREA_HUMAN O43280 tm anchored to plasma membrane 576 0
68667 Trpm4 TRPM4_MOUSE Q7TN37
Transient receptor potential cation 
channel subfamily M member 4 
(Long transient receptor potential 
channel 4) (LTrpC4)
2 2 1125 54795 TRPM4 TRPM4_HUMAN Q8TD43 tm integral to plasma membrane 1213 5
66109 Tspan13 TSN13_MOUSE Q9D8C2
Tetraspanin-13 (Tspan-13) 
(Transmembrane 4 superfamily 
member 13).
2 3 886 27075 TSPAN13 TSN13_HUMAN O95857 tm integral to plasma membrane 204 4
70423 Tspan15 Q99L35_MOUSE Q99L35 tetraspanin 15 2 2 978 23555 TSPAN15 TSN15_HUMAN O95858 tm integral to plasma membrane 206 3
216350 Tspan8 Q8R3G9_MOUSE Q8R3G9 tetraspanin 8 6 41 124 7103 TSPAN8 TSN8_HUMAN P19075 tm integral to plasma membrane 235 4
22146 Tuba1c TBA1C_MOUSE P68373
Tubulin alpha-1C chain (Tubulin 
alpha-6 chain) (Alpha-tubulin 6) 
(Alpha-tubulin isotype M-alpha-6).
16 105 47 84790 TUBA1C TBA1C_HUMAN Q9BQE3 tm cytoskeleton 449 0
22152 Tubb3 TBB3_MOUSE Q9ERD7 Tubulin beta-3 chain. 4 6 589 10381 TUBB3 TBB3_HUMAN Q13509 tm cytoskeleton 450 0
66958 Txndc14 TXD14_MOUSE Q9D710
Thioredoxin domain-containing 
protein 14 precursor.
2 2 1174 51075 TXNDC14 TXD14_HUMAN Q9Y320 tm integral to membrane 295 2
22201 Uba1 A6H6S6_MOUSE A6H6S6
ubiquitin-like modifier activating 
enzyme 1
2 4 801 7317 UBA1 UBA1_HUMAN P22314 tm - 1058 0
22235 Ugdh UGDH_MOUSE O70475 UDP-glucose dehydrogenase 16 22 220 7358 UGDH UGDH_HUMAN O60701 tm - 493 0
394436 Ugt1a1 UD11_MOUSE Q63886
UDP glucuronosyltransferase 1 
family, polypeptide A1
4 4 788 54658 UGT1A1 UD11_HUMAN P22309 tm integral to plasma membrane 535 2
394432 Ugt1a7c UD17C_MOUSE Q6ZQM8
UDP glucuronosyltransferase 1 
family, polypeptide A7C
8 9 462 - - - - tm integral to endoplasmic reticulum membrane 531 1
100727 Ugt2b34 Q8K154_MOUSE Q8K154
UDP glucuronosyltransferase 2 
family, polypeptide B34
3 3 927 10720 UGT2B11 UDB11_HUMAN O75310 tm integral to endoplasmic reticulum membrane 532 1
76589 Unc5cl UN5CL_MOUSE Q6R653
UNC5C-like protein (Protein unc-5 
homolog C-like) (ZU5 and death 
domain-containing protein).
5 13 338 222643 UNC5CL UN5CL_HUMAN Q8IV45 tm integral to membrane 518 0
22271 Upp1 UPP1_MOUSE P52624
Uridine phosphorylase 1 (EC 
2.4.2.3) (UrdPase 1) (UPase 1).
6 10 415 7378 UPP1 UPP1_HUMAN Q16831 tm cytoplasm 311 0
22319 Vamp3 VAMP3_MOUSE P63024
Vesicle-associated membrane 
protein 3 (VAMP-3) (Synaptobrevin-
3) (Cellubrevin) (CEB).
3 4 749 9341 VAMP3 VAMP3_HUMAN Q15836 tm integral to plasma membrane 103 1
20955 Vamp7 VAMP7_MOUSE P70280
Vesicle-associated membrane 
protein 7 (VAMP-7) (Synaptobrevin-
like protein 1).
2 1 1200 6845 VAMP7 VAMP7_HUMAN P51809 tm integral to late endosome membrane 220 1
22320 Vamp8 VAMP8_MOUSE O70404
Vesicle-associated membrane 
protein 8 (VAMP-8) (Endobrevin) 
(Edb).
5 8 502 8673 VAMP8 VAMP8_HUMAN Q9BV40 tm integral to early endosome membrane 101 1
22361 Vnn1 VNN1_MOUSE Q9Z0K8
Pantetheinase precursor (EC 
3.5.1.92) (Pantetheine hydrolase) 
(Vascular non-inflammatory 
molecule 1) (Vanin-1).
9 37 130 8876 VNN1 VNN1_HUMAN O95497 tm anchored to membrane 512 0
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66700 Vps24 CHMP3_MOUSE Q9CQ10
Charged multivesicular body protein 
3 (Chromatin-modifying protein 3) 
(Vacuolar protein-sorting-
associated protein 24).
4 8 505 51652 VPS24 CHMP3_HUMAN Q9Y3E7 tm integral to mitochondrial outer membrane 224 0
53612 Vti1b VTI1B_MOUSE O88384
Vesicle transport through interaction 
with t-SNAREs homolog 1B 
(Vesicle transport v-SNARE protein 
Vti1-like 1) (Vti1-rp1).
6 7 552 10490 VTI1B VTI1B_HUMAN Q9UEU0 tm integral to Golgi membrane 232 1
70465 Wdr77 MEP50_MOUSE Q99J09
Methylosome protein 50 (MEP-50) 
(WD repeat-containing protein 77).
2 2 1080 79084 WDR77 MEP50_HUMAN Q9BQA1 tm cytoplasm 342 0
170750 Xpnpep1 XPP1_MOUSE Q6P1B1
Xaa-Pro aminopeptidase 1 (EC 
3.4.11.9) (X-Pro aminopeptidase 1) 
(X- prolyl aminopeptidase 1, 
soluble)
11 13 339 7511 XPNPEP1 XPP1_HUMAN Q9NQW7 tm cytoplasm 623 0
22630 Ywhaq 1433T_MOUSE P68254
14-3-3 protein theta (14-3-3 protein 
tau)
19 50 101 10971 YWHAQ 1433T_HUMAN P27348 tm cytoplasm 245 0
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A2. BBM protein identification from small intestine sections 
Total list of the 1625 identified BBM proteins from sections or from whole mucosa. The 
protein must have at least a diff. peptide count of two in any of the 4 analysis to be included 
in the table. The proteins are listed by decreasing maximum number of different peptides. 
 
Gene Symbol: associated gene symbol 
Gene Description: description of gene product as provided by the internal Roche database 
entry 
Sum of Sum_Pep_count Pep count: sum of peptide counts for all the LC-MS analysis of a 
given protein for a section or the whole mucosa analysis. 
Max of Max_Diff_peptide: maximum number of different peptides observed in any of the 
LC-MS analysis from a given section or whole mucosa analysis  
Proximal, central, distal: small intestine sections in contrast to whole mucosa   186
Gene Symbol Gene Description Data proximal central distal total mucosa
Myo7b myosin VIIb Sum of Sum_pept_count 599 779 593 917
Max of Max_Dif_pept 108 114 80 118
2010204N08Rik RIKEN cDNA 2010204N08 gene Sum of Sum_pept_count 1508 1354 1408 1068
Max of Max_Dif_pept 96 91 86 83
Mgam maltase-glucoamylase Sum of Sum_pept_count 1358 1253 1822 901
Max of Max_Dif_pept 83 87 85 76
Cltc clathrin, heavy polypeptide (Hc) Sum of Sum_pept_count 0 0 0 464
Max of Max_Dif_pept 0 0 0 87
Dync1h1
dynein cytoplasmic 1 heavy chain 
1
Sum of Sum_pept_count 0 0 2 98
Max of Max_Dif_pept 0 0 1 83
Myo1a myosin IA Sum of Sum_pept_count 856 986 990 984
Max of Max_Dif_pept 73 80 75 78
Vil1 villin 1 Sum of Sum_pept_count 620 1041 817 1091
Max of Max_Dif_pept 56 66 60 59
Anpep
alanyl (membrane) 
aminopeptidase
Sum of Sum_pept_count 1616 1294 1593 1088
Max of Max_Dif_pept 62 55 57 60
Enpep glutamyl aminopeptidase Sum of Sum_pept_count 472 413 550 445
Max of Max_Dif_pept 56 45 51 53
Ace
angiotensin I converting enzyme 
(peptidyl-dipeptidase A) 1
Sum of Sum_pept_count 229 133 76 133
Max of Max_Dif_pept 56 36 29 47
Abcb1a
ATP-binding cassette, sub-family 
B (MDR/TAP), member 1A
Sum of Sum_pept_count 662 322 592 320
Max of Max_Dif_pept 54 43 45 48
Lct lactase Sum of Sum_pept_count 621 485 164 337
Max of Max_Dif_pept 53 45 40 51
Myo1d myosin ID Sum of Sum_pept_count 190 158 246 201
Max of Max_Dif_pept 40 42 43 47
Abcc2
ATP-binding cassette, sub-family 
C (CFTR/MRP), member 2
Sum of Sum_pept_count 205 81 61 88
Max of Max_Dif_pept 46 28 17 29
Nos2
nitric oxide synthase 2, inducible, 
macrophage
Sum of Sum_pept_count 0 20 171 29
Max of Max_Dif_pept 0 17 43 14
Pdzk1 PDZ domain containing 1 Sum of Sum_pept_count 205 356 218 297
Max of Max_Dif_pept 29 38 28 42
Mme membrane metallo endopeptidase Sum of Sum_pept_count 439 214 151 215
Max of Max_Dif_pept 41 37 32 38
AI427122 expressed sequence AI427122 Sum of Sum_pept_count 98 200 142 198
Max of Max_Dif_pept 32 41 38 38
Dpp4 dipeptidylpeptidase 4 Sum of Sum_pept_count 169 159 198 122
Max of Max_Dif_pept 32 33 37 32
Papss2
3'-phosphoadenosine 5'-
phosphosulfate synthase 2
Sum of Sum_pept_count 21 7 3 236
Max of Max_Dif_pept 14 6 3 36
Npc1l1 NPC1-like 1 Sum of Sum_pept_count 200 179 215 148
Max of Max_Dif_pept 36 31 33 29
Ezr ezrin Sum of Sum_pept_count 58 294 145 180
Max of Max_Dif_pept 16 36 23 34
Hspa8 heat shock protein 8 Sum of Sum_pept_count 80 118 144 113
Max of Max_Dif_pept 32 33 35 30
Duox2 dual oxidase 2 Sum of Sum_pept_count 1 18 191 41
Max of Max_Dif_pept 1 6 35 18
Atp1a1
ATPase, Na+/K+ transporting, 
alpha 1 polypeptide
Sum of Sum_pept_count 204 97 361 261
Max of Max_Dif_pept 22 18 29 34
Anxa2 annexin A2 Sum of Sum_pept_count 103 204 218 138
Max of Max_Dif_pept 25 34 34 32
Alb albumin Sum of Sum_pept_count 21 50 64 70
Max of Max_Dif_pept 19 33 34 25
Ace2
angiotensin I converting enzyme 
(peptidyl-dipeptidase A) 2
Sum of Sum_pept_count 432 335 330 234
Max of Max_Dif_pept 31 29 27 33
Akp3
alkaline phosphatase 3, intestine, 
not Mn requiring
Sum of Sum_pept_count 390 26 1 147
Max of Max_Dif_pept 32 10 1 26
Gna11
guanine nucleotide binding 
protein, alpha 11
Sum of Sum_pept_count 365 286 298 207
Max of Max_Dif_pept 30 31 31 27
Enpp3
ectonucleotide 
pyrophosphatase/phosphodiestera
se 3
Sum of Sum_pept_count 246 75 23 113
Max of Max_Dif_pept 31 17 11 23
Slc3a1 solute carrier family 3, member 1 Sum of Sum_pept_count 138 117 189 75
Max of Max_Dif_pept 25 30 28 24
Pcdh24 protocadherin 24 Sum of Sum_pept_count 340 232 242 283
Max of Max Dif pept1 8 1 6 1 4 3 0    187
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Eps8l3 ESP8-like 3 Sum of Sum_pept_count 224 404 299 272
Max of Max_Dif_pept 18 30 25 24
Treh
trehalase (brush-border membrane 
glycoprotein)
Sum of Sum_pept_count 186 110 79 92
Max of Max_Dif_pept 29 26 21 23
Anxa4 annexin A4 Sum of Sum_pept_count 98 271 208 118
Max of Max_Dif_pept 23 29 29 23
Prkg2
protein kinase, cGMP-dependent, 
type II
Sum of Sum_pept_count 104 94 62 79
Max of Max_Dif_pept 22 28 19 26
Pkm2 pyruvate kinase, muscle Sum of Sum_pept_count 37 74 49 142
Max of Max_Dif_pept 18 28 18 28
Naaladl1
N-acetylated alpha-linked acidic 
dipeptidase-like 1
Sum of Sum_pept_count 93 163 312 148
Max of Max_Dif_pept 22 28 28 25
Alpi alkaline phosphatase, intestinal Sum of Sum_pept_count 432 192 181 276
Max of Max_Dif_pept 28 25 22 23
Actg1 actin, gamma, cytoplasmic 1 Sum of Sum_pept_count 430 1225 802 1252
Max of Max_Dif_pept 25 28 23 27
Actb actin, beta Sum of Sum_pept_count 430 1225 802 1252
Max of Max_Dif_pept 25 28 23 27
Lta4h leukotriene A4 hydrolase Sum of Sum_pept_count 1 13 6 51
Max of Max_Dif_pept 1 9 4 27
Myo7a myosin VIIa Sum of Sum_pept_count 45 63 42 72
Max of Max_Dif_pept 8 16 8 26
Clca3
chloride channel calcium activated 
3
Sum of Sum_pept_count 33 52 51 56
Max of Max_Dif_pept 14 18 20 26
Prkcd protein kinase C, delta Sum of Sum_pept_count 50 73 56 36
Max of Max_Dif_pept 14 25 16 17
Pdcd6ip
programmed cell death 6 
interacting protein
Sum of Sum_pept_count 6 51 32 24
Max of Max_Dif_pept 3 25 16 18
Mep1b meprin 1 beta Sum of Sum_pept_count 267 223 309 196
Max of Max_Dif_pept 24 24 25 22
Gnaq
guanine nucleotide binding 
protein, alpha q polypeptide
Sum of Sum_pept_count 185 116 147 65
Max of Max_Dif_pept 25 23 24 19
Fasn fatty acid synthase Sum of Sum_pept_count 0 0 0 35
Max of Max_Dif_pept 0 0 0 25
Xpnpep2
X-prolyl aminopeptidase 
(aminopeptidase P) 2, membrane-
bound
Sum of Sum_pept_count 40 83 124 50
Max of Max_Dif_pept 14 22 24 18
Slc5a1
solute carrier family 5 
(sodium/glucose cotransporter), 
member 1
Sum of Sum_pept_count 407 353 391 287
Max of Max_Dif_pept 22 24 21 24
Hsp90ab1
heat shock protein 90kDa alpha 
(cytosolic), class B member 1
Sum of Sum_pept_count 14 22 45 149
Max of Max_Dif_pept 4 8 14 24
Anxa13 annexin A13 Sum of Sum_pept_count 106 133 161 84
Max of Max_Dif_pept 22 21 23 24
Abcg2
ATP-binding cassette, sub-family 
G (WHITE), member 2
Sum of Sum_pept_count 95 54 97 60
Max of Max_Dif_pept 24 20 21 17
Ush1c
Usher syndrome 1C homolog 
(human)
Sum of Sum_pept_count 44 138 60 103
Max of Max_Dif_pept 13 19 17 23
Slc9a3r1
solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 1
Sum of Sum_pept_count 44 140 78 127
Max of Max_Dif_pept 8 23 10 23
Iqgap2
IQ motif containing GTPase 
activating protein 2
Sum of Sum_pept_count 7 29 20 54
Max of Max_Dif_pept 3 6 6 23
Frk fyn-related kinase Sum of Sum_pept_count 62 55 47 68
Max of Max_Dif_pept 20 23 17 19
Dak
dihydroxyacetone kinase 2 
homolog (yeast)
Sum of Sum_pept_count 18 31 18 59
Max of Max_Dif_pept 14 20 15 23
Atp8b1
ATPase, class I, type 8B, member 
1
Sum of Sum_pept_count 87 63 113 52
Max of Max_Dif_pept 22 23 23 16
Abcb1b
ATP-binding cassette, sub-family 
B (MDR/TAP), member 1B
Sum of Sum_pept_count 28 15 74 14
Max of Max_Dif_pept 23 5 21 4
Stxbp2 syntaxin binding protein 2 Sum of Sum_pept_count 63 80 81 67
Max of Max_Dif_pept 12 19 13 22
Slc15a1
solute carrier family 15 
(oligopeptide transporter), member 
1
Sum of Sum_pept_count 113 115 144 93
Max of Max_Dif_pept 20 22 22 19  188
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Hsp90ab1
heat shock protein 90kDa alpha 
(cytosolic), class B member 1
Sum of Sum_pept_count 14 22 45 149
Max of Max_Dif_pept 4 8 14 24
Anxa13 annexin A13 Sum of Sum_pept_count 106 133 161 84
Max of Max_Dif_pept 22 21 23 24
Abcg2
ATP-binding cassette, sub-family 
G (WHITE), member 2
Sum of Sum_pept_count 95 54 97 60
Max of Max_Dif_pept 24 20 21 17
Ush1c
Usher syndrome 1C homolog 
(human)
Sum of Sum_pept_count 44 138 60 103
Max of Max_Dif_pept 13 19 17 23
Slc9a3r1
solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 1
Sum of Sum_pept_count 44 140 78 127
Max of Max_Dif_pept 8 23 10 23
Iqgap2
IQ motif containing GTPase 
activating protein 2
Sum of Sum_pept_count 7 29 20 54
Max of Max_Dif_pept 3 6 6 23
Frk fyn-related kinase Sum of Sum_pept_count 62 55 47 68
Max of Max_Dif_pept 20 23 17 19
Dak
dihydroxyacetone kinase 2 
homolog (yeast)
Sum of Sum_pept_count 18 31 18 59
Max of Max_Dif_pept 14 20 15 23
Atp8b1
ATPase, class I, type 8B, member 
1
Sum of Sum_pept_count 87 63 113 52
Max of Max_Dif_pept 22 23 23 16
Abcb1b
ATP-binding cassette, sub-family 
B (MDR/TAP), member 1B
Sum of Sum_pept_count 28 15 74 14
Max of Max_Dif_pept 23 5 21 4
Stxbp2 syntaxin binding protein 2 Sum of Sum_pept_count 63 80 81 67
Max of Max_Dif_pept 12 19 13 22
Slc15a1
solute carrier family 15 
(oligopeptide transporter), member 
1
Sum of Sum_pept_count 113 115 144 93
Max of Max_Dif_pept 20 22 22 19
Prkar2a
protein kinase, cAMP dependent 
regulatory, type II alpha
Sum of Sum_pept_count 171 103 119 98
Max of Max_Dif_pept 22 21 18 22
Plcb3 phospholipase C, beta 3 Sum of Sum_pept_count 32 120 87 21
Max of Max_Dif_pept 11 22 15 6
Ehd1 EH-domain containing 1 Sum of Sum_pept_count 37 41 29 41
Max of Max_Dif_pept 14 22 17 19
Eef2
eukaryotic translation elongation 
factor 2
Sum of Sum_pept_count 20 44 30 70
Max of Max_Dif_pept 4 12 7 22
Ywhaz
tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation 
protein, zeta polypeptide
Sum of Sum_pept_count 32 51 70 81
Max of Max_Dif_pept 13 16 17 21
Tubb5 tubulin, beta 5 Sum of Sum_pept_count 67 95 67 128
Max of Max_Dif_pept 16 19 16 21
Tubb2c tubulin, beta 2c Sum of Sum_pept_count 69 59 75 179
Max of Max_Dif_pept 16 18 14 21
Prkca protein kinase C, alpha Sum of Sum_pept_count 31 36 26 21
Max of Max_Dif_pept 14 21 15 12
Idh1
isocitrate dehydrogenase 1 
(NADP+), soluble
Sum of Sum_pept_count 27 19 23 34
Max of Max_Dif_pept 14 13 11 21
Gdi2
guanosine diphosphate (GDP) 
dissociation inhibitor 2
Sum of Sum_pept_count 28 50 39 26
Max of Max_Dif_pept 14 21 14 17
Eno1 enolase 1, alpha non-neuron Sum of Sum_pept_count 14 33 29 57
Max of Max_Dif_pept 9 17 13 21
Dpep1 dipeptidase 1 (renal) Sum of Sum_pept_count 135 134 155 108
Max of Max_Dif_pept 19 20 21 17
Actn4 actinin alpha 4 Sum of Sum_pept_count 0 11 9 28
Max of Max_Dif_pept 0 6 2 21
Tkt transketolase Sum of Sum_pept_count 10 24 26 68
Max of Max_Dif_pept 8 17 17 20
Susd2 sushi domain containing 2 Sum of Sum_pept_count 44 41 54 43
Max of Max_Dif_pept 18 17 20 19
Smpdl3b
sphingomyelin phosphodiesterase, 
acid-like 3B
Sum of Sum_pept_count 54 37 39 43
Max of Max_Dif_pept 20 17 16 13
Pld1 phospholipase D1 Sum of Sum_pept_count 100 57 85 51
Max of Max_Dif_pept 20 18 17 13
Iigp2 interferon inducible GTPase 2 Sum of Sum_pept_count 59 24 41 19
Max of Max_Dif_pept 20 11 8 11
Gna13
guanine nucleotide binding 
protein, alpha 13
Sum of Sum_pept_count 44 43 60 51
Max of Max_Dif_pept 20 16 15 12    189
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Ahcyl1
S-adenosylhomocysteine 
hydrolase-like 1
Sum of Sum_pept_count 3 25 4 17
Max of Max_Dif_pept 3 17 4 13
Gapdh
glyceraldehyde-3-phosphate 
dehydrogenase
Sum of Sum_pept_count 47 66 58 118
Max of Max_Dif_pept 12 14 13 17
2010002M12Rik RIKEN cDNA 2010002M12 gene Sum of Sum_pept_count 40 24 20 34
Max of Max_Dif_pept 17 14 10 14
Acta1 actin, alpha 1, skeletal muscle Sum of Sum_pept_count 154 360 376 379
Max of Max_Dif_pept 11 14 17 14
Cndp2
CNDP dipeptidase 2 
(metallopeptidase M20 family)
Sum of Sum_pept_count 6 46 21 32
Max of Max_Dif_pept 6 17 11 15
Baiap2l1 BAI1-associated protein 2-like 1 Sum of Sum_pept_count 25 123 88 60
Max of Max_Dif_pept 5 16 13 17
Asah2
N-acylsphingosine amidohydrolase 
2
Sum of Sum_pept_count 102 93 72 71
Max of Max_Dif_pept 17 17 16 16
Tuba4a tubulin, alpha 4A Sum of Sum_pept_count 5 6 43 14
Max of Max_Dif_pept 4 3 16 9
Slc9a3
solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3
Sum of Sum_pept_count 129 83 46 62
Max of Max_Dif_pept 13 16 8 13
Slc27a2
solute carrier family 27 (fatty acid 
transporter), member 2
Sum of Sum_pept_count 32 3 1 11
Max of Max_Dif_pept 16 3 1 10
Slc26a6 solute carrier family 26, member 6 Sum of Sum_pept_count 152 89 79 72
Max of Max_Dif_pept 16 14 12 15
Rab8a
RAB8A, member RAS oncogene 
family
Sum of Sum_pept_count 72 33 53 44
Max of Max_Dif_pept 16 16 15 14
Rab1b
RAB1B, member RAS oncogene 
family
Sum of Sum_pept_count 134 45 38 52
Max of Max_Dif_pept 16 13 11 14
Rab14
RAB14, member RAS oncogene 
family
Sum of Sum_pept_count 45 28 36 41
Max of Max_Dif_pept 15 16 13 13
Psmc5
protease (prosome, macropain) 
26S subunit, ATPase 5
Sum of Sum_pept_count 0 0 1 21
Max of Max_Dif_pept 0 0 1 16
Abcg5
ATP-binding cassette, sub-family 
G (WHITE), member 5
Sum of Sum_pept_count 55 34 41 29
Max of Max_Dif_pept 15 16 14 12
Ppp2r1a
protein phosphatase 2 (formerly 
2A), regulatory subunit A (PR 65), 
alpha isoform
Sum of Sum_pept_count 3 13 5 29
Max of Max_Dif_pept 3 8 2 16
Aldh1a1
aldehyde dehydrogenase family 1, 
subfamily A1
Sum of Sum_pept_count 3 12 3 21
Max of Max_Dif_pept 3 10 3 16
Pfkp phosphofructokinase, platelet Sum of Sum_pept_count 7 16 18 29
Max of Max_Dif_pept 4 11 12 16
Nars asparaginyl-tRNA synthetase Sum of Sum_pept_count 2 13 14 22
Max of Max_Dif_pept 2 12 13 16
Mttp
microsomal triglyceride transfer 
protein
Sum of Sum_pept_count 0 1 0 39
Max of Max_Dif_pept 0 1 0 16
Mep1a meprin 1 alpha Sum of Sum_pept_count 23 47 101 32
Max of Max_Dif_pept 8 16 16 10
Lgals4 lectin, galactose binding, soluble 4 Sum of Sum_pept_count 88 91 106 121
Max of Max_Dif_pept 11 13 11 16
Hsp90aa1
heat shock protein 90, alpha 
(cytosolic), class A member 1
Sum of Sum_pept_count 8 12 12 30
Max of Max_Dif_pept 2 6 5 16
Gpx2 glutathione peroxidase 2 Sum of Sum_pept_count 15 34 35 24
Max of Max_Dif_pept 11 16 16 15
Gnb1
guanine nucleotide binding protein 
(G protein), beta 1
Sum of Sum_pept_count 125 138 119 114
Max of Max_Dif_pept 15 16 16 16
Gnas
GNAS (guanine nucleotide binding 
protein, alpha stimulating) 
complex locus
Sum of Sum_pept_count 52 33 57 29
Max of Max_Dif_pept 16 16 14 11
Enpp7
ectonucleotide 
pyrophosphatase/phosphodiestera
se 7
Sum of Sum_pept_count 42 84 83 71
Max of Max_Dif_pept 10 12 16 11
EG638904 predicted gene, EG638904 Sum of Sum_pept_count 133 93 199 84
Max of Max_Dif_pept 15 14 16 14  190
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Dsp desmoplakin Sum of Sum_pept_count 21 10 43 14
Max of Max_Dif_pept 8 7 16 4
Casp1 caspase 1 Sum of Sum_pept_count 21 18 15 26
Max of Max_Dif_pept 16 12 10 13
Akr1a4
aldo-keto reductase family 1, 
member A4 (aldehyde reductase)
Sum of Sum_pept_count 7 15 14 51
Max of Max_Dif_pept 6 12 11 16
Ywhab
tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation 
protein, beta polypeptide
Sum of Sum_pept_count 20 23 27 52
Max of Max_Dif_pept 8 10 9 15
Tpi1 triosephosphate isomerase 1 Sum of Sum_pept_count 13 16 16 50
Max of Max_Dif_pept 10 7 10 15
Tmem16f transmembrane protein 16F Sum of Sum_pept_count 61 51 55 41
Max of Max_Dif_pept 15 14 14 14
Styk1 serine/threonine/tyrosine kinase 1 Sum of Sum_pept_count 87 69 108 44
Max of Max_Dif_pept 15 15 15 13
Slc30a10
solute carrier family 30, member 
10
Sum of Sum_pept_count 65 9 18 17
Max of Max_Dif_pept 15 2 3 5
Scin scinderin Sum of Sum_pept_count 2 14 10 17
Max of Max_Dif_pept 2 13 7 15
Rp2h
retinitis pigmentosa 2 homolog 
(human)
Sum of Sum_pept_count 36 25 38 30
Max of Max_Dif_pept 15 12 10 11
Rnpep
arginyl aminopeptidase 
(aminopeptidase B)
Sum of Sum_pept_count 2 13 7 19
Max of Max_Dif_pept 2 13 6 15
Rnh1 ribonuclease/angiogenin inhibitor 1 Sum of Sum_pept_count 7 17 12 17
Max of Max_Dif_pept 7 15 10 11
Rab1
RAB1, member RAS oncogene 
family
Sum of Sum_pept_count 264 76 102 117
Max of Max_Dif_pept 15 14 12 15
Prdx1 peroxiredoxin 1 Sum of Sum_pept_count 19 29 24 30
Max of Max_Dif_pept 10 15 10 13
Ppp1ca
protein phosphatase 1, catalytic 
subunit, alpha isoform
Sum of Sum_pept_count 8 23 17 24
Max of Max_Dif_pept 7 15 11 14
Anxa7 annexin A7 Sum of Sum_pept_count 3 40 24 12
Max of Max_Dif_pept 2 15 8 7
Pklr
pyruvate kinase liver and red 
blood cell
Sum of Sum_pept_count 3 12 8 28
Max of Max_Dif_pept 3 10 7 15
OTTMUSG0000000
predicted gene, 
OTTMUSG00000005723
Sum of Sum_pept_count 14 11 8 19
Max of Max_Dif_pept 10 10 6 15
Mupcdh mucin-like protocadherin Sum of Sum_pept_count 142 93 104 92
Max of Max_Dif_pept 15 14 12 14
Lyn
Yamaguchi sarcoma viral (v-yes-
1) oncogene homolog
Sum of Sum_pept_count 35 41 34 32
Max of Max_Dif_pept 13 15 11 12
Lap3 leucine aminopeptidase 3 Sum of Sum_pept_count 7 20 11 32
Max of Max_Dif_pept 4 14 10 15
Acsl5
acyl-CoA synthetase long-chain 
family member 5
Sum of Sum_pept_count 16 6 17 34
Max of Max_Dif_pept 13 5 8 15
Eps8l2 EPS8-like 2 Sum of Sum_pept_count 36 113 61 91
Max of Max_Dif_pept 5 12 6 15
Eif4a1
eukaryotic translation initiation 
factor 4A1
Sum of Sum_pept_count 19 34 28 41
Max of Max_Dif_pept 10 12 9 15
Coro1c coronin, actin binding protein 1C Sum of Sum_pept_count 14 25 27 14
Max of Max_Dif_pept 13 15 14 12
Clic5 chloride intracellular channel 5 Sum of Sum_pept_count 90 143 99 169
Max of Max_Dif_pept 11 15 12 14
Cfl1 cofilin 1, non-muscle Sum of Sum_pept_count 18 52 34 56
Max of Max_Dif_pept 8 15 11 15
Calml4 calmodulin-like 4 Sum of Sum_pept_count 9 45 13 31
Max of Max_Dif_pept 5 15 7 15
Ywhag
tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation 
protein, gamma polypeptide
Sum of Sum_pept_count 2 18 22 40
Max of Max_Dif_pept 2 12 9 14
Tmc4
transmembrane channel-like gene 
family 4
Sum of Sum_pept_count 33 32 50 33
Max of Max_Dif_pept 13 11 14 12    191
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Src Rous sarcoma oncogene Sum of Sum_pept_count 24 25 24 25
Max of Max_Dif_pept 11 14 10 10
Slc5a4b
solute carrier family 5 (neutral 
amino acid transporters, system 
A), member 4b
Sum of Sum_pept_count 88 85 100 52
Max of Max_Dif_pept 11 14 11 13
Slc13a2
solute carrier family 13 (sodium-
dependent dicarboxylate 
transporter), member 2
Sum of Sum_pept_count 52 43 72 37
Max of Max_Dif_pept 13 10 14 11
Rap1b RAS related protein 1b Sum of Sum_pept_count 70 40 50 33
Max of Max_Dif_pept 14 13 11 12
Rap1a RAS-related protein-1a Sum of Sum_pept_count 56 35 23 16
Max of Max_Dif_pept 14 13 6 7
Rab8b
RAB8B, member RAS oncogene 
family
Sum of Sum_pept_count 45 22 32 27
Max of Max_Dif_pept 14 12 12 12
Rab35
RAB35, member RAS oncogene 
family
Sum of Sum_pept_count 73 29 58 34
Max of Max_Dif_pept 14 12 14 10
Psmc2
proteasome (prosome, macropain) 
26S subunit, ATPase 2
Sum of Sum_pept_count 0 0 1 22
Max of Max_Dif_pept 0 0 1 14
Prdx6 peroxiredoxin 6 Sum of Sum_pept_count 17 9 14 29
Max of Max_Dif_pept 10 5 10 14
Aldh1b1
aldehyde dehydrogenase 1 family, 
member B1
Sum of Sum_pept_count 0 0 0 53
Max of Max_Dif_pept 0 0 0 14
Pafah1b1
platelet-activating factor 
acetylhydrolase, isoform 1b, beta1 
subunit
Sum of Sum_pept_count 0 0 0 16
Max of Max_Dif_pept 0 0 0 14
Muc13
mucin 13, epithelial 
transmembrane
Sum of Sum_pept_count 366 336 390 345
Max of Max_Dif_pept 13 13 14 12
Mapk3 mitogen-activated protein kinase 3 Sum of Sum_pept_count 8 16 9 44
Max of Max_Dif_pept 4 7 5 14
H2-K1 histocompatibility 2, K1, K region Sum of Sum_pept_count 24 12 36 31
Max of Max_Dif_pept 10 7 14 14
Gpr128 G protein-coupled receptor 128 Sum of Sum_pept_count 124 75 110 81
Max of Max_Dif_pept 13 12 12 14
Gnb2
guanine nucleotide binding protein 
(G protein), beta 2
Sum of Sum_pept_count 76 90 88 97
Max of Max_Dif_pept 11 14 14 13
Aldob aldolase B, fructose-bisphosphate Sum of Sum_pept_count 21 42 35 51
Max of Max_Dif_pept 10 14 12 11
Gfpt1
glutamine fructose-6-phosphate 
transaminase 1
Sum of Sum_pept_count 0 6 18 16
Max of Max_Dif_pept 0 5 11 14
Ephx2 epoxide hydrolase 2, cytoplasmic Sum of Sum_pept_count 11 11 1 24
Max of Max_Dif_pept 10 9 1 14
Eef1a1
eukaryotic translation elongation 
factor 1 alpha 1
Sum of Sum_pept_count 53 61 70 98
Max of Max_Dif_pept 9 14 11 13
Dstn destrin Sum of Sum_pept_count 34 62 44 53
Max of Max_Dif_pept 12 14 14 14
Abce1
ATP-binding cassette, sub-family 
E (OABP), member 1
Sum of Sum_pept_count 0 0 1 14
Max of Max_Dif_pept 0 0 1 13
Trim14 tripartite motif-containing 14 Sum of Sum_pept_count 12 9 17 8
Max of Max_Dif_pept 11 8 13 8
Stk25 serine/threonine kinase 25 (yeast) Sum of Sum_pept_count 17 28 19 22
Max of Max_Dif_pept 8 13 6 9
Anxa11 annexin A11 Sum of Sum_pept_count 31 68 55 31
Max of Max_Dif_pept 11 13 12 10
Sfn stratifin Sum of Sum_pept_count 12 16 18 23
Max of Max_Dif_pept 5 10 9 13
Rps6ka1
ribosomal protein S6 kinase 
polypeptide 1
Sum of Sum_pept_count 5 8 6 21
Max of Max_Dif_pept 4 8 6 13
Rab5c
RAB5C, member RAS oncogene 
family
Sum of Sum_pept_count 71 42 91 53
Max of Max_Dif_pept 13 9 8 11
Rab2a
RAB2A, member RAS oncogene 
family
Sum of Sum_pept_count 64 51 75 58
Max of Max_Dif_pept 13 13 12 12    192
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Rab11b
RAB11B, member RAS oncogene 
family
Sum of Sum_pept_count 63 49 84 47
Max of Max_Dif_pept 13 11 11 13
Rab10
RAB10, member RAS oncogene 
family
Sum of Sum_pept_count 55 22 50 41
Max of Max_Dif_pept 13 12 13 13
Psmd11
proteasome (prosome, macropain) 
26S subunit, non-ATPase, 11
Sum of Sum_pept_count 1 1 2 21
Max of Max_Dif_pept 1 1 1 13
Ppia peptidylprolyl isomerase A Sum of Sum_pept_count 22 40 47 53
Max of Max_Dif_pept 11 11 12 13
Nlrp6
NLR family, pyrin domain 
containing 6
Sum of Sum_pept_count 55 18 19 17
Max of Max_Dif_pept 13 7 7 8
Ap1m2
adaptor protein complex AP-1, mu 
2 subunit
Sum of Sum_pept_count 0 2 2 18
Max of Max_Dif_pept 0 2 2 13
Lgals2 lectin, galactose-binding, soluble 2 Sum of Sum_pept_count 39 27 37 59
Max of Max_Dif_pept 9 9 10 13
Lcp1 lymphocyte cytosolic protein 1 Sum of Sum_pept_count 0 20 16 21
Max of Max_Dif_pept 0 13 11 9
Hspa1b heat shock protein 1B Sum of Sum_pept_count 3 9 15 15
Max of Max_Dif_pept 1 8 12 13
Hspa1a heat shock protein 1A Sum of Sum_pept_count 3 9 15 15
Max of Max_Dif_pept 1 8 12 13
Gucy2c guanylate cyclase 2c Sum of Sum_pept_count 39 20 29 19
Max of Max_Dif_pept 13 7 12 6
Ahcy
S-adenosylhomocysteine 
hydrolase
Sum of Sum_pept_count 7 14 9 13
Max of Max_Dif_pept 7 13 8 12
Cpne2 copine II Sum of Sum_pept_count 7 20 13 7
Max of Max_Dif_pept 6 13 7 6
Cbr1 carbonyl reductase 1 Sum of Sum_pept_count 8 11 5 24
Max of Max_Dif_pept 5 6 4 13
Bpnt1 bisphosphate 3'-nucleotidase 1 Sum of Sum_pept_count 37 12 14 25
Max of Max_Dif_pept 12 9 7 13
Baiap2l2 BAI1-associated protein 2-like 2 Sum of Sum_pept_count 5 48 27 15
Max of Max_Dif_pept 2 13 7 7
Unc5cl unc-5 homolog C (C. elegans)-like Sum of Sum_pept_count 43 18 30 25
Max of Max_Dif_pept 12 7 7 8
Tagln2 transgelin 2 Sum of Sum_pept_count 12 35 19 26
Max of Max_Dif_pept 7 12 8 10
Stx3 syntaxin 3 Sum of Sum_pept_count 59 41 46 37
Max of Max_Dif_pept 12 9 9 12
Stom stomatin Sum of Sum_pept_count 75 76 142 92
Max of Max_Dif_pept 9 9 12 12
Sh3bgrl
SH3-binding domain glutamic acid-
rich protein like
Sum of Sum_pept_count 14 52 16 22
Max of Max_Dif_pept 6 12 7 10
Actg2
actin, gamma 2, smooth muscle, 
enteric
Sum of Sum_pept_count 65 51 70 113
Max of Max_Dif_pept 10 10 10 12
Rap2c
RAP2C, member of RAS 
oncogene family
Sum of Sum_pept_count 29 19 35 14
Max of Max_Dif_pept 12 10 10 9
Rab11a
RAB11a, member RAS oncogene 
family
Sum of Sum_pept_count 52 29 71 50
Max of Max_Dif_pept 12 10 10 11
Psmc3
proteasome (prosome, macropain) 
26S subunit, ATPase 3
Sum of Sum_pept_count 1 3 2 28
Max of Max_Dif_pept 1 3 2 12
Prkaca
protein kinase, cAMP dependent, 
catalytic, alpha
Sum of Sum_pept_count 15 18 18 16
Max of Max_Dif_pept 6 7 8 12
Arf4 ADP-ribosylation factor 4 Sum of Sum_pept_count 84 68 73 46
Max of Max_Dif_pept 12 10 9 7
P4hb
prolyl 4-hydroxylase, beta 
polypeptide
Sum of Sum_pept_count 0 1 11 16
Max of Max_Dif_pept 0 1 4 12
Myo15b myosin XVB Sum of Sum_pept_count 33 80 61 68
Max of Max_Dif_pept 10 12 12 11
Mtm1
X-linked myotubular myopathy 
gene 1
Sum of Sum_pept_count 1 14 8 16
Max of Max_Dif_pept 1 12 8 8
Aldh9a1
aldehyde dehydrogenase 9, 
subfamily A1
Sum of Sum_pept_count 2 13 7 16
Max of Max_Dif_pept 2 12 7 12  193
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Krt5 keratin 5 Sum of Sum_pept_count 13 7 29 22
Max of Max_Dif_pept 8 7 12 12
Kalrn kalirin, RhoGEF kinase Sum of Sum_pept_count 45 53 44 42
Max of Max_Dif_pept 10 12 11 9
Inadl InaD-like (Drosophila) Sum of Sum_pept_count 58 74 68 23
Max of Max_Dif_pept 12 12 11 6
Aldoa aldolase A, fructose-bisphosphate Sum of Sum_pept_count 6 19 21 15
Max of Max_Dif_pept 6 11 12 8
Gpi1 glucose phosphate isomerase 1 Sum of Sum_pept_count 0 20 9 19
Max of Max_Dif_pept 0 7 6 12
Gipc2
GIPC PDZ domain containing 
family, member 2
Sum of Sum_pept_count 2 18 6 15
Max of Max_Dif_pept 2 12 5 10
Acta2
actin, alpha 2, smooth muscle, 
aorta
Sum of Sum_pept_count 65 51 70 113
Max of Max_Dif_pept 10 10 10 12
Fabp2
fatty acid binding protein 2, 
intestinal
Sum of Sum_pept_count 12 208 32 36
Max of Max_Dif_pept 4 12 5 10
Ap2m1
adaptor protein complex AP-2, 
mu1
Sum of Sum_pept_count 5 12 8 12
Max of Max_Dif_pept 5 11 7 12
Cpne3 copine III Sum of Sum_pept_count 4 17 16 11
Max of Max_Dif_pept 4 12 10 9
Cobl cordon-bleu Sum of Sum_pept_count 45 90 34 94
Max of Max_Dif_pept 8 11 7 12
Ceacam20
carcinoembryonic antigen-related 
cell adhesion molecule 20
Sum of Sum_pept_count 40 31 43 27
Max of Max_Dif_pept 12 11 11 10
Calm3 calmodulin 3 Sum of Sum_pept_count 22 69 65 48
Max of Max_Dif_pept 6 12 9 7
Calm2 calmodulin 2 Sum of Sum_pept_count 22 69 65 48
Max of Max_Dif_pept 6 12 9 7
Calm1 calmodulin 1 Sum of Sum_pept_count 22 69 65 48
Max of Max_Dif_pept 6 12 9 7
Cab39 calcium binding protein 39 Sum of Sum_pept_count 6 16 11 9
Max of Max_Dif_pept 6 12 8 8
Adh1 alcohol dehydrogenase 1 (class I) Sum of Sum_pept_count 4 12 0 22
Max of Max_Dif_pept 4 7 0 11
Yes1
Yamaguchi sarcoma viral (v-yes) 
oncogene homolog 1
Sum of Sum_pept_count 30 28 26 25
Max of Max_Dif_pept 11 11 10 9
Vps4b vacuolar protein sorting 4b (yeast) Sum of Sum_pept_count 5 19 9 11
Max of Max_Dif_pept 5 11 8 7
Vnn1 vanin 1 Sum of Sum_pept_count 60 56 83 48
Max of Max_Dif_pept 11 8 10 9
Sult1b1
sulfotransferase family 1B, 
member 1
Sum of Sum_pept_count 16 18 10 25
Max of Max_Dif_pept 6 8 4 11
Snap23
synaptosomal-associated protein 
23
Sum of Sum_pept_count 74 44 54 55
Max of Max_Dif_pept 11 7 10 10
Slc5a4a solute carrier family 5, member 4a Sum of Sum_pept_count 42 41 32 32
Max of Max_Dif_pept 9 11 9 10
Slc44a4 solute carrier family 44, member 4 Sum of Sum_pept_count 13 20 35 18
Max of Max_Dif_pept 3 7 11 5
Akr1c12
aldo-keto reductase family 1, 
member C12
Sum of Sum_pept_count 3 0 3 14
Max of Max_Dif_pept 3 0 3 11
Rpn1 ribophorin I Sum of Sum_pept_count 0 0 9 11
Max of Max_Dif_pept 0 0 8 11
Rac1
RAS-related C3 botulinum 
substrate 1
Sum of Sum_pept_count 80 50 64 38
Max of Max_Dif_pept 10 10 9 11
Arf1 ADP-ribosylation factor 1 Sum of Sum_pept_count 81 83 95 52
Max of Max_Dif_pept 11 10 9 8
Anxa5 annexin A5 Sum of Sum_pept_count 5 13 13 8
Max of Max_Dif_pept 5 11 9 8
Psmc1
protease (prosome, macropain) 
26S subunit, ATPase 1
Sum of Sum_pept_count 0 0 0 20
Max of Max_Dif_pept 0 0 0 11
Prkag1
protein kinase, AMP-activated, 
gamma 1 non-catalytic subunit
Sum of Sum_pept_count 2 9 14 11
Max of Max_Dif_pept 2 9 9 11  194
Gene Symbol Gene Description Data proximal central distal total mucosa
Arf3 ADP-ribosylation factor 3 Sum of Sum_pept_count 81 83 95 52
Max of Max_Dif_pept 11 10 9 8
Ap1b1
adaptor protein complex AP-1, 
beta 1 subunit
Sum of Sum_pept_count 7 13 8 41
Max of Max_Dif_pept 5 6 4 11
Pi4ka
phosphatidylinositol 4-kinase, 
catalytic, alpha polypeptide
Sum of Sum_pept_count 11 10 4 13
Max of Max_Dif_pept 7 6 3 11
Arf5 ADP-ribosylation factor 5 Sum of Sum_pept_count 77 64 65 47
Max of Max_Dif_pept 11 10 10 9
Myl6
myosin, light polypeptide 6, alkali, 
smooth muscle and non-muscle
Sum of Sum_pept_count 50 51 37 90
Max of Max_Dif_pept 9 10 8 11
Mpp1 membrane protein, palmitoylated Sum of Sum_pept_count 8 16 8 23
Max of Max_Dif_pept 5 11 4 11
Lasp1 LIM and SH3 protein 1 Sum of Sum_pept_count 10 36 5 62
Max of Max_Dif_pept 4 6 2 11
Lad1 ladinin Sum of Sum_pept_count 34 35 11 66
Max of Max_Dif_pept 7 11 5 10
Jup junction plakoglobin Sum of Sum_pept_count 16 7 25 14
Max of Max_Dif_pept 11 7 9 5
Idh2
isocitrate dehydrogenase 2 
(NADP+), mitochondrial
Sum of Sum_pept_count 0 1 0 17
Max of Max_Dif_pept 0 1 0 11
Hspa5 heat shock protein 5 Sum of Sum_pept_count 0 0 12 8
Max of Max_Dif_pept 0 0 11 7
H2-Ab1
histocompatibility 2, class II 
antigen A, beta 1
Sum of Sum_pept_count 9 8 31 15
Max of Max_Dif_pept 7 7 11 8
Ap2a2
adaptor protein complex AP-2, 
alpha 2 subunit
Sum of Sum_pept_count 0 18 10 9
Max of Max_Dif_pept 0 11 8 8
Gda guanine deaminase Sum of Sum_pept_count 12 19 8 21
Max of Max_Dif_pept 10 8 6 11
Fabp6
fatty acid binding protein 6, ileal 
(gastrotropin)
Sum of Sum_pept_count 0 1 46 15
Max of Max_Dif_pept 0 1 11 7
Dnaja1
DnaJ (Hsp40) homolog, subfamily 
A, member 1
Sum of Sum_pept_count 10 12 9 12
Max of Max_Dif_pept 9 11 9 11
Ckb creatine kinase, brain Sum of Sum_pept_count 11 10 2 59
Max of Max_Dif_pept 6 5 2 11
Cib1
calcium and integrin binding 1 
(calmyrin)
Sum of Sum_pept_count 19 30 38 18
Max of Max_Dif_pept 11 9 10 8
Chmp4b chromatin modifying protein 4B Sum of Sum_pept_count 26 27 30 43
Max of Max_Dif_pept 8 9 9 11
Capzb
capping protein (actin filament) 
muscle Z-line, beta
Sum of Sum_pept_count 8 16 12 14
Max of Max_Dif_pept 5 10 7 11
Xpnpep1
X-prolyl aminopeptidase 
(aminopeptidase P) 1, soluble
Sum of Sum_pept_count 3 27 23 26
Max of Max_Dif_pept 1 10 8 9
Tubb3 tubulin, beta 3 Sum of Sum_pept_count 3 7 16 27
Max of Max_Dif_pept 1 4 9 10
Adh6a
alcohol dehydrogenase 6A (class 
V)
Sum of Sum_pept_count 8 15 6 21
Max of Max_Dif_pept 7 10 4 8
Tmc5
transmembrane channel-like gene 
family 5
Sum of Sum_pept_count 19 20 29 14
Max of Max_Dif_pept 8 8 10 6
Tlr3 toll-like receptor 3 Sum of Sum_pept_count 13 8 20 7
Max of Max_Dif_pept 5 4 10 4
Atp2b1
ATPase, Ca++ transporting, 
plasma membrane 1
Sum of Sum_pept_count 64 19 40 20
Max of Max_Dif_pept 10 9 9 8
Tacstd1
tumor-associated calcium signal 
transducer 1
Sum of Sum_pept_count 48 36 82 81
Max of Max_Dif_pept 8 9 9 10
Stk24
serine/threonine kinase 24 (STE20 
homolog, yeast)
Sum of Sum_pept_count 2 27 11 18
Max of Max_Dif_pept 1 10 4 8
2210407C18Rik RIKEN cDNA 2210407C18 gene Sum of Sum_pept_count 439 137 105 270
Max of Max_Dif_pept 10 9 8 9
Slc6a19
solute carrier family 6 
(neurotransmitter transporter), 
member 19
Sum of Sum_pept_count 57 45 50 38
Max of Max_Dif_pept 10 9 8 9
Slc5a11
solute carrier family 5 
(sodium/glucose cotransporter), 
member 11
Sum of Sum_pept_count 85 54 34 46
Max of Max_Dif_pept 10 9 8 10    195
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Sec31a SEC31 homolog A (S. cerevisiae) Sum of Sum_pept_count 0 1 0 61
Max of Max_Dif_pept 0 1 0 10
Rhoa
ras homolog gene family, member 
A
Sum of Sum_pept_count 73 53 52 38
Max of Max_Dif_pept 10 8 8 7
Bst1
bone marrow stromal cell antigen 
1
Sum of Sum_pept_count 80 69 59 53
Max of Max_Dif_pept 10 10 8 10
Rab21
RAB21, member RAS oncogene 
family
Sum of Sum_pept_count 20 9 14 13
Max of Max_Dif_pept 10 6 7 8
Psmd13
proteasome (prosome, macropain) 
26S subunit, non-ATPase, 13
Sum of Sum_pept_count 0 0 1 11
Max of Max_Dif_pept 0 0 1 10
Psmd12
proteasome (prosome, macropain) 
26S subunit, non-ATPase, 12
Sum of Sum_pept_count 0 0 1 11
Max of Max_Dif_pept 0 0 1 10
Arpc2
actin related protein 2/3 complex, 
subunit 2
Sum of Sum_pept_count 6 17 14 18
Max of Max_Dif_pept 5 10 9 9
Anxa6 annexin A6 Sum of Sum_pept_count 1 10 8 1
Max of Max_Dif_pept 1 10 8 1
Ppp1cc
protein phosphatase 1, catalytic 
subunit, gamma isoform
Sum of Sum_pept_count 7 1 17 2
Max of Max_Dif_pept 6 1 10 1
Ppp1cb
protein phosphatase 1, catalytic 
subunit, beta isoform
Sum of Sum_pept_count 7 21 17 20
Max of Max_Dif_pept 6 10 10 10
Pepd peptidase D Sum of Sum_pept_count 6 11 8 14
Max of Max_Dif_pept 5 8 7 10
Pafah2
platelet-activating factor 
acetylhydrolase 2
Sum of Sum_pept_count 0 3 0 10
Max of Max_Dif_pept 0 3 0 10
Napa
N-ethylmaleimide sensitive fusion 
protein attachment protein alpha
Sum of Sum_pept_count 10 13 11 13
Max of Max_Dif_pept 6 9 6 10
Atp6v1a
ATPase, H+ transporting, 
lysosomal V1 subunit A
Sum of Sum_pept_count 0 0 0 10
Max of Max_Dif_pept 0 0 0 10
Mpp5
membrane protein, palmitoylated 
5 (MAGUK p55 subfamily member 
5)
Sum of Sum_pept_count 23 23 20 18
Max of Max_Dif_pept 7 8 7 10
Mdh2
malate dehydrogenase 2, NAD 
(mitochondrial)
Sum of Sum_pept_count 0 10 6 11
Max of Max_Dif_pept 0 10 6 7
Mapk1 mitogen-activated protein kinase 1 Sum of Sum_pept_count 0 9 4 20
Max of Max_Dif_pept 0 6 4 10
Lgals3 lectin, galactose binding, soluble 3 Sum of Sum_pept_count 15 13 25 8
Max of Max_Dif_pept 10 9 10 4
Krt31 keratin 31 Sum of Sum_pept_count 34 10 6 0
Max of Max_Dif_pept 10 7 4 0
Cdh17 cadherin 17 Sum of Sum_pept_count 19 6 50 50
Max of Max_Dif_pept 6 3 10 9
Ifit1
interferon-induced protein with 
tetratricopeptide repeats 1
Sum of Sum_pept_count 16 7 5 14
Max of Max_Dif_pept 10 5 3 9
Gsdmd gasdermin D Sum of Sum_pept_count 17 22 13 21
Max of Max_Dif_pept 7 10 5 6
Csnk1g3 casein kinase 1, gamma 3 Sum of Sum_pept_count 31 27 24 17
Max of Max_Dif_pept 10 8 8 10
Celsr3
cadherin, EGF LAG seven-pass G-
type receptor 3 (flamingo 
homolog, Drosophila)
Sum of Sum_pept_count 13 29 33 12
Max of Max_Dif_pept 3 6 10 5
Vps35 vacuolar protein sorting 35 Sum of Sum_pept_count 2 7 9 12
Max of Max_Dif_pept 2 6 8 9
1500003O03Rik RIKEN cDNA 1500003O03 gene Sum of Sum_pept_count 14 5 6 7
Max of Max_Dif_pept 9 4 4 5
Actbl2 actin, beta-like 2 Sum of Sum_pept_count 0 8 34 4
Max of Max_Dif_pept 0 7 9 4
Car4 carbonic anhydrase 4 Sum of Sum_pept_count 14 11 23 16
Max of Max_Dif_pept 8 7 9 7
Tuba1a tubulin, alpha 1A Sum of Sum_pept_count 34 20 37 48
Max of Max_Dif_pept 6 9 9 9
Trim31 tripartite motif-containing 31 Sum of Sum_pept_count 1 8 4 10
Max of Max_Dif_pept 1 7 3 9
Sri sorcin Sum of Sum_pept_count 10 32 22 10
Max of Max Dif pept5 9 6 6  196
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Sphk2 sphingosine kinase 2 Sum of Sum_pept_count 36 26 16 18
Max of Max_Dif_pept 8 9 5 7
Capza2
capping protein (actin filament) 
muscle Z-line, alpha 2
Sum of Sum_pept_count 5 16 9 17
Max of Max_Dif_pept 3 7 4 9
Slc27a4
solute carrier family 27 (fatty acid 
transporter), member 4
Sum of Sum_pept_count 1 0 2 10
Max of Max_Dif_pept 1 0 1 9
Sec24a
SEC24 related gene family, 
member A (S. cerevisiae)
Sum of Sum_pept_count 0 5 1 21
Max of Max_Dif_pept 0 4 1 9
Rhog
ras homolog gene family, member 
G
Sum of Sum_pept_count 25 22 27 19
Max of Max_Dif_pept 8 9 8 7
Rhoc
ras homolog gene family, member 
C
Sum of Sum_pept_count 26 45 35 29
Max of Max_Dif_pept 6 9 7 8
Rars arginyl-tRNA synthetase Sum of Sum_pept_count 0 0 0 14
Max of Max_Dif_pept 0 0 0 9
Rala
v-ral simian leukemia viral 
oncogene homolog A (ras related)
Sum of Sum_pept_count 54 21 34 22
Max of Max_Dif_pept 9 6 8 8
Rac2
RAS-related C3 botulinum 
substrate 2
Sum of Sum_pept_count 17 4 3 4
Max of Max_Dif_pept 9 1 1 2
Rab4a
RAB4A, member RAS oncogene 
family
Sum of Sum_pept_count 16 8 15 11
Max of Max_Dif_pept 8 7 9 6
Prdx5 peroxiredoxin 5 Sum of Sum_pept_count 8 11 10 15
Max of Max_Dif_pept 6 8 6 9
Pgam1 phosphoglycerate mutase 1 Sum of Sum_pept_count 2 8 7 27
Max of Max_Dif_pept 1 6 4 9
Pfn1 profilin 1 Sum of Sum_pept_count 28 61 44 37
Max of Max_Dif_pept 6 9 7 9
Pdcd10 programmed cell death 10 Sum of Sum_pept_count 10 14 10 11
Max of Max_Dif_pept 8 5 5 9
2010106E10Rik RIKEN cDNA 2010106E10 gene Sum of Sum_pept_count 57 49 48 62
Max of Max_Dif_pept 8 9 7 8
Oas1g 2'-5' oligoadenylate synthetase 1G Sum of Sum_pept_count 9 9 6 14
Max of Max_Dif_pept 4 9 6 8
Oas1a 2'-5' oligoadenylate synthetase 1A Sum of Sum_pept_count 9 9 6 14
Max of Max_Dif_pept 4 9 6 8
Nme2
non-metastatic cells 2, protein 
(NM23B) expressed in
Sum of Sum_pept_count 0 19 10 9
Max of Max_Dif_pept 0 9 7 6
Clic1 chloride intracellular channel 1 Sum of Sum_pept_count 15 33 25 14
Max of Max_Dif_pept 7 8 8 9
Atp6v0d1
ATPase, H+ transporting, 
lysosomal V0 subunit D1
Sum of Sum_pept_count 16 11 19 11
Max of Max_Dif_pept 9 7 9 7
1200009I06Rik RIKEN cDNA 1200009I06 gene Sum of Sum_pept_count 16 20 10 15
Max of Max_Dif_pept 5 7 2 9
Myh9
myosin, heavy polypeptide 9, non-
muscle
Sum of Sum_pept_count 0 0 0 10
Max of Max_Dif_pept 0 0 0 9
Ap1m1
adaptor-related protein complex 
AP-1, mu subunit 1
Sum of Sum_pept_count 0 0 0 11
Max of Max_Dif_pept 0 0 0 9
Cdc42
cell division cycle 42 homolog (S. 
cerevisiae)
Sum of Sum_pept_count 51 49 46 47
Max of Max_Dif_pept 9 8 7 8
Map2k1
mitogen-activated protein kinase 
kinase 1
Sum of Sum_pept_count 6 2 6 13
Max of Max_Dif_pept 6 2 6 9
Actr2
ARP2 actin-related protein 2 
homolog (yeast)
Sum of Sum_pept_count 3 14 12 10
Max of Max_Dif_pept 3 7 9 5
Kras
v-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog
Sum of Sum_pept_count 36 26 21 15
Max of Max_Dif_pept 9 8 8 7
Inpp5a
inositol polyphosphate-5-
phosphatase A
Sum of Sum_pept_count 6 8 10 5
Max of Max_Dif_pept 6 7 9 5
Hbb-b2
hemoglobin, beta adult minor 
chain
Sum of Sum_pept_count 14 21 19 25
Max of Max_Dif_pept 6 9 7 9
Hbb-b1
hemoglobin, beta adult major 
chain
Sum of Sum_pept_count 14 21 19 25
Max of Max_Dif_pept 6 9 7 9
Cmpk2
cytidine monophosphate (UMP-
CMP) kinase 2, mitochondrial
Sum of Sum_pept_count 0 3 0 9
Max of Max_Dif_pept0 3 0 9    197
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H2-L histocompatibility 2, D region Sum of Sum_pept_count 7 2 17 15
Max of Max_Dif_pept 5 2 9 6
H2-D1
histocompatibility 2, D region locus 
1
Sum of Sum_pept_count 7 2 17 15
Max of Max_Dif_pept 5 2 9 6
Gpx1 glutathione peroxidase 1 Sum of Sum_pept_count 8 14 10 13
Max of Max_Dif_pept 5 9 6 8
B4galnt2
beta-1,4-N-acetyl-galactosaminyl 
transferase 2
Sum of Sum_pept_count 1 1 11 4
Max of Max_Dif_pept 1 1 9 4
Capn1 calpain 1 Sum of Sum_pept_count 0 4 9 5
Max of Max_Dif_pept 0 4 9 5
Ap2b1
adaptor-related protein complex 2, 
beta 1 subunit
Sum of Sum_pept_count 6 20 14 9
Max of Max_Dif_pept 5 9 7 6
Ehd4 EH-domain containing 4 Sum of Sum_pept_count 0 11 8 12
Max of Max_Dif_pept 0 9 5 9
Ehd3 EH-domain containing 3 Sum of Sum_pept_count 0 12 0 0
Max of Max_Dif_pept 0 9 0 0
Dnpep aspartyl aminopeptidase Sum of Sum_pept_count 2 9 4 15
Max of Max_Dif_pept 2 7 4 9
Dnaja2
DnaJ (Hsp40) homolog, subfamily 
A, member 2
Sum of Sum_pept_count 9 10 9 13
Max of Max_Dif_pept 6 9 7 8
Dars aspartyl-tRNA synthetase Sum of Sum_pept_count 0 0 0 9
Max of Max_Dif_pept 0 0 0 9
Atic
5-aminoimidazole-4-carboxamide 
ribonucleotide 
formyltransferase/IMP 
cyclohydrolase
Sum of Sum_pept_count 0 7 4 19
Max of Max_Dif_pept 0 7 4 9
Vcp valosin containing protein Sum of Sum_pept_count 2 13 10 13
Max of Max_Dif_pept 2 8 4 5
Coro1b coronin, actin binding protein 1B Sum of Sum_pept_count 9 24 14 14
Max of Max_Dif_pept 4 8 4 6
Vat1
vesicle amine transport protein 1 
homolog (T californica)
Sum of Sum_pept_count 13 16 5 15
Max of Max_Dif_pept 7 7 3 8
Atp1b1
ATPase, Na+/K+ transporting, beta 
1 polypeptide
Sum of Sum_pept_count 32 17 33 31
Max of Max_Dif_pept 7 4 8 7
Ugt1a7c
UDP glucuronosyltransferase 1 
family, polypeptide A7C
Sum of Sum_pept_count 5 1 4 8
Max of Max_Dif_pept 5 1 4 8
Tubb6 tubulin, beta 6 Sum of Sum_pept_count 6 7 4 28
Max of Max_Dif_pept 3 4 1 8
Adam10
a disintegrin and metallopeptidase 
domain 10
Sum of Sum_pept_count 1 0 8 6
Max of Max_Dif_pept 1 0 8 6
Tradd
TNFRSF1A-associated via death 
domain
Sum of Sum_pept_count 11 6 7 11
Max of Max_Dif_pept 8 4 5 5
Taldo1 transaldolase 1 Sum of Sum_pept_count 2 16 12 11
Max of Max_Dif_pept 1 8 5 6
Smpd3
sphingomyelin phosphodiesterase 
3, neutral
Sum of Sum_pept_count 37 11 26 17
Max of Max_Dif_pept 8 4 7 4
Slc28a2
solute carrier family 28 (sodium-
coupled nucleoside transporter), 
member 2
Sum of Sum_pept_count 19 11 8 9
Max of Max_Dif_pept 8 6 5 5
Slc28a1
solute carrier family 28 (sodium-
coupled nucleoside transporter), 
member 1
Sum of Sum_pept_count 26 4 0 12
Max of Max_Dif_pept 8 3 0 5
Slc26a3 solute carrier family 26, member 3 Sum of Sum_pept_count 12 0 30 10
Max of Max_Dif_pept 6 0 8 5
Atp5a1
ATP synthase, H+ transporting, 
mitochondrial F1 complex, alpha 
subunit, isoform 1
Sum of Sum_pept_count 0 0 1 17
Max of Max_Dif_pept 0 0 1 8
Serpinb6a
serine (or cysteine) peptidase 
inhibitor, clade B, member 6a
Sum of Sum_pept_count 7 13 11 17
Max of Max_Dif_pept 5 8 6 8
Sec23b SEC23B (S. cerevisiae) Sum of Sum_pept_count 0 3 2 16
Max of Max_Dif_pept 0 2 2 8
9130017N09Rik RIKEN cDNA 9130017N09 gene Sum of Sum_pept_count 19 28 38 53
Max of Max_Dif_pept 6 6 8 6
Rras2
related RAS viral (r-ras) oncogene 
homolog 2
Sum of Sum_pept_count 19 11 19 12
Max of Max_Dif_pept 8 6 7 7
Rpn2 ribophorin II Sum of Sum_pept_count 0 0 9 1
Max of Max_Dif_pept 0 0 8 1  198
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Rhpn2
rhophilin, Rho GTPase binding 
protein 2
Sum of Sum_pept_count 3 10 10 8
Max of Max_Dif_pept 3 8 7 7
Rdh7 retinol dehydrogenase 7 Sum of Sum_pept_count 0 0 0 9
Max of Max_Dif_pept 0 0 0 8
Atp5f1
ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit 
b, isoform 1
Sum of Sum_pept_count 0 0 4 15
Max of Max_Dif_pept 0 0 3 8
Ralb
v-ral simian leukemia viral 
oncogene homolog B (ras related)
Sum of Sum_pept_count 38 14 24 14
Max of Max_Dif_pept 8 6 8 8
Bsg basigin Sum of Sum_pept_count 27 10 29 22
Max of Max_Dif_pept 8 4 8 8
Rab5b
RAB5B, member RAS oncogene 
family
Sum of Sum_pept_count 16 7 18 12
Max of Max_Dif_pept 8 4 7 7
Rab5a
RAB5A, member RAS oncogene 
family
Sum of Sum_pept_count 28 5 33 24
Max of Max_Dif_pept 7 4 6 8
Rab3d
RAB3D, member RAS oncogene 
family
Sum of Sum_pept_count 11 8 15 16
Max of Max_Dif_pept 4 4 7 8
Cct4
chaperonin containing Tcp1, 
subunit 4 (delta)
Sum of Sum_pept_count 0 3 5 11
Max of Max_Dif_pept 0 3 5 8
Ctnnd1
catenin (cadherin associated 
protein), delta 1
Sum of Sum_pept_count 4 2 17 7
Max of Max_Dif_pept 3 1 8 2
Rab25
RAB25, member RAS oncogene 
family
Sum of Sum_pept_count 14 3 20 14
Max of Max_Dif_pept 7 3 8 7
Rab22a
RAB22A, member RAS oncogene 
family
Sum of Sum_pept_count 17 8 9 10
Max of Max_Dif_pept 8 6 4 7
Rab18
RAB18, member RAS oncogene 
family
Sum of Sum_pept_count 16 9 15 15
Max of Max_Dif_pept 8 6 7 6
Psmc6
proteasome (prosome, macropain) 
26S subunit, ATPase, 6
Sum of Sum_pept_count 1 1 3 13
Max of Max_Dif_pept 1 1 2 8
Psmc4
proteasome (prosome, macropain) 
26S subunit, ATPase, 4
Sum of Sum_pept_count 0 0 0 13
Max of Max_Dif_pept 0 0 0 8
Prss7 protease, serine, 7 (enterokinase) Sum of Sum_pept_count 48 1 0 12
Max of Max_Dif_pept 8 1 0 4
Aldh16a1
aldehyde dehydrogenase 16 
family, member A1
Sum of Sum_pept_count 0 2 2 17
Max of Max_Dif_pept 0 2 2 8
Prkag2
protein kinase, AMP-activated, 
gamma 2 non-catalytic subunit
Sum of Sum_pept_count 1 9 3 10
Max of Max_Dif_pept 1 8 3 7
Cd36 CD36 antigen Sum of Sum_pept_count 14 10 6 12
Max of Max_Dif_pept 8 8 5 7
Ppap2a phosphatidic acid phosphatase 2a Sum of Sum_pept_count 112 42 24 34
Max of Max_Dif_pept 8 5 3 5
Ap1g1
adaptor protein complex AP-1, 
gamma 1 subunit
Sum of Sum_pept_count 0 0 1 15
Max of Max_Dif_pept 0 0 1 8
Pdia3
protein disulfide isomerase 
associated 3
Sum of Sum_pept_count 0 0 0 8
Max of Max_Dif_pept 0 0 0 8
Pck1
phosphoenolpyruvate 
carboxykinase 1, cytosolic
Sum of Sum_pept_count 1 0 1 8
Max of Max_Dif_pept 1 0 1 8
Papss1
3'-phosphoadenosine 5'-
phosphosulfate synthase 1
Sum of Sum_pept_count 3 2 1 14
Max of Max_Dif_pept 1 2 1 8
Nsf
N-ethylmaleimide sensitive fusion 
protein
Sum of Sum_pept_count 3 0 5 8
Max of Max_Dif_pept 2 0 3 8
Cyp3a13
cytochrome P450, family 3, 
subfamily a, polypeptide 13
Sum of Sum_pept_count 12 1 8 19
Max of Max_Dif_pept 5 1 6 8
Nras neuroblastoma ras oncogene Sum of Sum_pept_count 7 21 7 10
Max of Max_Dif_pept3 8 4 8    199
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Clic4
chloride intracellular channel 4 
(mitochondrial)
Sum of Sum_pept_count 2 10 4 7
Max of Max_Dif_pept 2 8 4 6
D1Pas1
DNA segment, Chr 1, Pasteur 
Institute 1
Sum of Sum_pept_count 8 11 32 10
Max of Max_Dif_pept 3 2 8 4
Ncstn nicastrin Sum of Sum_pept_count 8 7 9 9
Max of Max_Dif_pept 7 7 8 5
Nat2
N-acetyltransferase 2 (arylamine N-
acetyltransferase)
Sum of Sum_pept_count 2 2 1 8
Max of Max_Dif_pept 2 2 1 8
Mvp major vault protein Sum of Sum_pept_count 0 0 2 20
Max of Max_Dif_pept 0 0 2 8
Muc3 mucin 3, intestinal Sum of Sum_pept_count 14 13 32 20
Max of Max_Dif_pept 7 5 8 6
Arf6 ADP-ribosylation factor 6 Sum of Sum_pept_count 36 27 42 33
Max of Max_Dif_pept 8 7 8 8
Msra methionine sulfoxide reductase A Sum of Sum_pept_count 3 2 3 14
Max of Max_Dif_pept 3 1 2 8
Mical1
microtubule associated 
monoxygenase, calponin and LIM 
domain containing 1
Sum of Sum_pept_count 3 16 5 9
Max of Max_Dif_pept 2 8 3 3
Mdh1
malate dehydrogenase 1, NAD 
(soluble)
Sum of Sum_pept_count 8 18 13 19
Max of Max_Dif_pept 4 8 6 7
Mapk13
mitogen-activated protein kinase 
13
Sum of Sum_pept_count 6 14 12 13
Max of Max_Dif_pept 3 6 5 8
LOC628409 similar to cytoplasmic beta-actin Sum of Sum_pept_count 15 0 22 0
Max of Max_Dif_pept 8 0 7 0
Lgals9 lectin, galactose binding, soluble 9 Sum of Sum_pept_count 44 27 41 29
Max of Max_Dif_pept 8 8 8 6
Krt8 keratin 8 Sum of Sum_pept_count 3 12 27 60
Max of Max_Dif_pept 2 4 8 8
Krt42 keratin 42 Sum of Sum_pept_count 4 5 20 12
Max of Max_Dif_pept 2 2 8 5
Igf2r insulin-like growth factor 2 receptor Sum of Sum_pept_count 0 0 0 8
Max of Max_Dif_pept 0 0 0 8
Ceacam1
carcinoembryonic antigen-related 
cell adhesion molecule 1
Sum of Sum_pept_count 27 25 67 30
Max of Max_Dif_pept 5 4 8 4
Cmpk1
cytidine monophosphate (UMP-
CMP) kinase 1
Sum of Sum_pept_count 8 9 10 10
Max of Max_Dif_pept 8 8 7 7
Gstm3 glutathione S-transferase, mu 3 Sum of Sum_pept_count 6 1 1 8
Max of Max_Dif_pept 6 1 1 8
Dera
2-deoxyribose-5-phosphate 
aldolase homolog (C. elegans)
Sum of Sum_pept_count 1 3 2 11
Max of Max_Dif_pept 1 3 2 8
Gsr glutathione reductase Sum of Sum_pept_count 0 7 7 8
Max of Max_Dif_pept 0 7 7 8
Golph3 golgi phosphoprotein 3 Sum of Sum_pept_count 13 15 10 7
Max of Max_Dif_pept 6 8 5 6
Gna14
guanine nucleotide binding protein, 
alpha 14
Sum of Sum_pept_count 26 31 25 26
Max of Max_Dif_pept 7 7 8 6
Gale galactose-4-epimerase, UDP Sum of Sum_pept_count 1 1 2 13
Max of Max_Dif_pept 1 1 2 8
Dhrs1
dehydrogenase/reductase (SDR 
family) member 1
Sum of Sum_pept_count 9 4 1 9
Max of Max_Dif_pept 8 4 1 8
Flnb filamin, beta Sum of Sum_pept_count 0 1 4 11
Max of Max_Dif_pept 0 1 3 8
Fkbp4 FK506 binding protein 4 Sum of Sum_pept_count 0 1 2 15
Max of Max_Dif_pept0 1 2 8
Fabp1 fatty acid binding protein 1, liver Sum of Sum_pept_count 18 39 5 26
Max of Max_Dif_pept 5 8 2 8
EG546101 predicted gene, EG546101 Sum of Sum_pept_count 33 3 37 5
Max of Max_Dif_pept 7 3 8 5
Efr3a EFR3 homolog A (S. cerevisiae) Sum of Sum_pept_count 11 9 13 2
Max of Max_Dif_pept 6 8 7 1
Efhd2 EF hand domain containing 2 Sum of Sum_pept_count 1 25 12 21
Max of Max_Dif_pept 1 8 4 6
Sept7 septin 7 Sum of Sum_pept_count 0 3 3 12
Max of Max_Dif_pept 0 2 2 7
Acox1
acyl-Coenzyme A oxidase 1, 
palmitoyl
Sum of Sum_pept_count 0 0 0 13
Max of Max_Dif_pept 0 0 0 7  200
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Vti1b
vesicle transport through 
interaction with t-SNAREs 1B 
homolog
Sum of Sum_pept_count 8 4 10 9
Max of Max_Dif_pept 4 3 7 3
Apoa1 apolipoprotein A-I Sum of Sum_pept_count 3 0 4 9
Max of Max_Dif_pept 3 0 4 7
Vdac2 voltage-dependent anion channel 2 Sum of Sum_pept_count 3 1 9 11
Max of Max_Dif_pept 3 1 6 7
Vdac1 voltage-dependent anion channel 1 Sum of Sum_pept_count 4 2 6 9
Max of Max_Dif_pept 4 2 6 7
Coro2a coronin, actin binding protein 2A Sum of Sum_pept_count 0 8 5 13
Max of Max_Dif_pept 0 5 4 7
Vasp
vasodilator-stimulated 
phosphoprotein
Sum of Sum_pept_count 3 7 1 5
Max of Max_Dif_pept 3 7 1 4
Upp1 uridine phosphorylase 1 Sum of Sum_pept_count 3 10 12 7
Max of Max_Dif_pept 2 7 7 4
2010003H20Rik RIKEN cDNA 2010003H20 gene Sum of Sum_pept_count 127 81 130 89
Max of Max_Dif_pept 7 7 7 7
Txn1 thioredoxin 1 Sum of Sum_pept_count 9 23 14 15
Max of Max_Dif_pept 3 7 5 7
Arl14 ADP-ribosylation factor-like 14 Sum of Sum_pept_count 8 4 1 3
Max of Max_Dif_pept 7 4 1 3
Tubb2b tubulin, beta 2b Sum of Sum_pept_count 14 4 12 30
Max of Max_Dif_pept 5 1 3 7
Tsta3
tissue specific transplantation 
antigen P35B
Sum of Sum_pept_count 0 1 2 10
Max of Max_Dif_pept 0 1 1 7
Arl1 ADP-ribosylation factor-like 1 Sum of Sum_pept_count 3 8 6 15
Max of Max_Dif_pept 3 6 5 7
Tspan8 tetraspanin 8 Sum of Sum_pept_count 38 33 59 41
Max of Max_Dif_pept 5 5 6 7
2400003C14Rik RIKEN cDNA 2400003C14 gene Sum of Sum_pept_count 16 23 17 21
Max of Max_Dif_pept 5 7 6 4
Tpm3 tropomyosin 3, gamma Sum of Sum_pept_count 1 2 3 8
Max of Max_Dif_pept 1 2 2 7
Tmigd1
transmembrane and 
immunoglobulin domain containing 
1
Sum of Sum_pept_count 0 6 24 5
Max of Max_Dif_pept 0 4 7 3
Tmem30b transmembrane protein 30B Sum of Sum_pept_count 38 34 40 27
Max of Max_Dif_pept 6 6 7 6
Tmem30a transmembrane protein 30A Sum of Sum_pept_count 6 7 17 5
Max of Max_Dif_pept 3 4 7 3
Casp6 caspase 6 Sum of Sum_pept_count 4 6 1 18
Max of Max_Dif_pept 2 3 1 7
Tcp1 t-complex protein 1 Sum of Sum_pept_count 0 2 2 8
Max of Max_Dif_pept 0 1 1 7
Coro1a coronin, actin binding protein 1A Sum of Sum_pept_count 1 7 5 3
Max of Max_Dif_pept 1 7 4 2
Stx12 syntaxin 12 Sum of Sum_pept_count 0 0 4 13
Max of Max_Dif_pept 0 0 3 7
Stat1
signal transducer and activator of 
transcription 1
Sum of Sum_pept_count 2 2 5 8
Max of Max_Dif_pept 2 2 3 7
Akr1b7
aldo-keto reductase family 1, 
member B7
Sum of Sum_pept_count 0 4 0 9
Max of Max_Dif_pept 0 4 0 7
Slc6a14
solute carrier family 6 
(neurotransmitter transporter), 
member 14
Sum of Sum_pept_count 0 0 9 2
Max of Max_Dif_pept 0 0 7 2
Slc5a12
solute carrier family 5 
(sodium/glucose cotransporter), 
member 12
Sum of Sum_pept_count 18 16 7 15
Max of Max_Dif_pept6 6 4 7
Slc2a5
solute carrier family 2 (facilitated 
glucose transporter), member 5
Sum of Sum_pept_count 28 8 3 13
Max of Max_Dif_pept 7 4 2 5
Akr1c13
aldo-keto reductase family 1, 
member C13
Sum of Sum_pept_count 3 7 3 0
Max of Max_Dif_pept 3 7 3 0
Slc25a5
solute carrier family 25 
(mitochondrial carrier, adenine 
nucleotide translocator), member 5
Sum of Sum_pept_count 2 2 13 25
Max of Max_Dif_pept 1 1 4 7
1810010M01Rik RIKEN cDNA 1810010M01 gene Sum of Sum_pept_count 13 10 33 28
Max of Max_Dif_pept 6 5 7 7
Shmt1
serine hydroxymethyltransferase 1 
(soluble)
Sum of Sum_pept_count 1 2 2 10
Max of Max_Dif_pept 1 1 1 7
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Sec13 SEC13 homolog (S. cerevisiae) Sum of Sum_pept_count 1 1 1 10
Max of Max_Dif_pept 1 1 1 7
Rps8 ribosomal protein S8 Sum of Sum_pept_count 6 0 7 8
Max of Max_Dif_pept 6 0 7 7
Rhod
ras homolog gene family, member 
D
Sum of Sum_pept_count 15 7 13 10
Max of Max_Dif_pept 7 4 7 6
Cct3
chaperonin containing Tcp1, 
subunit 3 (gamma)
Sum of Sum_pept_count 0 0 3 7
Max of Max_Dif_pept 0 0 2 7
Rdh9 retinol dehydrogenase 9 Sum of Sum_pept_count 0 0 0 9
Max of Max_Dif_pept 0 0 0 7
Rbp2 retinol binding protein 2, cellular Sum of Sum_pept_count 12 21 6 19
Max of Max_Dif_pept 5 7 2 7
Rap2b
RAP2B, member of RAS 
oncogene family
Sum of Sum_pept_count 0 11 17 10
Max of Max_Dif_pept 0 7 7 7
Araf
v-raf murine sarcoma 3611 viral 
oncogene homolog
Sum of Sum_pept_count 15 4 7 9
Max of Max_Dif_pept 5 2 3 7
Ran
RAN, member RAS oncogene 
family
Sum of Sum_pept_count 6 9 10 20
Max of Max_Dif_pept 5 4 4 7
Rab6
RAB6, member RAS oncogene 
family
Sum of Sum_pept_count 38 17 35 40
Max of Max_Dif_pept 7 6 7 7
Arl8a ADP-ribosylation factor-like 8A Sum of Sum_pept_count 9 6 8 7
Max of Max_Dif_pept 7 5 5 6
Arl8b ADP-ribosylation factor-like 8B Sum of Sum_pept_count 8 8 11 8
Max of Max_Dif_pept 5 6 7 6
Rab27b
RAB27b, member RAS oncogene 
family
Sum of Sum_pept_count 6 1 7 6
Max of Max_Dif_pept 5 1 7 6
Rab17
RAB17, member RAS oncogene 
family
Sum of Sum_pept_count 9 8 12 10
Max of Max_Dif_pept 7 7 7 7
Pycard PYD and CARD domain containing Sum of Sum_pept_count 2 8 4 8
Max of Max_Dif_pept 2 7 3 6
2210404O07Rik RIKEN cDNA 2210404O07 gene Sum of Sum_pept_count 187 155 150 161
Max of Max_Dif_pept 6 6 7 7
Cyb5r3 cytochrome b5 reductase 3 Sum of Sum_pept_count 4 3 4 10
Max of Max_Dif_pept 4 3 4 7
Prkacb
protein kinase, cAMP dependent, 
catalytic, beta
Sum of Sum_pept_count 0 0 0 8
Max of Max_Dif_pept 0 0 0 7
Prkaa1
protein kinase, AMP-activated, 
alpha 1 catalytic subunit
Sum of Sum_pept_count 0 4 2 8
Max of Max_Dif_pept 0 4 2 7
Pnp1 purine-nucleoside phosphorylase 1 Sum of Sum_pept_count 3 13 11 13
Max of Max_Dif_pept 2 6 5 7
Clca6
chloride channel calcium activated 
6
Sum of Sum_pept_count 33 31 46 42
Max of Max_Dif_pept 6 5 6 7
Pdcd6 programmed cell death 6 Sum of Sum_pept_count 3 11 4 6
Max of Max_Dif_pept 2 7 4 3
P2rx4
purinergic receptor P2X, ligand-
gated ion channel 4
Sum of Sum_pept_count 7 6 13 8
Max of Max_Dif_pept 7 6 7 7
Numb numb gene homolog (Drosophila) Sum of Sum_pept_count 16 13 20 7
Max of Max_Dif_pept 5 7 7 2
D10Bwg1364e
DNA segment, Chr 10, Brigham & 
Women's Genetics 1364 
expressed
Sum of Sum_pept_count 28 11 10 9
Max of Max_Dif_pept 7 4 4 6
Nme1
non-metastatic cells 1, protein 
(NM23A) expressed in
Sum of Sum_pept_count 5 10 9 6
Max of Max_Dif_pept 5 7 6 6
Aldh2
aldehyde dehydrogenase 2, 
mitochondrial
Sum of Sum_pept_count 0 0 0 13
Max of Max_Dif_pept0 0 0 7
Naprt1
nicotinate 
phosphoribosyltransferase domain 
containing 1
Sum of Sum_pept_count 0 3 1 7
Max of Max_Dif_pept 0 3 1 7
Nampt
nicotinamide 
phosphoribosyltransferase
Sum of Sum_pept_count 1 2 0 16
Max of Max_Dif_pept 1 2 0 7
Map2k2
mitogen-activated protein kinase 
kinase 2
Sum of Sum_pept_count 9 7 7 13
Max of Max_Dif_pept 6 4 7 7  202
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Maoa monoamine oxidase A Sum of Sum_pept_count 1 0 4 10
Max of Max_Dif_pept 1 0 4 7
Lrrc57 leucine rich repeat containing 57 Sum of Sum_pept_count 6 4 8 4
Max of Max_Dif_pept 5 4 7 4
Lman2 lectin, mannose-binding 2 Sum of Sum_pept_count 1 0 5 7
Max of Max_Dif_pept 1 0 5 7
Akp5 alkaline phosphatase 5 Sum of Sum_pept_count 8 10 14 14
Max of Max_Dif_pept 7 5 6 6
Krt86 keratin 86 Sum of Sum_pept_count 5 8 4 0
Max of Max_Dif_pept 4 7 4 0
Krt33a keratin 33A Sum of Sum_pept_count 25 13 2 0
Max of Max_Dif_pept 7 5 2 0
Krt14 keratin 14 Sum of Sum_pept_count 9 10 9 13
Max of Max_Dif_pept 7 6 3 5
Khk ketohexokinase Sum of Sum_pept_count 2 10 4 11
Max of Max_Dif_pept 2 7 4 5
Iqgap1
IQ motif containing GTPase 
activating protein 1
Sum of Sum_pept_count 1 14 8 8
Max of Max_Dif_pept 1 5 5 7
Ifi47
interferon gamma inducible protein 
47
Sum of Sum_pept_count 6 5 7 8
Max of Max_Dif_pept 6 4 6 7
Hras1
Harvey rat sarcoma virus 
oncogene 1
Sum of Sum_pept_count 13 25 15 8
Max of Max_Dif_pept 3 7 4 2
Gstp1 glutathione S-transferase, pi 1 Sum of Sum_pept_count 4 12 7 10
Max of Max_Dif_pept 3 6 5 7
Gsto1 glutathione S-transferase omega 1 Sum of Sum_pept_count 5 9 11 12
Max of Max_Dif_pept 3 3 4 7
Gpt
glutamic pyruvic transaminase, 
soluble
Sum of Sum_pept_count 4 8 3 8
Max of Max_Dif_pept 4 7 3 7
Gpa33 glycoprotein A33 (transmembrane) Sum of Sum_pept_count 16 11 22 27
Max of Max_Dif_pept 7 5 7 7
Golga7
golgi autoantigen, golgin subfamily 
a, 7
Sum of Sum_pept_count 12 7 10 9
Max of Max_Dif_pept 4 5 7 4
Gnb2l1
guanine nucleotide binding protein 
(G protein), beta polypeptide 2 like 
1
Sum of Sum_pept_count 1 0 0 11
Max of Max_Dif_pept 1 0 0 7
2810405K02Rik RIKEN cDNA 2810405K02 gene Sum of Sum_pept_count 5 11 8 23
Max of Max_Dif_pept 5 7 5 7
2210417D09Rik RIKEN cDNA 2210417D09 gene Sum of Sum_pept_count 3 4 12 6
Max of Max_Dif_pept 2 3 7 5
Fdps farnesyl diphosphate synthetase Sum of Sum_pept_count 9 16 13 8
Max of Max_Dif_pept 1 4 7 5
4931406C07Rik RIKEN cDNA 4931406C07 gene Sum of Sum_pept_count 4 8 5 5
Max of Max_Dif_pept 3 7 4 4
Adh5
alcohol dehydrogenase 5 (class 
III), chi polypeptide
Sum of Sum_pept_count 0 0 0 6
Max of Max_Dif_pept 0 0 0 6
Wars tryptophanyl-tRNA synthetase Sum of Sum_pept_count 0 3 3 14
Max of Max_Dif_pept 0 3 2 6
Cotl1 coactosin-like 1 (Dictyostelium) Sum of Sum_pept_count 3 8 9 8
Max of Max_Dif_pept 2 3 5 6
Ugp2 UDP-glucose pyrophosphorylase 2 Sum of Sum_pept_count 0 6 2 6
Max of Max_Dif_pept 0 5 2 6
Txnrd1 thioredoxin reductase 1 Sum of Sum_pept_count 1 8 4 3
Max of Max_Dif_pept 1 6 3 2
Txndc5 thioredoxin domain containing 5 Sum of Sum_pept_count 0 0 0 9
Max of Max_Dif_pept0 0 0 6
Tubal3 tubulin, alpha-like 3 Sum of Sum_pept_count 0 6 0 8
Max of Max_Dif_pept 0 5 0 6
Ttc7 tetratricopeptide repeat domain 7 Sum of Sum_pept_count 3 9 3 1
Max of Max_Dif_pept 3 6 2 1
0610010K06Rik RIKEN cDNA 0610010K06 gene Sum of Sum_pept_count 5 7 1 6
Max of Max_Dif_pept 4 6 1 5
Chmp2a chromatin modifying protein 2A Sum of Sum_pept_count 13 12 12 13
Max of Max_Dif_pept 3 3 4 6
Trf transferrin Sum of Sum_pept_count 0 6 0 1
Max of Max_Dif_pept 0 6 0 1
1110038D17Rik RIKEN cDNA 1110038D17 gene Sum of Sum_pept_count 15 0 0 5
Max of Max_Dif_pept 6 0 0 3
Tm9sf2
transmembrane 9 superfamily 
member 2
Sum of Sum_pept_count 6 2 16 9
Max of Max_Dif_pept 4 1 6 4
Tars threonyl-tRNA synthetase Sum of Sum_pept_count 0 3 3 7
Max of Max_Dif_pept 0 3 3 6    203
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Casp7 caspase 7 Sum of Sum_pept_count 4 10 7 6
Max of Max_Dif_pept 4 6 5 5
Arl2 ADP-ribosylation factor-like 2 Sum of Sum_pept_count 0 1 2 6
Max of Max_Dif_pept 0 1 2 6
Sord sorbitol dehydrogenase Sum of Sum_pept_count 0 7 4 6
Max of Max_Dif_pept 0 6 3 5
Sod1 superoxide dismutase 1, soluble Sum of Sum_pept_count 3 6 5 4
Max of Max_Dif_pept 3 6 4 4
Slc6a20a
solute carrier family 6 
(neurotransmitter transporter), 
member 20A
Sum of Sum_pept_count 21 11 11 15
Max of Max_Dif_pept 6 5 6 5
Slc5a9
solute carrier family 5 
(sodium/glucose cotransporter), 
member 9
Sum of Sum_pept_count 23 20 19 16
Max of Max_Dif_pept 6 6 6 6
Slc5a8
solute carrier family 5 (iodide 
transporter), member 8
Sum of Sum_pept_count 3 34 56 26
Max of Max_Dif_pept 1 5 6 6
Slc25a3
solute carrier family 25 
(mitochondrial carrier, phosphate 
carrier), member 3
Sum of Sum_pept_count 0 0 1 10
Max of Max_Dif_pept 0 0 1 6
Slc23a1
solute carrier family 23 
(nucleobase transporters), 
member 1
Sum of Sum_pept_count 13 14 5 10
Max of Max_Dif_pept 6 5 2 4
Slc10a2 solute carrier family 10, member 2 Sum of Sum_pept_count 0 3 35 15
Max of Max_Dif_pept 0 2 6 5
Sh3bgrl3
SH3 domain binding glutamic acid-
rich protein-like 3
Sum of Sum_pept_count 4 14 9 10
Max of Max_Dif_pept 3 6 3 5
Cryl1 crystallin, lambda 1 Sum of Sum_pept_count 1 7 3 7
Max of Max_Dif_pept 1 6 3 6
Sar1b
SAR1 gene homolog B (S. 
cerevisiae)
Sum of Sum_pept_count 2 6 3 6
Max of Max_Dif_pept 2 6 2 5
Samhd1 SAM domain and HD domain, 1 Sum of Sum_pept_count 0 0 0 7
Max of Max_Dif_pept 0 0 0 6
Rps3 ribosomal protein S3 Sum of Sum_pept_count 5 2 4 7
Max of Max_Dif_pept 3 2 4 6
Rps19 ribosomal protein S19 Sum of Sum_pept_count 10 5 9 2
Max of Max_Dif_pept 6 4 5 2
Rps18 ribosomal protein S18 Sum of Sum_pept_count 11 5 14 13
Max of Max_Dif_pept 5 4 5 6
Rhof
ras homolog gene family, member 
f
Sum of Sum_pept_count 10 8 18 7
Max of Max_Dif_pept 5 5 6 4
Capza1
capping protein (actin filament) 
muscle Z-line, alpha 1
Sum of Sum_pept_count 0 10 4 11
Max of Max_Dif_pept 0 4 2 6
BC022224 cDNA sequence BC022224 Sum of Sum_pept_count 2 2 4 9
Max of Max_Dif_pept 1 2 2 6
Rabggta
Rab geranylgeranyl transferase, a 
subunit
Sum of Sum_pept_count 0 0 0 6
Max of Max_Dif_pept 0 0 0 6
Akr1c19 aldo-keto reductase family 1, 
member C19
Sum of Sum_pept_count 0 0 2 8
Max of Max_Dif_pept 0 0 2 6
Rab4b
RAB4B, member RAS oncogene 
family
Sum of Sum_pept_count 7 5 0 14
Max of Max_Dif_pept 6 5 0 6
Ckmt1
creatine kinase, mitochondrial 1, 
ubiquitous
Sum of Sum_pept_count 0 5 6 14
Max of Max_Dif_pept 0 3 3 6
Ctnna1
catenin (cadherin associated 
protein), alpha 1
Sum of Sum_pept_count 0 0 8 1
Max of Max_Dif_pept 0 0 6 1
Rab33b
RAB33B, member of RAS 
oncogene family
Sum of Sum_pept_count 10 8 7 6
Max of Max_Dif_pept 6 3 4 4
Rab30
RAB30, member RAS oncogene 
family
Sum of Sum_pept_count 10 0 0 0
Max of Max_Dif_pept6 0 0 0
Rab13 RAB13, member RAS oncogene 
family
Sum of Sum_pept_count 15 0 12 1
Max of Max_Dif_pept 3 0 6 1
Psme2
proteasome (prosome, macropain) 
28 subunit, beta
Sum of Sum_pept_count 2 5 6 14
Max of Max_Dif_pept 2 4 3 6  204
Gene Symbol Gene Description Data proximal central distal total mucosa
Psmd6
proteasome (prosome, macropain) 
26S subunit, non-ATPase, 6
Sum of Sum_pept_count 0 0 0 6
Max of Max_Dif_pept 0 0 0 6
Psmd3
proteasome (prosome, macropain) 
26S subunit, non-ATPase, 3
Sum of Sum_pept_count 0 0 0 8
Max of Max_Dif_pept 0 0 0 6
Cct6a
chaperonin containing Tcp1, 
subunit 6a (zeta)
Sum of Sum_pept_count 1 3 5 10
Max of Max_Dif_pept 1 3 4 6
Arf2 ADP-ribosylation factor 2 Sum of Sum_pept_count 6 12 9 11
Max of Max_Dif_pept 5 6 5 4
Psma5
proteasome (prosome, macropain) 
subunit, alpha type 5
Sum of Sum_pept_count 0 0 6 7
Max of Max_Dif_pept 0 0 6 6
Prdx2 peroxiredoxin 2 Sum of Sum_pept_count 6 6 10 12
Max of Max_Dif_pept 2 4 4 6
Plscr1 phospholipid scramblase 1 Sum of Sum_pept_count 35 17 32 25
Max of Max_Dif_pept 6 4 5 4
Plb1 phospholipase B1 Sum of Sum_pept_count 0 18 29 14
Max of Max_Dif_pept 0 6 6 4
2610018G03Rik RIKEN cDNA 2610018G03 gene Sum of Sum_pept_count 2 13 11 7
Max of Max_Dif_pept 1 6 4 1
Cyp2b10
cytochrome P450, family 2, 
subfamily b, polypeptide 10
Sum of Sum_pept_count 2 0 0 6
Max of Max_Dif_pept 2 0 0 6
Pitpna
phosphatidylinositol transfer 
protein, alpha
Sum of Sum_pept_count 2 7 6 7
Max of Max_Dif_pept 2 6 6 5
Phb2 prohibitin 2 Sum of Sum_pept_count 0 0 3 6
Max of Max_Dif_pept 0 0 2 6
Pgls 6-phosphogluconolactonase Sum of Sum_pept_count 1 1 1 9
Max of Max_Dif_pept 1 1 1 6
Pdlim1 PDZ and LIM domain 1 (elfin) Sum of Sum_pept_count 3 15 6 20
Max of Max_Dif_pept 1 6 2 5
Pde9a phosphodiesterase 9A Sum of Sum_pept_count 0 8 8 3
Max of Max_Dif_pept 0 6 5 3
Pcyt2
phosphate cytidylyltransferase 2, 
ethanolamine
Sum of Sum_pept_count 1 3 1 6
Max of Max_Dif_pept 1 3 1 6
Pcbp1 poly(rC) binding protein 1 Sum of Sum_pept_count 15 11 15 22
Max of Max_Dif_pept 5 4 5 6
Cyp2d26
cytochrome P450, family 2, 
subfamily d, polypeptide 26
Sum of Sum_pept_count 2 0 1 6
Max of Max_Dif_pept 2 0 1 6
Pacsin2
protein kinase C and casein kinase 
substrate in neurons 2
Sum of Sum_pept_count 4 17 8 10
Max of Max_Dif_pept 2 6 6 6
Ostf1 osteoclast stimulating factor 1 Sum of Sum_pept_count 4 7 9 11
Max of Max_Dif_pept 3 4 6 6
Glod5 glyoxalase domain containing 5 Sum of Sum_pept_count 3 11 5 9
Max of Max_Dif_pept 2 5 4 6
Glrx glutaredoxin Sum of Sum_pept_count 6 19 19 11
Max of Max_Dif_pept 4 6 5 6
Ndufb10
NADH dehydrogenase 
(ubiquinone) 1 beta subcomplex, 
10
Sum of Sum_pept_count 0 0 3 7
Max of Max_Dif_pept 0 0 3 6
Acot11 acyl-CoA thioesterase 11 Sum of Sum_pept_count 1 1 0 7
Max of Max_Dif_pept 1 1 0 6
Gmds GDP-mannose 4, 6-dehydratase Sum of Sum_pept_count 2 7 10 10
Max of Max_Dif_pept 2 4 6 5
Ddost
dolichyl-di-phosphooligosaccharide-
protein glycotransferase
Sum of Sum_pept_count 2 0 6 3
Max of Max_Dif_pept 2 0 6 3
Mapbpip
mitogen-activated protein binding 
protein interacting protein
Sum of Sum_pept_count 4 10 15 5
Max of Max_Dif_pept2 4 6 3
Lipe lipase, hormone sensitive Sum of Sum_pept_count 15 12 4 6
Max of Max_Dif_pept 6 5 3 2
Lgals8 lectin, galactose binding, soluble 8 Sum of Sum_pept_count 8 2 5 0
Max of Max_Dif_pept 6 1 3 0
BC026682 cDNA sequence BC026682 Sum of Sum_pept_count 0 18 25 8
Max of Max_Dif_pept 0 6 5 3
Krt77 keratin 77 Sum of Sum_pept_count 15 0 16 8
Max of Max_Dif_pept 6 0 6 6
Aco2 aconitase 2, mitochondrial Sum of Sum_pept_count 0 0 0 8
Max of Max_Dif_pept 0 0 0 6  205
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Krt76 keratin 76 Sum of Sum_pept_count 36 11 36 32
Max of Max_Dif_pept 6 4 6 4
Krt75 keratin 75 Sum of Sum_pept_count 12 8 19 12
Max of Max_Dif_pept 6 4 6 6
Cap1
CAP, adenylate cyclase-associated 
protein 1 (yeast)
Sum of Sum_pept_count 0 6 6 8
Max of Max_Dif_pept 0 5 6 6
Krt72 keratin 72 Sum of Sum_pept_count 7 0 2 15
Max of Max_Dif_pept 4 0 2 6
Krt34 keratin 34 Sum of Sum_pept_count 13 7 6 0
Max of Max_Dif_pept 6 5 4 0
Krt17 keratin 17 Sum of Sum_pept_count 16 4 34 17
Max of Max_Dif_pept 4 2 6 4
Krt13 keratin 13 Sum of Sum_pept_count 13 14 17 7
Max of Max_Dif_pept 4 5 6 3
Apoa4 apolipoprotein A-IV Sum of Sum_pept_count 9 1 4 12
Max of Max_Dif_pept 5 1 4 6
Itfg1
integrin alpha FG-GAP repeat 
containing 1
Sum of Sum_pept_count 7 6 12 6
Max of Max_Dif_pept 5 4 6 5
Atp9a ATPase, class II, type 9A Sum of Sum_pept_count 13 2 15 1
Max of Max_Dif_pept 6 2 5 1
Ddx5
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 5
Sum of Sum_pept_count 0 4 3 15
Max of Max_Dif_pept 0 4 2 6
Acy1 aminoacylase 1 Sum of Sum_pept_count 0 8 0 10
Max of Max_Dif_pept 0 4 0 6
Camk2d
calcium/calmodulin-dependent 
protein kinase II, delta
Sum of Sum_pept_count 3 6 7 6
Max of Max_Dif_pept 3 5 6 3
Hspa4 heat shock protein 4 Sum of Sum_pept_count 0 8 7 0
Max of Max_Dif_pept 0 6 6 0
Hsp90b1
heat shock protein 90, beta 
(Grp94), member 1
Sum of Sum_pept_count 0 0 2 15
Max of Max_Dif_pept 0 0 1 6
Hba-a1 hemoglobin alpha, adult chain 1 Sum of Sum_pept_count 6 4 3 9
Max of Max_Dif_pept 5 3 3 6
2210412D01Rik RIKEN cDNA 2210412D01 gene Sum of Sum_pept_count 29 8 7 8
Max of Max_Dif_pept 6 5 3 6
Dgka diacylglycerol kinase, alpha Sum of Sum_pept_count 0 1 7 1
Max of Max_Dif_pept 0 1 6 1
Canx calnexin Sum of Sum_pept_count 1 0 7 3
Max of Max_Dif_pept 1 0 6 1
Gsn gelsolin Sum of Sum_pept_count 0 6 3 2
Max of Max_Dif_pept 0 6 3 2
Ceacam18
carcinoembryonic antigen-related 
cell adhesion molecule 1
Sum of Sum_pept_count 13 9 8 7
Max of Max_Dif_pept 6 4 4 5
Gpx4 glutathione peroxidase 4 Sum of Sum_pept_count 7 5 4 8
Max of Max_Dif_pept 6 5 4 6
Cnp
2',3'-cyclic nucleotide 3' 
phosphodiesterase
Sum of Sum_pept_count 9 6 7 4
Max of Max_Dif_pept 6 3 4 3
Gpd1l
glycerol-3-phosphate 
dehydrogenase 1-like
Sum of Sum_pept_count 3 7 6 6
Max of Max_Dif_pept 3 5 6 6
Sept11 septin 11 Sum of Sum_pept_count 0 1 1 10
Max of Max_Dif_pept 0 1 1 5
1810034K20Rik RIKEN cDNA 1810034K20 gene Sum of Sum_pept_count 0 8 4 2
Max of Max_Dif_pept 0 5 3 2
Dnajc7
DnaJ (Hsp40) homolog, subfamily 
C, member 7
Sum of Sum_pept_count 0 1 0 5
Max of Max_Dif_pept0 1 0 5
Vta1
Vps20-associated 1 homolog (S. 
cerevisiae)
Sum of Sum_pept_count 2 6 2 9
Max of Max_Dif_pept 1 5 2 4
Bco2 beta-carotene oxygenase 2 Sum of Sum_pept_count 3 5 0 4
Max of Max_Dif_pept 3 5 0 4
Aldoart1 aldolase 1, A isoform, retrogene 1 Sum of Sum_pept_count 5 0 0 5
Max of Max_Dif_pept 5 0 0 5
Dnm2 dynamin 2 Sum of Sum_pept_count 0 1 0 12
Max of Max_Dif_pept 0 1 0 5
Uqcrc2
ubiquinol cytochrome c reductase 
core protein 2
Sum of Sum_pept_count 0 0 6 0
Max of Max_Dif_pept 0 0 5 0
Grtp1 GH regulated TBC protein 1 Sum of Sum_pept_count 8 7 10 4
Max of Max_Dif_pept 5 4 5 4
Entpd8
ectonucleoside triphosphate 
diphosphohydrolase 8
Sum of Sum_pept_count 21 13 14 12
Max of Max_Dif_pept 4 5 3 4  206
Gene Symbol Gene Description Data proximal central distal total mucosa
Got2
glutamate oxaloacetate 
transaminase 2, mitochondrial
Sum of Sum_pept_count 0 0 0 5
Max of Max_Dif_pept 0 0 0 5
Uqcrc1
ubiquinol-cytochrome c reductase 
core protein 1
Sum of Sum_pept_count 2 0 8 4
Max of Max_Dif_pept 2 0 5 3
Cox4i1
cytochrome c oxidase subunit IV 
isoform 1
Sum of Sum_pept_count 2 0 5 24
Max of Max_Dif_pept 2 0 4 5
Gsta1
glutathione S-transferase, alpha 1 
(Ya)
Sum of Sum_pept_count 2 0 0 6
Max of Max_Dif_pept 2 0 0 5
Gsta2
glutathione S-transferase, alpha 2 
(Yc2)
Sum of Sum_pept_count 2 0 0 6
Max of Max_Dif_pept 2 0 0 5
Cftr
cystic fibrosis transmembrane 
conductance regulator homolog
Sum of Sum_pept_count 21 1 3 1
Max of Max_Dif_pept 5 1 1 1
Ubl3 ubiquitin-like 3 Sum of Sum_pept_count 11 8 9 8
Max of Max_Dif_pept 5 5 5 5
Ube2n ubiquitin-conjugating enzyme E2N Sum of Sum_pept_count 1 9 5 6
Max of Max_Dif_pept 1 5 2 4
Ube2m
ubiquitin-conjugating enzyme E2M 
(UBC12 homolog, yeast)
Sum of Sum_pept_count 3 4 5 3
Max of Max_Dif_pept 3 4 5 3
Ubc ubiquitin C Sum of Sum_pept_count 112 104 122 94
Max of Max_Dif_pept 4 5 4 4
Ubb ubiquitin B Sum of Sum_pept_count 224 208 244 188
Max of Max_Dif_pept 4 5 4 4
Gstt3 glutathione S-transferase, theta 3 Sum of Sum_pept_count 1 1 0 5
Max of Max_Dif_pept 1 1 0 5
Uba52
ubiquitin A-52 residue ribosomal 
protein fusion product 1
Sum of Sum_pept_count 56 52 61 47
Max of Max_Dif_pept 4 5 4 4
Gyk glycerol kinase Sum of Sum_pept_count 0 5 1 4
Max of Max_Dif_pept 0 5 1 4
Tubb2a-ps1 tubulin, beta 2a, pseudogene 1 Sum of Sum_pept_count 0 7 9 0
Max of Max_Dif_pept 0 5 5 0
Got1
glutamate oxaloacetate 
transaminase 1, soluble
Sum of Sum_pept_count 0 4 2 5
Max of Max_Dif_pept 0 4 2 5
2400001E08Rik RIKEN cDNA 2400001E08 gene Sum of Sum_pept_count 12 10 16 4
Max of Max_Dif_pept 5 5 4 2
Esd
esterase D/formylglutathione 
hydrolase
Sum of Sum_pept_count 3 8 6 4
Max of Max_Dif_pept 3 5 5 4
Casp3 caspase 3 Sum of Sum_pept_count 7 8 1 15
Max of Max_Dif_pept 4 5 1 5
Arhgap1 Rho GTPase activating protein 1 Sum of Sum_pept_count 0 1 4 9
Max of Max_Dif_pept 0 1 3 5
Golph3l golgi phosphoprotein 3-like Sum of Sum_pept_count 4 2 6 5
Max of Max_Dif_pept 4 2 3 5
Tes testis derived transcriptS u m  o f  S u m _pept_count 2 4 1 6
Max of Max_Dif_pept 1 4 1 5
Taok3 TAO kinase 3 Sum of Sum_pept_count 2 3 8 2
Max of Max_Dif_pept 1 2 5 2
F11r F11 receptor Sum of Sum_pept_count 19 10 18 12
Max of Max_Dif_pept 5 4 5 4
H2-T3
histocompatibility 2, T region locus 
3
Sum of Sum_pept_count 2 0 5 5
Max of Max_Dif_pept 2 0 5 5
Anxa1 annexin A1 Sum of Sum_pept_count 3 5 17 2
Max of Max_Dif_pept 2 4 5 1
Stx8 syntaxin 8 Sum of Sum_pept_count 5 0 6 7
Max of Max_Dif_pept4 0 5 5
Stx7 syntaxin 7 Sum of Sum_pept_count 10 6 8 7
Max of Max_Dif_pept 3 4 4 5
St3gal4
ST3 beta-galactoside alpha-2,3-
sialyltransferase 4
Sum of Sum_pept_count 5 1 6 4
Max of Max_Dif_pept 5 1 5 4
Chmp4c chromatin modifying protein 4C Sum of Sum_pept_count 13 11 6 8
Max of Max_Dif_pept 4 4 3 5
B930007M17Rik RIKEN cDNA B930007M17 gene Sum of Sum_pept_count 2 11 3 10
Max of Max_Dif_pept 2 4 2 5
Atp1a3
ATPase, Na+/K+ transporting, 
alpha 3 polypeptide
Sum of Sum_pept_count 12 8 4 9
Max of Max_Dif_pept 5 3 2 2
5730469M10Rik RIKEN cDNA 5730469M10 gene Sum of Sum_pept_count 1 0 0 6
Max of Max_Dif_pept 1 0 0 5
Slc39a4
solute carrier family 39 (zinc 
transporter), member 4
Sum of Sum_pept_count 35 18 42 16
Max of Max_Dif_pept 5 5 4 3    207
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Slc36a1
solute carrier family 36 
(proton/amino acid symporter), 
member 1
Sum of Sum_pept_count 12 13 12 9
Max of Max_Dif_pept 2 5 2 2
Slc35f2
solute carrier family 35, member 
F2
Sum of Sum_pept_count 27 18 21 13
Max of Max_Dif_pept 4 5 3 3
Slc2a7
solute carrier family 2 (facilitated 
glucose transporter), member 7
Sum of Sum_pept_count 13 7 4 6
Max of Max_Dif_pept 5 4 3 3
Slc22a5
solute carrier family 22 (organic 
cation transporter), member 5
Sum of Sum_pept_count 8 8 7 6
Max of Max_Dif_pept 4 4 5 3
Sh3bgrl2
SH3 domain binding glutamic acid-
rich protein like 2
Sum of Sum_pept_count 0 8 3 4
Max of Max_Dif_pept 0 5 2 4
Sec24c
SEC24 related gene family, 
member C (S. cerevisiae)
Sum of Sum_pept_count 0 0 1 5
Max of Max_Dif_pept 0 0 1 5
Scp2 sterol carrier protein 2, liver Sum of Sum_pept_count 2 6 0 2
Max of Max_Dif_pept 2 5 0 2
Fbp2 fructose bisphosphatase 2 Sum of Sum_pept_count 4 9 5 10
Max of Max_Dif_pept 4 5 3 5
Scarb2
scavenger receptor class B, 
member 2
Sum of Sum_pept_count 2 3 5 2
Max of Max_Dif_pept 2 3 5 2
Rps27a ribosomal protein S27a Sum of Sum_pept_count 56 52 61 50
Max of Max_Dif_pept 4 5 4 4
Atp1a2
ATPase, Na+/K+ transporting, 
alpha 2 polypeptide
Sum of Sum_pept_count 12 8 4 9
Max of Max_Dif_pept 5 3 2 2
Rpl12 ribosomal protein L12 Sum of Sum_pept_count 6 0 6 8
Max of Max_Dif_pept 2 0 3 5
2210016F16Rik RIKEN cDNA 2210016F16 gene Sum of Sum_pept_count 2 2 1 5
Max of Max_Dif_pept 2 2 1 5
Anxa3 annexin A3 Sum of Sum_pept_count 0 6 4 1
Max of Max_Dif_pept 0 5 4 1
Chn2 chimerin (chimaerin) 2 Sum of Sum_pept_count 7 1 1 4
Max of Max_Dif_pept 5 1 1 3
Rhob
ras homolog gene family, member 
B
Sum of Sum_pept_count 0 9 1 0
Max of Max_Dif_pept 0 5 1 0
EG625929 predicted gene, EG625929 Sum of Sum_pept_count 3 5 9 2
Max of Max_Dif_pept 3 4 5 2
Rab9
RAB9, member RAS oncogene 
family
Sum of Sum_pept_count 8 6 7 8
Max of Max_Dif_pept 5 5 4 5
Cth
cystathionase (cystathionine 
gamma-lyase)
Sum of Sum_pept_count 2 3 2 8
Max of Max_Dif_pept 1 2 1 5
Rab43
RAB43, member RAS oncogene 
family
Sum of Sum_pept_count 4 3 4 5
Max of Max_Dif_pept 4 3 4 5
Rab3a
RAB3A, member RAS oncogene 
family
Sum of Sum_pept_count 1 0 5 6
Max of Max_Dif_pept 1 0 5 4
Rab27a
RAB27A, member RAS oncogene 
family
Sum of Sum_pept_count 2 2 3 5
Max of Max_Dif_pept 2 2 3 5
Ctss cathepsin S Sum of Sum_pept_count 0 5 1 4
Max of Max_Dif_pept 0 5 1 4
Rab19
RAB19, member RAS oncogene 
family
Sum of Sum_pept_count 4 6 4 2
Max of Max_Dif_pept 3 5 3 1
Arpc1b
actin related protein 2/3 complex, 
subunit 1B
Sum of Sum_pept_count 2 5 8 7
Max of Max_Dif_pept 2 4 4 5
Ptpmt1
protein tyrosine phosphatase, 
mitochondrial 1
Sum of Sum_pept_count 6 0 3 0
Max of Max_Dif_pept 5 0 2 0
Ptk6 PTK6 protein tyrosine kinase 6 Sum of Sum_pept_count 0 4 2 5
Max of Max_Dif_pept0 4 2 5
Cct7
chaperonin containing Tcp1, 
subunit 7 (eta)
Sum of Sum_pept_count 0 5 3 8
Max of Max_Dif_pept 0 4 2 5
Cxadr
coxsackievirus and adenovirus 
receptor
Sum of Sum_pept_count 12 7 15 13
Max of Max_Dif_pept 5 4 5 5
Bub3
budding uninhibited by 
benzimidazoles 3 homolog (S. 
cerevisiae)
Sum of Sum_pept_count 0 0 0 6
Max of Max_Dif_pept 0 0 0 5  208
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Psma2
proteasome (prosome, macropain) 
subunit, alpha type 2
Sum of Sum_pept_count 1 0 4 5
Max of Max_Dif_pept 1 0 4 5
Cyb5 cytochrome b-5 Sum of Sum_pept_count 5 1 3 8
Max of Max_Dif_pept 3 1 3 5
Prkcz protein kinase C, zeta Sum of Sum_pept_count 9 11 10 2
Max of Max_Dif_pept 4 5 3 1
Ppp2cb
protein phosphatase 2 (formerly 
2A), catalytic subunit, beta isoform
Sum of Sum_pept_count 0 0 0 5
Max of Max_Dif_pept 0 0 0 5
Ppp2ca
protein phosphatase 2 (formerly 
2A), catalytic subunit, alpha 
isoform
Sum of Sum_pept_count 0 5 1 5
Max of Max_Dif_pept 0 3 1 5
Ppap2c
phosphatidic acid phosphatase 
type 2c
Sum of Sum_pept_count 8 7 8 10
Max of Max_Dif_pept 3 3 3 5
Pmm2 phosphomannomutase 2 Sum of Sum_pept_count 1 5 3 9
Max of Max_Dif_pept 1 4 2 5
Pi4k2b
phosphatidylinositol 4-kinase type 
2 beta
Sum of Sum_pept_count 5 1 3 3
Max of Max_Dif_pept 5 1 2 2
Pef1
penta-EF hand domain containing 
1
Sum of Sum_pept_count 5 10 6 6
Max of Max_Dif_pept 2 5 4 3
Hist1h4a histone cluster 1, H4a Sum of Sum_pept_count 18 4 11 16
Max of Max_Dif_pept 5 1 3 4
Hist1h4b histone cluster 1, H4b Sum of Sum_pept_count 18 4 11 16
Max of Max_Dif_pept 5 1 3 4
Hist1h4c histone cluster 1, H4c Sum of Sum_pept_count 18 4 11 16
Max of Max_Dif_pept 5 1 3 4
Hist1h4d histone cluster 1, H4d Sum of Sum_pept_count 18 4 11 16
Max of Max_Dif_pept 5 1 3 4
Hist1h4f histone cluster 1, H4f Sum of Sum_pept_count 18 4 11 16
Max of Max_Dif_pept 5 1 3 4
Hist1h4h histone cluster 1, H4h Sum of Sum_pept_count 18 4 11 16
Max of Max_Dif_pept 5 1 3 4
Hist1h4i histone cluster 1, H4i Sum of Sum_pept_count 18 4 11 16
Max of Max_Dif_pept 5 1 3 4
Hist1h4j histone cluster 1, H4j Sum of Sum_pept_count 18 4 11 16
Max of Max_Dif_pept 5 1 3 4
Hist1h4k histone cluster 1, H4k Sum of Sum_pept_count 18 4 11 16
Max of Max_Dif_pept 5 1 3 4
Hist1h4m histone cluster 1, H4m Sum of Sum_pept_count 18 4 11 16
Max of Max_Dif_pept 5 1 3 4
Cyp2c65
cytochrome P450, family 2, 
subfamily c, polypeptide 65
Sum of Sum_pept_count 2 0 1 5
Max of Max_Dif_pept 2 0 1 5
Cldn3 claudin 3 Sum of Sum_pept_count 22 14 27 23
Max of Max_Dif_pept 5 4 5 3
Otub1
OTU domain, ubiquitin aldehyde 
binding 1
Sum of Sum_pept_count 0 1 1 6
Max of Max_Dif_pept 0 1 1 5
Ap1g2
adaptor protein complex AP-1, 
gamma 2 subunit
Sum of Sum_pept_count 0 0 0 5
Max of Max_Dif_pept 0 0 0 5
Hist2h4 histone cluster 2, H4 Sum of Sum_pept_count 18 4 11 16
Max of Max_Dif_pept 5 1 3 4
Arpc4
actin related protein 2/3 complex, 
subunit 4
Sum of Sum_pept_count 9 11 16 23
Max of Max_Dif_pept 4 5 4 5
Nek6
NIMA (never in mitosis gene a)-
related expressed kinase 6
Sum of Sum_pept_count 5 6 3 4
Max of Max_Dif_pept 5 5 3 4
Gm1821 gene model 1821, (NCBI) Sum of Sum_pept_count 112 104 122 94
Max of Max_Dif_pept4 5 4 4
Hist4h4 histone cluster 4, H4 Sum of Sum_pept_count 18 4 11 16
Max of Max_Dif_pept 5 1 3 4
Acp2 acid phosphatase 2, lysosomal Sum of Sum_pept_count 6 3 7 4
Max of Max_Dif_pept 5 3 4 4
Hmgb1 high mobility group box 1 Sum of Sum_pept_count 0 5 1 4
Max of Max_Dif_pept 0 5 1 4
Myo5b myosin Vb Sum of Sum_pept_count 10 9 9 14
Max of Max_Dif_pept 3 3 4 5
Mylc2b myosin light chain, regulatory B Sum of Sum_pept_count 0 1 1 7
Max of Max_Dif_pept 0 1 1 5
Ms4a10
membrane-spanning 4-domains, 
subfamily A, member 10
Sum of Sum_pept_count 30 4 2 12
Max of Max_Dif_pept 5 2 1 3
Mogat2
monoacylglycerol O-
acyltransferase 2
Sum of Sum_pept_count 0 0 1 6
Max of Max_Dif_pept 0 0 1 5    209
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Clta clathrin, light polypeptide (Lca) Sum of Sum_pept_count 0 0 0 10
Max of Max_Dif_pept 0 0 0 5
Map2k1ip1
mitogen-activated protein kinase 
kinase 1 interacting protein 1
Sum of Sum_pept_count 1 4 11 1
Max of Max_Dif_pept 1 3 5 1
Lyz1 lysozyme 1 Sum of Sum_pept_count 8 13 11 17
Max of Max_Dif_pept 1 5 4 4
Lypla1 lysophospholipase 1 Sum of Sum_pept_count 7 3 4 8
Max of Max_Dif_pept 4 3 3 5
Hpgd
hydroxyprostaglandin 
dehydrogenase 15 (NAD)
Sum of Sum_pept_count 2 3 1 6
Max of Max_Dif_pept 2 3 1 5
Hprt1
hypoxanthine guanine 
phosphoribosyl transferase 1
Sum of Sum_pept_count 2 1 4 5
Max of Max_Dif_pept 2 1 4 5
2900073G15Rik RIKEN cDNA 2900073G15 gene Sum of Sum_pept_count 0 1 1 7
Max of Max_Dif_pept 0 1 1 5
Ddt D-dopachrome tautomerase Sum of Sum_pept_count 2 6 5 4
Max of Max_Dif_pept 2 4 5 3
Acaa2
acetyl-Coenzyme A 
acyltransferase 2 (mitochondrial 3-
oxoacyl-Coenzyme A thiolase)
Sum of Sum_pept_count 0 0 0 6
Max of Max_Dif_pept 0 0 0 5
Ddx39 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 39
Sum of Sum_pept_count 2 6 5 10
Max of Max_Dif_pept 2 5 5 5
Hsd17b6
hydroxysteroid (17-beta) 
dehydrogenase 6
Sum of Sum_pept_count 0 0 0 6
Max of Max_Dif_pept 0 0 0 5
B020010K11Rik RIKEN cDNA B020010K11 gene Sum of Sum_pept_count 36 15 18 29
Max of Max_Dif_pept 4 3 4 5
Gnao1
guanine nucleotide binding protein, 
alpha O
Sum of Sum_pept_count 26 12 23 25
Max of Max_Dif_pept 5 5 4 5
Krt6a keratin 6A Sum of Sum_pept_count 0 0 7 0
Max of Max_Dif_pept 0 0 5 0
Krt35 keratin 35 Sum of Sum_pept_count 12 0 0 0
Max of Max_Dif_pept 5 0 0 0
Eif5a eukaryotic translation initiation 
factor 5A
Sum of Sum_pept_count 0 6 2 3
Max of Max_Dif_pept 0 5 1 2
Krt19 keratin 19 Sum of Sum_pept_count 2 6 1 19
Max of Max_Dif_pept 2 2 1 5
Cmas
cytidine monophospho-N-
acetylneuraminic acid synthetase
Sum of Sum_pept_count 0 0 0 6
Max of Max_Dif_pept 0 0 0 5
Keap1
kelch-like ECH-associated protein 
1
Sum of Sum_pept_count 1 1 1 5
Max of Max_Dif_pept 1 1 1 5
Gnpda1
glucosamine-6-phosphate 
deaminase 1
Sum of Sum_pept_count 0 2 1 6
Max of Max_Dif_pept 0 2 1 5
Gng12 guanine nucleotide binding protein 
(G protein), gamma 12
Sum of Sum_pept_count 12 10 10 4
Max of Max_Dif_pept 5 5 4 2
Itln1
intelectin 1 (galactofuranose 
binding)
Sum of Sum_pept_count 0 2 4 5
Max of Max_Dif_pept 0 2 4 5
Agr2
anterior gradient 2 (Xenopus 
laevis)
Sum of Sum_pept_count 0 2 1 22
Max of Max_Dif_pept 0 1 1 5
Ilf3
interleukin enhancer binding factor 
3
Sum of Sum_pept_count 0 1 0 8
Max of Max_Dif_pept 0 1 0 5
Arhgap17 Rho GTPase activating protein 17 Sum of Sum_pept_count 8 12 3 8
Max of Max_Dif_pept 4 3 2 3
Apol10a apolipoprotein L 10a Sum of Sum_pept_count 3 6 6 10
Max of Max_Dif_pept 3 4 4 4
Idh3g
isocitrate dehydrogenase 3 
(NAD+), gamma
Sum of Sum_pept_count 0 0 0 5
Max of Max_Dif_pept0 0 0 4
Anp32b
acidic nuclear phosphoprotein 32 
family, member B
Sum of Sum_pept_count 4 7 6 4
Max of Max_Dif_pept 4 3 3 3
Ykt6 YKT6 homolog (S. Cerevisiae) Sum of Sum_pept_count 5 4 3 4
Max of Max_Dif_pept 4 4 2 2
Gne glucosamine Sum of Sum_pept_count 0 0 0 4
Max of Max_Dif_pept 0 0 0 4
Ddx3y
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 3, Y-linked
Sum of Sum_pept_count 8 11 23 10
Max of Max_Dif_pept 3 2 4 4  210
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Dnajc5
DnaJ (Hsp40) homolog, subfamily 
C, member 5
Sum of Sum_pept_count 12 9 8 10
Max of Max_Dif_pept 4 4 3 4
Agrp agouti related protein Sum of Sum_pept_count 2 0 5 1
Max of Max_Dif_pept 2 0 4 1
Impa1
inositol (myo)-1(or 4)-
monophosphatase 1
Sum of Sum_pept_count 0 2 2 6
Max of Max_Dif_pept 0 2 2 4
Wasf2 WAS protein family, member 2 Sum of Sum_pept_count 0 8 0 3
Max of Max_Dif_pept 0 4 0 1
Vps33b
vacuolar protein sorting 33B 
(yeast)
Sum of Sum_pept_count 0 1 0 4
Max of Max_Dif_pept 0 1 0 4
Vps26a
vacuolar protein sorting 26 
homolog A (yeast)
Sum of Sum_pept_count 4 1 2 4
Max of Max_Dif_pept 3 1 1 4
Cfl2 cofilin 2, muscle Sum of Sum_pept_count 0 0 5 6
Max of Max_Dif_pept 0 0 3 4
Vamp8
vesicle-associated membrane 
protein 8
Sum of Sum_pept_count 10 10 10 9
Max of Max_Dif_pept 4 4 4 4
Vamp3
vesicle-associated membrane 
protein 3
Sum of Sum_pept_count 5 2 5 12
Max of Max_Dif_pept 2 1 2 4
Uqcrq
ubiquinol-cytochrome c reductase, 
complex III subunit VII
Sum of Sum_pept_count 0 0 1 4
Max of Max_Dif_pept 0 0 1 4
Itch itchy, E3 ubiquitin protein ligase Sum of Sum_pept_count 1 5 4 1
Max of Max_Dif_pept 1 4 3 1
Ugt1a1
UDP glucuronosyltransferase 1 
family, polypeptide A1
Sum of Sum_pept_count 2 0 4 4
Max of Max_Dif_pept 2 0 4 4
Gstm2 glutathione S-transferase, mu 2 Sum of Sum_pept_count 0 0 0 4
Max of Max_Dif_pept 0 0 0 4
Ube2d3
ubiquitin-conjugating enzyme E2D 
3 (UBC4/5 homolog, yeast)
Sum of Sum_pept_count 3 7 3 4
Max of Max_Dif_pept 1 4 1 2
H2-Aa
histocompatibility 2, class II 
antigen A, alpha
Sum of Sum_pept_count 8 8 21 8
Max of Max_Dif_pept 3 3 4 3
Itgb1
integrin beta 1 (fibronectin receptor 
beta)
Sum of Sum_pept_count 0 0 6 6
Max of Max_Dif_pept 0 0 3 4
Uap1l1
UDP-N-acteylglucosamine 
pyrophosphorylase 1-like 1
Sum of Sum_pept_count 1 2 1 4
Max of Max_Dif_pept 1 2 1 4
Arhgef16
Rho guanine nucleotide exchange 
factor (GEF) 16
Sum of Sum_pept_count 6 8 5 5
Max of Max_Dif_pept 3 4 3 2
Cox5a cytochrome c oxidase, subunit Va Sum of Sum_pept_count 1 2 7 12
Max of Max_Dif_pept 1 1 4 4
Chmp1a chromatin modifying protein 1A Sum of Sum_pept_count 5 8 4 8
Max of Max_Dif_pept 3 3 3 4
Amy2-1 amylase 2-1, pancreatic Sum of Sum_pept_count 0 1 2 4
Max of Max_Dif_pept 0 1 2 4
Copa coatomer protein complex subunit 
alpha
Sum of Sum_pept_count 0 0 1 6
Max of Max_Dif_pept 0 0 1 4
Akr1b3
aldo-keto reductase family 1, 
member B3 (aldose reductase)
Sum of Sum_pept_count 0 2 3 5
Max of Max_Dif_pept 0 2 3 4
Cnnm4 cyclin M4 Sum of Sum_pept_count 0 0 5 0
Max of Max_Dif_pept 0 0 4 0
H2-DMb2
histocompatibility 2, class II, locus 
Mb2
Sum of Sum_pept_count 5 5 17 6
Max of Max_Dif_pept 3 4 4 4
Duoxa2 dual oxidase maturation factor 2 Sum of Sum_pept_count 0 1 36 6
Max of Max_Dif_pept 0 1 4 3
Kif5b kinesin family member 5B Sum of Sum_pept_count 0 0 0 4
Max of Max_Dif_pept0 0 0 4
Espn espin Sum of Sum_pept_count 0 6 0 8
Max of Max_Dif_pept 0 3 0 4
Tollip toll interacting protein Sum of Sum_pept_count 0 3 4 5
Max of Max_Dif_pept 0 2 3 4
Dync1li1
dynein cytoplasmic 1 light 
intermediate chain 1
Sum of Sum_pept_count 0 0 0 6
Max of Max_Dif_pept 0 0 0 4
Krt1 keratin 1 Sum of Sum_pept_count 27 21 28 33
Max of Max_Dif_pept 4 3 4 3  211
Gene Symbol Gene Description Data proximal central distal total mucosa
Tmem55b transmembrane protein 55b Sum of Sum_pept_count 7 2 9 3
Max of Max_Dif_pept 3 2 4 3
Tmem55a transmembrane protein 55A Sum of Sum_pept_count 5 1 8 2
Max of Max_Dif_pept 3 1 4 1
Epb4.1l5 erythrocyte protein band 4.1-like 5 Sum of Sum_pept_count 9 4 2 2
Max of Max_Dif_pept 4 1 1 1
Tmem33 transmembrane protein 33 Sum of Sum_pept_count 1 0 3 4
Max of Max_Dif_pept 1 0 2 4
Krt2 keratin 2 Sum of Sum_pept_count 13 7 4 6
Max of Max_Dif_pept 3 4 3 2
Tmed9
transmembrane emp24 protein 
transport domain containing 9
Sum of Sum_pept_count 2 0 3 8
Max of Max_Dif_pept 1 0 3 4
Tmed7
transmembrane emp24 protein 
transport domain containing 7
Sum of Sum_pept_count 1 0 3 4
Max of Max_Dif_pept 1 0 2 4
Tmed4
transmembrane emp24 protein 
transport domain containing 4
Sum of Sum_pept_count 2 0 4 7
Max of Max_Dif_pept 1 0 4 4
Tmed10
transmembrane emp24-like 
trafficking protein 10 (yeast)
Sum of Sum_pept_count 0 0 1 6
Max of Max_Dif_pept 0 0 1 4
Thop1 thimet oligopeptidase 1 Sum of Sum_pept_count 0 0 0 4
Max of Max_Dif_pept 0 0 0 4
Tgm2 transglutaminase 2, C polypeptide Sum of Sum_pept_count 0 1 0 4
Max of Max_Dif_pept 0 1 0 4
Atp8a2
ATPase, aminophospholipid 
transporter-like, class I, type 8A, 
member 2
Sum of Sum_pept_count 0 0 4 1
Max of Max_Dif_pept 0 0 4 1
Tfg Trk-fused gene Sum of Sum_pept_count 3 4 6 4
Max of Max_Dif_pept 3 3 4 2
Tceb2
transcription elongation factor B 
(SIII), polypeptide 2
Sum of Sum_pept_count 1 6 5 7
Max of Max_Dif_pept 1 4 4 4
Casp8 caspase 8 Sum of Sum_pept_count 0 6 1 7
Max of Max_Dif_pept 0 3 1 4
Krt73 keratin 73 Sum of Sum_pept_count 4 1 0 0
Max of Max_Dif_pept 4 1 0 0
Sult2b1
sulfotransferase family, cytosolic, 
2B, member 1
Sum of Sum_pept_count 1 7 2 5
Max of Max_Dif_pept 1 4 2 2
Stxbp3a syntaxin binding protein 3A Sum of Sum_pept_count 0 2 1 4
Max of Max_Dif_pept 0 2 1 4
Faah fatty acid amide hydrolase Sum of Sum_pept_count 0 0 0 4
Max of Max_Dif_pept 0 0 0 4
Spr sepiapterin reductase Sum of Sum_pept_count 1 2 4 3
Max of Max_Dif_pept 1 2 4 3
Snx6 sorting nexin 6 Sum of Sum_pept_count 1 0 0 7
Max of Max_Dif_pept 1 0 0 4
Krt81 keratin 81 Sum of Sum_pept_count 0 0 4 0
Max of Max_Dif_pept 0 0 4 0
Snx5 sorting nexin 5 Sum of Sum_pept_count 0 2 4 5
Max of Max_Dif_pept 0 2 3 4
Krt83 keratin 83 Sum of Sum_pept_count 5 0 4 0
Max of Max_Dif_pept 4 0 4 0
Snx3 sorting nexin 3 Sum of Sum_pept_count 7 5 3 8
Max of Max_Dif_pept 4 3 2 4
Efr3b EFR3 homolog B (S. cerevisiae) Sum of Sum_pept_count 17 0 2 1
Max of Max_Dif_pept 4 0 1 1
Slc7a9
solute carrier family 7 (cationic 
amino acid transporter, y+ 
system), member 9
Sum of Sum_pept_count 12 6 19 9
Max of Max_Dif_pept4 3 3 4
Slc6a8
solute carrier family 6 
(neurotransmitter transporter, 
creatine), member 8
Sum of Sum_pept_count 3 9 9 5
Max of Max_Dif_pept 2 4 3 3
Lamp2
lysosomal-associated membrane 
protein 2
Sum of Sum_pept_count 4 4 11 5
Max of Max_Dif_pept 2 2 4 2
Aqp1 aquaporin 1 Sum of Sum_pept_count 30 22 28 26
Max of Max_Dif_pept 4 3 3 3
Ap1s1
adaptor protein complex AP-1, 
sigma 1
Sum of Sum_pept_count 0 1 1 7
Max of Max_Dif_pept 0 1 1 4
Blvra biliverdin reductase A Sum of Sum_pept_count 2 2 3 4
Max of Max_Dif_pept 2 2 3 4
Slc46a1 solute carrier family 46, member 1 Sum of Sum_pept_count 47 13 5 27
Max of Max_Dif_pept 4 3 3 3    212
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Slc44a1 solute carrier family 44, member 1 Sum of Sum_pept_count 2 0 6 2
Max of Max_Dif_pept 1 0 4 2
Adss
adenylosuccinate synthetase, non 
muscle
Sum of Sum_pept_count 1 6 4 4
Max of Max_Dif_pept 1 4 4 4
2310046K01Rik RIKEN cDNA 2310046K01 gene Sum of Sum_pept_count 8 28 40 17
Max of Max_Dif_pept 2 4 3 3
Hint1
histidine triad nucleotide binding 
protein 1
Sum of Sum_pept_count 3 4 4 10
Max of Max_Dif_pept 2 3 2 4
Slc2a9
solute carrier family 2 (facilitated 
glucose transporter), member 9
Sum of Sum_pept_count 20 17 22 14
Max of Max_Dif_pept 4 4 4 4
Chmp5 chromatin modifying protein 5 Sum of Sum_pept_count 4 7 4 7
Max of Max_Dif_pept 2 3 2 4
Bpgm 2,3-bisphosphoglycerate mutase Sum of Sum_pept_count 0 0 0 5
Max of Max_Dif_pept 0 0 0 4
EG432987 predicted gene, EG432987 Sum of Sum_pept_count 3 0 10 0
Max of Max_Dif_pept 3 0 4 0
Cr1l
complement component (3b/4b) 
receptor 1-like
Sum of Sum_pept_count 0 0 6 3
Max of Max_Dif_pept 0 0 4 3
Slc13a1
solute carrier family 13 
(sodium/sulfate symporters), 
member 1
Sum of Sum_pept_count 8 0 9 4
Max of Max_Dif_pept 4 0 4 3
Shmt2
serine hydroxymethyltransferase 2 
(mitochondrial)
Sum of Sum_pept_count 0 0 0 4
Max of Max_Dif_pept 0 0 0 4
Sec24d
SEC24 related gene family, 
member D (S. cerevisiae)
Sum of Sum_pept_count 1 1 0 10
Max of Max_Dif_pept 1 1 0 4
Chmp6 chromatin modifying protein 6 Sum of Sum_pept_count 17 13 6 18
Max of Max_Dif_pept 4 4 3 4
Crot carnitine O-octanoyltransferase Sum of Sum_pept_count 0 0 0 4
Max of Max_Dif_pept 0 0 0 4
Fbxl20
F-box and leucine-rich repeat 
protein 20
Sum of Sum_pept_count 3 1 4 1
Max of Max_Dif_pept 3 1 4 1
Cs citrate synthase Sum of Sum_pept_count 0 2 1 4
Max of Max_Dif_pept 0 2 1 4
Rras
Harvey rat sarcoma oncogene, 
subgroup R
Sum of Sum_pept_count 12 9 13 10
Max of Max_Dif_pept 4 3 4 4
Rps9 ribosomal protein S9 Sum of Sum_pept_count 2 2 5 4
Max of Max_Dif_pept 1 2 3 4
Rps5 ribosomal protein S5 Sum of Sum_pept_count 5 2 6 4
Max of Max_Dif_pept 1 1 4 2
Rps2 ribosomal protein S2 Sum of Sum_pept_count 2 0 5 1
Max of Max_Dif_pept 2 0 4 1
Hsd17b11
hydroxysteroid (17-beta) 
dehydrogenase 11
Sum of Sum_pept_count 1 1 4 6
Max of Max_Dif_pept 1 1 2 4
Rps16 ribosomal protein S16 Sum of Sum_pept_count 3 3 6 4
Max of Max_Dif_pept 2 3 3 4
Rps15a ribosomal protein S15a Sum of Sum_pept_count 5 2 3 5
Max of Max_Dif_pept 4 1 2 3
Rps13 ribosomal protein S13 Sum of Sum_pept_count 4 2 5 5
Max of Max_Dif_pept 4 2 4 4
Rpl35a ribosomal protein L35a Sum of Sum_pept_count 0 0 2 6
Max of Max_Dif_pept 0 0 2 4
Rpl23 ribosomal protein L23 Sum of Sum_pept_count 3 2 5 9
Max of Max_Dif_pept 1 1 2 4
Rhoq
ras homolog gene family, member 
Q
Sum of Sum_pept_count 5 2 0 3
Max of Max_Dif_pept4 2 0 3
Rasgef1a
RasGEF domain family, member 
1A
Sum of Sum_pept_count 2 4 1 4
Max of Max_Dif_pept 1 4 1 2
EG625055 predicted gene, EG625055 Sum of Sum_pept_count 0 0 4 1
Max of Max_Dif_pept 0 0 4 1
Arbp
acidic ribosomal phosphoprotein 
P0
Sum of Sum_pept_count 1 0 1 8
Max of Max_Dif_pept 1 0 1 4
1700009N14Rik RIKEN cDNA 1700009N14 gene Sum of Sum_pept_count 1 6 10 5
Max of Max_Dif_pept 1 4 4 2
Csnk2a1
casein kinase 2, alpha 1 
polypeptide
Sum of Sum_pept_count 0 4 4 0
Max of Max_Dif_pept 0 3 4 0
Hpcal1 hippocalcin-like 1 Sum of Sum_pept_count 3 4 4 2
Max of Max_Dif_pept 3 4 4 2  213
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Csrp1 cysteine and glycine-rich protein 1 Sum of Sum_pept_count 0 5 0 4
Max of Max_Dif_pept 0 2 0 4
Akr7a5
aldo-keto reductase family 7, 
member A5 (aflatoxin aldehyde 
reductase)
Sum of Sum_pept_count 1 4 1 6
Max of Max_Dif_pept 1 4 1 4
Atp5h
ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit 
d
Sum of Sum_pept_count 0 0 0 5
Max of Max_Dif_pept 0 0 0 4
Btbd7 BTB (POZ) domain containing 7 Sum of Sum_pept_count 2 0 5 1
Max of Max_Dif_pept 2 0 4 1
Ptp4a1 protein tyrosine phosphatase 4a1 Sum of Sum_pept_count 4 4 3 4
Max of Max_Dif_pept 3 3 3 4
Ptgr1 prostaglandin reductase 1 Sum of Sum_pept_count 0 6 1 2
Max of Max_Dif_pept 0 4 1 2
Psme1
proteasome (prosome, macropain) 
28 subunit, alpha
Sum of Sum_pept_count 1 4 3 4
Max of Max_Dif_pept 1 4 2 4
Psmd7
proteasome (prosome, macropain) 
26S subunit, non-ATPase, 7
Sum of Sum_pept_count 0 0 0 7
Max of Max_Dif_pept 0 0 0 4
Psmd5
proteasome (prosome, macropain) 
26S subunit, non-ATPase, 5
Sum of Sum_pept_count 0 0 0 5
Max of Max_Dif_pept 0 0 0 4
Psmb10
proteasome (prosome, macropain) 
subunit, beta type 10
Sum of Sum_pept_count 6 3 3 9
Max of Max_Dif_pept 3 1 2 4
Psmb1
proteasome (prosome, macropain) 
subunit, beta type 1
Sum of Sum_pept_count 1 3 5 2
Max of Max_Dif_pept 1 3 4 2
Psma7
proteasome (prosome, macropain) 
subunit, alpha type 7
Sum of Sum_pept_count 1 4 5 7
Max of Max_Dif_pept 1 3 3 4
Mapk14
mitogen-activated protein kinase 
14
Sum of Sum_pept_count 0 0 0 6
Max of Max_Dif_pept 0 0 0 4
Arg2 arginase type II Sum of Sum_pept_count 0 0 0 5
Max of Max_Dif_pept 0 0 0 4
Psma6
proteasome (prosome, macropain) 
subunit, alpha type 6
Sum of Sum_pept_count 0 2 2 5
Max of Max_Dif_pept 0 1 1 4
Psma1
proteasome (prosome, macropain) 
subunit, alpha type 1
Sum of Sum_pept_count 1 2 4 3
Max of Max_Dif_pept 1 1 4 2
Mat2b
methionine adenosyltransferase II, 
beta
Sum of Sum_pept_count 0 0 0 7
Max of Max_Dif_pept 0 0 0 4
Bzw1
basic leucine zipper and W2 
domains 1
Sum of Sum_pept_count 3 2 3 4
Max of Max_Dif_pept 3 2 3 4
3110049J23Rik RIKEN cDNA 3110049J23 gene Sum of Sum_pept_count 0 4 2 4
Max of Max_Dif_pept 0 3 2 4
Ppp2r5d
protein phosphatase 2, regulatory 
subunit B (B56), delta isoform
Sum of Sum_pept_count 0 3 1 8
Max of Max_Dif_pept 0 2 1 4
Ppp2r4
protein phosphatase 2A, regulatory 
subunit B (PR 53)
Sum of Sum_pept_count 1 3 1 6
Max of Max_Dif_pept 1 2 1 4
4930539N22Rik RIKEN cDNA 4930539N22 gene Sum of Sum_pept_count 0 0 1 4
Max of Max_Dif_pept 0 0 1 4
Cd38 CD38 antigen Sum of Sum_pept_count 2 0 9 6
Max of Max_Dif_pept 2 0 4 3
Arpc3
actin related protein 2/3 complex, 
subunit 3
Sum of Sum_pept_count 2 5 7 6
Max of Max_Dif_pept 2 3 4 4
Ppcs
phosphopantothenoylcysteine 
synthetase
Sum of Sum_pept_count 0 0 0 4
Max of Max_Dif_pept 0 0 0 4
Cycs cytochrome c, somatic Sum of Sum_pept_count 2 5 1 3
Max of Max_Dif_pept 2 4 1 3
Ppa1 pyrophosphatase (inorganic) 1S u m  o f  S u m _pept_count 6 7 1 7
Max of Max_Dif_pept3 4 1 4
Plcd1 phospholipase C, delta 1 Sum of Sum_pept_count 1 2 6 1
Max of Max_Dif_pept 1 2 4 1
Gclm
glutamate-cysteine ligase , 
modifier subunit
Sum of Sum_pept_count 4 2 1 7
Max of Max_Dif_pept 2 1 1 4    214
Gene Symbol Gene Description Data proximal central distal total mucosa
Pkp3 plakophilin 3 Sum of Sum_pept_count 4 8 4 6
Max of Max_Dif_pept 1 4 2 4
1810065E05Rik RIKEN cDNA 1810065E05 gene Sum of Sum_pept_count 1 1 15 2
Max of Max_Dif_pept 1 1 4 1
Abhd14b
abhydrolase domain containing 
14b
Sum of Sum_pept_count 1 1 0 6
Max of Max_Dif_pept 1 1 0 4
Pitpnb
phosphatidylinositol transfer 
protein, beta
Sum of Sum_pept_count 3 4 2 2
Max of Max_Dif_pept 3 4 2 2
Gdpd1
glycerophosphodiester 
phosphodiesterase domain 
containing 1
Sum of Sum_pept_count 0 0 4 6
Max of Max_Dif_pept 0 0 2 4
Mosc2
MOCO sulphurase C-terminal 
domain containing 2
Sum of Sum_pept_count 1 0 0 9
Max of Max_Dif_pept 1 0 0 4
Arhgdia
Rho GDP dissociation inhibitor 
(GDI) alpha
Sum of Sum_pept_count 1 5 3 7
Max of Max_Dif_pept 1 4 2 3
Pfkl phosphofructokinase, liver, B-type Sum of Sum_pept_count 0 2 0 5
Max of Max_Dif_pept 0 2 0 4
Pebp1
phosphatidylethanolamine binding 
protein 1
Sum of Sum_pept_count 1 5 1 3
Max of Max_Dif_pept 1 4 1 3
Hnrnpf
heterogeneous nuclear 
ribonucleoprotein F
Sum of Sum_pept_count 5 8 2 6
Max of Max_Dif_pept 2 3 2 4
Pdxdc1
pyridoxal-dependent 
decarboxylase domain containing 
1
Sum of Sum_pept_count 0 0 2 7
Max of Max_Dif_pept 0 0 1 4
Pdlim5 PDZ and LIM domain 5 Sum of Sum_pept_count 1 2 1 6
Max of Max_Dif_pept 1 1 1 4
Pcyt1a
phosphate cytidylyltransferase 1, 
choline, alpha isoform
Sum of Sum_pept_count 4 4 2 5
Max of Max_Dif_pept 4 2 2 3
Pctk3 PCTAIRE-motif protein kinase 3 Sum of Sum_pept_count 9 5 4 4
Max of Max_Dif_pept 4 2 2 3
2310057J18Rik RIKEN cDNA 2310057J18 gene Sum of Sum_pept_count 1 5 1 3
Max of Max_Dif_pept 1 4 1 3
Gk5 glycerol kinase 5 (putative) Sum of Sum_pept_count 4 0 0 0
Max of Max_Dif_pept 4 0 0 0
Pbld
phenazine biosynthesis-like protein 
domain containing
Sum of Sum_pept_count 7 1 3 3
Max of Max_Dif_pept 4 1 1 2
Pard6b
par-6 (partitioning defective 6) 
homolog beta (C. elegans)
Sum of Sum_pept_count 2 2 1 4
Max of Max_Dif_pept 1 1 1 4
Glipr2 GLI pathogenesis-related 2 Sum of Sum_pept_count 0 5 6 5
Max of Max_Dif_pept 0 4 4 2
Oxsr1 oxidative-stress responsive 1 Sum of Sum_pept_count 0 0 0 6
Max of Max_Dif_pept 0 0 0 4
Muc2 mucin 2 Sum of Sum_pept_count 0 0 0 6
Max of Max_Dif_pept 0 0 0 4
Nptn neuroplastin Sum of Sum_pept_count 8 6 8 7
Max of Max_Dif_pept 3 3 3 4
Clrn3 clarin 3 Sum of Sum_pept_count 60 45 53 38
Max of Max_Dif_pept 4 4 4 4
1810046J19Rik RIKEN cDNA 1810046J19 gene Sum of Sum_pept_count 0 4 0 1
Max of Max_Dif_pept 0 4 0 1
Myh14 myosin, heavy polypeptide 14 Sum of Sum_pept_count 0 0 0 8
Max of Max_Dif_pept 0 0 0 4
D6Wsu176e
DNA segment, Chr 6, Wayne State 
University 176, expressed
Sum of Sum_pept_count 1 0 4 3
Max of Max_Dif_pept 1 0 4 3
Nlrp4e
NLR family, pyrin domain 
containing 4E
Sum of Sum_pept_count 3 2 7 14
Max of Max_Dif_pept2 2 3 4
Nlrc4
NLR family, CARD domain 
containing 4
Sum of Sum_pept_count 0 1 1 8
Max of Max_Dif_pept 0 1 1 4
Mylk myosin, light polypeptide kinase Sum of Sum_pept_count 2 8 2 11
Max of Max_Dif_pept 1 4 1 4
Dad1 defender against cell death 1 Sum of Sum_pept_count 1 0 4 3
Max of Max_Dif_pept 1 0 4 3
Clint1 clathrin interactor 1 Sum of Sum_pept_count 0 0 0 6
Max of Max_Dif_pept 0 0 0 4
Copg
coatomer protein complex, subunit 
gamma
Sum of Sum_pept_count 0 2 4 16
Max of Max_Dif_pept 0 1 2 4  215
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Cd81 CD81 antigen Sum of Sum_pept_count 6 3 7 4
Max of Max_Dif_pept 3 3 4 2
2700060E02Rik RIKEN cDNA 2700060E02 gene Sum of Sum_pept_count 0 0 2 5
Max of Max_Dif_pept 0 0 2 4
01.09.2005 septin 5 Sum of Sum_pept_count 1 1 3 7
Max of Max_Dif_pept 1 1 2 3
Zdhhc9
zinc finger, DHHC domain 
containing 9
Sum of Sum_pept_count 7 0 5 1
Max of Max_Dif_pept 3 0 2 1
Bcap31
B-cell receptor-associated protein 
31
Sum of Sum_pept_count 0 0 2 7
Max of Max_Dif_pept 0 0 1 3
Idi1
isopentenyl-diphosphate delta 
isomerase
Sum of Sum_pept_count 0 0 2 3
Max of Max_Dif_pept 0 0 2 3
Ap3m1
adaptor-related protein complex 3, 
mu 1 subunit
Sum of Sum_pept_count 0 1 0 3
Max of Max_Dif_pept 0 1 0 3
Hnrnpa2b1
heterogeneous nuclear 
ribonucleoprotein A2/B1
Sum of Sum_pept_count 0 4 0 10
Max of Max_Dif_pept 0 2 0 3
Bcl2l14 Bcl2-like 14 (apoptosis facilitator) Sum of Sum_pept_count 6 1 1 1
Max of Max_Dif_pept 3 1 1 1
5730446C15Rik RIKEN cDNA 5730446C15 gene Sum of Sum_pept_count 2 2 4 3
Max of Max_Dif_pept 2 2 2 3
Grb2
growth factor receptor bound 
protein 2
Sum of Sum_pept_count 0 5 3 3
Max of Max_Dif_pept 0 3 3 3
Vps28 vacuolar protein sorting 28 (yeast) Sum of Sum_pept_count 2 3 0 3
Max of Max_Dif_pept 2 3 0 3
Vps24 vacuolar protein sorting 24 (yeast) Sum of Sum_pept_count 8 7 5 8
Max of Max_Dif_pept 3 2 2 3
Vdac3 voltage-dependent anion channel 3 Sum of Sum_pept_count 0 0 3 3
Max of Max_Dif_pept 0 0 2 3
Cope
coatomer protein complex, subunit 
epsilon
Sum of Sum_pept_count 0 0 0 4
Max of Max_Dif_pept 0 0 0 3
1810020D17Rik RIKEN cDNA 1810020D17 gene Sum of Sum_pept_count 0 4 0 3
Max of Max_Dif_pept 0 3 0 3
Myo1c myosin IC Sum of Sum_pept_count 0 0 4 3
Max of Max_Dif_pept 0 0 2 3
Dab1 disabled homolog 1 (Drosophila) Sum of Sum_pept_count 4 7 7 3
Max of Max_Dif_pept 2 3 3 2
Ndufa13
NADH dehydrogenase 
(ubiquinone) 1 alpha subcomplex, 
13
Sum of Sum_pept_count 1 0 1 5
Max of Max_Dif_pept 1 0 1 3
Isoc1
isochorismatase domain 
containing 1
Sum of Sum_pept_count 1 2 1 3
Max of Max_Dif_pept 1 2 1 3
9130404H23Rik RIKEN cDNA 9130404H23 gene Sum of Sum_pept_count 0 4 2 3
Max of Max_Dif_pept 0 3 1 3
Epb4.1l4b erythrocyte protein band 4.1-like 4b Sum of Sum_pept_count 4 6 7 4
Max of Max_Dif_pept 1 2 3 3
Ndufb4
NADH dehydrogenase 
(ubiquinone) 1 beta subcomplex 4
Sum of Sum_pept_count 1 0 1 4
Max of Max_Dif_pept 1 0 1 3
Ndufb5
NADH dehydrogenase 
(ubiquinone) 1 beta subcomplex, 5
Sum of Sum_pept_count 0 0 1 5
Max of Max_Dif_pept 0 0 1 3
Uqcrfs1
ubiquinol-cytochrome c reductase, 
Rieske iron-sulfur polypeptide 1
Sum of Sum_pept_count 0 0 0 4
Max of Max_Dif_pept 0 0 0 3
Ndufb9
NADH dehydrogenase 
(ubiquinone) 1 beta subcomplex, 9
Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 3
Dgat1 diacylglycerol O-acyltransferase 1 Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept0 0 0 3
Gss glutathione synthetase Sum of Sum_pept_count 0 3 0 2
Max of Max_Dif_pept 0 3 0 2
Uqcrb
ubiquinol-cytochrome c reductase 
binding protein
Sum of Sum_pept_count 0 0 3 0
Max of Max_Dif_pept 0 0 3 0
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Ngef
neuronal guanine nucleotide 
exchange factor
Sum of Sum_pept_count 2 9 6 2
Max of Max_Dif_pept 1 3 3 2
Nit2 nitrilase family, member 2 Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 3
Cd82 CD82 antigen Sum of Sum_pept_count 13 10 16 8
Max of Max_Dif_pept 3 3 3 2
Ugt2b34
UDP glucuronosyltransferase 2 
family, polypeptide B34
Sum of Sum_pept_count 0 0 2 5
Max of Max_Dif_pept 0 0 1 3
Gstm1 glutathione S-transferase, mu 1 Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 3
Abcb6
ATP-binding cassette, sub-family B 
(MDR/TAP), member 6
Sum of Sum_pept_count 3 0 6 3
Max of Max_Dif_pept 3 0 3 2
Itfg3
integrin alpha FG-GAP repeat 
containing 3
Sum of Sum_pept_count 0 1 3 1
Max of Max_Dif_pept 0 1 3 1
Uevld
UEV and lactate/malate 
dehyrogenase domains
Sum of Sum_pept_count 0 3 1 0
Max of Max_Dif_pept 0 3 1 0
Ube2v2
ubiquitin-conjugating enzyme E2 
variant 2
Sum of Sum_pept_count 1 5 1 3
Max of Max_Dif_pept 1 3 1 3
Ube2v1
ubiquitin-conjugating enzyme E2 
variant 1
Sum of Sum_pept_count 1 5 1 3
Max of Max_Dif_pept 1 3 1 3
Itga6 integrin alpha 6 Sum of Sum_pept_count 2 0 5 3
Max of Max_Dif_pept 1 0 3 2
Gstt1 glutathione S-transferase, theta 1 Sum of Sum_pept_count 1 0 0 3
Max of Max_Dif_pept 1 0 0 3
Aadac
arylacetamide deacetylase 
(esterase)
Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 3
Aspa aspartoacylase Sum of Sum_pept_count 0 2 3 1
Max of Max_Dif_pept 0 2 3 1
EG668668 predicted gene, EG668668 Sum of Sum_pept_count 6 5 5 5
Max of Max_Dif_pept 3 1 2 3
Iah1
isoamyl acetate-hydrolyzing 
esterase 1 homolog (S. cerevisiae)
Sum of Sum_pept_count 0 1 3 7
Max of Max_Dif_pept 0 1 2 3
Uba1
ubiquitin-like modifier activating 
enzyme 1
Sum of Sum_pept_count 0 2 0 5
Max of Max_Dif_pept 0 2 0 3
Itm2b integral membrane protein 2B Sum of Sum_pept_count 4 0 2 1
Max of Max_Dif_pept 3 0 2 1
Akap7 A kinase (PRKA) anchor protein 7 Sum of Sum_pept_count 10 6 5 6
Max of Max_Dif_pept 3 2 2 3
Arhgap18 Rho GTPase activating protein 18 Sum of Sum_pept_count 0 3 0 1
Max of Max_Dif_pept 0 3 0 1
Clec2h
C-type lectin domain family 2, 
member h
Sum of Sum_pept_count 0 1 7 3
Max of Max_Dif_pept 0 1 3 1
Dsg4 desmoglein 4 Sum of Sum_pept_count 4 0 1 0
Max of Max_Dif_pept 3 0 1 0
Ogdh
oxoglutarate dehydrogenase 
(lipoamide)
Sum of Sum_pept_count 0 0 0 4
Max of Max_Dif_pept 0 0 0 3
Tubb4 tubulin, beta 4 Sum of Sum_pept_count 2 2 0 8
Max of Max_Dif_pept 1 1 0 3
ORF9 open reading frame 9 Sum of Sum_pept_count 1 0 3 1
Max of Max_Dif_pept 1 0 3 1
Tuba3b tubulin, alpha 3B Sum of Sum_pept_count 3 3 3 3
Max of Max_Dif_pept 2 1 2 3
Glrx3 glutaredoxin 3 Sum of Sum_pept_count 0 3 2 3
Max of Max_Dif_pept0 2 2 3
Otop3 otopetrin 3 Sum of Sum_pept_count 15 0 0 2
Max of Max_Dif_pept 3 0 0 2
OTTMUSG0000000
predicted gene, 
OTTMUSG00000001634
Sum of Sum_pept_count 20 23 20 13
Max of Max_Dif_pept 2 3 2 2
Tuba3a tubulin, alpha 3A Sum of Sum_pept_count 3 3 3 3
Max of Max_Dif_pept 2 1 2 3
Adsl adenylosuccinate lyase Sum of Sum_pept_count 0 3 2 3
Max of Max_Dif_pept 0 3 2 3
Chmp1b chromatin modifying protein 1B Sum of Sum_pept_count 9 9 4 10
Max of Max_Dif_pept 3 2 1 3  217
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Ttc38 tetratricopeptide repeat domain 38 Sum of Sum_pept_count 0 3 1 0
Max of Max_Dif_pept 0 3 1 0
Duox1 dual oxidase 1 Sum of Sum_pept_count 1 0 9 0
Max of Max_Dif_pept 1 0 3 0
Tspan15 tetraspanin 15 Sum of Sum_pept_count 2 0 6 2
Max of Max_Dif_pept 1 0 3 1
Tsg101 tumor susceptibility gene 101 Sum of Sum_pept_count 1 3 0 3
Max of Max_Dif_pept 1 2 0 3
Try4 trypsin 4 Sum of Sum_pept_count 0 3 1 6
Max of Max_Dif_pept 0 2 1 3
Arl15 ADP-ribosylation factor-like 15 Sum of Sum_pept_count 3 3 1 2
Max of Max_Dif_pept 3 3 1 2
Pabpc1
poly A binding protein, cytoplasmic 
1
Sum of Sum_pept_count 0 0 0 4
Max of Max_Dif_pept 0 0 0 3
Glo1 glyoxalase 1 Sum of Sum_pept_count 0 1 1 3
Max of Max_Dif_pept 0 1 1 3
BC085271 cDNA sequence BC085271 Sum of Sum_pept_count 0 7 2 4
Max of Max_Dif_pept 0 3 2 2
Ela1 elastase 1, pancreatic Sum of Sum_pept_count 3 0 2 4
Max of Max_Dif_pept 3 0 2 3
Kng2 kininogen 2 Sum of Sum_pept_count 0 0 1 5
Max of Max_Dif_pept 0 0 1 3
Cpne1 copine I Sum of Sum_pept_count 0 3 3 0
Max of Max_Dif_pept 0 3 3 0
Kpnb1 karyopherin (importin) beta 1 Sum of Sum_pept_count 0 1 0 5
Max of Max_Dif_pept 0 1 0 3
Mtus1 mitochondrial tumor suppressor 1 Sum of Sum_pept_count 0 0 3 0
Max of Max_Dif_pept 0 0 3 0
Tpd52 tumor protein D52 Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 3
Aldh3a2
aldehyde dehydrogenase family 3, 
subfamily A2
Sum of Sum_pept_count 0 0 2 3
Max of Max_Dif_pept 0 0 2 3
Tnpo1 transportin 1 Sum of Sum_pept_count 0 0 1 5
Max of Max_Dif_pept 0 0 1 3
Tmprss8
transmembrane protease, serine 8 
(intestinal)
Sum of Sum_pept_count 9 13 30 8
Max of Max_Dif_pept 2 3 3 1
Pcbp2 poly(rC) binding protein 2 Sum of Sum_pept_count 0 4 1 3
Max of Max_Dif_pept 0 3 1 3
Mtmr2 myotubularin related protein 2 Sum of Sum_pept_count 0 2 3 2
Max of Max_Dif_pept 0 2 3 2
Tmprss4 transmembrane protease, serine 4 Sum of Sum_pept_count 6 2 6 4
Max of Max_Dif_pept 3 1 2 2
Pck2
phosphoenolpyruvate 
carboxykinase 2 (mitochondrial)
Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 3
Arhgap27 Rho GTPase activating protein 27 Sum of Sum_pept_count 0 1 3 2
Max of Max_Dif_pept 0 1 3 2
Eif6
eukaryotic translation initiation 
factor 6
Sum of Sum_pept_count 2 1 3 3
Max of Max_Dif_pept 2 1 1 3
Arhgef3
Rho guanine nucleotide exchange 
factor (GEF) 3
Sum of Sum_pept_count 0 0 3 3
Max of Max_Dif_pept 0 0 2 3
Eef1a2
eukaryotic translation elongation 
factor 1 alpha 2
Sum of Sum_pept_count 7 7 5 9
Max of Max_Dif_pept 2 2 2 3
Tmem189 transmembrane protein 189 Sum of Sum_pept_count 1 5 1 3
Max of Max_Dif_pept1 3 1 3
Cldn23 claudin 23 Sum of Sum_pept_count 13 3 7 6
Max of Max_Dif_pept 3 1 3 2
Tmem106b transmembrane protein 106B Sum of Sum_pept_count 0 0 3 0
Max of Max_Dif_pept 0 0 3 0
4930471M23Rik RIKEN cDNA 4930471M23 gene Sum of Sum_pept_count 11 4 10 7
Max of Max_Dif_pept 3 2 2 2
Cdk5 cyclin-dependent kinase 5 Sum of Sum_pept_count 0 0 1 3
Max of Max_Dif_pept 0 0 1 3
Tmed2
transmembrane emp24 domain 
trafficking protein 2
Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 3
Anp32a
acidic (leucine-rich) nuclear 
phosphoprotein 32 family, member 
A
Sum of Sum_pept_count 0 4 0 4
Max of Max_Dif_pept 0 2 0 3
Tm4sf5
transmembrane 4 superfamily 
member 5
Sum of Sum_pept_count 20 9 6 4
Max of Max_Dif_pept 3 2 1 2    218
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Eef1d
eukaryotic translation elongation 
factor 1 delta (guanine nucleotide 
exchange protein)
Sum of Sum_pept_count 0 0 0 8
Max of Max_Dif_pept 0 0 0 3
Dctn2 dynactin 2 Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 3
Pdxk
pyridoxal (pyridoxine, vitamin B6) 
kinase
Sum of Sum_pept_count 0 3 0 4
Max of Max_Dif_pept 0 3 0 3
Acadl
acyl-Coenzyme A dehydrogenase, 
long-chain
Sum of Sum_pept_count 0 0 0 5
Max of Max_Dif_pept 0 0 0 3
Thy1 thymus cell antigen 1, theta Sum of Sum_pept_count 0 0 2 4
Max of Max_Dif_pept 0 0 1 3
Ada adenosine deaminase Sum of Sum_pept_count 1 3 0 2
Max of Max_Dif_pept 1 3 0 1
Thnsl2
threonine synthase-like 2 
(bacterial)
Sum of Sum_pept_count 0 1 0 3
Max of Max_Dif_pept 0 1 0 3
H2-Q6
histocompatibility 2, Q region locus 
6
Sum of Sum_pept_count 2 2 3 3
Max of Max_Dif_pept 2 2 3 2
Cda cytidine deaminase Sum of Sum_pept_count 2 6 0 5
Max of Max_Dif_pept 1 3 0 2
Tcirg1
T-cell, immune regulator 1, 
ATPase, H+ transporting, 
lysosomal V0 protein A3
Sum of Sum_pept_count 2 0 3 0
Max of Max_Dif_pept 1 0 3 0
H2-Q7
histocompatibility 2, Q region locus 
7
Sum of Sum_pept_count 2 2 3 3
Max of Max_Dif_pept 2 2 3 2
Dhfr dihydrofolate reductase Sum of Sum_pept_count 3 1 0 3
Max of Max_Dif_pept 2 1 0 3
Hadh
hydroxyacyl-Coenzyme A 
dehydrogenase
Sum of Sum_pept_count 1 4 1 5
Max of Max_Dif_pept 1 3 1 3
Stx4a syntaxin 4A (placental) Sum of Sum_pept_count 2 0 4 3
Max of Max_Dif_pept 1 0 2 3
Stk16 serine/threonine kinase 16 Sum of Sum_pept_count 0 2 3 2
Max of Max_Dif_pept 0 2 3 2
Acyp1
acylphosphatase 1, erythrocyte 
(common) type
Sum of Sum_pept_count 0 3 0 0
Max of Max_Dif_pept 0 3 0 0
Pgm2l1 phosphoglucomutase 2-like 1 Sum of Sum_pept_count 0 3 0 0
Max of Max_Dif_pept 0 3 0 0
Pgm3 phosphoglucomutase 3 Sum of Sum_pept_count 0 3 1 1
Max of Max_Dif_pept 0 3 1 1
Pgrmc1
progesterone receptor membrane 
component 1
Sum of Sum_pept_count 0 0 0 4
Max of Max_Dif_pept 0 0 0 3
Phb prohibitin Sum of Sum_pept_count 0 0 2 3
Max of Max_Dif_pept 0 0 1 3
BC046404 cDNA sequence BC046404 Sum of Sum_pept_count 5 5 3 0
Max of Max_Dif_pept 3 3 2 0
Pi4k2a
phosphatidylinositol 4-kinase type 
2 alpha
Sum of Sum_pept_count 2 0 4 0
Max of Max_Dif_pept 2 0 3 0
Capn5 calpain 5 Sum of Sum_pept_count 0 2 4 0
Max of Max_Dif_pept 0 2 3 0
C77080 expressed sequence C77080 Sum of Sum_pept_count 2 5 2 0
Max of Max_Dif_pept 1 3 1 0
Hagh hydroxyacyl glutathione hydrolase Sum of Sum_pept_count 0 2 0 4
Max of Max_Dif_pept 0 1 0 3
St14
suppression of tumorigenicity 14 
(colon carcinoma)
Sum of Sum_pept_count 0 0 5 3
Max of Max_Dif_pept 0 0 3 3
St13 suppression of tumorigenicity 13 Sum of Sum_pept_count 1 1 1 4
Max of Max_Dif_pept1 1 1 3
Ssr4 signal sequence receptor, delta Sum of Sum_pept_count 1 0 3 3
Max of Max_Dif_pept 1 0 3 2
Capg
capping protein (actin filament), 
gelsolin-like
Sum of Sum_pept_count 0 7 1 1
Max of Max_Dif_pept 0 3 1 1
Pkn2 protein kinase N2 Sum of Sum_pept_count 5 2 7 0
Max of Max_Dif_pept 3 2 3 0
Pkn3 protein kinase N3 Sum of Sum_pept_count 0 7 2 4
Max of Max_Dif_pept 0 3 2 2
Pkp1 plakophilin 1 Sum of Sum_pept_count 4 0 3 0
Max of Max_Dif_pept 3 0 2 0
Chmp2b chromatin modifying protein 2B Sum of Sum_pept_count 2 7 2 3
Max of Max_Dif_pept 1 3 1 1  219
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Plac8 placenta-specific 8 Sum of Sum_pept_count 19 12 16 8
Max of Max_Dif_pept 3 2 2 1
Mif
macrophage migration inhibitory 
factor
Sum of Sum_pept_count 1 4 4 3
Max of Max_Dif_pept 1 3 2 2
Aprt
adenine phosphoribosyl 
transferase
Sum of Sum_pept_count 1 3 0 2
Max of Max_Dif_pept 1 3 0 2
Ddc dopa decarboxylase Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 3
Acly ATP citrate lyase Sum of Sum_pept_count 0 0 3 8
Max of Max_Dif_pept 0 0 1 3
Cnbp cellular nucleic acid binding protein Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 3
Plekhf1
pleckstrin homology domain 
containing, family F (with FYVE 
domain) member 1
Sum of Sum_pept_count 4 1 0 2
Max of Max_Dif_pept 3 1 0 2
Krt82 keratin 82 Sum of Sum_pept_count 3 1 0 0
Max of Max_Dif_pept 3 1 0 0
Eif5
eukaryotic translation initiation 
factor 5
Sum of Sum_pept_count 0 0 0 4
Max of Max_Dif_pept 0 0 0 3
Krtcap3 keratinocyte associated protein 3 Sum of Sum_pept_count 1 0 4 3
Max of Max_Dif_pept 1 0 3 2
Snx2 sorting nexin 2 Sum of Sum_pept_count 0 0 0 10
Max of Max_Dif_pept 0 0 0 3
Snx1 sorting nexin 1 Sum of Sum_pept_count 0 0 0 10
Max of Max_Dif_pept 0 0 0 3
Blmh bleomycin hydrolase Sum of Sum_pept_count 0 2 3 2
Max of Max_Dif_pept 0 2 3 1
Cav1 caveolin, caveolae protein 1 Sum of Sum_pept_count 1 1 2 9
Max of Max_Dif_pept 1 1 1 3
Smad2 MAD homolog 2 (Drosophila) Sum of Sum_pept_count 4 1 2 1
Max of Max_Dif_pept 3 1 1 1
Slc7a8
solute carrier family 7 (cationic 
amino acid transporter, y+ 
system), member 8
Sum of Sum_pept_count 9 2 6 6
Max of Max_Dif_pept 3 2 3 3
0910001A06Rik RIKEN cDNA 0910001A06 gene Sum of Sum_pept_count 2 3 2 4
Max of Max_Dif_pept 2 3 1 3
Lancl2
LanC (bacterial lantibiotic 
synthetase component C)-like 2
Sum of Sum_pept_count 0 1 0 3
Max of Max_Dif_pept 0 1 0 3
Ppme1
protein phosphatase 
methylesterase 1
Sum of Sum_pept_count 0 0 0 5
Max of Max_Dif_pept 0 0 0 3
Slc6a20b
solute carrier family 6 
(neurotransmitter transporter), 
member 20B
Sum of Sum_pept_count 1 0 3 0
Max of Max_Dif_pept 1 0 3 0
Comt catechol-O-methyltransferase Sum of Sum_pept_count 0 0 1 4
Max of Max_Dif_pept 0 0 1 3
Mfge8
milk fat globule-EGF factor 8 
protein
Sum of Sum_pept_count 0 0 3 0
Max of Max_Dif_pept 0 0 3 0
Slc5a6
solute carrier family 5 (sodium-
dependent vitamin transporter), 
member 6
Sum of Sum_pept_count 7 0 9 3
Max of Max_Dif_pept 3 0 3 2
Lck lymphocyte protein tyrosine kinase Sum of Sum_pept_count 2 0 4 2
Max of Max_Dif_pept 2 0 3 2
EG243302 predicted gene, EG243302 Sum of Sum_pept_count 4 1 4 4
Max of Max_Dif_pept 2 1 2 3
Slc4a1
solute carrier family 4 (anion 
exchanger), member 1
Sum of Sum_pept_count 0 0 3 3
Max of Max_Dif_pept 0 0 3 2
Atp5o
ATP synthase, H+ transporting, 
mitochondrial F1 complex, O 
subunit
Sum of Sum_pept_count 1 0 1 3
Max of Max_Dif_pept1 0 1 3
Blvrb
biliverdin reductase B (flavin 
reductase (NADPH))
Sum of Sum_pept_count 0 1 0 4
Max of Max_Dif_pept 0 1 0 3
Gmfb glia maturation factor, beta Sum of Sum_pept_count 1 3 1 1
Max of Max_Dif_pept 1 3 1 1
Slc43a2 solute carrier family 43, member 2 Sum of Sum_pept_count 1 0 2 8
Max of Max_Dif_pept 1 0 1 3  220
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Cyc1 cytochrome c-1 Sum of Sum_pept_count 0 0 2 7
Max of Max_Dif_pept 0 0 2 3
1110012J17Rik RIKEN cDNA 1110012J17 gene Sum of Sum_pept_count 4 1 5 2
Max of Max_Dif_pept 2 1 3 2
Slc37a2
solute carrier family 37 (glycerol-3-
phosphate transporter), member 2
Sum of Sum_pept_count 12 0 0 3
Max of Max_Dif_pept 3 0 0 1
Hint3
histidine triad nucleotide binding 
protein 3
Sum of Sum_pept_count 0 3 0 3
Max of Max_Dif_pept 0 3 0 2
Bzw2
basic leucine zipper and W2 
domains 2
Sum of Sum_pept_count 2 3 1 3
Max of Max_Dif_pept 2 2 1 3
Prg2 proteoglycan 2, bone marrow Sum of Sum_pept_count 5 0 0 3
Max of Max_Dif_pept 3 0 0 2
EG667525 predicted gene, EG667525 Sum of Sum_pept_count 3 1 3 0
Max of Max_Dif_pept 3 1 3 0
Prkaa2
protein kinase, AMP-activated, 
alpha 2 catalytic subunit
Sum of Sum_pept_count 0 1 0 3
Max of Max_Dif_pept 0 1 0 3
Prkab1
protein kinase, AMP-activated, 
beta 1 non-catalytic subunit
Sum of Sum_pept_count 0 0 1 5
Max of Max_Dif_pept 0 0 1 3
Hip1r
huntingtin interacting protein 1 
related
Sum of Sum_pept_count 3 0 0 4
Max of Max_Dif_pept 2 0 0 3
Slc2a2
solute carrier family 2 (facilitated 
glucose transporter), member 2
Sum of Sum_pept_count 5 3 1 4
Max of Max_Dif_pept 3 2 1 1
Cps1 carbamoyl-phosphate synthetase 1 Sum of Sum_pept_count 0 0 0 5
Max of Max_Dif_pept 0 0 0 3
Cpt2 carnitine palmitoyltransferase 2 Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 3
Slc26a2
solute carrier family 26 (sulfate 
transporter), member 2
Sum of Sum_pept_count 24 23 30 13
Max of Max_Dif_pept 3 3 3 3
Slc25a1
solute carrier family 25 
(mitochondrial carrier, citrate 
transporter), member 1
Sum of Sum_pept_count 0 0 1 3
Max of Max_Dif_pept 0 0 1 3
Lin7c lin-7 homolog C (C. elegans) Sum of Sum_pept_count 3 5 3 3
Max of Max_Dif_pept 3 3 3 3
Slc12a2 solute carrier family 12, member 2 Sum of Sum_pept_count 3 0 10 2
Max of Max_Dif_pept 1 0 3 1
Prkci protein kinase C, iota Sum of Sum_pept_count 5 7 6 2
Max of Max_Dif_pept 2 3 1 1
Slc11a2
solute carrier family 11 (proton-
coupled divalent metal ion 
transporters), member 2
Sum of Sum_pept_count 7 1 3 2
Max of Max_Dif_pept 3 1 1 1
2610002M06Rik RIKEN cDNA 2610002M06 gene Sum of Sum_pept_count 6 2 4 5
Max of Max_Dif_pept 3 2 3 3
Skp1a
S-phase kinase-associated protein 
1A
Sum of Sum_pept_count 2 4 0 2
Max of Max_Dif_pept 2 3 0 2
Shq1 SHQ1 homolog (S. cerevisiae) Sum of Sum_pept_count 1 5 1 3
Max of Max_Dif_pept 1 3 1 3
Fbp1 fructose bisphosphatase 1 Sum of Sum_pept_count 0 4 0 4
Max of Max_Dif_pept 0 3 0 3
Arl5a ADP-ribosylation factor-like 5A Sum of Sum_pept_count 3 2 1 1
Max of Max_Dif_pept 3 2 1 1
Set SET translocation Sum of Sum_pept_count 0 7 2 4
Max of Max_Dif_pept 0 3 2 2
Crip1 cysteine-rich protein 1 (intestinal) Sum of Sum_pept_count 2 3 2 7
Max of Max_Dif_pept 1 1 1 3
Psen1 presenilin 1 Sum of Sum_pept_count 16 7 21 15
Max of Max_Dif_pept3 2 3 2
Serpina1d
serine (or cysteine) peptidase 
inhibitor, clade A, member 1d
Sum of Sum_pept_count 0 5 1 3
Max of Max_Dif_pept 0 3 1 3
Serpina1c
serine (or cysteine) peptidase 
inhibitor, clade A, member 1c
Sum of Sum_pept_count 0 5 0 0
Max of Max_Dif_pept 0 3 0 0
Serpina1b
serine (or cysteine) preptidase 
inhibitor, clade A, member 1b
Sum of Sum_pept_count 0 5 0 0
Max of Max_Dif_pept 0 3 0 0
Psma3
proteasome (prosome, macropain) 
subunit, alpha type 3
Sum of Sum_pept_count 1 3 3 6
Max of Max_Dif_pept 1 2 2 3
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Psma4
proteasome (prosome, macropain) 
subunit, alpha type 4
Sum of Sum_pept_count 1 2 3 3
Max of Max_Dif_pept 1 2 2 3
Serhl serine hydrolase-like Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 3
Selenbp1 selenium binding protein 1 Sum of Sum_pept_count 1 5 2 3
Max of Max_Dif_pept 1 3 1 3
Mark2
MAP/microtubule affinity-regulating 
kinase 2
Sum of Sum_pept_count 6 3 4 1
Max of Max_Dif_pept 3 1 1 1
Cct2
chaperonin containing Tcp1, 
subunit 2 (beta)
Sum of Sum_pept_count 0 1 1 6
Max of Max_Dif_pept 0 1 1 3
Sec24b
SEC24 related gene family, 
member B (S. cerevisiae)
Sum of Sum_pept_count 0 1 0 3
Max of Max_Dif_pept 0 1 0 3
Lman1 lectin, mannose-binding, 1 Sum of Sum_pept_count 0 0 2 4
Max of Max_Dif_pept 0 0 1 3
Atp5b
ATP synthase, H+ transporting 
mitochondrial F1 complex, beta 
subunit
Sum of Sum_pept_count 1 2 1 6
Max of Max_Dif_pept 1 1 1 3
Psmb8
proteasome (prosome, macropain) 
subunit, beta type 8 (large 
multifunctional peptidase 7)
Sum of Sum_pept_count 0 1 1 3
Max of Max_Dif_pept 0 1 1 3
Sec14l2 SEC14-like 2 (S. cerevisiae) Sum of Sum_pept_count 6 4 1 4
Max of Max_Dif_pept 3 3 1 3
Galm galactose mutarotase Sum of Sum_pept_count 0 3 2 5
Max of Max_Dif_pept 0 3 2 3
Sdcbp2
syndecan binding protein 
(syntenin) 2
Sum of Sum_pept_count 1 5 4 5
Max of Max_Dif_pept 1 2 2 3
Scarb1
scavenger receptor class B, 
member 1
Sum of Sum_pept_count 3 0 0 0
Max of Max_Dif_pept 3 0 0 0
EG638487 predicted gene, EG638487 Sum of Sum_pept_count 0 7 2 4
Max of Max_Dif_pept 0 3 2 2
S100a10
S100 calcium binding protein A10 
(calpactin)
Sum of Sum_pept_count 4 9 9 6
Max of Max_Dif_pept 3 3 3 3
Cct8
chaperonin containing Tcp1, 
subunit 8 (theta)
Sum of Sum_pept_count 0 2 3 3
Max of Max_Dif_pept 0 1 1 3
Lmtk2 lemur tyrosine kinase 2 Sum of Sum_pept_count 4 0 1 2
Max of Max_Dif_pept 3 0 1 2
Rragd Ras-related GTP binding D Sum of Sum_pept_count 2 1 0 3
Max of Max_Dif_pept 2 1 0 3
Rragc Ras-related GTP binding C Sum of Sum_pept_count 2 1 2 3
Max of Max_Dif_pept 2 1 2 3
Rraga Ras-related GTP binding A Sum of Sum_pept_count 2 0 2 3
Max of Max_Dif_pept 2 0 2 3
LOC620497
solute carrier family 5 (sodium-
dependent vitamin transporter), 
member 6 pseudogene
Sum of Sum_pept_count 7 0 9 3
Max of Max_Dif_pept 3 0 3 2
Rps7 ribosomal protein S7 Sum of Sum_pept_count 3 0 3 3
Max of Max_Dif_pept 3 0 3 3
Rps6 ribosomal protein S6 Sum of Sum_pept_count 5 0 3 3
Max of Max_Dif_pept 3 0 2 1
Psmd8
proteasome (prosome, macropain) 
26S subunit, non-ATPase, 8
Sum of Sum_pept_count 0 0 0 6
Max of Max_Dif_pept 0 0 0 3
Rps4x ribosomal protein S4, X-linked Sum of Sum_pept_count 6 5 8 5
Max of Max_Dif_pept 3 1 3 3
Rps27l ribosomal protein S27-like Sum of Sum_pept_count 0 2 4 9
Max of Max_Dif_pept 0 2 3 3
Rps25 ribosomal protein S25 Sum of Sum_pept_count 4 1 4 4
Max of Max_Dif_pept2 1 2 3
Rps20 ribosomal protein S20 Sum of Sum_pept_count 3 1 1 4
Max of Max_Dif_pept 3 1 1 3
Fgd4
FYVE, RhoGEF and PH domain 
containing 4
Sum of Sum_pept_count 2 1 3 2
Max of Max_Dif_pept 2 1 3 1
Ptges3
prostaglandin E synthase 3 
(cytosolic)
Sum of Sum_pept_count 4 7 2 6
Max of Max_Dif_pept 2 2 1 3
Rps17 ribosomal protein S17 Sum of Sum_pept_count 2 2 5 4
Max of Max_Dif_pept 1 1 2 3  222
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Rps11 ribosomal protein S11 Sum of Sum_pept_count 3 0 2 3
Max of Max_Dif_pept 2 0 2 3
Csk c-src tyrosine kinase Sum of Sum_pept_count 0 3 1 3
Max of Max_Dif_pept 0 3 1 3
Ptp4a2 protein tyrosine phosphatase 4a2 Sum of Sum_pept_count 2 4 3 3
Max of Max_Dif_pept 2 3 3 3
Rpl34 ribosomal protein L34 Sum of Sum_pept_count 4 0 5 2
Max of Max_Dif_pept 2 0 3 2
Rpl27a ribosomal protein L27a Sum of Sum_pept_count 3 2 6 6
Max of Max_Dif_pept 1 2 2 3
Ptprj
protein tyrosine phosphatase, 
receptor type, J
Sum of Sum_pept_count 1 6 5 3
Max of Max_Dif_pept 1 3 2 2
Pttg1ip
pituitary tumor-transforming 1 
interacting protein
Sum of Sum_pept_count 9 1 6 5
Max of Max_Dif_pept 3 1 2 2
Rpl24 ribosomal protein L24 Sum of Sum_pept_count 7 3 7 7
Max of Max_Dif_pept 2 1 2 3
Rpl18a ribosomal protein L18A Sum of Sum_pept_count 0 0 3 3
Max of Max_Dif_pept 0 0 3 3
Rpl14 ribosomal protein L14 Sum of Sum_pept_count 1 0 1 4
Max of Max_Dif_pept 1 0 1 3
Cltb clathrin, light polypeptide (Lcb) Sum of Sum_pept_count 0 0 0 5
Max of Max_Dif_pept 0 0 0 3
Rpl10 ribosomal protein 10 Sum of Sum_pept_count 0 0 3 3
Max of Max_Dif_pept 0 0 3 2
Maob monoamine oxidase B Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 3
RP23-357I14.1
novel protein similar to solute 
carrier family 28 (sodium-coupled 
nucleoside transporter) member 2 
(Slc28a2)
Sum of Sum_pept_count 1 3 3 0
Max of Max_Dif_pept 1 3 3 0
Rnf128 ring finger protein 128 Sum of Sum_pept_count 9 1 5 3
Max of Max_Dif_pept 3 1 2 1
Rit1 Ras-like without CAAX 1 Sum of Sum_pept_count 4 1 0 3
Max of Max_Dif_pept 3 1 0 3
Alad
aminolevulinate, delta-, 
dehydratase
Sum of Sum_pept_count 0 2 2 3
Max of Max_Dif_pept 0 2 2 3
Fgr
Gardner-Rasheed feline sarcoma 
viral (Fgr) oncogene homolog
Sum of Sum_pept_count 0 0 3 1
Max of Max_Dif_pept 0 0 3 1
EG545332 predicted gene, EG545332 Sum of Sum_pept_count 1 5 1 0
Max of Max_Dif_pept 1 3 1 0
Rfk riboflavin kinase Sum of Sum_pept_count 2 3 0 2
Max of Max_Dif_pept 2 3 0 1
Reep6 receptor accessory protein 6 Sum of Sum_pept_count 2 1 2 10
Max of Max_Dif_pept 2 1 2 3
Csnk1g1 casein kinase 1, gamma 1 Sum of Sum_pept_count 6 3 2 4
Max of Max_Dif_pept 3 2 1 2
Dlat
dihydrolipoamide S-
acetyltransferase (E2 component 
of pyruvate dehydrogenase 
complex)
Sum of Sum_pept_count 0 0 0 5
Max of Max_Dif_pept 0 0 0 3
Arpc5
actin related protein 2/3 complex, 
subunit 5
Sum of Sum_pept_count 3 9 4 7
Max of Max_Dif_pept 2 3 2 2
Ranbp1 RAN binding protein 1 Sum of Sum_pept_count 1 0 3 6
Max of Max_Dif_pept 1 0 2 3
M6pr
mannose-6-phosphate receptor, 
cation dependent
Sum of Sum_pept_count 2 0 5 9
Max of Max_Dif_pept 2 0 3 3
Cisd2 CDGSH iron sulfur domain 2 Sum of Sum_pept_count 0 0 0 4
Max of Max_Dif_pept0 0 0 3
Rabif RAB interacting factor Sum of Sum_pept_count 3 3 2 4
Max of Max_Dif_pept 2 2 2 3
EG629575 predicted gene, EG629575 Sum of Sum_pept_count 5 0 3 3
Max of Max_Dif_pept 3 0 2 1
Ctdspl
CTD (carboxy-terminal domain, 
RNA polymerase II, polypeptide A) 
small phosphatase-like
Sum of Sum_pept_count 6 5 4 1
Max of Max_Dif_pept 3 3 2 1
Rab31
RAB31, member RAS oncogene 
family
Sum of Sum_pept_count 4 4 1 0
Max of Max_Dif_pept 3 3 1 0
Aacs acetoacetyl-CoA synthetase Sum of Sum_pept_count 0 0 0 3
Max of Max Dif pept0 0 0 3  223
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Frs2
fibroblast growth factor receptor 
substrate 2
Sum of Sum_pept_count 4 1 1 0
Max of Max_Dif_pept 3 1 1 0
Ctps2 cytidine 5'-triphosphate synthase 2 Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 3
Frmd8 FERM domain containing 8 Sum of Sum_pept_count 2 1 1 3
Max of Max_Dif_pept 2 1 1 3
Rab3c
RAB3C, member RAS oncogene 
family
Sum of Sum_pept_count 0 2 3 0
Max of Max_Dif_pept 0 2 3 0
2210010C04Rik RIKEN cDNA 2210010C04 gene Sum of Sum_pept_count 13 16 18 18
Max of Max_Dif_pept 1 2 1 2
Hist1h2bf histone cluster 1, H2bf Sum of Sum_pept_count 5 1 4 7
Max of Max_Dif_pept 2 1 2 2
Hist1h2be histone cluster 1, H2be Sum of Sum_pept_count 5 1 4 7
Max of Max_Dif_pept 2 1 2 2
Frmd3 FERM domain containing 3 Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 2
Rab39
RAB39, member RAS oncogene 
family
Sum of Sum_pept_count 4 0 1 4
Max of Max_Dif_pept 1 0 1 2
Hist1h2bc histone cluster 1, H2bc Sum of Sum_pept_count 5 1 4 7
Max of Max_Dif_pept 2 1 2 2
Rab32
RAB32, member RAS oncogene 
family
Sum of Sum_pept_count 2 1 0 2
Max of Max_Dif_pept 2 1 0 2
EG629557 predicted gene, EG629557 Sum of Sum_pept_count 4 0 3 0
Max of Max_Dif_pept 2 0 2 0
EG628596 predicted gene, EG628596 Sum of Sum_pept_count 0 3 2 2
Max of Max_Dif_pept 0 1 1 2
Actn1 actinin, alpha 1 Sum of Sum_pept_count 0 5 11 7
Max of Max_Dif_pept 0 2 2 2
Fmo5 flavin containing monooxygenase 5 Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Arcn1 archain 1 Sum of Sum_pept_count 0 2 1 6
Max of Max_Dif_pept 0 2 1 2
Hist1h2bb histone cluster 1, H2bb Sum of Sum_pept_count 5 1 4 7
Max of Max_Dif_pept 2 1 2 2
Dirc2
disrupted in renal carcinoma 2 
(human)
Sum of Sum_pept_count 0 1 6 1
Max of Max_Dif_pept 0 1 2 1
Ftl2 ferritin light chain 2 Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
M6prbp1
mannose-6-phosphate receptor 
binding protein 1
Sum of Sum_pept_count 6 1 1 2
Max of Max_Dif_pept 2 1 1 2
Capns1 calpain, small subunit 1 Sum of Sum_pept_count 2 1 3 2
Max of Max_Dif_pept 1 1 2 1
Rac3
RAS-related C3 botulinum 
substrate 3
Sum of Sum_pept_count 4 4 3 4
Max of Max_Dif_pept 2 1 1 2
EG632352 predicted gene, EG632352 Sum of Sum_pept_count 0 2 2 0
Max of Max_Dif_pept 0 2 2 0
Hist1h2bg histone cluster 1, H2bg Sum of Sum_pept_count 5 1 4 7
Max of Max_Dif_pept 2 1 2 2
EG627371 predicted gene, EG627371 Sum of Sum_pept_count 3 0 2 4
Max of Max_Dif_pept 2 0 1 1
Ctrb1 chymotrypsinogen B1 Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Lypla2 lysophospholipase 2 Sum of Sum_pept_count 1 0 2 2
Max of Max_Dif_pept1 0 2 2
Hist1h2ba histone cluster 1, H2ba Sum of Sum_pept_count 0 1 2 1
Max of Max_Dif_pept 0 1 2 1
Rap1gds1
RAP1, GTP-GDP dissociation 
stimulator 1
Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Rap2a RAS related protein 2a Sum of Sum_pept_count 0 1 4 0
Max of Max_Dif_pept 0 1 2 0
Rab24
RAB24, member RAS oncogene 
family
Sum of Sum_pept_count 2 0 1 1
Max of Max_Dif_pept 2 0 1 1
Hist1h2bh histone cluster 1, H2bh Sum of Sum_pept_count 5 1 4 7
Max of Max_Dif_pept 2 1 2 2
Cisd1 CDGSH iron sulfur domain 1 Sum of Sum_pept_count 0 0 1 2
Max of Max_Dif_pept 0 0 1 2
Ly6d
lymphocyte antigen 6 complex, 
locus D
Sum of Sum_pept_count 0 0 2 2
Max of Max_Dif_pept 0 0 2 2  224
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Qdpr quinoid dihydropteridine reductase Sum of Sum_pept_count 0 4 0 2
Max of Max_Dif_pept 0 2 0 2
Rpl21 ribosomal protein L21 Sum of Sum_pept_count 1 0 0 2
Max of Max_Dif_pept 1 0 0 2
Rpl22 ribosomal protein L22 Sum of Sum_pept_count 3 2 1 2
Max of Max_Dif_pept 2 2 1 2
Eif3e
eukaryotic translation initiation 
factor 3, subunit E
Sum of Sum_pept_count 0 0 1 2
Max of Max_Dif_pept 0 0 1 2
Pycrl
pyrroline-5-carboxylate reductase-
like
Sum of Sum_pept_count 2 2 2 3
Max of Max_Dif_pept 2 2 2 2
EG637273 predicted gene, EG637273 Sum of Sum_pept_count 0 0 4 2
Max of Max_Dif_pept 0 0 2 1
Rpl28 ribosomal protein L28 Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Rpl30 ribosomal protein L30 Sum of Sum_pept_count 4 0 2 4
Max of Max_Dif_pept 2 0 2 2
Rpl31 ribosomal protein L31 Sum of Sum_pept_count 7 0 3 4
Max of Max_Dif_pept 2 0 1 2
Ptprc
protein tyrosine phosphatase, 
receptor type, C
Sum of Sum_pept_count 0 0 1 2
Max of Max_Dif_pept 0 0 1 2
Lrrc40 leucine rich repeat containing 40 Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Rpl36 ribosomal protein L36 Sum of Sum_pept_count 2 0 2 3
Max of Max_Dif_pept 2 0 2 2
Rpl4 ribosomal protein L4 Sum of Sum_pept_count 2 0 0 1
Max of Max_Dif_pept 2 0 0 1
Rpl7a ribosomal protein L7a Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 2
Hist1h2ag histone cluster 1, H2ag Sum of Sum_pept_count 2 3 2 3
Max of Max_Dif_pept 1 2 1 2
Hist1h2bl histone cluster 1, H2bl Sum of Sum_pept_count 5 1 4 7
Max of Max_Dif_pept 2 1 2 2
Hnrnpu
heterogeneous nuclear 
ribonucleoprotein U
Sum of Sum_pept_count 4 0 0 0
Max of Max_Dif_pept 2 0 0 0
Lrrc1 leucine rich repeat containing 1 Sum of Sum_pept_count 0 0 3 0
Max of Max_Dif_pept 0 0 2 0
Rps14 ribosomal protein S14 Sum of Sum_pept_count 6 1 3 3
Max of Max_Dif_pept 2 1 2 2
Lrp1
low density lipoprotein receptor-
related protein 1
Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 2
LOC665622 H2b histone family member Sum of Sum_pept_count 5 1 4 7
Max of Max_Dif_pept 2 1 2 2
Hist1h2bm histone cluster 1, H2bm Sum of Sum_pept_count 5 1 4 7
Max of Max_Dif_pept 2 1 2 2
Eif1b
eukaryotic translation initiation 
factor 1B
Sum of Sum_pept_count 0 3 2 2
Max of Max_Dif_pept 0 1 1 2
Epha6 Eph receptor A6 Sum of Sum_pept_count 0 0 2 0
Max of Max_Dif_pept 0 0 2 0
LOC632454
similar to tumor protein, 
translationally-controlled 1
Sum of Sum_pept_count 0 6 0 3
Max of Max_Dif_pept 0 2 0 2
Ptbp1
polypyrimidine tract binding protein 
1
Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 2
Rps24 ribosomal protein S24 Sum of Sum_pept_count 3 1 2 2
Max of Max_Dif_pept2 1 1 1
Psmg3
proteasome (prosome, macropain) 
assembly chaperone 3
Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Rps26 ribosomal protein S26 Sum of Sum_pept_count 4 2 6 5
Max of Max_Dif_pept 2 2 2 2
Rps27 ribosomal protein S27 Sum of Sum_pept_count 0 2 0 1
Max of Max_Dif_pept 0 2 0 1
Hist1h2af histone cluster 1, H2af Sum of Sum_pept_count 2 3 2 3
Max of Max_Dif_pept 1 2 1 2
G6pd2
glucose-6-phosphate 
dehydrogenase 2
Sum of Sum_pept_count 0 1 2 0
Max of Max_Dif_pept 0 1 2 0
Fcgrt
Fc receptor, IgG, alpha chain 
transporter
Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Rps3a ribosomal protein S3a Sum of Sum_pept_count 2 0 0 1
Max of Max_Dif_pept 2 0 0 1
Map2k3
mitogen-activated protein kinase 
kinase 3
Sum of Sum_pept_count 0 0 2 1
Max of Max_Dif_pept 0 0 2 1    225
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Max of Max_Dif_pept 0 0 2 1
EG545267 predicted gene, EG545267 Sum of Sum_pept_count 0 0 2 3
Max of Max_Dif_pept 0 0 2 2
G6pdx
glucose-6-phosphate 
dehydrogenase X-linked
Sum of Sum_pept_count 0 1 2 2
Max of Max_Dif_pept 0 1 2 2
Rqcd1
rcd1 (required for cell 
differentiation) homolog 1 (S. 
pombe)
Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Gmppa
GDP-mannose pyrophosphorylase 
A
Sum of Sum_pept_count 0 2 0 2
Max of Max_Dif_pept 0 2 0 2
Rragb Ras-related GTP binding B Sum of Sum_pept_count 0 0 2 0
Max of Max_Dif_pept 0 0 2 0
Diap1
diaphanous homolog 1 
(Drosophila)
Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Psmd2
proteasome (prosome, macropain) 
26S subunit, non-ATPase, 2
Sum of Sum_pept_count 0 1 0 3
Max of Max_Dif_pept 0 1 0 2
LOC554292 UbiE-YGHL1 fusion protein Sum of Sum_pept_count 1 0 0 2
Max of Max_Dif_pept 1 0 0 2
Galk1 galactokinase 1 Sum of Sum_pept_count 2 0 0 4
Max of Max_Dif_pept 1 0 0 2
Rtn3 reticulon 3 Sum of Sum_pept_count 0 0 3 6
Max of Max_Dif_pept 0 0 2 2
Hist1h2bn histone cluster 1, H2bn Sum of Sum_pept_count 5 1 4 7
Max of Max_Dif_pept 2 1 2 2
S100a11
S100 calcium binding protein A11 
(calgizzarin)
Sum of Sum_pept_count 1 3 4 1
Max of Max_Dif_pept 1 2 2 1
Fbxo6 F-box protein 6 Sum of Sum_pept_count 2 1 1 1
Max of Max_Dif_pept 2 1 1 1
Sar1a
SAR1 gene homolog A (S. 
cerevisiae)
Sum of Sum_pept_count 2 0 1 2
Max of Max_Dif_pept 2 0 1 2
Eif4a2
eukaryotic translation initiation 
factor 4A2
Sum of Sum_pept_count 0 1 1 3
Max of Max_Dif_pept 0 1 1 2
Sars seryl-aminoacyl-tRNA synthetase Sum of Sum_pept_count 0 2 3 2
Max of Max_Dif_pept 0 2 2 2
Sbds
Shwachman-Bodian-Diamond 
syndrome homolog (human)
Sum of Sum_pept_count 1 0 2 2
Max of Max_Dif_pept 1 0 2 2
Cul4b cullin 4B Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Hist1h2ae histone cluster 1, H2ae Sum of Sum_pept_count 2 3 2 3
Max of Max_Dif_pept 1 2 1 2
Hist1h2ac histone cluster 1, H2ac Sum of Sum_pept_count 2 3 2 3
Max of Max_Dif_pept 1 2 1 2
Hist1h2ab histone cluster 1, H2ab Sum of Sum_pept_count 2 3 2 3
Max of Max_Dif_pept 1 2 1 2
Scye1
small inducible cytokine subfamily 
E, member 1
Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 2
Sdcbp syndecan binding protein Sum of Sum_pept_count 0 1 2 1
Max of Max_Dif_pept 0 1 2 1
Hist1h2bp histone cluster 1, H2bp Sum of Sum_pept_count 5 1 4 7
Max of Max_Dif_pept 2 1 2 2
Sdha
succinate dehydrogenase 
complex, subunit A, flavoprotein 
(Fp)
Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Sdhc
succinate dehydrogenase 
complex, subunit C, integral 
membrane protein
Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Sec11a SEC11 homolog A (S. cerevisiae) Sum of Sum_pept_count 0 0 1 2
Max of Max_Dif_pept 0 0 1 2
EG544954 predicted gene, EG544954 Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Atp5j2
ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit 
f, isoform 2
Sum of Sum_pept_count 0 1 3 7
Max of Max_Dif_pept 0 1 1 2
Sec22b
SEC22 vesicle trafficking protein 
homolog B (S. cerevisiae)
Sum of Sum_pept_count 0 0 1 2
Max of Max_Dif_pept 0 0 1 2  226
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Hist1h3a histone cluster 1, H3a Sum of Sum_pept_count 3 0 2 4
Max of Max_Dif_pept 2 0 1 1
Psmb3
proteasome (prosome, macropain) 
subunit, beta type 3
Sum of Sum_pept_count 0 2 3 2
Max of Max_Dif_pept 0 2 1 1
Litaf LPS-induced TN factor Sum of Sum_pept_count 3 0 2 0
Max of Max_Dif_pept 2 0 1 0
Psmb2
proteasome (prosome, macropain) 
subunit, beta type 2
Sum of Sum_pept_count 1 1 2 2
Max of Max_Dif_pept 1 1 2 2
Hist1h2aa histone cluster 1, H2aa Sum of Sum_pept_count 2 3 2 3
Max of Max_Dif_pept 1 2 1 2
Gmppb
GDP-mannose pyrophosphorylase 
B
Sum of Sum_pept_count 0 2 0 1
Max of Max_Dif_pept 0 2 0 1
Hnrnpk
heterogeneous nuclear 
ribonucleoprotein K
Sum of Sum_pept_count 0 2 1 5
Max of Max_Dif_pept 0 1 1 2
Gmfg glia maturation factor, gamma Sum of Sum_pept_count 0 2 1 0
Max of Max_Dif_pept 0 2 1 0
Mat2a
methionine adenosyltransferase II, 
alpha
Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Serinc3 serine incorporator 3 Sum of Sum_pept_count 0 0 2 1
Max of Max_Dif_pept 0 0 2 1
Bat1a HLA-B-associated transcript 1A Sum of Sum_pept_count 2 1 0 0
Max of Max_Dif_pept 2 1 0 0
Hist1h3b histone cluster 1, H3b Sum of Sum_pept_count 3 0 2 4
Max of Max_Dif_pept 2 0 1 1
Ddi2 DNA-damage inducible protein 2 Sum of Sum_pept_count 0 2 0 0
Max of Max_Dif_pept 0 2 0 0
Serpina3k
serine (or cysteine) peptidase 
inhibitor, clade A, member 3K
Sum of Sum_pept_count 0 2 1 2
Max of Max_Dif_pept 0 2 1 2
Acp1 acid phosphatase 1, soluble Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 2
Psenen
presenilin enhancer 2 homolog (C. 
elegans)
Sum of Sum_pept_count 4 2 5 2
Max of Max_Dif_pept 2 1 2 2
Pscd2
pleckstrin homology, Sec7 and 
coiled-coil domains 2
Sum of Sum_pept_count 0 2 0 2
Max of Max_Dif_pept 0 1 0 2
Hist1h3c histone cluster 1, H3c Sum of Sum_pept_count 3 0 2 4
Max of Max_Dif_pept 2 0 1 1
Sft2d2 SFT2 domain containing 2 Sum of Sum_pept_count 3 1 3 4
Max of Max_Dif_pept 1 1 2 2
Crb3 crumbs homolog 3 (Drosophila) Sum of Sum_pept_count 4 0 3 0
Max of Max_Dif_pept 2 0 1 0
Hist1h1d histone cluster 1, H1d Sum of Sum_pept_count 3 0 1 0
Max of Max_Dif_pept 2 0 1 0
Prss32 protease, serine, 32 Sum of Sum_pept_count 4 2 12 2
Max of Max_Dif_pept 1 2 2 1
EG434460 predicted gene, EG434460 Sum of Sum_pept_count 0 2 3 1
Max of Max_Dif_pept 0 1 2 1
Lincr
lung-inducible neuralized-related 
C3HC4 RING domain protein
Sum of Sum_pept_count 4 1 1 3
Max of Max_Dif_pept 2 1 1 1
Prss2 protease, serine, 2 Sum of Sum_pept_count 0 0 3 0
Max of Max_Dif_pept 0 0 2 0
Sirt2
sirtuin 2 (silent mating type 
information regulation 2, homolog) 
2 (S. cerevisiae)
Sum of Sum_pept_count 0 0 1 3
Max of Max_Dif_pept 0 0 1 2
Prpsap1
phosphoribosyl pyrophosphate 
synthetase-associated protein 1
Sum of Sum_pept_count 1 2 1 0
Max of Max_Dif_pept1 2 1 0
Epha7 Eph receptor A7 Sum of Sum_pept_count 0 0 2 0
Max of Max_Dif_pept 0 0 2 0
Prosc proline synthetase co-transcribed Sum of Sum_pept_count 0 1 0 2
Max of Max_Dif_pept 0 1 0 2
Hist1h3d histone cluster 1, H3d Sum of Sum_pept_count 3 0 2 4
Max of Max_Dif_pept 2 0 1 1
Prkce protein kinase C, epsilon Sum of Sum_pept_count 4 2 5 0
Max of Max_Dif_pept 1 1 2 0
Aqp7 aquaporin 7 Sum of Sum_pept_count 12 1 2 7
Max of Max_Dif_pept 2 1 1 2
EG434426 predicted gene, EG434426 Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 2  227
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Slc16a1
solute carrier family 16 
(monocarboxylic acid 
transporters), member 1
Sum of Sum_pept_count 7 1 9 7
Max of Max_Dif_pept 2 1 2 2
Slc1a1
solute carrier family 1 
(neuronal/epithelial high affinity 
glutamate transporter, system 
Xag), member 1
Sum of Sum_pept_count 6 6 33 8
Max of Max_Dif_pept 1 2 2 2
Slc1a5
solute carrier family 1 (neutral 
amino acid transporter), member 5
Sum of Sum_pept_count 1 0 8 2
Max of Max_Dif_pept 1 0 2 1
Slc22a4
solute carrier family 22 (organic 
cation transporter), member 4
Sum of Sum_pept_count 3 5 6 2
Max of Max_Dif_pept 2 2 2 2
Hist1h1c histone cluster 1, H1c Sum of Sum_pept_count 3 0 1 0
Max of Max_Dif_pept 2 0 1 0
Farsa
phenylalanyl-tRNA synthetase, 
alpha subunit
Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
4921506J03Rik RIKEN cDNA 4921506J03 gene Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Slc25a10
solute carrier family 25 
(mitochondrial carrier, 
dicarboxylate transporter), member 
10
Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Fahd1
fumarylacetoacetate hydrolase 
domain containing 1
Sum of Sum_pept_count 1 0 0 2
Max of Max_Dif_pept 1 0 0 2
EG433328 predicted gene, EG433328 Sum of Sum_pept_count 0 0 3 0
Max of Max_Dif_pept 0 0 2 0
Cyb5b cytochrome b5 type B Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 2
Hsd17b4
hydroxysteroid (17-beta) 
dehydrogenase 4
Sum of Sum_pept_count 2 2 3 2
Max of Max_Dif_pept 1 1 2 1
Lhfpl2
lipoma HMGIC fusion partner-like 
2
Sum of Sum_pept_count 0 0 4 1
Max of Max_Dif_pept 0 0 2 1
Ddx1
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 1
Sum of Sum_pept_count 0 1 0 3
Max of Max_Dif_pept 0 1 0 2
Epha2 Eph receptor A2 Sum of Sum_pept_count 0 0 2 0
Max of Max_Dif_pept 0 0 2 0
Aarsd1
alanyl-tRNA synthetase domain 
containing 1
Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Amy1 amylase 1, salivary Sum of Sum_pept_count 0 1 2 0
Max of Max_Dif_pept 0 1 2 0
Cdc2a
cell division cycle 2 homolog A (S. 
pombe)
Sum of Sum_pept_count 0 0 1 2
Max of Max_Dif_pept 0 0 1 2
EG386551 predicted gene, EG386551 Sum of Sum_pept_count 13 15 10 11
Max of Max_Dif_pept 2 2 2 2
EG664891 predicted gene, EG664891 Sum of Sum_pept_count 4 2 6 5
Max of Max_Dif_pept 2 2 2 2
Atp6v1e1
ATPase, H+ transporting, 
lysosomal V1 subunit E1
Sum of Sum_pept_count 1 0 4 3
Max of Max_Dif_pept 1 0 2 2
Arl4a ADP-ribosylation factor-like 4A Sum of Sum_pept_count 2 0 0 0
Max of Max_Dif_pept 2 0 0 0
Slc31a1 solute carrier family 31, member 1 Sum of Sum_pept_count 12 3 3 4
Max of Max_Dif_pept 2 1 1 1
Agbl3 ATP/GTP binding protein-like 3 Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 2
Atp5l
ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit 
g
Sum of Sum_pept_count 0 0 3 4
Max of Max_Dif_pept 0 0 1 2
Cdh1 cadherin 1 Sum of Sum_pept_count 1 1 5 6
Max of Max_Dif_pept 1 1 1 2
Med21 mediator complex subunit 21 Sum of Sum_pept_count 4 2 6 5
Max of Max_Dif_pept2 2 2 2
Hdhd2
haloacid dehalogenase-like 
hydrolase domain containing 2
Sum of Sum_pept_count 0 0 0 4
Max of Max_Dif_pept 0 0 0 2
Arpc5l
actin related protein 2/3 complex, 
subunit 5-like
Sum of Sum_pept_count 0 1 0 2
Max of Max_Dif_pept 0 1 0 2
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Prdx4 peroxiredoxin 4 Sum of Sum_pept_count 2 3 4 7
Max of Max_Dif_pept 1 2 2 2
Gars glycyl-tRNA synthetase Sum of Sum_pept_count 0 2 1 1
Max of Max_Dif_pept 0 2 1 1
1810011O10Rik RIKEN cDNA 1810011O10 gene Sum of Sum_pept_count 1 3 2 0
Max of Max_Dif_pept 1 2 2 0
Ppp3r1
protein phosphatase 3, regulatory 
subunit B, alpha isoform 
(calcineurin B, type I)
Sum of Sum_pept_count 0 2 1 1
Max of Max_Dif_pept 0 2 1 1
As3mt
arsenic (+3 oxidation state) 
methyltransferase
Sum of Sum_pept_count 0 2 0 0
Max of Max_Dif_pept 0 2 0 0
Mettl7a1 methyltransferase like 7A1 Sum of Sum_pept_count 1 0 2 2
Max of Max_Dif_pept 1 0 2 2
Hck hemopoietic cell kinase Sum of Sum_pept_count 5 4 1 7
Max of Max_Dif_pept 2 2 1 2
2210010C17Rik RIKEN cDNA 2210010C17 gene Sum of Sum_pept_count 5 2 1 2
Max of Max_Dif_pept 2 1 1 1
Hist1h3e histone cluster 1, H3e Sum of Sum_pept_count 3 0 2 4
Max of Max_Dif_pept 2 0 1 1
Hist1h3f histone cluster 1, H3f Sum of Sum_pept_count 3 0 2 4
Max of Max_Dif_pept 2 0 1 1
Gna12
guanine nucleotide binding protein, 
alpha 12
Sum of Sum_pept_count 5 4 5 6
Max of Max_Dif_pept 2 2 2 2
Ppp1r7
protein phosphatase 1, regulatory 
(inhibitor) subunit 7
Sum of Sum_pept_count 0 2 2 0
Max of Max_Dif_pept 0 2 2 0
Fadd
Fas (TNFRSF6)-associated via 
death domain
Sum of Sum_pept_count 2 0 2 4
Max of Max_Dif_pept 1 0 2 2
Ppp1r16a
protein phosphatase 1, regulatory 
(inhibitor) subunit 16A
Sum of Sum_pept_count 3 2 0 0
Max of Max_Dif_pept 2 2 0 0
EG241053 predicted gene, EG241053 Sum of Sum_pept_count 2 0 0 2
Max of Max_Dif_pept 2 0 0 1
Cbara1
calcium binding atopy-related 
autoantigen 1
Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 2
Fabp4
fatty acid binding protein 4, 
adipocyte
Sum of Sum_pept_count 0 2 0 2
Max of Max_Dif_pept 0 1 0 2
Cd47
CD47 antigen (Rh-related antigen, 
integrin-associated signal 
transducer)
Sum of Sum_pept_count 2 2 5 5
Max of Max_Dif_pept 1 1 2 1
C530008M17Rik RIKEN cDNA C530008M17 gene Sum of Sum_pept_count 0 5 2 0
Max of Max_Dif_pept 0 2 2 0
Slc7a15
solute carrier family 7 (cationic 
amino acid transporter, y+ 
system), member 15
Sum of Sum_pept_count 6 2 3 3
Max of Max_Dif_pept 2 1 2 2
Ppl periplakin Sum of Sum_pept_count 0 0 3 0
Max of Max_Dif_pept 0 0 2 0
Lamp1
lysosomal-associated membrane 
protein 1
Sum of Sum_pept_count 7 5 9 6
Max of Max_Dif_pept 2 2 2 2
BC022651 cDNA sequence BC022651 Sum of Sum_pept_count 4 3 5 4
Max of Max_Dif_pept 1 1 2 1
A130092J06Rik RIKEN cDNA A130092J06 gene Sum of Sum_pept_count 4 1 1 1
Max of Max_Dif_pept 2 1 1 1
Slco6d1
solute carrier organic anion 
transporter family, member 6d1
Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Smad1 MAD homolog 1 (Drosophila) Sum of Sum_pept_count 3 1 2 0
Max of Max_Dif_pept 2 1 1 0
Mgrn1 mahogunin, ring finger 1 Sum of Sum_pept_count 2 0 0 0
Max of Max_Dif_pept2 0 0 0
Depdc7 DEP domain containing 7 Sum of Sum_pept_count 1 0 3 1
Max of Max_Dif_pept 1 0 2 1
Hist1h3g histone cluster 1, H3g Sum of Sum_pept_count 3 0 2 4
Max of Max_Dif_pept 2 0 1 1
Mgst1
microsomal glutathione S-
transferase 1
Sum of Sum_pept_count 1 0 1 3
Max of Max_Dif_pept 1 0 1 2
Snap29
synaptosomal-associated protein 
29
Sum of Sum_pept_count 3 2 3 4
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Mgst3
microsomal glutathione S-
transferase 3
Sum of Sum_pept_count 0 0 0 4
Max of Max_Dif_pept 0 0 0 2
Pnpo pyridoxine 5'-phosphate oxidase Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
EG667806 predicted gene, EG667806 Sum of Sum_pept_count 4 0 3 0
Max of Max_Dif_pept 2 0 2 0
Snx4 sorting nexin 4 Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Hist1h3h histone cluster 1, H3h Sum of Sum_pept_count 3 0 2 4
Max of Max_Dif_pept 2 0 1 1
Plxnb2 plexin B2 Sum of Sum_pept_count 1 0 6 0
Max of Max_Dif_pept 1 0 2 0
Gas2 growth arrest specific 2 Sum of Sum_pept_count 0 2 1 1
Max of Max_Dif_pept 0 2 1 1
Dmn desmuslin Sum of Sum_pept_count 8 6 14 6
Max of Max_Dif_pept 1 1 2 1
Spata6 spermatogenesis associated 6 Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 2
Spcs2
signal peptidase complex subunit 2 
homolog (S. cerevisiae)
Sum of Sum_pept_count 0 0 3 1
Max of Max_Dif_pept 0 0 2 1
Spcs3
signal peptidase complex subunit 3 
homolog (S. cerevisiae)
Sum of Sum_pept_count 0 0 2 2
Max of Max_Dif_pept 0 0 2 2
Golm1 golgi membrane protein 1 Sum of Sum_pept_count 0 0 5 0
Max of Max_Dif_pept 0 0 2 0
Spint2
serine protease inhibitor, Kunitz 
type 2
Sum of Sum_pept_count 2 0 4 3
Max of Max_Dif_pept 1 0 2 1
6330409N04Rik RIKEN cDNA 6330409N04 gene Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Spsb2
splA/ryanodine receptor domain 
and SOCS box containing 2
Sum of Sum_pept_count 0 0 2 0
Max of Max_Dif_pept 0 0 2 0
Plekhb2
pleckstrin homology domain 
containing, family B (evectins) 
member 2
Sum of Sum_pept_count 2 3 2 3
Max of Max_Dif_pept 2 1 1 1
Abcb4
ATP-binding cassette, sub-family B 
(MDR/TAP), member 4
Sum of Sum_pept_count 0 3 0 1
Max of Max_Dif_pept 0 2 0 1
Ssr1 signal sequence receptor, alpha Sum of Sum_pept_count 0 0 3 1
Max of Max_Dif_pept 0 0 2 1
Mobkl2b
MOB1, Mps One Binder kinase 
activator-like 2B (yeast)
Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Ssu72
Ssu72 RNA polymerase II CTD 
phosphatase homolog (yeast)
Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Mobkl3
MOB1, Mps One Binder kinase 
activator-like 3 (yeast)
Sum of Sum_pept_count 0 0 2 3
Max of Max_Dif_pept 0 0 1 2
Hnrnph1
heterogeneous nuclear 
ribonucleoprotein H1
Sum of Sum_pept_count 0 1 2 1
Max of Max_Dif_pept 0 1 2 1
Mpi mannose phosphate isomerase Sum of Sum_pept_count 0 1 0 2
Max of Max_Dif_pept 0 1 0 2
Stard3 START domain containing 3 Sum of Sum_pept_count 1 0 2 1
Max of Max_Dif_pept 1 0 2 1
Stard4
StAR-related lipid transfer 
(START) domain containing 4
Sum of Sum_pept_count 1 0 0 2
Max of Max_Dif_pept 1 0 0 2
Pip5k1b
phosphatidylinositol-4-phosphate 5-
kinase, type 1 beta
Sum of Sum_pept_count 1 3 1 2
Max of Max_Dif_pept 1 2 1 2
Stip1 stress-induced phosphoprotein 1 Sum of Sum_pept_count 0 1 0 2
Max of Max_Dif_pept0 1 0 2
Hist1h3i histone cluster 1, H3i Sum of Sum_pept_count 3 0 2 4
Max of Max_Dif_pept 2 0 1 1
Cast calpastatin Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Krt78 keratin 78 Sum of Sum_pept_count 0 2 2 2
Max of Max_Dif_pept 0 2 2 2
Stk38 serine/threonine kinase 38 Sum of Sum_pept_count 1 0 0 3
Max of Max_Dif_pept 1 0 0 2
Stk38l serine/threonine kinase 38 like Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2  230
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Atp2b4
ATPase, Ca++ transporting, 
plasma membrane 4
Sum of Sum_pept_count 2 0 4 1
Max of Max_Dif_pept 1 0 2 1
Stub1
STIP1 homology and U-Box 
containing protein 1
Sum of Sum_pept_count 0 2 2 0
Max of Max_Dif_pept 0 2 2 0
Cops2
COP9 (constitutive 
photomorphogenic) homolog, 
subunit 2 (Arabidopsis thaliana)
Sum of Sum_pept_count 0 1 1 2
Max of Max_Dif_pept 0 1 1 2
Atp2b2
ATPase, Ca++ transporting, 
plasma membrane 2
Sum of Sum_pept_count 0 1 2 0
Max of Max_Dif_pept 0 1 2 0
Pgk2 phosphoglycerate kinase 2 Sum of Sum_pept_count 0 2 0 0
Max of Max_Dif_pept 0 2 0 0
Hadha
hydroxyacyl-Coenzyme A 
dehydrogenase/3-ketoacyl-
Coenzyme A thiolase/enoyl-
Coenzyme A hydratase 
(trifunctional protein), alpha subunit
Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Actn2 actinin alpha 2 Sum of Sum_pept_count 0 1 9 4
Max of Max_Dif_pept 0 1 2 2
Abcb11
ATP-binding cassette, sub-family B 
(MDR/TAP), member 11
Sum of Sum_pept_count 0 4 1 7
Max of Max_Dif_pept 0 1 1 2
Actn3 actinin alpha 3 Sum of Sum_pept_count 0 1 5 4
Max of Max_Dif_pept 0 1 2 2
Stxbp5
syntaxin binding protein 5 
(tomosyn)
Sum of Sum_pept_count 2 0 0 0
Max of Max_Dif_pept 2 0 0 0
H3f3b H3 histone, family 3B Sum of Sum_pept_count 3 0 2 4
Max of Max_Dif_pept 2 0 1 1
Bdh1
3-hydroxybutyrate dehydrogenase, 
type 1
Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Sult1d1
sulfotransferase family 1D, 
member 1
Sum of Sum_pept_count 0 1 1 4
Max of Max_Dif_pept 0 1 1 2
Gnai1
guanine nucleotide binding protein 
(G protein), alpha inhibiting 1
Sum of Sum_pept_count 5 0 2 8
Max of Max_Dif_pept 2 0 1 2
1700022A21Rik RIKEN cDNA 1700022A21 gene Sum of Sum_pept_count 0 2 0 0
Max of Max_Dif_pept 0 2 0 0
Sypl synaptophysin-like protein Sum of Sum_pept_count 5 0 7 6
Max of Max_Dif_pept 1 0 2 2
2900024O10Rik RIKEN cDNA 2900024O10 gene Sum of Sum_pept_count 1 0 2 0
Max of Max_Dif_pept 1 0 2 0
Tagln transgelin Sum of Sum_pept_count 0 4 2 1
Max of Max_Dif_pept 0 2 1 1
H3f3a H3 histone, family 3A Sum of Sum_pept_count 3 0 2 4
Max of Max_Dif_pept 2 0 1 1
Abcb7
ATP-binding cassette, sub-family B 
(MDR/TAP), member 7
Sum of Sum_pept_count 0 0 4 0
Max of Max_Dif_pept 0 0 2 0
EG668182 predicted gene, EG668182 Sum of Sum_pept_count 3 0 1 1
Max of Max_Dif_pept 2 0 1 1
2010109I03Rik RIKEN cDNA 2010109I03 gene Sum of Sum_pept_count 0 1 2 3
Max of Max_Dif_pept 0 1 1 2
Tbc1d2b TBC1 domain family, member 2B Sum of Sum_pept_count 0 0 2 0
Max of Max_Dif_pept 0 0 2 0
Tceb1
transcription elongation factor B 
(SIII), polypeptide 1
Sum of Sum_pept_count 0 3 2 4
Max of Max_Dif_pept 0 2 2 2
Epb4.1l3 erythrocyte protein band 4.1-like 3 Sum of Sum_pept_count 1 2 3 4
Max of Max_Dif_pept 1 2 2 2
Cldn15 claudin 15 Sum of Sum_pept_count 4 2 4 4
Max of Max_Dif_pept 2 2 2 2
Eef1g
eukaryotic translation elongation 
factor 1 gamma
Sum of Sum_pept_count 1 0 0 4
Max of Max_Dif_pept1 0 0 2
Aldh1l1
aldehyde dehydrogenase 1 family, 
member L1
Sum of Sum_pept_count 0 1 4 1
Max of Max_Dif_pept 0 1 2 1
Krt6b keratin 6B Sum of Sum_pept_count 0 0 2 0
Max of Max_Dif_pept 0 0 2 0
Asns asparagine synthetase Sum of Sum_pept_count 0 0 1 2
Max of Max_Dif_pept 0 0 1 2    231
Gene Symbol Gene Description Data proximal central distal total mucosa
Them2
thioesterase superfamily member 
2
Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 2
Cd63 Cd63 antigen Sum of Sum_pept_count 2 2 3 2
Max of Max_Dif_pept 1 1 2 1
Hist2h2aa2 histone cluster 2, H2aa2 Sum of Sum_pept_count 2 3 2 3
Max of Max_Dif_pept 1 2 1 2
Msn moesin Sum of Sum_pept_count 3 0 1 1
Max of Max_Dif_pept 2 0 1 1
Tjp2 tight junction protein 2 Sum of Sum_pept_count 0 6 0 0
Max of Max_Dif_pept 0 2 0 0
1810049H19Rik RIKEN cDNA 1810049H19 gene Sum of Sum_pept_count 0 3 1 3
Max of Max_Dif_pept 0 2 1 2
Agpat1
1-acylglycerol-3-phosphate O-
acyltransferase 1 (lysophosphatidic 
acid acyltransferase, alpha)
Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Tm4sf20
transmembrane 4 L six family 
member 20
Sum of Sum_pept_count 6 2 4 0
Max of Max_Dif_pept 2 1 2 0
Mtch2
mitochondrial carrier homolog 2 
(C. elegans)
Sum of Sum_pept_count 0 0 0 7
Max of Max_Dif_pept 0 0 0 2
Etf1
eukaryotic translation termination 
factor 1
Sum of Sum_pept_count 2 1 0 0
Max of Max_Dif_pept 2 1 0 0
Apol9b apolipoprotein L 9b Sum of Sum_pept_count 4 0 0 6
Max of Max_Dif_pept 2 0 0 2
H2-Q1
histocompatibility 2, Q region locus 
1
Sum of Sum_pept_count 2 2 0 3
Max of Max_Dif_pept 2 2 0 2
Gimap3 GTPase, IMAP family member 3 Sum of Sum_pept_count 0 0 2 0
Max of Max_Dif_pept 0 0 2 0
Hist2h2bb histone cluster 2, H2bb Sum of Sum_pept_count 5 1 4 7
Max of Max_Dif_pept 2 1 2 2
4930544G11Rik RIKEN cDNA 4930544G11 gene Sum of Sum_pept_count 3 6 1 1
Max of Max_Dif_pept 2 2 1 1
Hspa1l heat shock protein 1-like Sum of Sum_pept_count 3 1 1 2
Max of Max_Dif_pept 1 1 1 2
Pdhb
pyruvate dehydrogenase 
(lipoamide) beta
Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 2
Tmem106a transmembrane protein 106A Sum of Sum_pept_count 4 0 2 1
Max of Max_Dif_pept 2 0 1 1
Gimap5 GTPase, IMAP family member 5 Sum of Sum_pept_count 0 0 2 0
Max of Max_Dif_pept 0 0 2 0
1700003O08Rik RIKEN cDNA 1700003O08 gene Sum of Sum_pept_count 1 2 0 0
Max of Max_Dif_pept 1 2 0 0
EG668192 predicted gene, EG668192 Sum of Sum_pept_count 4 0 3 0
Max of Max_Dif_pept 2 0 2 0
B4galnt1
beta-1,4-N-acetyl-galactosaminyl 
transferase 1
Sum of Sum_pept_count 0 0 3 1
Max of Max_Dif_pept 0 0 2 1
Pcyt1b
phosphate cytidylyltransferase 1, 
choline, beta isoform
Sum of Sum_pept_count 0 2 0 0
Max of Max_Dif_pept 0 2 0 0
Krt20 keratin 20 Sum of Sum_pept_count 3 3 3 3
Max of Max_Dif_pept 2 2 1 2
Hspa2 heat shock protein 2 Sum of Sum_pept_count 3 1 1 2
Max of Max_Dif_pept 1 1 1 2
Mthfd1
methylenetetrahydrofolate 
dehydrogenase (NADP+ 
dependent), 
methenyltetrahydrofolate 
cyclohydrolase, 
formyltetrahydrofolate synthase
Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 2
Tmem59 transmembrane protein 59 Sum of Sum_pept_count 0 0 2 3
Max of Max_Dif_pept0 0 1 2
Atp6v1d
ATPase, H+ transporting, 
lysosomal V1 subunit D
Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 2
Tmod3 tropomodulin 3 Sum of Sum_pept_count 0 3 0 0
Max of Max_Dif_pept 0 2 0 0
Pcna proliferating cell nuclear antigen Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Cyp2c66
cytochrome P450, family 2, 
subfamily c, polypeptide 66
Sum of Sum_pept_count 2 0 1 0
Max of Max_Dif_pept 2 0 1 0
Tnni1 troponin I, skeletal, slow 1 Sum of Sum_pept_count 1 0 0 3
Max of Max_Dif_pept 1 0 0 2  232
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Mtpn myotrophin Sum of Sum_pept_count 1 2 1 2
Max of Max_Dif_pept 1 2 1 2
Gnpnat1
glucosamine-phosphate N-
acetyltransferase 1
Sum of Sum_pept_count 0 2 2 1
Max of Max_Dif_pept 0 2 2 1
Tom1l2 target of myb1-like 2 (chicken) Sum of Sum_pept_count 2 6 4 2
Max of Max_Dif_pept 1 2 2 2
Pcbd1
pterin 4 alpha carbinolamine 
dehydratase/dimerization cofactor 
of hepatocyte nuclear factor 1 
alpha (TCF1) 1
Sum of Sum_pept_count 0 2 1 2
Max of Max_Dif_pept 0 2 1 2
Anp32c
acidic leucine-rich nuclear 
phosphoprotein 32 family member 
C
Sum of Sum_pept_count 0 2 0 0
Max of Max_Dif_pept 0 2 0 0
Park7
Parkinson disease (autosomal 
recessive, early onset) 7
Sum of Sum_pept_count 3 4 3 3
Max of Max_Dif_pept 2 2 2 2
Tpt1
tumor protein, translationally-
controlled 1
Sum of Sum_pept_count 0 6 0 3
Max of Max_Dif_pept 0 2 0 2
Hist2h2be histone cluster 2, H2be Sum of Sum_pept_count 3 1 4 7
Max of Max_Dif_pept 1 1 2 2
Dbnl drebrin-like Sum of Sum_pept_count 2 3 2 11
Max of Max_Dif_pept 1 2 1 2
Pak4 p21 (CDKN1A)-activated kinase 4 Sum of Sum_pept_count 1 4 3 2
Max of Max_Dif_pept 1 2 2 1
Cd74
CD74 antigen (invariant 
polypeptide of major 
histocompatibility complex, class II 
antigen-associated)
Sum of Sum_pept_count 0 1 3 1
Max of Max_Dif_pept 0 1 2 1
Erlin2 ER lipid raft associated 2 Sum of Sum_pept_count 0 0 1 3
Max of Max_Dif_pept 0 0 1 2
Try10 trypsin 10 Sum of Sum_pept_count 13 15 10 11
Max of Max_Dif_pept 2 2 2 2
Atp6v0c
ATPase, H+ transporting, 
lysosomal V0 subunit C
Sum of Sum_pept_count 1 0 2 2
Max of Max_Dif_pept 1 0 2 2
EG668319 predicted gene, EG668319 Sum of Sum_pept_count 1 0 0 2
Max of Max_Dif_pept 1 0 0 2
Tspan13 tetraspanin 13 Sum of Sum_pept_count 1 0 4 4
Max of Max_Dif_pept 1 0 2 2
Copz1
coatomer protein complex, subunit 
zeta 1
Sum of Sum_pept_count 0 1 0 2
Max of Max_Dif_pept 0 1 0 2
Tspan3 tetraspanin 3 Sum of Sum_pept_count 1 0 0 2
Max of Max_Dif_pept 1 0 0 2
Erlin1 ER lipid raft associated 1 Sum of Sum_pept_count 0 0 1 3
Max of Max_Dif_pept 0 0 1 2
Hist2h3b histone cluster 2, H3b Sum of Sum_pept_count 3 0 2 4
Max of Max_Dif_pept 2 0 1 1
OTTMUSG00000012
predicted gene, 
OTTMUSG00000012957
Sum of Sum_pept_count 2 0 2 3
Max of Max_Dif_pept 2 0 2 2
Hsph1
heat shock 105kDa/110kDa 
protein 1
Sum of Sum_pept_count 0 0 1 2
Max of Max_Dif_pept 0 0 1 2
OTTMUSG00000008
predicted gene, 
OTTMUSG00000008659
Sum of Sum_pept_count 5 5 3 2
Max of Max_Dif_pept 2 2 1 1
2810459M11Rik RIKEN cDNA 2810459M11 gene Sum of Sum_pept_count 5 1 4 4
Max of Max_Dif_pept 1 1 2 1
OTTMUSG00000007
predicted gene, 
OTTMUSG00000007855
Sum of Sum_pept_count 3 0 2 4
Max of Max_Dif_pept 2 0 1 1
OTTMUSG00000005
predicted gene, 
OTTMUSG00000005885
Sum of Sum_pept_count 2 5 0 2
Max of Max_Dif_pept 2 2 0 2
Hist3h2a histone cluster 3, H2a Sum of Sum_pept_count 2 3 2 3
Max of Max_Dif_pept1 2 1 2
Kdr
kinase insert domain protein 
receptor
Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Kdelr1
KDEL (Lys-Asp-Glu-Leu) 
endoplasmic reticulum protein 
retention receptor 1
Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Tubb1 tubulin, beta 1 Sum of Sum_pept_count 1 1 0 4
Max of Max_Dif_pept 1 1 0 2    233
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Cox5b cytochrome c oxidase, subunit Vb Sum of Sum_pept_count 1 0 1 4
Max of Max_Dif_pept 1 0 1 2
H2afv H2A histone family, member V Sum of Sum_pept_count 3 3 2 6
Max of Max_Dif_pept 1 2 1 2
Kank1
KN motif and ankyrin repeat 
domains 1
Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 2
9130404D14Rik RIKEN cDNA 9130404D14 gene Sum of Sum_pept_count 0 1 3 1
Max of Max_Dif_pept 0 1 2 1
Aars alanyl-tRNA synthetase Sum of Sum_pept_count 0 0 0 4
Max of Max_Dif_pept 0 0 0 2
Ostb organic solute transporter beta Sum of Sum_pept_count 1 1 7 2
Max of Max_Dif_pept 1 1 2 1
Oit1 oncoprotein induced transcript 1 Sum of Sum_pept_count 0 0 4 2
Max of Max_Dif_pept 0 0 2 1
Cldn7 claudin 7 Sum of Sum_pept_count 7 5 17 9
Max of Max_Dif_pept 2 2 2 1
Twf1
twinfilin, actin-binding protein, 
homolog 1 (Drosophila)
Sum of Sum_pept_count 1 2 2 3
Max of Max_Dif_pept 1 2 2 2
Dsg1b desmoglein 1 beta Sum of Sum_pept_count 0 0 3 1
Max of Max_Dif_pept 0 0 2 1
Txndc17 thioredoxin domain containing 17 Sum of Sum_pept_count 0 5 3 2
Max of Max_Dif_pept 0 2 2 1
Numbl numb-like Sum of Sum_pept_count 1 1 2 1
Max of Max_Dif_pept 1 1 2 1
Txnl1 thioredoxin-like 1 Sum of Sum_pept_count 1 3 0 1
Max of Max_Dif_pept 1 2 0 1
Itpka
inositol 1,4,5-trisphosphate 3-
kinase A
Sum of Sum_pept_count 4 5 1 3
Max of Max_Dif_pept 2 2 1 2
EG668559 predicted gene, EG668559 Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 2
Nudcd3 NudC domain containing 3S u m  o f  S u m _pept_count 0 2 3 1
Max of Max_Dif_pept 0 1 2 1
Nt5e 5' nucleotidase, ecto Sum of Sum_pept_count 3 1 2 0
Max of Max_Dif_pept 1 1 2 0
Nt5c 5',3'-nucleotidase, cytosolic Sum of Sum_pept_count 1 2 2 4
Max of Max_Dif_pept 1 2 2 2
D10Wsu52e
DNA segment, Chr 10, Wayne 
State University 52, expressed
Sum of Sum_pept_count 0 2 0 1
Max of Max_Dif_pept 0 2 0 1
Npepps
aminopeptidase puromycin 
sensitive
Sum of Sum_pept_count 0 1 1 3
Max of Max_Dif_pept 0 1 1 2
Ube2l3
ubiquitin-conjugating enzyme E2L 
3
Sum of Sum_pept_count 1 2 1 2
Max of Max_Dif_pept 1 1 1 2
2310008M10Rik RIKEN cDNA 2310008M10 gene Sum of Sum_pept_count 0 0 1 2
Max of Max_Dif_pept 0 0 1 2
Amn amnionless Sum of Sum_pept_count 0 1 4 1
Max of Max_Dif_pept 0 1 2 1
2010106G01Rik RIKEN cDNA 2010106G01 gene Sum of Sum_pept_count 3 0 2 1
Max of Max_Dif_pept 2 0 2 1
Npc1 Niemann Pick type C1 Sum of Sum_pept_count 9 7 12 5
Max of Max_Dif_pept 2 1 2 1
Ubie UbiE-YGHL1 fusion protein Sum of Sum_pept_count 1 0 0 2
Max of Max_Dif_pept 1 0 0 2
Dfna5h
deafness, autosomal dominant 5 
homolog (human)
Sum of Sum_pept_count 0 0 1 2
Max of Max_Dif_pept0 0 1 2
Npas2 neuronal PAS domain protein 2 Sum of Sum_pept_count 2 0 3 2
Max of Max_Dif_pept 2 0 2 2
Itga3 integrin alpha 3 Sum of Sum_pept_count 3 1 3 4
Max of Max_Dif_pept 2 1 2 2
Ephb4 Eph receptor B4 Sum of Sum_pept_count 0 0 2 0
Max of Max_Dif_pept 0 0 2 0
Clpb
ClpB caseinolytic peptidase B 
homolog (E. coli)
Sum of Sum_pept_count 7 0 3 4
Max of Max_Dif_pept 2 0 1 2
Cacybp calcyclin binding protein Sum of Sum_pept_count 0 4 2 1
Max of Max_Dif_pept 0 2 1 1
Hist3h2ba histone cluster 3, H2ba Sum of Sum_pept_count 3 1 4 7
Max of Max_Dif_pept 1 1 2 2
Ephb3 Eph receptor B3 Sum of Sum_pept_count 0 0 2 0
Max of Max_Dif_pept 0 0 2 0
Dsg1a desmoglein 1 alpha Sum of Sum_pept_count 0 0 3 1
Max of Max_Dif_pept 0 0 2 1
Hnrnpa3
heterogeneous nuclear 
ribonucleoprotein A3
Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 2  234
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Hist3h2bb histone cluster 3, H2bb Sum of Sum_pept_count 3 1 4 7
Max of Max_Dif_pept 1 1 2 2
Nedd4l
neural precursor cell expressed, 
developmentally down-regulated 
gene 4-like
Sum of Sum_pept_count 8 5 4 2
Max of Max_Dif_pept 2 1 2 1
Nedd4
neural precursor cell expressed, 
developmentally down-regulated 
gene 4
Sum of Sum_pept_count 2 5 4 2
Max of Max_Dif_pept 1 1 2 1
Uqcrh
ubiquinol-cytochrome c reductase 
hinge protein
Sum of Sum_pept_count 0 0 1 2
Max of Max_Dif_pept 0 0 1 2
Ndufb7
NADH dehydrogenase 
(ubiquinone) 1 beta subcomplex, 7
Sum of Sum_pept_count 2 0 1 6
Max of Max_Dif_pept 2 0 1 2
Ndufb3
NADH dehydrogenase 
(ubiquinone) 1 beta subcomplex 3
Sum of Sum_pept_count 0 0 0 3
Max of Max_Dif_pept 0 0 0 2
Usp12 ubiquitin specific peptidase 12 Sum of Sum_pept_count 1 3 0 0
Max of Max_Dif_pept 1 2 0 0
Usp46 ubiquitin specific peptidase 46 Sum of Sum_pept_count 1 3 0 0
Max of Max_Dif_pept 1 2 0 0
Vamp2
vesicle-associated membrane 
protein 2
Sum of Sum_pept_count 5 2 5 1
Max of Max_Dif_pept 2 1 2 1
Hkdc1 hexokinase domain containing 1 Sum of Sum_pept_count 1 1 1 2
Max of Max_Dif_pept 1 1 1 2
Vamp5
vesicle-associated membrane 
protein 5
Sum of Sum_pept_count 2 0 0 1
Max of Max_Dif_pept 2 0 0 1
Ick intestinal cell kinase Sum of Sum_pept_count 2 0 3 1
Max of Max_Dif_pept 2 0 2 1
Abr active BCR-related gene Sum of Sum_pept_count 1 2 0 1
Max of Max_Dif_pept 1 2 0 1
Dopey2 dopey family member 2 Sum of Sum_pept_count 0 0 2 0
Max of Max_Dif_pept 0 0 2 0
Ap2s1
adaptor-related protein complex 2, 
sigma 1 subunit
Sum of Sum_pept_count 1 3 2 4
Max of Max_Dif_pept 1 2 2 2
Dok4 docking protein 4 Sum of Sum_pept_count 2 0 3 0
Max of Max_Dif_pept 2 0 2 0
Copg2
coatomer protein complex, subunit 
gamma 2
Sum of Sum_pept_count 0 1 2 2
Max of Max_Dif_pept 0 1 2 2
Ndufa8
NADH dehydrogenase 
(ubiquinone) 1 alpha subcomplex, 
8
Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
AA986860 expressed sequence AA986860 Sum of Sum_pept_count 0 5 2 0
Max of Max_Dif_pept 0 2 2 0
Bcr breakpoint cluster region homolog Sum of Sum_pept_count 1 2 1 0
Max of Max_Dif_pept 1 2 1 0
Napg
N-ethylmaleimide sensitive fusion 
protein attachment protein gamma
Sum of Sum_pept_count 0 2 3 1
Max of Max_Dif_pept 0 2 2 1
Emd emerin Sum of Sum_pept_count 0 3 2 2
Max of Max_Dif_pept 0 1 1 2
Myo5a myosin Va Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Vps29
vacuolar protein sorting 29 (S. 
pombe)
Sum of Sum_pept_count 0 1 1 2
Max of Max_Dif_pept 0 1 1 2
Ipo5 importin 5 Sum of Sum_pept_count 0 0 3 0
Max of Max_Dif_pept 0 0 2 0
Nap1l4
nucleosome assembly protein 1-
like 4
Sum of Sum_pept_count 0 2 0 0
Max of Max_Dif_pept 0 2 0 0
Gpc4 glypican 4 Sum of Sum_pept_count 0 0 2 0
Max of Max_Dif_pept0 0 2 0
Ass1 argininosuccinate synthetase 1 Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Entpd2
ectonucleoside triphosphate 
diphosphohydrolase 2
Sum of Sum_pept_count 6 1 2 3
Max of Max_Dif_pept 2 1 2 1
Ephb2 Eph receptor B2 Sum of Sum_pept_count 0 0 2 0
Max of Max_Dif_pept 0 0 2 0
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Gene Symbol Gene Description Data proximal central distal total mucosa
Cmbl
carboxymethylenebutenolidase-like 
(Pseudomonas)
Sum of Sum_pept_count 0 1 1 2
Max of Max_Dif_pept 0 1 1 2
Gnb4
guanine nucleotide binding protein 
(G protein), beta 4
Sum of Sum_pept_count 0 3 0 0
Max of Max_Dif_pept 0 2 0 0
Wdr61 WD repeat domain 61 Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Xdh xanthine dehydrogenase Sum of Sum_pept_count 0 0 0 5
Max of Max_Dif_pept 0 0 0 2
Car3 carbonic anhydrase 3 Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Eif1
eukaryotic translation initiation 
factor 1
Sum of Sum_pept_count 0 3 2 2
Max of Max_Dif_pept 0 1 1 2
Xpo1 exportin 1, CRM1 homolog (yeast) Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Nagk N-acetylglucosamine kinase Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Aco1 aconitase 1 Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Abi1 abl-interactor 1 Sum of Sum_pept_count 0 4 1 1
Max of Max_Dif_pept 0 2 1 1
Acot7 acyl-CoA thioesterase 7 Sum of Sum_pept_count 0 1 2 0
Max of Max_Dif_pept 0 1 2 0
Nadsyn1 NAD synthetase 1 Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Ephb1 Eph receptor B1 Sum of Sum_pept_count 0 0 2 0
Max of Max_Dif_pept 0 0 2 0
3110043O21Rik RIKEN cDNA 3110043O21 gene Sum of Sum_pept_count 2 0 1 1
Max of Max_Dif_pept 2 0 1 1
Calr calreticulin Sum of Sum_pept_count 0 0 1 3
Max of Max_Dif_pept 0 0 1 2
Hnrnpa1
heterogeneous nuclear 
ribonucleoprotein A1
Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Zfp119 zinc finger protein 119 Sum of Sum_pept_count 1 0 0 2
Max of Max_Dif_pept 1 0 0 2
Myo5c myosin VC Sum of Sum_pept_count 0 0 0 2
Max of Max_Dif_pept 0 0 0 2
Dnajb6
DnaJ (Hsp40) homolog, subfamily 
B, member 6
Sum of Sum_pept_count 2 0 1 2
Max of Max_Dif_pept 2 0 1 2
Sept8 septin 8 Sum of Sum_pept_count 0 1 1 4
Max of Max_Dif_pept 0 1 1 2
B2m beta-2 microglobulin Sum of Sum_pept_count 5 4 4 4
Max of Max_Dif_pept 2 1 1 2
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Appendix B: Sample comparison by precursor ion signal intensity 
B1. Filenames convention 
Technical step Band No Given Name  Original study name
Pool_wBBM_1_2_a ET72_sameGel_BM_mix_2_3_a
Pool_wBBM_1_2_b ET72_sameGel_BM_mix_2_3_b
Pool_wBBM_1_2_c ET72_sameGel_BM_mix_2_3_c
Pool_wBBM_1_9_a ET72_sameGel_BM_mix_9_3_a
Pool_wBBM_1_9_b ET72_sameGel_BM_mix_9_3_b
Pool_wBBM_1_9_c ET72_sameGel_BM_mix_9_3_c
SameGel_pool_wBBM_1_2 ET72_sameGel_BM_mix_2_1
SameGel_pool_wBBM_2_2 ET72_sameGel_BM_mix_2_2
SameGel_pool_wBBM_3_2 ET72_sameGel_BM_mix_2_3_a
SameGel_pool_wBBM_1_9 ET72_sameGel_BM_mix_9_1
SameGel_pool_wBBM_2_9 ET72_sameGel_BM_mix_9_2
SameGel_pool_wBBM_3_9 ET72_sameGel_BM_mix_9_3_a
SameGel_pool_wBBM_1_11 ET72_sameGel_BM_mix_11_1
SameGel_pool_wBBM_2_11 ET72_sameGel_BM_mix_11_2
SameGel_pool_wBBM_3_11 ET72_sameGel_BM_mix_11_3_a
Difgel_pool_wBBM_A_2 ET72_difgel_BM_mix_2_1
Difgel_pool_wBBM_B_2 ET72_difGel_BM_mix_2_2
Difgel_pool_wBBM_C_2 ET72_sameGel_BM_mix_2_2
Difgel_pool_wBBM_A_9 ET72_difgel_BM_mix_9_1
Difgel_pool_wBBM_B_9 ET72_difGel_BM_mix_9_2
Difgel_pool_wBBM_C_9 ET72_sameGel_BM_mix_9_2
Difgel_pool_wBBM_A_11 ET72_difgel_BM_mix_11_1
Difgel_pool_wBBM_B_11 ET72_difGel_BM_mix_11_2
Difgel_pool_wBBM_C_11 ET72_sameGel_BM_mix_11_2
PV_wBBM_1_2 ET72_PV_BM_1_2
PV_wBBM_2_2 ET72_PV_BM_2_2
PV_wBBM_3_2 ET72_PV_BM_3_2
PV_wBBM_1_9 ET72_PV_BM_1_9
PV_wBBM_2_9 ET72_PV_BM_2_9
PV_wBBM_3_9 ET72_PV_BM_3_9
PV_wBBM_1_11 ET72_PV_BM_1_11
PV_wBBM_2_11 ET72_PV_BM_2_11
PV_wBBM_3_11 ET72_PV_BM_3_11
TV_wBBM_1_2 ET65_TV_BM_1_2
TV_wBBM_2_2 ET65_TV_BM_2_2
TV_wBBM_3_2 ET65_TV_BM_3_2
TV_wBBM_1_9 ET65_TV_BM_1_9
TV_wBBM_2_9 ET65_TV_BM_2_9
TV_wBBM_3_9 ET65_TV_BM_3_9
TV_wBBM_1_11 ET65_TV_BM_1_11
TV_wBBM_2_11 ET65_TV_BM_2_11
TV_wBBM_3_11 ET65_TV_BM_3_11
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B2. Analytical time scale for the sample measurement used in the process 
variation analysis 
 
 
 
For naming convention, please refer to appendix B1.   239
B3. Scatter plots and Spearmann correlation values for all the sample 
comparisons described in the section 4.5.3.2.2 
B.3.1 Injection replicates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scatter plot representations of the injection replicates of the bands 2 and 9. Panel A: Scatter 
plots of all the common MS signals between the replicates. Panel B: Scatter plots of the MS 
signals that correspond to successful MS/MS measurements. N is the number of common 
signals. The Spearman value reflects the similarity of the signal intensities between the 
compared samples (ideal case Spearman correlation=1). Each red dot line parallel to the 
diagonal represents a two fold difference, i.e. across three lines, the fold change is 2*2*2=8. 
Accordingly, the axes represent an arbitrary mass spectrometric intensity (in counts) in log2 
units. All sample denominations are as described in Fig. 4.21. 
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B.3.2 “Same gel variation”replicates 
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Scatter plot representations of the variability for the band 2, 9 and 11, cut horizontally from 
adjacent identical lanes. Panel A: Scatter plots of all the common MS signals between the 
replicates. Panel B: Scatter plots of the MS signals that correspond to successful MS/MS 
measurements. N is the number of common signals. The Spearman value reflects the 
similarity of the signal intensities between the compared samples (ideal case Spearman 
correlation=1). Each red dot line parallel to the diagonal represents a two fold difference, i.e. 
across three lines, the fold change is 2*2*2=8. Accordingly, the axes represent an arbitrary 
mass spectrometric intensity (in counts) in log2 units. All sample denominations are as 
described in Fig. 4.21. 
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B.3.3 “Different gel variation”replicates 
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Scatter plot representations of the band 2, 9 and 11 from identical BBM samples, loaded in 
three different gels.  Panel A: Scatter plots of all the common MS signals between the 
replicates. Panel B: Scatter plots of the MS signals that correspond to successful MS/MS 
measurements. N is the number of common signals. The Spearman value reflects the 
similarity of the signal intensities between the compared samples (ideal case Spearman 
correlation=1). Each red dot line parallel to the diagonal represents a two fold difference, i.e. 
across three lines, the fold change is 2*2*2=8. Accordingly, the axes represent an arbitrary 
mass spectrometric intensity (in counts) in log2 units. All sample denominations are as 
described in Fig. 4.21. 
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B.3.4 “Preparation variation”replicates 
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Scatter plot representations of the preparation variability for the band 2, 9 and 11 from 
three BBM technical replicate preparations. Panel A: Scatter plots of all the common MS 
signals between the replicates. Panel B: Scatter plots of the MS signals that correspond to 
successful MS/MS measurements. N is the number of common signals. The Spearman value 
reflects the similarity of the signal intensities between the compared samples (ideal case 
Spearman correlation=1). Each red dot line parallel to the diagonal represents a two fold 
difference, i.e. across three lines, the fold change is 2*2*2=8. Accordingly, the axis 
represents an arbitrary mass spectrometric intensity (in counts) in log2 units. All sample 
denominations are as described in Fig. 4.21. 
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B.3.5 “Total variation”replicates 
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Scatter plot representations of the total variability for the bands 2, 9 and 11 from three 
BBM technical replicate preparations, randomly analyzed. Panel A: Scatter plots of all the 
common MS signals between the replicates. Panel B: Scatter plots of the MS signals that 
correspond to successful MS/MS measurements. N is the number of common signals. The 
Spearman value reflects the similarity of the signal intensities between the compared samples 
(ideal case Spearman correlation=1). Each red dot line parallel to the diagonal represents a 
two fold difference, i.e. across three lines, the fold change is 2*2*2=8. Accordingly, the axes 
represent an arbitrary mass spectrometric intensity (in counts) in log2 units. All sample 
denominations are as described in Fig. 4.21 
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Appendix C: Separation of hydrophobic peptides by hydrophilic-
interaction liquid chromatography 
 
C.1 Introduction 
Reversed-Phase Liquid Chromatography (RPLC) has become an indispensable technique for 
the separation and purification of peptides using hydrophobic stationary phases, such as 
octyl- or octadecyl-derivatized silica beads. In RPLC, a solute molecule binds to an 
immobilized hydrophobic molecule in a polar solvent. This partitioning occurs as a result of 
the solute molecule tending to have hydrophobic patches at its surface and binding occuring 
via those patches to the matrix. A buffer of increasing hydrophobicity is used to dissociate the 
bound molecule at a point at which the hydrophobic interaction between the exposed patches 
and the immobilized matrix is less favorable than the interaction between the bound molecule 
and the solvent. The molecule releases from the matrix and elutes. One of the major 
advantages of the RPLC technique, apart from its extensive resolving power, is the 
availability of volatile mobile phases, of which aqueous trifluoroacetic acid (TFA), acetic 
acid or formic acid–acetonitrile (ACN) are the most frequently employed (123). Thus, RPLC 
can be directly coupled to an electrospray ionization interface for the online analysis of 
molecules using mass spectrometry. 
Although a powerful separation mode, a major limitation of RPLC is the lack of adequate 
retention of polar molecules. In 1990, the name Hydrophilic-Interaction Chromatography 
(HILIC) was coined by Alpert (120) for the separation of hydrophilic substances such as 
proteins, peptides and nucleic acids using polar stationary phase, such as polyhydroxyethyl 
aspartamide or polyhydroxysulfotamide aspartamide. In HILIC, polar peptides are retained 
by the polar stationary phase in a hydrophobic solvent. The solute molecule is then eluted 
from the chromatographic beads by increasing the polarity of the mobile phase, for example 
by increasing the proportion of water or by adding salt. Similarly to normal phase liquid 
chromatography (or in opposite to the trends observed in RPLC) peptide retention time 
increases with the polarity (hydrophilicity) of the peptide and critically depends on the 
polarity of the stationary phase and on the initial polarity of the mobile phase (124-126). It 
has been considered that the interaction forces governing selectivity in HILIC are polar in 
origin, encompassing both hydrogen bonding, the extent of which depends upon the acidity 
or basicity (in the Lewis sense) of the solutes, and dipole–dipole interaction, which is 
dependent upon the dipole moments and polarizability of molecules (124). Similarly to RPLC, 
HILIC can be directly coupled to an electrospray ionization interface if the salt concentration   249
is kept to a minimum to avoid interference with the ionization process. However, so far, 
HILIC has been suggested as an alternative to cation-exchange chromatography for the 
separation of polar peptides, such as glycopeptides, phosphopeptides and modified histone 
peptides (121). It is then typically coupled off-line with a RPLC-MS for peptide 
characterization. 
In contrast to most studies, where HILIC has been used to chromatography very polar 
peptides, the main point of interest in this work was to investigate the potential of HILIC to 
cope with the separation of very hydrophobic peptides, such as typically found in 
transmembrane helices of membrane proteins. Such peptides, which consist of long stretches 
of aliphatic and hydrophobic amino acids, and which might count an average of 40-50 amino 
acids in a tryptic digest, are typically not observed in a classical RPLC-MS separation. One 
likely explanation is that they might not survive the initial buffer conditions of a RPLC 
separation: those peptides cannot be kept soluble in aqueous solutions as they form secondary 
structure and precipitate before being injected into the RPLC system. In addition, their 
hydrophobicity might cause them to stick so strongly to the stationary phase that their elution 
might not be possible with conventional buffer systems. In contrast, the highly organic 
character of the initial buffer composition of a HILIC separation would favor the stability of 
those kinds of peptides while the polarity of the carbonyl backbone should ensure their 
retention onto the polar chromatographic medium. 
The purpose of this work was to compare side-by-side the behavior of commercially 
available RPLC and HILIC chromatographic media in the separation of peptides of various 
hydrophobicities and to derive a first impression whether the premises delineated above could 
be verified.   250
C.2 Materials and Methods 
C.2.1 Peptide synthesis 
Selected peptides from bacteriorhodopsin were synthesized using standard peptide synthesis 
chemistry. Peptides 1-3 were synthesized at Peptide Specialty Laboratory (Heidelberg, 
Germany) while peptides 1-43 and 129 were synthesized at the peptide synthesis group at 
Roche Penzberg. 
 
Table A.I: List of synthetic tryptic and C-terminal (peptide3) peptides from 
bacteriorhodopsin. The GRAVY score (grand average of hydropathicity, see Kyte, J. and 
Doolittle, R.F. (1982) A simple method for displaying the hydropathic character of a protein. 
J. Mol. Biol. 157, 105-132) was calculated using the ProtParam tool on the Expasy web site 
(www.expasy.ch). A positive GRAVY score indicates an hydrophobic sequence while a 
negative GRAVY score points to hydrophilic sequence. The theoretical mass of the peptide 
was calculated for a charge state of 1+. 
 
C.2.2 Capillary RPLC 
Peptide mixtures were analyzed by capillary reverse phase liquid chromatography using an 
Agilent 1100 microflow chromatographic system using a 0.3 mm i.d x 15 cm length C18 
PepMap100 (3 μm particle, 100 Ǻ pore size, Dionex) column. 
The peptide mixture of each sample was dissolved in buffer A (5% ACN, 0.1% FA). 20 μl of 
the sample was transferred to a glass Micro-V vial (Agilent) of which 10 μl were injected into 
the system at a flow rate of 5 μl/min at 5% buffer B (90% ACN, 0.5% FA) for 9 min. The 
peptides were eluted from the reverse phase column by increasing the ACN concentration in a 
linear gradient as follows: 9—48 min, 5—60% buffer B. The column was then washed for 10 
min with 90% buffer B after which it was re-equilibrated for 28 min in 5% buffer B. 
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C.2.3 Capillary HILIC 
Peptide mixtures were analyzed by HILIC chromatography with the same Agilent 1100 
HPLC system that was used for the capillary RPLC method using a 0.3 μm i.d. x 15 cm 
length PolyHYDROXYETHYL-A (5 μm particle, 300 Ǻ pore size, PolyLC Inc) column. 
The peptide mixture of each sample was dissolved in buffer A (90% ACN, 0.1% FA, 5 mM 
ammonium formate). In some cases samples were dissolved in buffer A with the addition of 
either 0.05% SDS, 0.05% Triton X-100 or 10% tetrahydrofurane. 20 μl of the sample was 
transferred to a glass Micro-V vial (Agilent) of which 10 μl were injected into the system at a 
flow rate of 5 μl/min at 100% buffer A for 9 min. The peptides were eluted from the HILIC 
column by decreasing the ACN concentration in a linear gradient as follows: 9—48 min, 0—
61% buffer B (5 mM ammonium formate, 0.1% FA). The column was then washed for 10 
min with 88.5% buffer B after which it was re-equilibrated for 28 min in 100 % buffer B. 
C.2.4 MALDI MS analysis, data processing and analysis 
Peptides eluted between 10 and 70 min retention time were directly spotted onto the 384 
positions of an Anchorchip target plate (Bruker Daltonics) pre-coated with matrix. Shortly, 
each position of the 384 anchorchip target plate was pre-spoted with 1 μl of α-cyano-4-
hydroxycinnamic acid (0.25 mg/ml in 0.2 %TFA, 65 % Ethanol and 32% ACN containing 20 
fmol/μl ACTH and bradykinin as peptide standards). After spotting, spots were re-crystallized 
at 4 
oC using 1 μl of 65% Ethanol, 32% ACN. Peptides were analyzed in a LC-MALDI 
modus with an Ultraflex I MALDI mass spectrometer (Bruker Daltonics) in reflector mode 
using standard operating procedures. 
The LC-MALDI raw data of each fraction-spot were processed and filtered using an in-house 
software (MEDUSA). The algorithm (developed in the Proteomics group by Peter Berndt) 
removes most of the chemical noise introduced by the MALDI process and group related MS 
signal to a single variable (a chain). All spectral features (i.e., a peptide mass spectrometric 
signal) detected over a minimal signal over noise were extracted and internally calibrated. All 
those masses obeying a chromatographic behavior (i.e., the mass of an eluting peptide is 
expected to be observed in several consecutive fractions) were then clustered together using a 
star-shaped tolerance region and a nearest neighbor connected graph is build. For each 
connected component of the graph, the weighted mass and rf average and its error is estimated 
The algorithm removes most of the chemical noise, i.e. chemical components that are either 
continuously observed over the whole LC-MS procedure or that are randomly measured in   252
one or the other fraction, while keeping real features. The filtered signals were then 
graphically displayed using the Spotfire software package (TIBCO). 
Protein identification from LC-MALDI analyses was performed as follows: The compiled 
peptide m/z masses obtained from the MEDUSA software package were analyzed using the 
MASCOT search algorithm (MASCOT version 2.1.04, Matrix Science). Searches were 
performed against the Human SwissProt database (version 49.1 February 2006, 13488 entries) 
with a mass tolerance of 50 ppm .Methionines (reduced/oxidized; +15.9949 Da) were 
considered as differential modifications while cysteines were considered as fully 
carbamidomethylated (+57.0199 Da). Only fully tryptic peptides with no more than two 
miscleavages were considered for data analysis.   253
C.3 Results  
We examined in this study the chromatographic behavior of model peptides in respect to their 
retention time using either a RPLC or a HILIC modus. We were particularly interested in 
investigating the influence of peptide length and hydrophobicity onto peptide separation. We 
further examined the generality of both chromatographic systems by analyzing a simple 
protein digest by LC-MALDI MS and by identifying the population of peptides preferentially 
separated by a given separation modus. 
C.3.1 Model peptides separation 
A peptide mixture consisting of five synthetic peptides from bacteriorhodopsin (see Table 
A.1) and of ACTH was dissolved in the appropriate buffer and 10 μl of the mixture was then 
injected in the Agilent 1100 LC system. The final amount of each peptide in the injected 
sample was 1 pmol. Samples were analyzed either freshly after dilution in the initial buffer 
condition or after overnight incubation at 4 
oC so that the peptide stability in the sample could 
be monitored. 
The elution profiles of the peptide mixture using either RPLC or HILIC are shown in figure 
C.I. 
Using the RPLC modus, all peptides could be chromatographically resolved except P129 (25 
AA length and Gravy score of 1.424). The peptides’ retention time followed roughly their 
hydrophobicity reverse order, with P2 (Gravy: -0.523) eluted first followed by P3, ACTH, P1 
and P1-43. The elution of the very hydrophobic P1 peptide (according to the Gravy score) 
prior to P1-43 shows that the length of the peptide plays an important role. In particular, it 
can be inferred that the C-terminal Arg might significantly affect the chromatographic 
behavior of this otherwise rather short peptide. Interestingly, P1-43 (43 AA length and Gravy: 
0.74) was only observed in the elution profile when the sample was analyzed freshly after 
dilution. These data suggest that long and/or hydrophobic peptides might not remain in 
solution using the polar solvent system required by the RPLC chromatography. In addition, 
such peptides will tend to stick on the surface of the vial or will be irreversibly bound to the 
C18 column. 
Using the HILIC modus, all peptides including P129 could be chromatographically resolved. 
As expected, the peptides’ retention time followed roughly their hydrophobicity order, with 
P129 (Gravy: -1.424) eluted first followed by P1, P2, P1-43, P3 and ACTH. The early elution 
of the hydrophilic peptide P2 (according to the Gravy score) prior to P3 and P1-43 also  
Fig.C.I:  Elution profiles of the Bacteriorhodopsin peptide mix plus ACTH. Ppeptide 
elution was monitored online at 214 nm. RPLC: 10 μl of the peptide mixture dissolved in 5% 
ACN and 0.1% FA were injected onto a C18 column and eluted using an ACN linear gradient 
(5– 56% ACN). HILIC: 10 μl of the peptide mixture dissolved in 80% ACN, 0.1% FA, 5 mM 
AF and 10% THF were injected onto a HILIC PolyHYDROXYETHYL-A column. The 
peptides were eluted by lowering the ACN concentration in a linear gradient (90–10.35% 
ACN). 
indicates that hydrophilic interaction might not explain all the principles behind retention and 
separation in HILIC. An interesting aspect of HILIC is its compatibility with the use of very 
hydrophobic organic solvent, such as tetrahyrofurane (THF), and with the use of detergents, 
such as SDS or Triton-X100. In this experiment, the peptide mixture was either dissolved in 
buffer A (90% ACN, 0.1 % FA, 5 mM ammonium formate), or with the addition of 0.05% 
RPLC 
HILIC   255
SDS, 0.05% Triton X100 or using 10% THF. The presence of those modifiers didn’t affect 
the chromatographic behavior of the HILIC column (as they were eluted in the injection peak) 
and all the peptide were eluted with the same order in all the condition described above (data 
not shown). The addition of THF in the sample buffer was observed to slightly increase the 
signal intensity in the elution chromatogram. The addition of those modifiers, combined with 
the organic character of the sample buffer, had a beneficial effect on the peptide’s stability: 
all peptides could be observed in the elution chromatogram even after an overnight 
incubation at 4 
oC. 
C.3.2 Separation of a peptide digest 
In a subsequent experiment an HSA digest was analyzed using the Agilent 1100 HPLC 
system comparing the chromatographic separation of the C18 and the HILIC stationary phases. 
The HSA digest was prepared in the appropriate buffer and 10 μl (corresponding to 20 pmol 
of the digest) were injected into the system. LC fractions were collected every 9.4 sec and 
directly spotted onto the pre-coated 384 anchorchip target plate for subsequent MALDI MS 
analysis. 
The elution profile of the 20 pmol HSA tryptic digest using either the RPLC or the HILIC 
chromatographic system is represented in the figure C.II. 
Using the RPLC modus, the chromatographic separation of the HSA digest resulted in well 
resolved, sharp, intense peaks. Peak width was around 20-30 sec, ensuring maximum 
sensitivity for UV and MALDI MS measurement. In contrast, using the HILIC modus, the 
separation of the HSA digest resulted in an apparently poorly resolved elution chromatogram 
with peak elution time in the min range. As a consequence, typical peak only reached 100-
200 mOD sensitivity at 214 nm absorption compared to 600-800 mOD reached with the 
RPLC modus. The presence of SDS, Triton X-100 or THF in the starting buffer did not have 
any noticeable effect on the chromatographic behavior of the HILIC column, except to cause 
a rather large injection peak. Interestingly, none of the HSA tryptic peptides eluted as early in 
the HILIC mode as the very hydrophobic rhodopsin peptides, indicating that the HSA digest 
contains mostly hydrophilic peptides. This is consistent with the elution chromatogram of the 
same digest in RPLC modus, where most peptides were eluted rather early in the 
chromatogram.   256
 
Fig.C.II: Elution profiles of a 20 pmol HSA digest. Peptide elution was monitored online at 
214 nm. RPLC: 10 μl of the digest dissolved in 5% ACN and 0.1% FA were injected onto a 
C18 column and eluted using an ACN linear gradient (5– 56% ACN). HILIC: 10 μl of the 
digest were injected onto a HILIC PolyHYDROXYETHYL-A column. The peptides were 
eluted by lowering the ACN concentration in a linear gradient (90–10.35% ACN). Blue, HSA 
digest in 90% ACN, 0.1 % FA, 5 mM AF; Red, HSA digest in 90% ACN, 0.1 % FA, 5 mM AF 
plus 0.005 % SDS. Green, HSA digest in 90% ACN, 0.1 % FA, 5 mM AF plus 0.05 % Triton 
X-100; Pink, HSA digest in 80% ACN, 0.1 % FA, 5 mM AF plus 10 % THF.  
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HILIC   257
The LC-fractions spotted onto the MALDI target were measured using an Ultraflex I MALDI 
mass spectrometer operated in the reflector mode. The raw data files of each fraction were 
filtered by the in-house MEDUSA software (Signal-to-noise ratio:12, chain length: 4) and 
then searched using the MASCOT search engine against the human SwissProt database at 50 
ppm mass accuracy . The identified HSA tryptc peptides and their elution pattern in the 
RPLC or in the HILIC chromatography are schematically represented in Fig. C.III. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Human serum albumin: 56 % sequence coverage
RPLC
Human serum albumin: 56 % sequence coverage
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Fig. CIII: Scatter plot and sequence coverage of the 20 pmol HSA digest analyzed in the 
RPLC (panel A) or in the HILIC (panel B) modus. The scatter plot represents the LC-
MALDI MS signals observed above the set threshold and chainlength (LoN: 12, chainlength: 
4). The x axis represents the 384 fractions (the retention time) that have been collected 
during the RPLC run while the y axis stands for the molecular mass of the signals. The 
MALDI MS signal intensity is denoted by a color gradient from blue (low) to red (high). The 
number of fractions for which a signal has been observed is represented by the length of the 
horizontal line. The HSA amino acid sequence coverage for each chromatographic modi is 
schematically represented by highlighting the identified peptides in red. Peptides that were 
identified in only one of the two chromatographic separations are underlined. 
 
The peptides that were exclusively identified in one of the two chromatographic systems are 
listed in the table C.II 
Scatter Plot
Frac1D
50 100 150 200 250 300 350
1000
1500
2000
2500
3000
3500
Human serum albumin: 61 % sequence coverage 
HILIC
Scatter Plot
Frac1D
50 100 150 200 250 300 350
1000
1500
2000
2500
3000
3500
Human serum albumin: 61 % sequence coverage 
HILIC B   259
 
 
 
 
 
 
 
 
 
Table C.II: Amino acid sequences and characteristics of the tryptic peptides identified 
exclusively through the HILIC or the RPLC system 
 
566-584
301-337
250-257
170-183
45-65
position HILIC RPLC GRAVY mass # AA Peptide sequence
X 0.047 2175 19 EQLKAVMDDFAAFVEKCCK
X 0.354 4091.6 37
ECCEKPLLEKSHCIAEVENDE
MPADLPSLAADFESK
X -0.138 879.9 8 AEFAEVSK
X 0.229 1743 14 HPYFYAPELLFFAK
X 0.49 2433.8 21 ALVLIAFAQYLQQCPFEDHVK
566-584
301-337
250-257
170-183
45-65
position HILIC RPLC GRAVY mass # AA Peptide sequence
X 0.047 2175 19 EQLKAVMDDFAAFVEKCCK
X 0.354 4091.6 37
ECCEKPLLEKSHCIAEVENDE
MPADLPSLAADFESK
X -0.138 879.9 8 AEFAEVSK
X 0.229 1743 14 HPYFYAPELLFFAK
X 0.49 2433.8 21 ALVLIAFAQYLQQCPFEDHVK  260
C.4 Discussion 
Reverse-phase chromatography is at present the most commonly used chromatographic 
separation method for the analysis of peptides and proteins by mass spectrometry. Since its 
first use in the late 70’ (127), 30 years of intense and systematic research has resulted in the 
development of stationary phases and columns with excellent resolution and sensitivity, for 
example, for the separation of small molecules and of peptides in complex biological samples. 
In particular, the decreasing size of the chromatographic beads (from 8 to 5, then 3 to today 
1.8 μm diameter) enables the packing of nanoLC column (typically from 100 to 50 μm inner 
diameter) with unmatched resolution and sensitivity. Their coupling to the latest generation 
of mass spectrometers (e.g. Orbitrap or Q-ToF) allows the characterization of peptides in 
complex mixtures at the attomole level. 
The optimal use of RPLC in the separation and analysis of peptides by mass spectrometry 
requires the analyzed biological samples to be void of salt (which would significant impair 
the electrospray process) and to be dissolved in an almost 100% aqueous solution before 
separation. While most peptides (and in particular tryptic peptides) withstand such conditions 
without problems, long, hydrophobic peptides and some proteins might stick to vial surfaces 
or precipitate out of solution. In addition, the hydrophobic nature of the RPLC 
chromatographic material will cause very hydrophilic peptides (such as phosphopeptides) to 
wash through the column at injection. On the other hand, very hydrophobic peptides (such as 
transmembrane peptides) will tend to bind strongly to a RP stationary phase and might not be 
eluted from the column even at high organic content of the mobile phase. This last problem 
can be partially alleviated by using less hydrophobic column material, such as C8 or C4, 
however at the cost of lower chromatographic resolution. 
Since its description (120) in the early 90’s, hydrophilic interaction liquid chromatography 
(HILIC) has been mainly used to chromatography and separate very polar analytes. Its mode 
of separation, which appears to be complementary to the RPLC chromatographic modus, has 
been best characterized using aspartimide-derivatized silica beads available commercially 
under the brand name PolyHYDROXYETHYL-A. Several studies demonstrated that 
mechanisms for retention and selectivity could mainly be explained by polar interactions 
(hydrogen bonding, dipole-dipole moments) and ion-exchange mechanisms, while the 
residual charges of the column’s silanol groups might also provide selectivity for polar 
molecules (124, 128).   261
In this report our interest was mainly focused on the chromatographic behavior of long, 
hydrophobic peptides (such as generated from a tryptic digestion from membrane proteins) 
using HILIC. The main hypothesis behind this study relies on the observation that even long 
transmembrane peptides display a significant share of polar functions in the form of the 
carbonyl groups distributed on the peptide backbone, which should enable their retention on a 
HILIC stationary phase. In addition, the organic conditions typically used in HILIC and the 
compatibility of this chromatographic modus with various non-ionic detergents and modifiers 
should stabilize hydrophobic peptides better than in aqueous conditions prior to 
chromatographic separation. The elution profile of synthetic peptides from bacteriorhodopsin 
and ACTH (table A.I) using a PolyHYDROXYETHYL-A column confirmed the above idea. 
All the investigated peptides could be retained and separated by HILIC even if the sample 
was stored overnight at 4 
oC to test peptide stability in those conditions. In contrast, only five 
of the six investigated peptides could be investigated using the C18 RPLC column. Peptide 
p1-43 could only be analyzed if the freshly-made sample was immediately injected into the 
HPLC system while peptide p129 was never detected, either because it precipitated out in 
aqueous conditions and/or because it could not be eluted from the column. Most interestingly, 
HILIC is compatible with organic modifiers, such as 10% THF, or detergents, such as 0.05% 
Triton-X100 or 0.05% SDS, as these chemicals are eluted with the injection peak and don’t 
appear to interfere with the chromatographic separation. These reagents also contribute to the 
stability and the solubility of long, hydrophobic peptides or proteins in aqueous solution. 
Their use might open the possibility to directly analyze by HILIC-MS intact hydrophobic 
proteins or to digest hydrophobic proteins in presence of detergents or hydrophobic modifiers 
using experimental conditions that would be otherwise incompatible with RPLC. 
The separation of a HSA tryptic digest using either RPLC or HILIC essentially confirmed the 
observations made with the bacteriorhodopsin and ACTH peptides, with the note that the 
chromatographic separation and resolution of the C18 column was considerably higher than 
those of the HILIC material. The eluent of the LC columns was directly spotted onto the 384-
positions MALDI target, which allowed the analysis of the peptide mixture by MALDI-ToF 
MS. Based on sequence coverage, both chromatographic methods roughly equaled each other 
(61% vs. 56% for HILIC vs. RPLC). As expected, peptides commonly analyzed in both 
chromatographic modi were eluted in a “complementary” order (that is, peptides eluted early 
in the RPLC column tended to be eluted late in the HILIC column, and vice versa). Only five 
peptides were found in a single chromatographic modus (table A.II) with a trend for short, 
hydrophilic (probably not retained in a RPLC column) and long, hydrophobic (probably not   262
eluted from the RPLC column) peptides preferably observed on the HILIC column. The 
reason for observing p45-65 and p170-183 only in RPLC modus is not clear and might be due to 
the inferior performance of the HILIC column. A more systematic study using protein digests 
of diverse origins (especially from membrane preparation, see also below) should clarify in 
which conditions HILIC chromatography might provide advantages compared to RPLC. 
This study summarizes a first set of experiments that was performed in our group to assess 
the use of HILIC for the chromatographic separation of peptides, and its potential for direct 
coupling to mass spectrometers. The ability to analyze peptide and protein samples in 
presence of high content of organic solvents (that is, for an enzymatic digestion, directly after 
digestion without a need for evaporation and reconstitution in aqueous conditions) leads to 
higher sensitivity. In particular, these conditions are beneficial to keep hydrophobic, long 
peptides in solution. Concomitantly, a chromatography performed with organic, volatile 
mobile phases is ideal for efficient desolvation and peptide ionization, in effect enhancing 
signal response in MS and leading to higher limits of detections (129). Interestingly, we have 
now several lines of evidence that even highly hydrophobic peptides (such as p1-43 or p129, 
table A.I) are amenable to mass spectrometric detection using electrospray ionization, 
provided they survive the reconstitution and the chromatographic steps. These peptides 
typically exhibit lower charge state as their hydrophilic counterpart and might not be detected 
in the “typical” mass range window scanned by the mass spectrometer.  
In this study, due to time constrains, only one HILIC stationary phase (polyhydroxyethyl 
aspartamide) could be tested among many others that are potentially available, such as silica, 
amino, diol, or cyano. All these phases share roughly the same mode of operation but with a 
large range of specificity. In particular, the amino stationary phase appears to be particularly 
suited for peptide separation using solvent conditions close to RPLC as it does not require 
salt to minimize ion-exchange interactions. However, optimal separation conditions were 
achieved using TFA as an organic modifier (to shield from uncapped silanol groups), 
compromising thereby sensitivity using an electrospray ionization interface (125). One of the 
major difficulty performing this study was to find columns in the sub-microbore range (<500 
μm i.d.) and/or bulk chromatographic media compatible with the packing of nanoLC column. 
Since the first report in 1990, HILIC has remained a niche chromatographic method for the 
separation of very polar compound and has lacked the development that has witnessed RPLC. 
However, recently, several groups have started to use HILIC for peptide separation (in 
particular, for the analysis of post-translational modifications, such as phosphorylation or 
glycosylation of peptides) and several chromatographic companies are now offering   263
stationary phases that could be used for the packing of nanoLC HILIC columns. A further 
improvement in separation could be obtained by monolithic structures instead of porous 
material, enabling the use of longer columns with improved peak capacity (130). 
While this study provides some directions on how to analyze very hydrophobic peptides by 
LC-MS, the problem on how to generate such peptides and on how to keep them amenable to 
LC-MS analysis has not been considered here. One obvious limitation of the in-gel digest 
procedure remains the conditions in which the enzymatic digestion step has to be performed 
to avoid denaturing the proteolytic enzyme. There is at the moment no evidence that such 
hydrophobic peptides are generated in this procedure, and whether these peptides can be 
extracted efficiently from the gel matrix before they precipitate or aggregate. In the future, it 
will be of great importance to study the problematic in its entirety to understand whether an 
improved digestion protocol for membrane proteins, which should generate a better sequence 
coverage, in particular for transmembrane domains, can be expected at all.   264  265
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